



(51) International Patent Classification:

C07D 487/08 (2006.01) *A61P 25/00* (2006.01)
A61K 31/407 (2006.01) *C07D 471/08* (2006.01)
C07D 519/00 (2006.01)

(21) International Application Number:

PCT/US2014/024293

(22) International Filing Date:

12 March 2014 (12.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/780,378 13 March 2013 (13.03.2013) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(71) Applicants (*for US only*): **GELIN, Christine F.** [US/US];
 5678 Scripps Street, San Diego, California 92122 (US).
LEBOLD, Terry P. [US/US]; 11296 Del Diablo Way,
 San Diego, California 92129 (US). **SHIREMAN, Brock
 T.** [US/US]; 12625 Birchbrook Court, Poway, California
 92064 (US). **ZIFF, Jeannie M.** [US/US]; 3611 Florida
 Street, #4, San Diego, California 92104 (US).

(74) Agents: **JOHNSON, Philip S.** et al.; Johnson & Johnson,
 One Johnson & Johnson Plaza, New Brunswick, New Jer-
 sey 08933 (US).

(81) Designated States (*unless otherwise indicated, for every
 kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
 ZW.

(84) Designated States (*unless otherwise indicated, for every
 kind of regional protection available*): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS

(57) Abstract: The present invention is directed to compounds of Formula I: wherein X is N or CR¹; Y is N or CR²; R¹ is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R² is H, alkyl, alkoxy, or halo; Z is NH or O; R³ is H, alkyl, alkoxy, halo, or triazolyl; R⁴ is H or alkyl; or R³ and R⁴, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R⁵ is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.



WO 2014/165070 A1

SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR
MODULATORS

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 61/780,378, filed
5 March 13, 2013, which is incorporated herein by reference in its entirety.

TECHNICAL FIELD

The present invention is directed to substituted 2-azabicyclic compounds, pharmaceutical
compositions comprising them, methods of making them, and methods of using them for the
modulation of the orexin receptor for the treatment of disease states, disorders, and conditions
10 mediated by orexin receptor activity.

BACKGROUND

Orexin/hypocretin signaling is mediated by two receptors and two peptide agonists. The
peptides (orexin-A and orexin-B) are cleavage products of the same gene, pre-pro orexin. In the
central nervous system, neurons producing pre-pro orexin are found solely in the perifornical
15 nucleus, the dorsal hypothalamus, and the lateral hypothalamus (Peyron et al., 1998, *J. Neurosci.*
18: 9996-10015). Orexigenic cells in these regions project to many areas of the brain, extending
rostrally to the olfactory bulbs and caudally to the spinal cord (Van den Pol, 1999, *J. Neurosci.* 19:
3171-3182).

The orexins bind to two high affinity receptors, referred to as orexin-1 and orexin-2
20 receptors. Orexin-1 and orexin-2 receptors are G-protein-coupled, seven transmembrane receptors
that share over 64% amino acid sequence identity with one another. Both receptors are generally
excitatory, the common cellular response to orexin-induced receptor activation being increases in
intracellular calcium. Homology between the species orthologs is high and there are no known
pharmacological differences. Orexin-A and -B are usually considered equal ligands for orexin-2
25 receptor but orexin-B is thought to be 5- to 100-fold weaker ligand than orexin-A at the orexin-1
receptor (Sakurai et al., 1998, *Cell* 92: 573-585; Ammoun et al., 2003, *J. Pharmacol. Exp. Ther.*
305: 507-514).

Many regions of the brain have fairly selective expression of the orexin-1 or orexin-2
receptors (Marcus et al., 2001, *J. Comp Neurology* 435, 6-25; Trivedi et al., 1998, *FEBS Letters*,

438, 71-75). Orexin-1 receptors are selective for the limbic system (bed nucleus of the stria terminalis and amygdala), cingulate cortex and noradrenergic neurons in the locus coeruleus. Conversely, the orexin-2 receptor is almost the exclusive orexin receptor in the histaminergic neurons in the tuberomammillary nucleus which play a critical role in wake promotion; in
5 paraventricular neurons and the parabrachial nucleus. In other brain regions like the dorsal raphe, the ventral tegmental area or the prefrontal cortex both receptors are coexpressed.

The broad CNS distribution of cells producing orexin, as well as cells expressing the orexin receptors, suggests involvement of orexin in a number of physiological functions, including feeding and metabolism, regulation of wakefulness and sleep, sympathetic activation and stress response (de
10 Lecea, 2012, *Progress in Brain Research*, 198, 15-24; Kukkonen, 2013, *Am J. Physiol. Cell Physiol.*, 304, C2-C32). Orexin also plays a key role regulating motivation and reward associated with food intake and with drugs of abuse (Mahler et al., 2012, *Progress in Brain Research*, 198, 79-121).

Several lines of evidence indicate that the orexin system is an important modulator of
15 arousal. Rodents administered orexin intracerebroventricularly spend more time awake (Piper et al., 2000, *J. Neurosci.* 12: 726-730. Orexin-mediated effects on arousal have been linked to orexin neuronal projections to histaminergic neurons in the tuberomammillary nucleus (Yamanaka et al., 2002, *Biochem. Biophys. Res. Comm.* 290: 1237-1245). Rodents whose pre-pro orexin gene has been knocked out, or whose orexigenic neurons have been killed, display altered sleep/wake cycles
20 similar to narcolepsy (Chemelli et al., 1999, *Cell* 98: 437-451; Hara et al., 2001, *Neuron* 30: 345-354). Dog models of narcolepsy have been shown to have mutant or non-functional orexin-2 receptors (Lin et al., 1999, *Cell* 98: 365-376). Orexin signaling as a target for sleep-promoting therapies was further validated clinically by findings of attenuated orexin levels and loss of orexinergic neurons in human narcoleptic patients (Mignot et al., 2001, *Am. J. Hum. Genet.* 68: 686-
25 699; Minot & Thorsby, 2001, *New England J. Med.* 344: 692) or, in rare cases, to mutations in the orexin-2 gene (Peyron et al., 2000, *Nature Med.* 6: 991-997). Disorders of the sleep-wake cycle are therefore likely targets for orexin-2 receptor modulator activity. Examples of sleep-wake disorders that may be treated by agonists or other modulators that up-regulate orexin-2 receptor-mediated
30 disorders such as depression. Examples of disorders that may be treated by antagonists or other modulators that down-regulate orexin-2 receptor-mediated processes include insomnia, restless leg

syndrome, jet lag (wakefulness) and sleep disorders secondary to neurological disorders such as mania, schizophrenia, pain syndromes and the like.

Evidence has accumulated to demonstrate a clear involvement of orexin signaling in reward pathways associated with drug dependence (Mahler et al., 2012, *Progress in Brain Research*, 198, 79-121). Orexinergic neurons send projections to the ventral tegmental area and other brain regions involved in reward processing. Orexin ligands mediate reward behavior, and antagonizing these effects with a selective orexin-1 receptor antagonist in various preclinical model of addiction has suggested that these actions are mediated through orexin-1 receptor. Specifically, a selective orexin-1 antagonist attenuates morphine conditioned place preference and reinstatement (Harris et al., 2005, *Nature*, 437, 556-559; Narita et al., 2006, *J Neurosci.*, 26, 398-405; Harris et al., 2007, *Behav Brain Res*, 183, 43-51), stress-induced cocaine reinstatement, cocaine-induced behavioral and synaptic plasticity (Borgland et al., 2006, *Neuron*, 49, 589-601), and intake and cue and stress-induced reinstatement of ethanol (Lawrence et al., 2006, *Br J Pharmacol*, 148, 752-759), in addition to attenuating precipitated morphine withdrawal (Sharf et al., 2008, *Biol Psychiatry*, 64, 175-183) and nicotine self-administration (Hollander et al., 2008, *Proc Natl Acad Sci U S A.*, 105, 19480-19485). Another recent study has also suggested a role for OX2R (Shoblock et al., 2011, *Psychopharmacology*, 215, 191-203).

Orexin's role in more complex emotional behavior is also emerging (Johnson et al., 2012, *Progress in Brain Research*, 198, 133-161). Changes in orexin levels in patients with panic and posttraumatic stress disorders have been noted as have changes in the prevalence of anxiety behaviors in narcoleptic patients (Johnson et al., 2010, *Nature Medicine*, 16, 111-115; Fortuyn et al., 2010, *General Hospital Psychiatry*, 32, 49-56; Strawn et al., 2010, *Psychoneuroendocrinology*, 35, 1001-1007). Lactate infusion or acute hypercapnia, which causes panic in humans, and are used as an animal model of panic, activates orexin neurons in the perifornical hypothalamus. This activation correlates with anxiety in the social interaction test or open field test. Blocking orexin signaling with either siRNA or selective orexin-1 receptor antagonists attenuates panic-like responses to lactate (Johnson et al., 2010, *Nature Medicine*, 16, 111-115; Johnson et al., 2012, *Neuropsychopharmacology*, 37, 1911, 1922).

Cerebral spinal fluid (CSF) levels of orexin are lower in depressed or suicidal patients, and the level of orexin inversely correlates with illness severity (Brundin et al., 2007, *European Neuropsychopharmacology*, 17, 573-579; Salomon et al., 2003, *Biol Psychiatry*, 54, 96-104). A positive correlation between orexin-1 receptor mRNA in the amygdala and depressive behavior in

the forced swim test in mice has been reported (Arendt, 2013, *Behavioral Neuroscience*, 127, 86-94).

The orexin system also interacts with brain dopamine systems. Intracerebroventricular injections of orexin in mice increase locomotor activity, grooming and stereotypy; these behavioral effects are reversed by administration of D2 dopamine receptor antagonists (Nakamura et al., 2000, *Brain Res.* 873: 181-187). Therefore, orexin receptor modulators may be useful to treat various neurological disorders; e.g., agonists or up-regulators to treat catatonia, antagonists or down-regulators to treat Parkinson's disease, Tourette's syndrome, anxiety, delirium and dementias.

Orexins and their receptors have been found in both the myenteric and submucosal plexus of the enteric nervous system, where orexins have been shown to increase motility *in vitro* (Kirchgessner & Liu, 1999, *Neuron* 24: 941-951) and to stimulate gastric acid secretion *in vitro* (Takahashi et al., 1999, *Biochem. Biophys. Res. Comm.* 254: 623-627). Orexin effects on the gut may be driven by a projection via the vagus nerve (van den Pol, 1999, *supra*), as vagotomy or atropine prevent the effect of an intracerebroventricular injection of orexin on gastric acid secretion (Takahashi et al., 1999, *supra*). Orexin receptor antagonists or other down-regulators of orexin receptor-mediated systems are therefore potential treatments for ulcers, irritable bowel syndrome, diarrhea and gastroesophageal reflux.

Body weight may also be affected by orexin-mediated regulation of appetite and metabolism. Some effects of orexin on metabolism and appetite may be mediated in the gut, where, as mentioned, orexins alter gastric motility and gastric acid secretion. Orexin antagonists therefore are likely to be useful in treatment of overweight or obesity and conditions related to overweight or obesity, such as insulin resistance/type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins and osteoarthritis. Conversely, orexin agonists are likely to be useful in treatment of underweight and related conditions such as hypotension, bradycardia, amenorrhea and related infertility, and eating disorders such as anorexia and bulimia.


Intracerebroventricularly administered orexins have been shown to increase mean arterial pressure and heart rate in freely moving (awake) animals (Samson et al., 1999, *Brain Res.* 831: 248-253; Shirasaka et al., 1999, *Am. J. Physiol.* 277: R1780-R1785) and in urethane-anesthetized animals (Chen et al., 2000, *Am. J. Physiol.* 278: R692-R697), with similar results. Orexin receptor agonists may therefore be candidates for treatment of hypotension, bradycardia and heart failure

related thereto, while orexin receptor antagonists may be useful for treatment of hypertension, tachycardia and other arrhythmias, angina pectoris and acute heart failure.

From the foregoing discussion, it can be seen that the identification of orexin receptor modulators, will be of great advantage in the development of therapeutic agents for the treatment of a wide variety of disorders that are mediated through these receptor systems.

SUMMARY

The present invention is directed to compounds of Formula I:



wherein X is N or CR₁; Y is N or CR₂; R₁ is H, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl; R₂ is H, alkyl, alkoxy, or halo; Z is NH, N-CH₃, N-CH₂CH₃, N-CH₂-cyclopropyl, N-C(=O)CH₃, N-CH₂CH₂OCH₃ or O; R₃ is H, alkyl, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl; R₄ is H or alkyl; or R₃ and R₄, together with the atoms to which they are attached, form a 6- membered aryl ring or a 5- membered or 6-membered heteroaryl ring; R₅ is pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl, wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl is optionally substituted with up to two groups selected from halo, alkoxy, hydroxymethyl and alkyl; and n is 1 or 2. Enantiomers and diastereomers of the compounds of Formula I are also described, as well as the pharmaceutically acceptable salts.

Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising therapeutically effective amounts of compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

BRIEF DESCRIPTION OF DRAWINGS

Figure 1 depicts an Oak Ridge Thermal Ellipsoid Plot Program (ORTEP), shown at 40% probability level, of one embodiment of the invention, Example 13.

5 **Figure 2** depicts an ORTEP, shown at 40% probability level, of one embodiment of the invention, Example 14.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The invention may be more fully appreciated by reference to the following description, including the following glossary of terms and the concluding examples.

10 The term "alkyl" refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain. In some embodiments, an alkyl group is a C₁-C₆ alkyl group. In some embodiments, an alkyl group is a C₁-C₄ alkyl group. Examples of alkyl groups include methyl (Me) ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples. Alkyl groups
15 of the invention can be substituted with, for example, halogen atoms. One exemplary substituent is fluoro. Preferred substituted alkyl groups of the invention include trihalogenated alkyl groups such as trifluoromethyl groups.

Alkyl groups of the invention can also refer to "cycloalkyl" moieties. Cycloalkyl refers to monocyclic, non-aromatic hydrocarbon groups having from 3 to 7 carbon atoms. Examples of
20 cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-methylcyclopropyl, 2-methylcyclopentyl, and the like.

The term "alkoxy" includes a straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule. In some embodiments, an alkoxy group is a C₁-C₆ alkoxy group. In some embodiments, an alkoxy group is a C₁-C₄ alkoxy group. Alkoxy includes
25 methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and so on.

The term "aryl ring" represents a mono- or bi-cyclic aromatic, hydrocarbon ring structure. Aryl rings can have 6 or 10 carbon atoms in the ring.


The term "halogen" represents chlorine, fluorine, bromine, or iodine. The term "halo" represents chloro, fluoro, bromo, or iodo.

The term “heteroaryl ring” represents a mono-or bicyclic aromatic ring structure including carbon atoms as well as up to four heteroatoms selected from nitrogen, oxygen, and sulfur.

Heteroaryl rings can include a total of 5, 6, 9, or 10 ring atoms.

The term “isoxazolyl” represents the following moiety:


5 The term “isoxazolyl” represents the following moiety:



The isoxazolyl moiety can be attached through any one of the 3-, 4-, or 5-position carbon atoms.


Isoxazolyl groups of the invention can be optionally substituted with, for example, one or two alkyl groups, for example, one or two methyl groups.

10 The term “oxazolyl” represents the following moiety:




The oxazolyl moiety can be attached through any one of the carbon atoms.

The term “oxadiazolyl” represents a 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, or 1,3,4-oxadiazole moiety:




The oxadiazolyl moieties can be attached through any one of the carbon or nitrogen atoms. Within the scope of the invention, “oxadiazolyl” groups can be substituted with an alkyl or halo group, preferably a methyl group.

The term “pyridyl” represents the following moiety:




The pyridyl moiety can be attached through any one of the 2-, 3-, 4-, 5-, or 6-position carbon atoms.

The term “pyrimidinyl” represents the following moiety:




The pyrimidinyl moiety can be attached through any one of the 2-, 4-, 5-, or 6-position carbon atoms. Within the scope of the invention, “pyrimidinyl” groups of the invention can be substituted with halogen, for example fluoro, or alkyl, for example methyl.

- 5 The term “pyrazinyl” represents the following moiety:




The pyrazinyl moiety can be attached through any one of the 2-, 3-, 5-, or 6-position carbon atoms.

The term “pyridazinyl” represents the following moiety:




- 10 The pyridazinyl moiety can be attached through any one of the 3-, 4-, 5-, or 6-position carbon atoms.

The term “pyrazolyl” represents the following moiety:




- 15 The pyrazolyl moiety can be attached through any one of the 1-, 2-, 3-, 4-, or 5-position carbon atoms. Pyrazolyl groups of the invention can be optionally substituted with, for example, one or two alkyl groups, for example, one or two methyl groups.

The term “triazolyl” represents a 1,2,3-triazole or a 1,2,4-triazole moiety:



The triazolyl moieties can be attached through any one of their atoms.

The term “imidazolyl” represents the following moiety:



The imidazolyl moiety can be attached through any one of the 2-, 4-, or 5-position carbon atoms, or via the N-1 nitrogen atom. Imidazolyl groups of the invention can be optionally substituted with,

5 for example, one or two alkyl groups, for example, one or two methyl groups.


The term “thiazolyl” represents the following moiety:



The thiazolyl moiety can be attached through any one of the carbon atoms. Thiazolyl groups of the invention can be optionally substituted with, for example, one or two alkyl groups, for example, one or two methyl groups.

10


The term “naphthyridinyl” represents the following moiety:



The naphthyridinyl moiety can be attached through any one of the carbon atoms. Naphthyridinyl groups of the invention can be optionally substituted with, for example, one or two alkyl groups, for example, one or two methyl groups, or halo groups.

15

The term “imidazothiazolyl” represents the following moiety:



The imidazothiazolyl moiety can be attached through any one of the carbon atoms. imidazothiazolyl groups of the invention can be optionally substituted with, for example, one or two alkyl groups, for example, one or two methyl groups.

20

“Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.

“Pharmaceutically acceptable salt” refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.

“Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered. A “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of a agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

“Subject” includes humans. The terms “human,” “patient,” and “subject” are used interchangeably herein.

“Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.

In treatment methods according to the invention, a therapeutically effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition. A "therapeutically effective amount" means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the compounds of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. An example of a dose is in the range of from about 0.001 to about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.

“Compounds of the present invention,” and equivalent expressions, are meant to embrace compounds of the Formula (I) as described herein, which expression includes the pharmaceutically acceptable salts, and the solvates, e.g., hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits.

As used herein, the term “isotopic variant” refers to a compound that contains unnatural proportions of isotopes at one or more of the atoms that constitute such compound. For example, an “isotopic variant” of a compound can be radiolabeled, that is, contain one or more non-radioactive or radioactive isotopes, such as for example, deuterium (^2H or D), carbon-13 (^{13}C), nitrogen-15

(^{15}N), or the like. It will be understood that, in a compound where such isotopic substitution is made, the following atoms, where present, may vary, so that for example, any hydrogen may be $^2\text{H/D}$, any carbon may be ^{13}C , or any nitrogen may be ^{15}N , and that the presence and placement of such atoms may be determined within the skill of the art. Likewise, the invention may include the preparation of isotopic variants with radioisotopes, in the instance for example, where the resulting compounds may be used for drug and/or substrate tissue distribution studies. Radiolabeled compounds of the invention can be used in diagnostic methods such as Single-photon emission computed tomography (SPECT). The radioactive isotopes tritium, *i.e.* ^3H , and carbon-14, *i.e.* ^{14}C , are particularly useful for their ease of incorporation and ready means of detection. Further, compounds may be prepared that are substituted with positron emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O and ^{13}N , and would be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.

All isotopic variants of the compounds of the invention, radioactive or not, are intended to be encompassed within the scope of the invention. In one aspect, provided herein are deuterated analogs of compounds of Formula I as described in the Examples section. In one embodiment, deuterated analogs of compounds of Formula I comprise deuterium atoms attached to one or more positions on the 2-azabicyclic ring, such as bridgehead carbons, or non-bridgehead carbons of the 2-azabicyclic ring, and preferably comprise one or more deuterium atoms attached to non-bridgehead carbons of the 2-azabicyclic ring. Also contemplated within the scope of embodiments described herein are compounds in which a single proton in compounds of Formula I is replaced with a deuterium, or 2 protons in compounds of Formula I are replaced with deuterium, or more than 2 protons in compounds of Formula I are replaced with deuterium. Deuteration of a compound of Formula I may also be effected on one or more substituents (such as e.g., ring A, R^1 , R^2 , or R^5) present on the 2-azabicyclic ring.

It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers." Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers."

Stereoisomers that are not mirror images of one another are termed "diastereomers" and those that are non-superimposable mirror images of each other are termed "enantiomers." When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its

asymmetric center and is described by the R-and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (*i.e.*, as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture.”

“Tautomers” refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of π electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro-forms of phenyl nitromethane, that are likewise formed by treatment with acid or base.


Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.

Compounds of the invention may also exist as “rotamers,” that is, conformational isomers that occur when the rotation leading to different conformations is hindered, resulting a rotational energy barrier to be overcome to convert from one conformational isomer to another.

The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (*R*)-or (*S*)-stereoisomers or as mixtures thereof.

Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.

The present invention is directed to compounds of Formula I:



wherein

X is N or CR₁

Y is N or CR₂

R₁ is H, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl;

R₂ is H, alkyl, alkoxy, or halo;

Z is NH, N-CH₃, N-CH₂CH₃, N-CH₂-cyclopropyl, N-C(=O)CH₃, N-CH₂CH₂OCH₃ or O;

R₃ is H, alkyl, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl;


R₄ is H or alkyl;

or R₃ and R₄, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring;

R₅ is phenyl, pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl, wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl is optionally substituted with up to two groups selected from halo, alkoxy, hydroxymethyl and alkyl; and

n is 1 or 2.

In one aspect, the invention is directed to compounds of Formula I:



wherein

X is N or CR₁

Y is N or CR₂

R₁ is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, or pyrazolyl;

R₂ is H, alkyl, alkoxy, or halo;

Z is NH, or O;

R₃ is H, alkyl, alkoxy, halo, or triazolyl;

R₄ is H or alkyl;

or R₃ and R₄, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring;

R₅ is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and

n is 1 or 2.

Enantiomers and diastereomers of the compounds of Formula I are also within the scope of the invention. Also within the scope of the invention are the pharmaceutically acceptable salts of the compounds of Formula I, as well as the pharmaceutically acceptable salts of the enantiomers and diastereomers of the compounds of Formula I. Also within the scope of the invention are isotopic variations of compounds of Formula I, such as, e.g., deuterated compounds of Formula I.

In preferred embodiments, Z is NH. In other embodiments, Z is O. In yet other embodiments, Z is NH, N-CH₃, N-CH₂CH₃, N-CH₂-cyclopropyl, N-C(=O)CH₃, or N-CH₂CH₂OCH₃.

In preferred embodiments, X is CR₁ and Y is CR₂.

In other embodiments, X is CR₁ and Y is N.

In yet other embodiments, X is N and Y is CR₂.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is H. In other embodiments, R₁ is alkoxy, for example, C₁₋₆alkoxy such as methoxy or ethoxy.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is halo, preferably F, Cl, or Br.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is triazolyl, optionally substituted with up to two substituents selected from halo and alkyl, with 1,2,3-triazolyl being preferred. In preferred embodiments, the 1,2,3-triazolyl is attached through the 2-position nitrogen atom. In other embodiments, the 1,2,3-triazolyl is attached through the 1-position nitrogen atom.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is pyrimidinyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom.

5 In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is oxazolyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is isoxazolyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom.

10 In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is oxadiazolyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom. The oxadiazolyl group can optionally be substituted with alkyl, for example methyl. In exemplary embodiments, the substituted oxadiazolyl moiety is 1,2,4-oxadiazolyl substituted with methyl.

15 In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is pyridyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom. The pyridyl group can optionally be substituted with alkyl, for example methyl or halo.

20 In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is imidazolyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom. The imidazolyl group can optionally be substituted with alkyl, for example methyl or halo.

25 In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is phenyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom. The phenyl group can optionally be substituted with alkyl, for example methyl or halo.

30 In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is pyrazolyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom. The pyrazolyl group can optionally be substituted with one or two C₁₋₆alkyl, for example methyl.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is thiazolyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom.

5 In those embodiments wherein X is CR₁, for example, where X is CR₁ and Y is CR₂ or X is CR₁ and Y is N, R₁ is pyridazinyl, optionally substituted with up to two substituents selected from halo and alkyl, which can be attached through any available atom.

In preferred embodiments wherein Y is CR₂, for example, X is CR₁ and Y is CR₂ or X is N and Y is CR₂, R₂ is H. In other embodiments, R₂ is alkyl, for example C₁₋₆alkyl such as methyl.

10 In those embodiments wherein Y is CR₂, for example, X is CR₁ and Y is CR₂ or X is N and Y is CR₂, R₂ is alkoxy, for example, C₁₋₆alkoxy such as methoxy or ethoxy.

In those embodiments wherein Y is CR₂, for example, X is CR₁ and Y is CR₂ or X is N and Y is CR₂, R₂ is halo, preferably one of F, Cl, or Br.

In preferred embodiments, R₃ is H. In other embodiments, R₃ is alkyl, for example, C₁₋₆alkyl such as methyl.

15 In yet other embodiments, R₃ is alkoxy, for example, C₁₋₆alkoxy such as methoxy or ethoxy.

In still other embodiments, R₃ is halo, preferably F, Cl, or Br.

In other embodiments, R₃ is triazolyl, with 1,2,3-triazolyl being preferred. In preferred embodiments, the 1,2,3-triazolyl is attached through the 2-position nitrogen atom. In other embodiments, the 1,2,3-triazolyl is attached through the 1-position nitrogen atom.

20 In preferred embodiments, R₄ is H. In other embodiments, R₃ is alkyl, for example C₁₋₆alkyl such as methyl.

In alternative embodiments, R₃ and R₄, together with the atoms to which they are attached, form a 6-membered aryl ring.

25 In other embodiments, R₃ and R₄, together with the atoms to which they are attached, form a 5-membered heteroaryl ring. Preferably, the 5-membered heteroaryl ring includes one nitrogen atom.

In other embodiments, R₃ and R₄, together with the atoms to which they are attached, form a 6-membered heteroaryl ring. Preferably, the 6-membered heteroaryl ring includes one nitrogen atom.

In some embodiments of the invention, R₅ is a phenyl ring optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, cyano, alkoxy, and halo, or from the group consisting of alkyl and halo. In some embodiments of the invention, R₅ is a heteroaryl ring. In some of such embodiments, R₅ is a heteroaryl optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, cyano, alkoxy, and halo, or from the group consisting of alkyl and halo. In preferred embodiments, R₅ is pyridyl, which can be attached through any available atom, optionally substituted with halo (preferably F, Cl, or Br) or alkyl. In some embodiments, the alkyl is substituted with one or more halogen atoms. A preferred substituted alkyl group is trihaloalkyl such as trifluoromethyl. Other substituted alkyl groups include difluoromethyl or monofluoromethyl. Preferably, R₅ is pyridyl substituted at any available position with trifluoromethyl.

In preferred embodiments, R₅ is pyrazinyl, which can be attached through any available atom, optionally substituted with halo (preferably F, Cl, or Br) or alkyl. In some embodiments, the alkyl is substituted with one or more halogen atoms. A preferred substituted alkyl group is trihaloalkyl such as trifluoromethyl. Other substituted alkyl groups include difluoromethyl or monofluoromethyl. Preferably, R₅ is pyrazinyl substituted at any available position with trifluoromethyl.

In preferred embodiments, R₅ is pyrimidinyl, which can be attached through any available atom, optionally substituted with halo (preferably F, Cl, or Br) or alkyl. In some embodiments, the alkyl is substituted with one or more halogen atoms. A preferred substituted alkyl group is trihaloalkyl such as trifluoromethyl. Other substituted alkyl groups include difluoromethyl or monofluoromethyl. Preferably, R₅ is pyrimidinyl substituted at any available position with trifluoromethyl.

In other embodiments, R₅ is benzoxazolyl which can be attached through any available atom, optionally substituted with halo (preferably F, Cl, or Br) or alkyl. In some embodiments, the alkyl is substituted with one or more halogen atoms. A preferred substituted alkyl group is trifluoromethyl. Other substituted alkyl groups include difluoromethyl or monofluoromethyl. Preferably, R₅ is benzoxazolyl, pyridazinyl, or naphthyridinyl substituted at any available position with trifluoromethyl.


In other embodiments, R₅ is pyridazinyl which can be attached through any available atom, optionally substituted with halo (preferably F, Cl, or Br) or alkyl. In some embodiments, the alkyl


is substituted with one or more halogen atoms. A preferred substituted alkyl group is trifluoromethyl. Other substituted alkyl groups include difluoromethyl or monofluoromethyl. Preferably, R₅ is benzoxazolyl, pyridazinyl, or naphthyridinyl substituted at any available position with trifluoromethyl.


5 In other embodiments, R₅ is naphthyridinyl which can be attached through any available atom, optionally substituted with halo (preferably F, Cl, or Br) or alkyl. In some embodiments, the alkyl is substituted with one or more halogen atoms. A preferred substituted alkyl group is trifluoromethyl. Other substituted alkyl groups include difluoromethyl or monofluoromethyl. Preferably, R₅ is benzoxazolyl, pyridazinyl, or naphthyridinyl substituted at any available position
10 with trifluoromethyl.


In preferred embodiments, n is 1. In other embodiments, n is 2.


In some embodiments of Formula I, R₁ is H and R₃ is as defined above for Formula I, preferably R₃ is triazolyl, oxazolyl, pyridyl or pyrimidinyl. In other embodiments of Formula I, R₃ is H and R₁ is as defined above for Formula I, preferably R₁ is triazolyl, oxazolyl, isoxazolyl,
15 oxadiazolyl, pyridyl or pyrimidinyl.




In some embodiments of Formula I, the group  is a pyridyl group, preferably X is N, R₃ is a ring selected from triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl; preferably triazolyl or pyridyl or pyrimidinyl;
20 R₄ is H or alkyl, preferably methyl; Z is NH or O, preferably O; preferably NH, R₅ is a heteroaryl, preferably pyridyl or pyrazinyl. In some of such embodiments, R₃ is a ring at the ortho position relative to the carbonyl group in Formula I, and R₄ is at the ortho, meta or para position on the relative to the carbonyl group in Formula I, preferably R₄ is at the meta position adjacent to R₃. In some other such embodiments, R₃ is a ring at the ortho position relative to the carbonyl group in
25 Formula I, and R₄ is at the ortho, meta or para position relative to the carbonyl group in Formula I, preferably R₄ is at the meta position not adjacent to R₃. R₃ and R₅ are optionally substituted as described above.




In some embodiments of Formula I, the group  is a pyridyl group, preferably Y is N, R₁ is a ring selected from triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl; preferably triazolyl or pyridyl or pyrimidinyl; R₄ is H or alkyl, preferably methyl; Z is NH or O, preferably O; preferably NH, R₅ is a heteroaryl, preferably pyridyl or pyrazinyl. In some of such embodiments, R₁ is a ring at the ortho position relative to the carbonyl group in Formula I, and R₄ is at the ortho, meta or para position on the relative to the carbonyl group in Formula I, preferably R₄ is at the meta position adjacent to R₁. In some other such embodiments, R₁ is a ring at the ortho position relative to the carbonyl group in Formula I, and R₄ is at the ortho, meta or para position relative to the carbonyl group in Formula I, preferably R₄ is at the meta position not adjacent to R₁. R₁ and R₅ are optionally substituted as described above.



In some embodiments of Formula I, the group  is a phenyl group, R₃ is a ring selected from triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl; preferably triazolyl or pyridyl or pyrimidinyl at the ortho position; R₄ is H or alkyl, preferably methyl; Z is NH or O, preferably O; preferably NH, R₅ is a heteroaryl, preferably pyridyl or pyrazinyl. In some of such embodiments, R₃ is a ring at the ortho position relative to the carbonyl group in Formula I, and R₄ is at the ortho, meta or para position on the relative to the carbonyl group in Formula I, preferably R₄ is at the meta position adjacent to R₃. In some other such embodiments, R₃ is a ring at the ortho position relative to the carbonyl group in Formula I, and R₄ is at the ortho, meta or para position relative to the carbonyl group in Formula I, preferably R₄ is at the meta position not adjacent to R₃. R₃ and R₅ are optionally substituted as described above.

Also provided herein is a compound of Formula IA:



wherein

ring A is a heteroaryl ring selected from furanyl, thiazolyl, imidazothiazolyl, and pyrazinyl;

R₁ is H, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl,

5 oxadiazolyl, pyridyl, phenyl, or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl;

R₂ is H, alkyl, alkoxy, or halo;

Z is NH, N-CH₃, N-CH₂CH₃, N-CH₂-cyclopropyl, N-C(=O)CH₃, N-CH₂CH₂OCH₃ or O;

10 R₃ is H, alkyl, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl, or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl;

15 R₄ is H or alkyl;

 or R₃ and R₄, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring;

R₅ is pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl, wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl is
20 optionally substituted with up to two substituents selected from halo, alkoxy, hydroxymethyl and alkyl; and

n is 1 or 2.

Enantiomers and diastereomers of the compounds of Formula IA are also within the scope of the invention. Also within the scope of the invention are the pharmaceutically acceptable salts of
25 the compounds of Formula IA, as well as the pharmaceutically acceptable salts of the enantiomers and diastereomers of the compounds of Formula IA. Also within the scope of the invention are isotopic variations of compounds of Formula IA, such as, e.g., deuterated compounds of Formula IA.

In some embodiments, ring A is a furanyl ring. In some embodiments, ring A is a thiazolyl ring. In some embodiments, ring A is a imidazothiazolyl ring. In other embodiments, ring A is a pyrazinyl ring.

5 All of the embodiments described for Formula I above, with respect to the variables R₁, R₂, Z, R₃, R₄, R₅ and n, also apply for Formula IA, and are expressly contemplated herein.

The invention relates to methods of using the compounds described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated by orexin receptor activity. These methods are accomplished by administering to the subject a compound of the
10 invention. In some embodiments, the compounds described herein are selective for orexin-1 receptor activity. In some embodiments, the compounds described herein are selective for orexin-1 receptor activity over orexin-2 receptor activity.

Diseases, disorders, and conditions mediated by orexin receptor activity include disorders of the sleep-wake cycle, insomnia, restless legs syndrome, jet-lag, disturbed sleep, sleep disorders
15 secondary to neurological disorders, mania, depression, manic depression, schizophrenia, pain syndromes, fibromyalgia, neuropathic pain, catatonia, Parkinson's disease, Tourette's syndrome, anxiety, delirium, dementia, overweight, obesity, or conditions related to overweight or obesity, insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins, osteoarthritis, hypertension,
20 tachycardia, arrhythmias, angina pectoris, acute heart failure, ulcers, irritable bowel syndrome, diarrhea gastroesophageal reflux, mood disorders, post-traumatic stress disorder, panic disorders, attention deficit disorders, cognitive deficiencies, or substance abuse.

Compounds of the invention are particularly suited for the treatment of mood disorders, post-traumatic stress disorder, panic disorders, attention deficit disorders, cognitive deficiencies, or
25 substance abuse.

In one aspect, compounds of the invention are particularly suited for the treatment of mood disorders. Non-limiting examples of mood disorders include anxiety-related mood disorders, depression, panic-related mood disorders, stress related mood disorders and the like. In another aspect, compounds of the invention are suitable for the treatment of post-traumatic stress disorder,
30 panic disorders, attention deficit disorders, cognitive deficiencies, or substance abuse (e.g., morphine abuse, cocaine abuse, alcohol abuse and the like). It will be understood that certain

disorders such as, for example, depression and/or schizophrenia and/or substance abuse and/or cognitive impairments also have elements of anxiety and/or panic and/or stress associated with them and the treatment of such conditions and/or combinations of conditions are also contemplated within the scope of embodiments presented herein. In some embodiments, advantageously, compounds of the invention treat a mood disorder (e.g., anxiety) with reduced concomitant sedation and/or with reduced effect on sleep (e.g. attenuated arousal effects). In one embodiment, compounds of the invention are particularly suited for the treatment of anxious depression. In another embodiment, compounds of the invention are particularly suited for the treatment of panic, schizophrenia, and substance abuse.

Sleep disorders include, but are not limited to, sleep-wake transition disorders, insomnia, restless legs syndrome, jet-lag, disturbed sleep, and sleep disorders secondary to neurological disorders (e.g., manias, depressions, manic depression, schizophrenia, and pain syndromes (e.g., fibromyalgia, neuropathic).

Metabolic disorders include, but are not limited to, overweight or obesity and conditions related to overweight or obesity, such as insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins and osteoarthritis.

Neurological disorders include, but are not limited to, Parkinson's disease, Alzheimer's disease, Tourette's Syndrome, catatonia, anxiety, delirium and dementias.

In treatment methods according to the invention, a therapeutically effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition. A "therapeutically effective amount" means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the compounds of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. An example of a dose is in the range of from about 0.001 to

about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.

5 Once improvement of the patient's disease, disorder, or condition has occurred, the dose may be adjusted for preventative or maintenance treatment. For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Patients may, however, require
10 intermittent treatment on a long-term basis upon any recurrence of symptoms.

 In addition, the compounds of the invention may be used in combination with additional active ingredients in the treatment of the above conditions. The additional active ingredients may be coadministered separately with a compound of the invention or included with such an agent in a pharmaceutical composition according to the invention. In an exemplary embodiment, additional
15 active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by orexin activity, such as another orexin modulator or a compound active against another target associated with the particular condition, disorder, or disease. The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an active agent according to the invention), decrease one
20 or more side effects, or decrease the required dose of the active agent according to the invention.

 The compounds of the invention are used, alone or in combination with one or more additional active ingredients, to formulate pharmaceutical compositions of the invention. A pharmaceutical composition of the invention comprises: (a) an effective amount of at least one compound in accordance with the invention; and (b) a pharmaceutically acceptable excipient.

25 Delivery forms of the pharmaceutical compositions containing one or more dosage units of the active agents may be prepared using suitable pharmaceutical excipients and compounding techniques known or that become available to those skilled in the art. The compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.

The preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories. Preferably, the compositions are formulated for intravenous infusion, topical administration, or oral administration.

For oral administration, the compounds of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. To prepare the oral compositions, the compounds may be formulated to yield a dosage of, e.g., from about 0.05 to about 100 mg/kg daily, or from about 0.05 to about 35 mg/kg daily, or from about 0.1 to about 10 mg/kg daily. For example, a total daily dosage of about 5 mg to 5 g daily may be accomplished by dosing once, twice, three, or four times per day.

Oral tablets may include a compound according to the invention mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.

Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinylpyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.

Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, compounds of the invention may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the compound of the invention with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.

Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil),

propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.


The active agents of this invention may also be administered by non-oral routes. For example, the compositions may be formulated for rectal administration as a suppository. For parenteral use, including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the compounds of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms will be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses may range from about 1 to 1000 .mu.g/kg/minute of compound, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.


For topical administration, the compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle. Another mode of administering the compounds of the invention may utilize a patch formulation to affect transdermal delivery.

Compounds of the invention may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.

Exemplary compounds useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. Unless otherwise specified, the variables are as defined above in reference to Formula (I). Reactions may be performed between the melting point and the reflux temperature of the solvent, and preferably between 0 °C and the reflux temperature of the solvent. Reactions may be heated employing conventional heating or microwave heating. Reactions


may also be conducted in sealed pressure vessels above the normal reflux temperature of the solvent.



The synthesis of exemplary intermediates having the structure  is described in Schemes 1-6 below and in the Examples section below (Intermediates A-1 to A-59).


5

Scheme 1




Intermediate compounds of formula (IIIa) and (IIIb) can be prepared as outlined in Scheme 1 from commercially available or synthetically accessible compounds of formula (A) where R_{3A} , R_{4A} are -H, halo, -C₁₋₄alkyl, -C₁₋₄alkoxy or R_{3A} and R_{4A} together with the atoms to which they are attached form a 6-membered aryl or 6 membered heteroaryl ring and X and Y are as defined in formula (I) as above. Compounds of formula (IIa) and (IIb), are obtained by reacting a compound of formula (A), with commercially available 1,2,3-triazole, in the presence K_2CO_3 in DMF or dioxane, at temperatures ranging from about 60 °C to about 100 °C. Compounds of formula (IIIa) and (IIIb) are obtained by reacting compounds of formula (II) in the presence of a base such as NaOH in a solvent such as EtOH at temperatures ranging from about 80 °C to about 100 °C. One skilled in the art will recognize that 1,2,3-triazole can exist in two tautomeric forms defined as 2H-[1,2,3]triazole and 1H-[1,2,3]triazole thus accounting for the formation of (IIIa) and (IIIb).

Scheme 2




Intermediate compounds of formula (III) can be prepared as outlined in Scheme 2 from commercially available or synthetically accessible compounds of formula (IV_{a-c}). Compounds of formula (Va) and (Vb) are obtained by reacting compounds of formula (IVa), (IVb) and (IVc) where Hal is -Br, or -I; W is CO_2H , CO_2Alkyl , or CN and R_{3A} and R_{4A} are -H, halo, -C₁₋₄alkyl, -C₁₋₄alkoxy or R_{3A} and R_{4A} together with the atoms to which they are attached form a 6-membered aryl or 6 membered heteroaryl ring, and X and Y are as defined in Formula I above, with commercially available 1,2,3-triazole, in the presence of, for example, copper(I)iodide, Cs_2CO_3 and trans-N,N'-dimethyl-1,2-cyclohexanediamine in, for example, DMF or dioxane, at temperatures ranging from about 60 °C to about 120 °C. Compounds of formula (IVc) can be converted to the corresponding esters (Vb) by treatment with, for example, alkyl iodide in the presence of a base such as K_2CO_3 in a solvent such as DMF. Compounds of formula (III) are obtained by reacting a compound of formula (Va) and (Vb) in the presence of a base such as NaOH in a solvent such as EtOH at temperatures ranging from about 80 °C to about 100 °C. One skilled in the art will recognize that 1,2,3-triazole can exist in two tautomeric forms defined as 2H-[1,2,3]triazole and 1H-[1,2,3]triazole thus compounds of formula (Va), (Vb), and (III) can also exist as the N1 linked variant (structure not shown). It will be understood that the heterocycle in (Va) and (Vb) is not limited to triazole and may be any other suitable heterocycle.

Scheme 3



Intermediate compounds of formula (IX) can be prepared as outlined in Scheme 3 from commercially available or synthetically accessible compounds of formula (VI) where R_{3A} , R_{4A} are - H, halo, $-C_{1-4}$ alkyl, $-C_{1-4}$ alkoxy or R_{3A} and R_{4A} together with the atoms to which they are attached form a 6- membered aryl or 6 membered heteroaryl ring, and X and Y are as defined in formula (I) as above, G is $SnBu_3$, or 4,4,5,5 tetramethyl-1,dioxaboralane, and HAL is Cl, or Br, preferably Br. Compounds of formula (VIII) are obtained by reacting a compound of formula (VI) with commercially available (VII) in the presence of a catalyst such as 1,1'-Bis(di-tert-butylphosphino)ferrocene palladium dichloride and a base such as Na_2CO_3 in a solvent such as 2-MeTHF or THF at temperatures ranging from about 60 °C to about 90 °C. Compounds of formula (IX) are obtained by reacting a compound of formula (VIII) in the presence of a base such as NaOH in a solvent such as MeOH at temperatures ranging from about 80 °C to about 100°C or acids such as H_2SO_4 in solvents such as H_2O at temperatures ranging from about 80 °C to about 100 °C. It will be understood that the heterocycle in (VII) is not limited to pyrimidine and may be any other suitable heterocycle.

Scheme 4




Intermediate compound of formula (XIV) can be prepared as outlined in Scheme 4 from commercially available compound (X). Compound (XI) is obtained by reacting compound (X) with commercially available acrolein in a solvent such as 1,4 dioxane at temperatures of about 200 °C in, for example, a microwave reactor. Compound (XII) can be prepared from compound (XI) by treatment with an acid such as HBr in a solvent such as toluene at a temperature of about 90 °C. Compound (XIII) can be obtained by treatment of compound (XII) with, for example,

commercially available iodoethane and a base such as K_2CO_3 in a solvent such as DMF at temperatures ranging from about 45 °C to about 65 °C. Compound (XIV) is obtained by treating compound (XIII) with a base such as NaOH in a solvent such as MeOH at temperatures ranging from about 80 °C to about 100 °C.


5

Scheme 5



Intermediate compounds of formula (XVI) are prepared as outlined in Scheme 5 from commercially available or synthetically accessible compounds of formula (XIV) where R_{2B} is -H, -
 10 C_{1-4} alkyl, or $-C_{1-4}$ alkoxy, or R_{2B} is -H, halo, $-C_{1-4}$ alkyl, or $-C_{1-4}$ alkoxy, and HAL is halo, preferably Cl, or Br. Compounds of formula (XV) are obtained by reacting a compound of formula (XIV) with commercially available (VII) in the presence of a catalyst such as $Pd(dppf)Cl_2$ and a base such as Na_2CO_3 in a solvent such as 2-MeTHF at temperatures ranging from about 75 °C to about 150 °C. Compounds of formula (XVI) are obtained by reacting a compound of formula (XV) in the
 15 presence of a base such as NaOH in a solvent such as MeOH at temperatures ranging from about 80 °C to about 100 °C. It will be understood that the heterocycle in (VII) is not limited to pyrimidine and may be any other suitable heterocycle.

Scheme 6




Intermediate compounds of formula (XXI) can be prepared as outlined in Scheme 6 from commercially available or synthetically accessible compounds of formula (XVII) where Hal is Br or I; and where R_{3A} and R_{4A} are -H, halo, $-C_{1-4}alkyl$, $-C_{1-4}alkoxy$, or R_{3A} and R_{4A} together with the atoms to which they are attached form a 6-membered aryl or 6 membered heteroaryl ring.

Compounds of formula (XVIII_a) can be converted to the corresponding ester (XVIII_b) by treatment with, for example, thionyl chloride in a solvent such as MeOH. Compounds of the formula (XX) are obtained by reacting compounds of formula (XVIII_b) with commercially available compounds

of the formula XIX where L is a heterocycle such as pyrazole, pyridyl, or oxazole or any other heterocycle described herein; G is $SnBu_3$ or 4,4,5,5 tetramethyl-1,3-dioxaboralane and R_{1A} and R_{2A} are -H, $-C_{1-4}alkyl$, or $-C_{1-4}alkoxy$, or R_{1A} and R_{2A} are -H, halo, $-C_{1-4}alkyl$, or $-C_{1-4}alkoxy$; in the presence of a catalyst such as $Pd(Ph_3P)_4$ and a base such as Na_2CO_3 in a mixture of solvents such as DME and H_2O at temperatures ranging from about 100 °C to about 150 °C. Compounds of formula

(XXI) are obtained by reacting a compound of formula (XX) in the presence of a base such as NaOH in a solvent such as MeOH at temperatures ranging from about 80 °C to about 100 °C.

Scheme 7



According to Scheme 7, compound (XXV), where n is 1 or 2, is obtained by reaction of (XXII), (XXIII) where PG of H₂N-PG is H, benzyl (Bn), methyl benzyl, and the like, and (XXIV) in an aqueous medium where H⁺ is HCl, AcOH and the like as described in C. Chiu *et al. Synthetic Communications* **1996**, 26, 577-584 and S. Larsen *et al. J. Am. Chem. Soc.* **1985**, 107, 1768-1769.

In a particularly preferred embodiment, a compound of formula (XXV), where n is 1, is obtained by reacting, for example, commercially available cyclopentadiene, (+)-α-methyl-benzylamine and formaldehyde in an aqueous medium with AcOH. Enantio-enriched compounds of formula (XXVa) and (XXVb) are obtained by chiral resolution of (XXV) using a chiral acid, such as commercially available L or D-dibenzoyl tartaric acid and the like, followed by formation of the free base using a base such as aqueous NaOH and the like, as described in C. Chiu *et al. Synthetic Communications* **1996**, 26, 577-584. In a preferred embodiment, a compound of formula (XXV) is treated with, for example, D-dibenzoyl tartaric acid followed by a base such as aqueous NaOH to afford an enantio-enriched compound of formula (XXVa). Compound (XXVII) is obtained from (XXVa) through a hydroboration/oxidation sequence of the olefin to install the hydroxyl group; followed by, for example, an optional one-pot palladium-mediated hydrogenolysis and PG “swap” (*i.e.* methyl benzyl to Boc); and subsequent oxidation of the hydroxyl group using an oxidant such as IBX, SO₃-pyridine, Swern conditions [(COCl)₂, DMSO, Et₃N], and the like, in a solvent such as EtOAc, DMSO, DCM, and the like, at temperatures ranging from about -78 °C to room temperature (about 23 °C). In a preferred embodiment, a compound of formula (XXVa) where PG is methyl benzyl, is treated with, for example, BH₃ followed by H₂O₂ and NaOH to install the hydroxyl group, and, for

example, a one-pot palladium mediated hydrogenolysis using hydrogen gas (1 atm), Pd/C, and Boc₂O, in EtOH at room temperature (23 °C) exchanges the methyl benzyl for a Boc group. The Boc-protected intermediate is oxidized with, for example, IBX in refluxing such as, for example, EtOAc to afford a compound of formula (XXVII). Compound (XXVb) could also be subjected to
5 the same set of transformations as compound (XXVa) to obtain the corresponding opposite enantiomer (structure not shown).

A compound of formula (XXVIII) where Z is OH, is obtained from reduction ([R]) of the ketone in a compound of formula (XXVII), with a reducing agent such as L-Selectride, NaBH₄ and the like, in a solvent such as THF, MeOH and the like at temperatures ranging from about -78 °C to
10 room temperature (about 23 °C). Alternatively, the racemic form of a compound of formula (XXVIII) can be obtained from reduction of commercially available (R/S)-tert-butyl 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate as described in R. Nencka *et al. Tetrahedron* **2012**, 68, 1286-1298.


An alternative route to a compound of formula (XXVII) can be prepared from commercially
15 available (1S,4R)-2-azabicyclo[2.2.1]hept-5-en-3-one (XXVI). A compound of formula (XXV) is obtained from treatment of compound (XXVI) with a reducing agent such as LiAlH₄ and the like, followed by protection of the free amine with a suitable protecting group. A compound of formula (XXVII) is obtained from a compound of formula (XXV) by a hydroboration/oxidation sequence of the olefin to install the hydroxyl group; followed by oxidation of the hydroxyl group using an
20 oxidant such as IBX, SO₃-pyridine, Swern conditions [(COCl)₂, DMSO, Et₃N], and the like, in a solvent such as EtOAc, DMSO, DCM, and the like at temperatures ranging from about -78 °C to room temperature (about 23 °C); and, optionally, a one-pot palladium mediated hydrogenolysis and PG “swap” (*i.e.* Bn to Boc). In a preferred embodiment, a compound of formula (XXV) where PG is Bn is subjected to the conditions described in F. Carroll *et al. J. of Med. Chem.* **1992**, 35, 2184-
25 2191, followed by PG swap (Bn to Boc) to obtain a compound of formula (XXVII) where PG is Boc.

A compound of formula (XXVIII) where Z is NH₂, is obtained by reacting a compound of formula (XXVII) with an amine NH₂-Q, where Q is OH or Bn, followed by reduction of the corresponding oxime or imine with a suitable reducing agent such as NaBH₄ (with or without a
30 metal salt additive such as NiCl₂ and the like), Raney Ni (H₂ atm), Zn(BH₄)₂, and the like in a solvent such as MeOH and the like. In a particular embodiment, the oxime intermediate from reaction of a compound of formula (XXVII) with an amine NH₂-Q, where Q is OH, is obtained by

reacting a compound of formula (XXVII) with commercially available hydroxylamine hydrochloride and triethylamine in EtOH at temperatures ranging from room temperature (about 23 °C) to reflux. The oxime intermediate is reduced with NaBH₄ in combination with NiCl₂ in MeOH to give a compound of formula (XXVIII) where Z is NH₂. Alternatively, the imine intermediate from reaction of a compound of formula (XXVII) with an amine NH₂-Q, where Q is Bn, is obtained by reacting a compound of formula (XXVII) with commercially available benzylamine. *In-situ* reduction of the imine intermediate with a reducing agent such as sodium triacetoxyborohydride and the like, followed by debenzylation under, for example, palladium mediated hydrogenolysis affords a compound of formula (XXVIII) where Z is NH₂.

- 10 Referring to Scheme 7, the synthesis of compounds wherein n is 2 is described in the Examples section, for instance in Intermediates C-1 – C-11, and in Examples 248 - 283.

Scheme 8



- According to Scheme 8, a compound of formula (XXIX), where Z is O or NH, is obtained from a compound of formula (XXVIII), by a S_NAr reaction or metal mediated cross-coupling reaction with a compound R₅-U; where R₅-U is a suitable commercially available or synthetically accessible halogen-substituted heteroaryl compound, where R₅ is defined in formula (I) as above and W is F, Cl, Br, I, or OTf. A compound of formula (XXIX) where Z is O, is obtained from a compound of formula (XXVIII), where Z is OH, by S_NAr coupling with a compound R₅-W as described above, in the presence of a base, such as NaH, K₂CO₃ and the like, in a solvent such as DMF at temperatures ranging from room temperature (about 23 °C) to about 90 °C. In a preferred embodiment the base is NaH and the solvent is DMF. A compound of formula (XXIX), where Z is NH, is obtained from a compound of formula (XXVIII), where Z is NH₂, by metal mediated cross-coupling with a compound R₅-W as described above, in the presence of a palladium catalyst, a phosphine ligand such as BINAP and the like, a base such as NaOtBu and the like, in a solvent such as toluene, DME, and DMF, at temperatures ranging from room temperature (about 23 °C) to about 100 °C. In a preferred embodiment the palladium catalyst is Pd(OAc)₂, the ligand is BINAP, the

base is NaOtBu, and the solvent is toluene. Alternatively, a compound of formula (XXIX) where Z is NH, is obtained from a compound of formula (XXVIII), where Z is NH₂, by S_NAr coupling with a compound R₅-W as described above, in the presence of a base, such as NaH, K₂CO₃ in a solvent such as DMF at temperatures ranging from room temperature (about 23 °C) to about 90 °C. In a preferred embodiment the base is K₂CO₃ and the solvent is DMF. Removal of PG (where PG is Boc, Bn, methyl benzyl, and the like) in compounds of formula (XXIX) is accomplished using methods known to one skilled in the art to give compounds of formula (XXX). In a preferred embodiment, where PG is Boc in a compound of formula (XXIX) and Z is O or NH, is treated with, for example, HCl in dioxane to afford a compound of formula (XXX).

A compound of formula (XXXI) is obtained from a compound of formula (XXX), by reaction of a compound of formula (XXX) with a compound of formula (XXXII), under amide bond formation conditions. Compounds of formula (XXXII), where X, Y, R₃, and R₄ are as defined in formula (I), are commercially available, as described, or synthetically accessible appropriately substituted aryl or heteroaryl carboxylic acids or acid salts. A compound of formula (XXX), either as a free base or as an acid salt, is reacted with a compound of formula (XXXII) in the presence of a dehydrating agent such as HOBt/EDAC, CDI, HATU, HOAT, T₃P; a suitably selected base such as DIPEA, TEA; in an organic solvent or mixture thereof, such as toluene, MeCN, EtOAc, DMF, THF, DCM to afford a compound of formula (XXXI). In a particularly preferred embodiment a compound of formula (XXXI) is obtained using, for example, the dehydrating agent HATU, the base DIPEA, and the solvent DMF; or the dehydrating agent T₃P, the base Et₃N, and the solvent mixture of DCM/DMF. Alternatively, one skilled in the art can transform a compound of formula (XXXII) to the corresponding acid chloride or an activated ester before amide formation with a compound of formula (XXX).

Referring to Scheme 8, the synthesis of compounds wherein n is 2 is described in the Examples section, for instance in Intermediates C-1 – C-11, and in Examples 248-283.

In one group of embodiments, provided herein is a compound of Formula I of Examples 1-84 with structures and names as set forth in the Examples section. In another group of embodiments, provided herein is a compound of Formula I of Examples 1-4, 7-92, 94-204, 206, 208-660 with structures and names as set forth in the Examples section below. In yet another embodiment, provided herein is a compound of Formula I of Examples 85-92, 94-204, 206, 208-660 with structures and names as set forth in the Examples section below. In one group of embodiments, provided herein is a compound of Formula IA selected from Examples 5, 6, 93, 205,

and 207 having the structures and names as set forth in the Examples section below. In one group of embodiments, provided herein is a compound of Formula I or Formula IA having structures and names as set forth in Table 2 below.

5 **EXAMPLES**

Abbreviations:

Term	Acronym
Acetic Acid	HOAc
Acetonitrile	ACN
Apparent	app
Aqueous	aq
Atmosphere	atm
2-(1H-9-Azobenzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate	HATU
Benzyl	Bn
2,2'-bis(diphenylphosphino)-1,1'-binaphthalene	BINAP
[1,1'-Bis(di- <i>tert</i> -butylphosphino)ferrocene]dichloropalladium(II)	PdCl ₂ (dtbpf)
Broad	br
<i>tert</i> -Butylcarbonyl	Boc/Boc
Dichloromethane	DCM
Diisopropylethylamine	DIPEA
1,2-Dimethoxyethane	DME

Term	Acronym
<i>N,N</i> -Dimethylformamide	DMF
Dimethylsulfoxide	DMSO
Doublet	d
Electrospray ionization	ESI
Enantiomeric excess	ee
Ethanol	EtOH
Ethyl Acetate	EtOAc, or EA
Grams	g
Hertz	Hz
High-pressure liquid chromatography	HPLC
Hours	h
Liquid chromatography and mass spectrometry	LCMS
Mass spectrometry	MS
Mass to charge ratio	m/z
Methanol	MeOH
Microliter	μL
Milligrams	mg
Milliliter	mL
Millimoles	mmol

Term	Acronym
Minute	min
Molar	M
Multiplet	m
Normal	N
Nuclear magnetic resonance	NMR
Palladium on carbon	Pd/C
Palladium hydroxide on carbon	Pd(OH) ₂ /C
Parts per million	ppm
Phenyl	Ph
Propylphosphonic anhydride	T ₃ P
Retention time	R _t
Room temperature	rt
Quartet	q
Singlet	S
Supercritical Fluid Chromatography	SFC
Temperature	T
Thin layer chromatography	TLC
Times	X
Triethylamine	TEA

Term	Acronym
Trifluoroacetic acid	TFA
Triplet	t

Chemistry:

In obtaining the compounds described in the examples below and the corresponding analytical data, the following experimental and analytical protocols were followed unless otherwise indicated.

Unless otherwise stated, reaction mixtures were magnetically stirred at room temperature (rt) under a nitrogen atmosphere. Where solutions were “dried,” they were generally dried over a drying agent such as Na₂SO₄ or MgSO₄. Where mixtures, solutions, and extracts were “concentrated”, they were typically concentrated on a rotary evaporator under reduced pressure.

Reactions under microwave irradiation conditions were carried out in a Biotage Initiator or CEM Discover instrument.

Where compounds were “purified via silica gel chromatography” normal-phase flash column chromatography was performed on silica gel (SiO₂) using prepackaged cartridges, eluting with the indicated solvents.

Where compounds were purified by “Shimadzu Method X” the method employed was either:

Preparative reverse-phase high performance liquid chromatography (HPLC) was performed on a Shimadzu LC-8A Series HPLC with an Inertsil ODS-3 column (3 μm, 30 x 100mm, T = 45 °C), mobile phase of 5% ACN in H₂O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 6 min, then held at 99% ACN for 3 min, with a flow rate of 80 mL/min.

or

Preparative reverse-phase high performance liquid chromatography (HPLC) was performed on a Shimadzu LC-8A Series HPLC with an XBridge C18 OBD column (5 μm, 50 x 100mm), mobile phase of 5% ACN in H₂O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 14 min, then held at 99% ACN for 10 min, with a flow rate of 80 mL/min.

Where compounds were purified by "Agilent Prep Method X" the method employed was either:

Preparative reverse-phase high performance liquid chromatography (HPLC) was performed on a Agilent 1100 Series HPLC with an XBridge C18 OBD column (5 μ m, 30 x 100mm), mobile phase of 5% ACN in 20mM NH₄OH was held for 2 min, then a gradient of 5-99% ACN over 15 min, then held at 99% ACN for 5 min, with a flow rate of 40 mL/min.

or

Preparative reverse-phase high performance liquid chromatography (HPLC) was performed on a Agilent 1100 Series HPLC with an XBridge C18 OBD column (5 μ m, 50 x 100mm), mobile phase of 5% ACN in 20mM NH₄OH was held for 2min, then a gradient of 5-99% ACN over 15 min, then held at 99% ACN for 5 min, with a flow rate of 80 mL/min.

Where compounds were purified by "Gilson Prep Method X" the method employed was: Preparative reverse-phase high performance liquid chromatography (HPLC) was performed on a Gilson HPLC with an XBridge C18 column (5 μ m, 100 x 50mm), mobile phase of 5-99% ACN in 20 mM NH₄OH over 10 min and then hold at 99 ACN for 2 min, at a flow rate of 80 mL/min.

Mass spectra (MS) were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass corresponds to the exact mass.

Where acids are employed for amide bond coupling the free acid or acid salt may be used interchangeably.





Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers. The format of the ¹H NMR data below is: chemical shift in ppm downfield of the tetramethylsilane reference (multiplicity, coupling constant J in Hz, integration). Definitions for multiplicity are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. For compounds that are present as a mixture of rotamers the ratio is represented so that the total is 1, e.g. 0.80:0.20. Alternatively, ¹H NMR data may be reported for only the major rotamer as indicated, or the data may be reported for one or more rotamers such that the total is less than 1. It will be understood that for compounds comprising an exchangeable proton, said proton may or may not be visible on an NMR spectrum depending on the choice of solvent used for running the NMR spectrum and the concentration of the compound in the solution.

Chemical names were generated using ChemDraw Ultra 12.0 (CambridgeSoft Corp., Cambridge, MA) or ACD/Name Version 10.01 (Advanced Chemistry).







Compounds designated (R/S) are racemic compounds where the relative stereochemistry is as drawn.


- 5 Examples 63-65, 68-72, 75, 78-79, 81-82, 84, 164-165, 303-419, 421-660 are suitable for preparation using methods analogous to the methods described in the synthetic schemes and in the Examples section.

INTERMEDIATES


Intermediate	Name	Structure	Reference
A-1	2-(2H-1,2,3-triazol-2-yl)benzoic acid		Prepared according to WO 2011/050198 Intermediate 2
A-2	3-fluoro-2-(pyrimidin-2-yl)benzoic acid		Prepared according to WO 2011/050198 Intermediate 50
A-3	6-methyl-2-(2H-1,2,3-triazol-2-yl)nicotinic acid		Prepared according to WO 2011/050198 Intermediate 70
A-4	6-methyl-2-(1H-1,2,3-triazol-1-yl)nicotinic acid		Prepared according to WO 2011/050198 Intermediate 71

Intermediate	Name	Structure	Reference
A-5	4-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid		Prepared according to WO 2011/050198 Intermediate 54
A-6	2-fluoro-6-(pyrimidin-2-yl)benzoic acid		Prepared according to WO 2011/050198 Intermediate 14
A-7	5-fluoro-2-(pyrimidin-2-yl)benzoic acid.		Prepared according to WO 2011/050198 Intermediate 13
A-8	3-ethoxy-6-methylpicolinic acid		WO 2010/063663 Description 39
A-9	2-(4H-1,2,4-triazol-4-yl)benzoic acid		Commercially available, CAS 167626-65-5
A-10	5-fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid		Prepared according to WO 2011/050198 Intermediate 1
A-11	2-fluoro-6-(2H-1,2,3-triazol-2-yl)benzoic acid		Prepared according to WO 2011/050198 Intermediate 12

Intermediate	Name	Structure	Reference
A-12	4-fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid		Prepared according to WO 2011/050198 Intermediate 4
A-13	2-methoxy-6-(2H-1,2,3-triazol-2-yl)benzoic acid		Prepared analogous to Intermediate A-X using 2-bromo-6-(2H-1,2,3-triazol-2-yl)benzoic acid
A-14	5-(4-fluorophenyl)-2-methylthiazole-4-carboxylic acid		Commercially available, CAS 433283-22-8
A-15	4-methoxy-2-(pyrimidin-2-yl)benzoic acid		Prepared according to WO 2011/050198 Intermediate 88
A-16	3-fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid		Prepared according to WO 2011/050198 Intermediate 5
A-17	6-methylimidazo[2,1-b]thiazole-5-carboxylic acid		Commercially available, CAS 77628-51-4


Intermediate	Name	Structure	Reference
A-18	3-fluoro-2-methoxybenzoic acid		Commercially available, CAS 106428-05-1

Synthesis of 3-fluoro-2-(pyrimidin-2-yl)benzonitrile (Intermediate in the synthesis of intermediate A-2)



- 5 To a solution of 3-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (4.98 g, 19.1 mmol) and 2-bromopyrimidine (3.85 g, 23 mmol) in THF (96 mL) was added Na₂CO₃ (6 g, 57.4 mmol) followed by water (43 mL). The reaction mixture was degassed with N₂ for 10 minutes. PdCl₂(dtbpf) (374 mg, 0.57 mmol) was added and the reaction mixture was stirred at 80 °C for 5h.
- 10 The solution was cooled to room temperature and a mixture of EtOAc and water was added. The aqueous was extracted twice with EtOAc and the combined organic layers were dried over MgSO₄, filtered and evaporated. The title compound was precipitated by dissolving the residue in a minimum amount of EtOAc and then adding hexanes. The solid was filtered, washed with hexanes and dried to afford the title compound (2.46 g, 64%). MS (ESI) mass calcd. for C₁₁H₆FN₃, 199.1; m/z found 200.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 9.02 – 8.91 (m, 2H), 7.65 (dt, J =
- 15 7.7, 1.0 Hz, 1H), 7.60 – 7.52 (m, 1H), 7.51 – 7.43 (m, 1H), 7.41 (t, J = 4.9 Hz, 1H).

Intermediate A-19: 5-methyl-3-(2H-1,2,3-triazol-2-yl)picolinic acid.




Step A: 5-methyl-3-(2H-1,2,3-triazol-2-yl)picolinonitrile. To 3-bromo-5-methylpicolinic acid (1.5 g, 7.6 mmol) in DMF (19 mL) was added K_2CO_3 (1.2 g, 8.4 mmol) and 2H-1,2,3-triazole (440 μ L, 7.6 mmol). The mixture was heated to 100 °C for 16 h, cooled to room temperature and extracted with EtOAc (2X). The combined organics were dried (Na_2SO_4) and concentrated.

- 5 Purification via silica gel chromatography (5-60% EtOAc in hexanes) gave the title compound (490 mg, 35%) ^1H NMR (500 MHz, Chloroform- d) 8.58 – 8.53 (m, 1H), 8.29 – 8.24 (m, 1H), 7.98 (s, 2H), 2.54 (s, 3H) and 5-methyl-3-(1H-1,2,3-triazol-1-yl)picolinonitrile (387 mg, 27%).

- Step B: (sodium 5-methyl-3-(2H-1,2,3-triazol-2-yl)picolinate). To a solution of the title compound of Step A (489 mg, 2.6 mmol) in EtOH (7 mL) was added 4 N NaOH (660 μ L, 2.6 mmol). The mixture was heated at 100°C for 24 h. The reaction mixture was concentrated in vacuo to a white solid which was used without further purification in subsequent steps. MS (ESI) mass calcd. for $C_9H_8N_4O_2$, 204.1; m/z found 205.0 $[M+H]^+$.
- 10

Intermediate A-20: 6-methyl-3-(2H-1,2,3-triazol-2-yl)picolinic acid.




15

- Step A: 6-methyl-3-(2H-1,2,3-triazol-2-yl)picolinonitrile. To 3-bromo-6-methylpicolinonitrile (2.2 g, 11 mmol) in DMF (28 mL) was added K_2CO_3 (1.7 g, 12 mmol) and 2H-1,2,3-triazole (650 μ L, 11 mmol). The mixture was heated to 100 °C for 36 h, cooled to rt and extracted with EtOAc. The combined organics were dried (Na_2SO_4) and concentrated. Purification via silica gel chromatography (10-100% EtOAc in hexanes) gave the title compound (1 g, 48%).
- 20

- Step B: 6-methyl-3-(2H-1,2,3-triazol-2-yl)picolinic acid. To a solution of the title compound of Step A (730 mg, 4 mmol) in EtOH (10 mL) was added 4 N NaOH (1 mL, 4 mmol). The mixture was heated at 100°C for 24 h. The reaction mixture was concentrated in vacuo to a white solid which was used without further purification in subsequent steps. MS (ESI) mass calcd. for $C_9H_8N_4O_2$, 204.1; m/z found 205.1 $[M+H]^+$.
- 25

Intermediate A-21: 3-ethoxyisoquinoline-4-carboxylic acid.





Step A: ethyl 3-hydroxyisoquinoline-4-carboxylate. To a suspension of ethyl 3-aminoisoquinoline-4-carboxylate (583 mg, 2.70 mmol) in 6.8 mL of H₂SO₄ 5N cooled to 0 °C was added sodium nitrite (223 mg, 3.24 mmol, dissolved in 1 mL of water). The reaction mixture was stirred at 0 °C for 2.5 h and then NaOH_(aq) 1N was added until pH=7. The aqueous phase was extracted twice with DCM and the combined organic phases were dried over MgSO₄, filtered and evaporated to give the title compound of Step A which was used without further purification in the next step (583 mg, 99%). MS (ESI) mass calcd. for C₁₂H₁₁NO₃, 217.1; m/z found 218.1 [M+H]⁺.


Step B: ethyl 3-ethoxyisoquinoline-4-carboxylate. To the title compound of Step A (583 mg, 2.68 mmol) in THF (13 mL) was added triphenylphosphine (1.06 g, 4.03 mmol), ethanol (0.24 mL, 4.03 mmol) and DIAD (0.79 mL, 4.03 mmol). The reaction mixture was stirred at room temperature for 16h and then the solvent was evaporated. The crude was purified via silica gel chromatography (0-30% EtOAc in hexanes) to afford the title compound of Step B (498 mg, 76%). MS (ESI) mass calcd. for C₁₄H₁₅NO₃, 245.1; m/z found 246.1 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 8.97 (s, 1H), 7.91 – 7.82 (m, 2H), 7.65 – 7.60 (m, 1H), 7.42 – 7.36 (m, 1H), 4.59 – 4.48 (m, 4H), 1.48 – 1.39 (m, 6H).

Step C: 3-ethoxyisoquinoline-4-carboxylic acid. The title compound of Step B (492 mg, 2 mmol) dissolved in MeOH (15 mL) was added NaOH_(aq) 2M (2.5 mL). The reaction mixture was stirred at 60 °C for 16h and then NaOH_(aq) 4M (2 mL) was added and the mixture was stirred at 70 °C for 4h. MeOH was evaporated and the aqueous phase was cooled to 0 °C and acidified with the addition of HCl_(aq) 6N. The solid was filtered, washed with cold water and dried to afford the title compound (285 mg, 65%). MS (ESI) mass calcd. for C₁₂H₁₁NO₃, 217.1; m/z found 218.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 13.36 (s, 1H), 9.15 (s, 1H), 8.13 – 8.06 (m, 1H), 7.82 – 7.70 (m, 2H), 7.54 – 7.47 (m, 1H), 4.50 (q, J = 7.0 Hz, 2H), 1.35 (t, J = 7.0 Hz, 3H).

Intermediate	Name	Structure	Reference

A-22	3-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid		Prepared according to WO 2011/050198 Intermediate 82
A-23	4-fluoro-2-(pyrimidin-2-yl)benzoic acid		Prepared according to WO 2011/050198 Intermediate 87

Intermediate A-24: 2-methoxy-6-(pyrimidin-2-yl)benzoic acid




Step A: Methyl 2-methoxy-6-(pyrimidin-2-yl)benzoate. In a microwave vial was dissolved
 5 methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (CAS 1146214-77-8) (500 mg, 1.71 mmol) and 2-bromopyrimidine (344 mg, 2.05 mmol) in THF (8.5 mL). Na₂CO₃ (544 mg, 5.14 mmol) was then added followed by water (4 mL) and the reaction mixture was degassed with N₂ for 10 minutes. PdCl₂(dtbpf) (CAS 95408-45-0) (45 mg, 0.069 mmol) was then added and the reaction mixture was heated at 80 °C for 4 h. The mixture was cooled to room temperature and
 10 water and EtOAc added. The reaction mixture was extracted with EtOAc (3X). The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The crude was purified via silica gel chromatography (0-70% EtOAc in hexanes) to afford the title compound (265 mg, 63%). MS (ESI) mass calcd. for C₁₃H₁₂N₂O₃, 244.1; m/z found 245.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 8.78 (d, J = 4.9 Hz, 2H), 7.99 (dd, J = 7.9, 0.9 Hz, 1H), 7.49 (t, J = 8.1 Hz, 1H),
 15 7.19 (t, J = 4.8 Hz, 1H), 7.09 (dd, J = 8.3, 0.9 Hz, 1H), 3.90 (s, 3H), 3.89 (s, 3H).

Step B: 2-methoxy-6-(pyrimidin-2-yl)benzoic acid. To a solution of the title compound of Step A (265 mg, 1.09 mmol) in THF (4 mL) was added 2 M NaOH (2 mL). The mixture was heated at 50°C for 72 h. The reaction mixture was cooled to room temperature and concentrated in vacuo to remove THF. Then, 1 M HCl_(aq) was added and the aqueous was extracted with 10:1 DCM/2,2,2-trifluoroethanol (3X). The combined organic layers were dried over Na₂SO₄, filtered and
 20

concentrated to give intermediate A-24, which was used without further purification in subsequent steps. MS (ESI) mass calcd. for $C_{12}H_{10}N_2O_3$, 230.1; m/z found 231.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO- d_6) δ 12.63 (s, 1H), 8.86 (d, J = 4.9 Hz, 2H), 7.77 (dd, J = 7.9, 1.0 Hz, 1H), 7.51 (t, J = 8.1 Hz, 1H), 7.45 (t, J = 4.9 Hz, 1H), 7.25 (dd, J = 8.4, 1.0 Hz, 1H), 3.83 (s, 3H).

5

Intermediate A-25: 7-ethoxyquinoline-8-carboxylic acid



Step A: 7-methoxyquinoline-8-carboxylic acid. In separate batches (1 g) a mixture of 2-amino-6-methoxybenzoic acid (11 g, 66 mmol) and acrolein (4.8 mL, 72 mmol) in 1,4-dioxane (66 mL) was heated in a microwave reactor for 20 min at 200 °C. After combining the reactions, the mixture was concentrated and purified via silica gel chromatography (0-10% MeOH in DCM) to give the title compound (2.8 g, 20%). MS (ESI) mass calcd. for $C_{11}H_9NO_3$, 203.1; m/z found 204.0 $[M+H]^+$.


Step B: 7-hydroxyquinoline-8-carboxylic acid. The title compound of Step A (2.9 g, 14.1 mmol) in HBr (14 mL) was heated at 90 °C for 1 h. The mixture was then concentrated washed with $PhCH_3$ and used without further purification in subsequent steps.

Step C: ethyl 7-ethoxyquinoline-8-carboxylate. To the title compound of Step B (800 mg, 3.9 mmol) and K_2CO_3 (1.4 g, 10.4 mmol) in DMF (15 mL) was added iodoethane (560 mL, 6.9 mmol). After stirring overnight at room temperature, the reaction was concentrated and purified via silica gel chromatography (0-30% EtOAc in hexanes) to give the title compound. MS (ESI) mass calcd. for $C_{14}H_{15}NO_3$, 245.1; m/z found 246.0 $[M+H]^+$.

Step D: 7-ethoxyquinoline-8-carboxylic acid. To the title compound of Step C (1.3 g, 5.4 mmol) in THF (22 mL) and H_2O (11 mL) was added LiOH hydrate (675 mg, 16.5 mmol) and MeOH. The mixture was heated at 67 °C for 12 h. Additional LiOH hydrate (675 mg, 16.5 mmol) was added and the heating was continued at 70 °C for 1 day. Additional LiOH hydrate (1.4 g, 33 mmol) was added and the heating was continued at 75 °C for 1 day. The reaction was allowed to cool to room temperature, acidified to pH=3 with 1 N $HCl_{(aq)}$ and concentrated. Purification via

prep HPLC gave the title compound (1 g, 84%). MS (ESI) mass calcd. for $C_{12}H_{11}NO_3$, 217.1; m/z found 218.0 $[M+H]^+$.

Intermediate A-27: 3-methyl-2-(oxazol-2-yl)benzoic acid



5

Step A: ethyl 3-methyl-2-(oxazol-2-yl)benzoate. In a microwave vial was dissolved ethyl 2-iodo-3-methylbenzoate (627 mg, 2.16 mmol) and 2-(tributylstannyl)oxazole (0.54 mL, 0.07 mmol) in DME (2.59 mL). The solution was degassed with N_2 for 5 minutes then CuI (21 mg, 0.11 mmol) and $Pd(PPh_3)_4$ (125 mg, 0.11 mmol) were added. The reaction was purged with N_2 and heated at 150 °C for 1 h. The reaction was cooled to room temperature, filtered through a pad of Celite and purified via silica gel chromatography (0-40% EtOAc in hexanes) to give the title compound of step A (333 mg, 67%). MS (ESI) mass calcd. for $C_{13}H_{13}NO_3$, 231.1; m/z found 232.1 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d) δ 7.89 – 7.82 (m, 1H), 7.79 (d, J = 0.8 Hz, 1H), 7.48 – 7.43 (m, 2H), 7.30 (d, J = 0.9 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 2.27 (s, 3H), 1.18 (t, J = 7.1 Hz, 3H).


10

Step B: 3-methyl-2-(oxazol-2-yl)benzoic acid. To the title compound of step A (166 mg, 0.72 mmol) was added MeOH (7.2 mL) and 1M NaOH_(aq) (7.2 mL). MeOH was evaporated and then 1 M HCl_(aq) was added. To the solution was added DCM and the aqueous was extracted with DCM (3X). The combined organic layers were dried over $MgSO_4$, filtered and evaporated to give the title compound (145 mg). MS (ESI) mass calcd. for $C_{11}H_9NO_3$, 203.1; m/z found 204.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO- d_6) δ 8.20 (s, 1H), 7.79 – 7.68 (m, 1H), 7.65 – 7.49 (m, 2H), 7.35 (s, 1H), 4.34 (s, 1H), 2.20 (s, 3H).


15

20

Intermediate	Name	Structure	Reference
A-28	3-(2H-1,2,3-triazol-2-yl)picolinic acid		Prepared according to WO 2011/050198 Intermediate 72

A-29	1H-indole-7-carboxylic acid		Commercially available, CAS 1670-83-3


Intermediate A-30: 2-methoxy-6-(1H-pyrazol-5-yl)benzoic acid



Step A: Ethyl 2-methoxy-6-(1H-pyrazol-5-yl)benzoate. In a microwave vial was dissolved ethyl 2-bromo-6-methoxybenzoate (500 mg, 1.54 mmol) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (330 mg, 1.70 mmol) in DME (10 mL) and water (2 mL). Na₂CO₃ (259 mg, 3.09 mmol) was then added followed by Pd(PPh₃)₄ (89 mg, 0.077 mmol) and the reaction mixture was degassed with N₂ for 10 minutes. The reaction mixture was then heated at 100 °C for 1 h in the microwave. The mixture was cooled to room temperature, filtered through Celite and washed with EtOAc and DCM. The crude solution was concentrated in vacuo and directly purified via silica gel chromatography (10-80% EtOAc in hexanes) to afford the title compound (125 mg, 33%). MS (ESI) mass calcd. for C₁₃H₁₄N₂O₃, 246.3; m/z found 247.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 7.63 (d, J = 2.2 Hz, 1H), 7.44 - 7.37 (m, 1H), 7.24 (d, J = 8.1 Hz, 1H), 6.94 (dd, J = 8.3, 0.9 Hz, 1H), 6.53 (d, J = 2.3 Hz, 1H), 4.29 (q, J = 7.2 Hz, 2H), 3.88 (s, 3H), 1.25 - 1.16 (m, 3H).

Step B: 2-methoxy-6-(1H-pyrazol-5-yl)benzoic acid. Prepared analogous to intermediate A-24 step B to give title compound. MS (ESI) mass calcd. for C₁₁H₁₀N₂O₃, 218.1; m/z found 219.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 12.85 (br. s, 1H), 7.71 (d, J = 2.2 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.35 - 7.28 (m, 1H), 7.04 (dd, J = 8.3, 1.0 Hz, 1H), 6.51 (d, J = 2.3 Hz, 1H), 3.80 (s, 3H).

Intermediate A-31: 2-(1,4-dimethyl-1H-pyrazol-5-yl)benzoic acid




Step A: Methyl 2-(1,4-dimethyl-1H-pyrazol-5-yl)benzoate. Prepared analogous to intermediate A-30 step A to give title compound. MS (ESI) mass calcd. for $C_{13}H_{14}N_2O_2$, 230.1; m/z found 231.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d) δ 8.04 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.61 (td, $J = 7.5, 1.5$ Hz, 1H), 7.53 (td, $J = 7.7, 1.4$ Hz, 1H), 7.35 (s, 1H), 7.28 (dd, $J = 7.6, 1.4$ Hz, 1H), 3.71 (s, 3H), 3.58 (s, 3H), 1.84 (s, 3H).

Step B: 2-(1,4-dimethyl-1H-pyrazol-5-yl)benzoic acid. To a solution of the title compound of Step A (680 mg, 2.95 mmol) in MeOH (15 mL) was added 4 M LiOH (4 mL). The mixture was heated at 50°C overnight. MeOH was removed and HCl added until pH=2. White solids precipitated from the reaction mixture and the precipitate was filtered, washed with EtOAc and collected to give intermediate A-31, which was used without further purification in subsequent steps. MS (ESI) mass calcd. for $C_{12}H_{12}N_2O_2$, 216.1; m/z found 217.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO- d_6) δ 12.87 (s, 1H), 7.95 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.67 (td, $J = 7.5, 1.5$ Hz, 1H), 7.59 (td, $J = 7.6, 1.4$ Hz, 1H), 7.33 (dd, $J = 7.6, 1.4$ Hz, 1H), 7.25 (s, 1H), 3.48 (s, 3H), 1.77 (s, 3H).


Intermediate	Name	Structure	Reference
A-33	2-bromo-3-fluorobenzoic acid		Commercially available, CAS 132715-69-6

Intermediate A-33: 3-fluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid



To 3-fluoro-2-iodobenzoic acid (4.5 g, 16.9 mmol) dissolved in dioxane (33.8 mL) and H₂O (0.09 mL) was added Cs₂CO₃ (11.02 g, 33.8 mmol), CuI (161 mg, 0.85 mmol), 2H-1,2,3-triazole (1.96 mL, 33.8 mmol), and trans-N,N-dimethyl-1,2-cyclohexanediamine (0.53 mL, 3.38 mmol). The mixture was then heated to 100 °C overnight, cooled to room temperature, diluted with H₂O, and extracted with EtOAc. The aqueous layer was then acidified and extracted with EtOAc. The combined organics were dried and concentrated. From this concentrate a solid precipitated to provide intermediate A-33 (285 mg, 8%). MS (ESI) mass calcd for C₉H₆FN₃O₂, 207.0; m/z found 208.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄) δ 6.81 - 6.77 (m, 1H), 6.46 - 6.40 (m, 2H), 6.30 - 6.23 (m, 1H), 6.18 - 6.12 (m, 1H).

10 Intermediate A-34: 2-(5-fluoropyrimidin-2-yl)benzoic acid.




Step A: 5-fluoro-2-iodopyrimidine. To a solution of 2-chloro-5-fluoropyrimidine (4 mL, 32 mmol) in propionitrile (33 mL) was added chlorotrimethylsilane (12 mL, 97 mmol) and sodium iodide (15 g, 97 mmol), and the reaction mixture was heated to 150 °C for 1 h. Upon completion of the reaction, the reaction mixture was cooled to room temperature and the solvent removed. The residue was taken up in EtOAc and a solution of saturated NaHCO₃. The organic layer was dried over MgSO₄, filtered and evaporated. Purification via silica gel chromatography (0-20% EtOAc in hexanes) gave the title compound (2.82 g, 39%).

Step B: 2-(5-fluoropyrimidin-2-yl)benzonitrile. In a microwave vial was dissolved 2-cyanophenylboronic acid (500 mg, 3.40 mmol) in THF (15 mL), and the reaction mixture was degassed with N₂. Then, the title compound of step A (915 mg, 4.08 mmol), Na₂CO₃ (1.08 g, 10.2 mmol), water (5 mL), and PdCl₂(dtbpf) (CAS 95408-45-0) (89 mg, 0.14 mmol) were added, and the reaction mixture was stirred at room temperature for 1 h and then heated via microwave heating to 75 °C for 2 h. The mixture was cooled to room temperature and water and EtOAc added. The reaction mixture was extracted with EtOAc. The combined organic layers were dried over MgSO₄, filtered and concentrated. The crude was purified via silica gel chromatography (0-30% EtOAc in

hexanes) to afford the title compound (280 mg, 41%). MS (ESI) mass calcd. for $C_{11}H_6FN_3$, 199.1; m/z found 200.0 $[M+H]^+$.


Step C: 2-(5-fluoropyrimidin-2-yl)benzoic acid. A solution of the title compound of step B (1.24 g, 6.22 mmol) in H_2SO_4 (6 mL) and water (6 mL) was stirred at 80 °C for 1 h. Then, the reaction mixture was cooled to 0 °C and the aqueous phase extracted with DCM (2X). A solution of 20 M NaOH (11 mL) was added to the aqueous layer until pH ~3-4. The aqueous layer was extracted again with EtOAc and DCM. The combined organic layers were dried over $MgSO_4$, filtered and concentrated to afford the title compound (672 mg, 50%). MS (ESI) mass calcd. for $C_{11}H_7FN_2O_2$, 218.1; m/z found 219.1 $[M+H]^+$.

Intermediate A-35: 3-fluoro-2-(5-fluoropyrimidin-2-yl)benzoic acid.



Prepared analogous to Intermediate A-34, substituting 2-cyanophenylboronic acid with (2-cyano-6-fluorophenyl)boronic acid (CAS 656235-44-8). MS (ESI) mass calcd. for $C_{11}H_6F_2N_2O_2$, 236.0; m/z found 237.1 $[M+H]^+$.




Intermediate A-36: 2-(5-fluoropyrimidin-2-yl)-3-methylbenzoic acid









Step A: Methyl 2-(5-fluoropyrimidin-2-yl)-3-methylbenzoate. A solution of methyl 3-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (CAS 887234-98-2) (3 g, 11 mmol) in THF (30 mL) was degassed with N_2 . Then, 2-chloro-5-fluoropyrimidine (1.6 mL, 13.04


mmol), Na₂CO₃ (3.45 g, 32.6 mmol), water (10 mL), and Pd(dppf)Cl₂ (354 mg, 0.434 mmol) were added, and the reaction mixture was stirred at 100 °C overnight. The mixture was cooled to room temperature and water and EtOAc added. The reaction mixture was extracted with EtOAc. The combined organic layers were dried over MgSO₄, filtered and concentrated. The crude was purified
 5 via silica gel chromatography (0-40% EtOAc in hexanes) to afford the title compound (1.07 g, 40%).

Step B: 2-(5-fluoropyrimidin-2-yl)-3-methylbenzoic acid. To a solution of the title compound of Step A (1.46 g, 5.93 mmol) in MeOH (20 mL) was added 1 M NaOH (12 mL), and the reaction mixture was stirred at room temperature overnight. The solvent was removed and the
 10 crude was diluted with water until pH = 10. The aqueous layer was extracted with EtOAc. The aqueous layer was further acidified with 12 M HCl_(aq) until pH = 2 and extracted with EtOAc. The combined organic layers were dried over MgSO₄, filtered and concentrated to afford the title compound (1.19 g, 83%). MS (ESI) mass calcd. for C₁₂H₉FN₂O₂, 232.1; m/z found 233.1 [M+H]⁺.

Intermediate	Name	Structure	Reference
A-37	2-(pyrimidin-2-yl)benzoic acid		Commercially available, CAS 400892-62-8
A-38	5-methyl-2-(2H-1,2,3-triazol-2-yl)nicotinic acid		Prepared analogous to WO 2011/050200 Intermediate 47, Example 160
A-39	2-(2H-1,2,3-triazol-2-yl)nicotinic acid		Commercially available, CAS 1369497-44-8

Intermediate	Name	Structure	Reference
A-40	6-methyl-3-(2H-1,2,3-triazol-2-yl)picolinic acid		2012/089606 Intermediate D40.
A-41	6-methyl-3-(pyrimidin-2-yl)picolinic acid		WO 2010/122151 Intermediate D28
A-42	3-(pyrimidin-2-yl)picolinic acid		WO 2010/122151 Intermediate D105
A-43	3-phenylpyrazine-2-carboxylic acid		Commercially available, CAS 2881- 85-8
A-44	1H-indazole-7-carboxylic acid		Commercially available, CAS 677304-69-7
A-45	3-phenylfuran-2-carboxylic acid		Commercially available, CAS169772-63-8


Intermediate A-46: 5-methyl-2-(pyrimidin-2-yl)nicotinic acid.



Step A: Methyl 5-methyl-2-(pyrimidin-2-yl)nicotinate. To a sealed tube containing methyl 2-chloro-5-methylnicotinate (CAS 65169-43-9) (745 mg, 4.01 mmol), CuI (38 mg, 0.2 mmol), LiCl (169 mg, 4.01 mmol), and Pd(PPh₃)₄ (231 mg, 0.2 mmol) in toluene (15 mL) was added 2-(tributylstannyl)pyrimidine (1.5 mL, 4.4 mmol), and the reaction mixture was heated at 120 °C overnight. The reaction mixture was diluted with water and extracted with DCM. The combined organic layers were dried over MgSO₄, filtered and evaporated. Purification via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (494 mg, 52%). MS (ESI) mass calcd. for C₁₂H₁₁N₃O₂, 229.1; m/z found 229.99.

Step B: 5-methyl-2-(pyrimidin-2-yl)nicotinic acid. To a solution of the title compound of step A (466 mg, 2.03 mmol) in MeOH (10 mL) was added 10 M NaOH (1 mL), and the reaction mixture was stirred at room temperature for 2 h. The solvent was removed and the crude was diluted with water and acidified with 6 M HCl_(aq) until pH = 3. The aqueous layer was saturated with solid NaCl and extracted with 20% *i*PrOH in CHCl₃ (3X). The combined organic layers were dried over MgSO₄, filtered and concentrated to afford the title compound (432 mg, 99%). MS (ESI) mass calcd. for C₁₁H₉N₃O₂, 215.1; m/z found 216.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄) δ 8.90 (br. s, 2H), 8.64 (br. s, 1H), 8.17 (s, 1H), 7.55 (br. s, 1H), 2.51 (s, 3H).


Intermediate A-47: Lithium 5-methyl-3-(pyrimidin-2-yl)picolinate.



Step A: Methyl 5-methyl-3-(pyrimidin-2-yl)picolinate. Prepared analogous to intermediate A-46, step A substituting methyl 2-chloro-5-methylnicotinate with methyl 3-bromo-5-methylpicolinate. MS (ESI) mass calcd. for $C_{12}H_{11}N_3O_2$, 229.1; m/z found 230.0 $[M+H]^+$.

Step B: Lithium 5-methyl-3-(pyrimidin-2-yl)picolinate. To a solution of the title compound
5 of step A (592 mg, 2.58 mmol) in THF (5 mL) was added 4 M LiOH (0.8 mL) and water (1.5 mL), and the reaction mixture was stirred at room temperature for 2.5 h. The solvent was removed and the crude reaction mixture placed under vacuum overnight to give the title compound (591 mg), which was used in the next step without further purification. MS (ESI) mass calcd. for $C_{11}H_9N_3O_2$, 215.1; m/z found 216.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4) δ 8.83 (d, $J = 4.9$ Hz, 2H), 8.39
10 (br. s, 1H), 8.23 - 8.18 (m, 1H), 7.38 (t, $J = 4.9$ Hz, 1H), 2.44 (s, 3H).

Intermediate A-48: 3-fluoro-2-(oxazol-2-yl)benzoic acid.



Step A: 2-bromo-N-(2,2-dimethoxyethyl)-6-fluorobenzamide. To a solution of 2-bromo-6-
15 fluorobenzoic acid (2 g, 9.1 mmol) in DMF (27 mL) was added HBTU (5.20 g, 13.7 mmol) and DIPEA (4.7 mL, 27 mmol), and the reaction mixture was stirred for 10 min. Then, 2,2-dimethoxyethylamine (1.3 mL, 11.9 mmol) was added and the reaction mixture stirred at room temperature for 12 h. The reaction mixture was diluted with EtOAc and washed with saturated aqueous $NaHCO_3$. The combined organic layers were dried over $MgSO_4$, filtered and concentrated.
20 Purification via silica gel chromatography (0-25% EtOAc in hexanes) gave the title compound (2.3 g, 82%).

Step B: 2-(2-bromo-6-fluorophenyl)oxazole. To P_2O_5 (6.4 g, 22.6 mmol) was added
methanesulfonic acid (52 mL, 801 mmol), and the reaction mixture was stirred at room temperature
for 1 h. Then, the title compound of step A (2.3 g, 7.54 mmol) was added to the reaction mixture,
25 and the mixture heated to 140 °C for 2 h. DCM was added and the mixture was slowly poured into a saturated solution of aqueous $NaHCO_3$ on ice. The mixture was extracted with DCM. The combined organic layers were dried over $MgSO_4$, filtered and concentrated. Purification via silica gel

chromatography (0-10% EtOAc in hexanes) gave the title compound (1.5 g, 82%). MS (ESI) mass calcd. for C_9H_5BrFNO , 240.95; m/z found 242.0 $[M+H]^+$.


Step C: Methyl 3-fluoro-2-(oxazol-2-yl)benzoate. A solution of the title compound of step B (2.18 g, 8.99 mmol), $Pd(OAc)_2$ (40 mg, 0.18 mmol), 1,1'-bis(diphenylphosphino)ferrocene (199 mg, 0.36 mmol), and Et_3N (3.7 mL, 27 mmol) in 1:1 MeOH/1,4-dioxane (36 mL) was degassed

with N_2 for 15 min. Then, the mixture was stirred at 95 °C under an atmosphere of carbon monoxide overnight. The reaction mixture was diluted with EtOAc and washed with a solution of $NaHCO_3$. The organic layer was separated, dried over $MgSO_4$, filtered, and concentrated.

Purification via silica gel chromatography (0-12% EtOAc in hexanes) gave the title compound (1.7 g, 83%). MS (ESI) mass calcd. for $C_{11}H_8FNO_3$, 221.1; m/z found 222.0 $[M+H]^+$.

Step D: 3-fluoro-2-(oxazol-2-yl)benzoic acid. To a solution of the title compound of step C (1.65 g, 7.46 mmol) in MeOH (22 mL) was added 2 M NaOH (7.5 mL), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was acidified with 1 M $HCl_{(aq)}$ and the solvents evaporated in vacuo. The mixture was diluted with water and extracted with DCM. The combined organic were dried over $MgSO_4$, filtered and concentrated to afford the title compound (905 mg, 58%). MS (ESI) mass calcd. for $C_{10}H_6FNO_3$, 207.0; m/z found 208.0 $[M+H]^+$. MP = 182 °C.

Intermediate A-49: 5-fluoro-2-(oxazol-2-yl)benzoic acid.




Step A: Methyl 5-fluoro-2-(oxazol-2-yl)benzoate. To a solution of methyl 2-bromo-5-fluorobenzoate (1.1 g, 4.8 mmol) and 2-(tri-n-butylstannyl)oxazole (1.3 mL, 6.2 mmol) in toluene (14 mL) was added $Pd(PPh_3)_4$ (550 mg, 0.476 mmol), and the reaction mixture was heated via microwave heating to 150 °C for 30 min. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over $MgSO_4$, filtered and concentrated. Purification via silica gel chromatography (0-40% EtOAc in hexanes, followed by a second column

0-10% EtOAc in hexanes) gave the title compound (553 mg, 52%). MS (ESI) mass calcd. for $C_{11}H_6FNO_3$, 221.1; m/z found 222.1 $[M+H]^+$.


Step B: 5-fluoro-2-(oxazol-2-yl)benzoic acid. Prepared analogous to intermediate 48, step D, to give the title compound (858 mg, 99%). MS (ESI) mass calcd. for $C_{10}H_6FNO_3$, 207.0; m/z found 208.1 $[M+H]^+$.

Intermediate A-50: 2-fluoro-6-(oxazol-2-yl)benzoic acid.



Prepared analogous to intermediate 48, substituting 2-bromo-6-fluorobenzoic acid with 2-bromo-3-fluorobenzoic acid. MS (ESI) mass calcd. for $C_{10}H_6FNO_3$, 207.0; m/z found 208.0 $[M+H]^+$.

Intermediate A-51: 4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid




Step A: 5-(2-bromo-5-fluorophenyl)-3-methyl-1,2,4-oxadiazole. To a solution of bromo-5-fluorobenzoyl chloride (2.17 g, 9.13 mmol) in THF (18 mL) was added DIPEA (1.7 mL, 10 mmol). Then, acetamide oxime (676 mg, 9.13 mmol) was added portionwise, and the reaction mixture was stirred at 70 °C for 16 h. The reaction mixture was diluted with EtOAc and washed with a saturated solution of $NaHCO_3$. The combined organic layers were dried over $MgSO_4$, filtered and concentrated. Purification via silica gel chromatography (0-20% EtOAc in hexanes) gave the title compound (2.35 g, 57%). MS (ESI) mass calcd. for $C_9H_6BrFN_2O$, 255.96; m/z found 257.0 $[M+H]^+$.

Step B: 4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid. Prepared analogous to intermediate 48, steps C and D, to give the title compound. MS (ESI) mass calcd. for $C_{10}H_7FN_2O_3$, 222.0; m/z found 223.0 $[M+H]^+$.


5 Enantiopure Route A (2-azabicyclo[2.2.1]heptan-6-ol):

Intermediate B-1: (1S,4R)-2-((R)-1-phenylethyl)-2-azabicyclo[2.2.1]hept-5-ene



Intermediate B-1 was prepared according to the procedure of C. Chiu *et al.* [*Synthetic Communications* **1996**, 26, 577-584] with the substitution of (+)- α -Methyl-benzylamine for (-)- α -Methyl-benzylamine and D-dibenzoyl tartaric acid for L- dibenzoyl tartaric acid. MS (ESI) mass calcd. for $C_{14}H_{17}N$, 199.1; m/z found 200.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d) δ 7.36 - 7.25 (m, 4H), 7.23 - 7.17 (m, 1H), 6.35 - 6.30 (m, 1H), 6.11 (dd, J = 5.7, 2.0 Hz, 1H), 4.16 - 4.12 (m, 1H), 3.05 (q, J = 6.5 Hz, 1H), 2.89 (dd, J = 8.9, 3.1 Hz, 1H), 2.85 - 2.81 (m, 1H), 1.65 - 1.59 (m, 1H), 1.48 - 1.43 (m, 1H), 1.37 - 1.31 (m, 4H).

Intermediate B-2: (1S,4R,6S)-2-((R)-1-phenylethyl)-2-azabicyclo[2.2.1]heptan-6-ol




Intermediate B-2 was synthesized according to the procedure of F. Carroll *et al.* [*J. Med. Chem.* **1992**, 35, 2184-2191] on a similar substrate. A 1 M solution of BH_3 -THF (1 M BH_3 -THF in THF, 359.3 mL, 359.3 mmol) was added dropwise via addition funnel to a stirred solution of intermediate B-1 (35.8 g, 179.6 mmol) in THF (359 mL) at 0 °C. Upon complete addition of BH_3 -THF, the reaction mixture was stirred at 0 °C for 2 h. Then, excess BH_3 was quenched with a solution of THF- H_2O . A 3 M NaOH (132 mL) solution was added followed by the dropwise addition of H_2O_2 (30% w/w in H_2O , 140 mL), and the reaction mixture was warmed to 40 °C and stirred for 1.5 h. The biphasic mixture was then cooled to room temperature and K_2CO_3 (17 g)

added in one portion. The resulting mixture was concentrated under reduced pressure to remove THF and re-dissolved in DCM. The crude reaction mixture was washed with H₂O and the aqueous phase extracted with DCM (3X). The combined organics were then washed with brine, dried with Na₂SO₄, filtered, and concentrated to give a clear oil, which was further purified by silica gel

chromatography (5-10% MeOH (with 10% 2 M NH₃) in DCM) to give intermediate B-2 as a clear oil (20.2 g, 93.0 mmol, 52%). MS (ESI) mass calcd. for C₁₄H₁₉NO, 217.2; m/z found 218.1


[M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 7.34 - 7.27 (m, 4H), 7.24 - 7.19 (m, 1H), 4.03 (d, *J* = 6.9 Hz, 1H), 3.46 (q, *J* = 6.5 Hz, 1H), 3.01 (s, 1H), 2.56 - 2.48 (m, 1H), 2.42 - 2.33 (m, 1H), 2.25 (dd, *J* = 8.8, 1.3 Hz, 1H), 1.82 (ddd, *J* = 13.1, 6.9, 2.2 Hz, 1H), 1.53 - 1.43 (m, 2H), 1.33 - 1.28 (m, 1H), 1.27 (d, *J* = 6.5 Hz, 3H).

Intermediate B-3: (1S,4R,6S)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate



To a solution of intermediate B-2 (500 mg, 2.3 mmol) in EtOH (11.5 mL) was added Boc₂O (603 mg, 2.76 mmol) and 10 wt% Pd/C wet Degussa (490 mg, 0.46 mmol). The reaction mixture was stirred under an atmosphere of H₂ (balloon) at room temperature for 22 h. Then, the reaction mixture was filtered through a pad of Celite and washed with EtOAc. The filtrate was concentrated to a clear oil to give the title compound in quantitative yield, which was used without further purification. MS (ESI) mass calcd. for C₁₁H₁₉NO₃, 213.1; m/z found 158.1 [M+2H-*t*Bu]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 4.08 - 3.99 (m, 1H), 3.99 - 3.92 (m, 1H), 3.18 - 3.09 (m, 1H), 2.80 (dd, *J* = 28.1, 9.2 Hz, 1H), 2.18 - 1.37 (m, 14H).


Intermediate B-4: (1S,4R)-tert-butyl 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate



To a solution of intermediate B-3 (7 g, 33 mmol) in EtOAc (219 mL) was added IBX (24.5 g, 39.4 mmol), and the heterogeneous reaction mixture was stirred at 80 °C overnight. Upon completion, the reaction mixture was then filtered through Celite, washed with EtOAc and

concentrated to a white solid. The crude reaction mixture was re-dissolved in EtOAc and washed once with a 5% aqueous Na₂CO₃ solution. The aqueous layer was further extracted with EtOAc (2X) and the combined organics were washed with brine, dried with Na₂SO₄, filtered, and concentrated to afford intermediate B-4 as a light yellow solid (6.12 g, 28.9 mmol, 88%), which was used in the next step without further purification. MS (ESI) mass calcd. for C₁₁H₁₇NO₃, 211.1; m/z found 156.1 [M+2H-*t*Bu]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 4.32 - 4.04 (m, 1H), 3.45 (ddd, *J* = 9.6, 3.1, 1.8 Hz, 1H), 3.25 - 3.04 (m, 1H), 2.89 - 2.77 (m, 1H), 2.21 (ddd, *J* = 18.0, 4.6, 1.8 Hz, 1H), 2.04 - 1.96 (m, 1H), 1.95 - 1.82 (m, 1H), 1.75 - 1.66 (m, 1H), 1.45 (s, 9H).

10 Intermediate B-5: (1*S*,4*R*,6*R*)-*tert*-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate




A 1 M solution of L-Selectride (1 M in THF, 19.8 mL, 19.8 mmol) was added to a solution of intermediate B-4 (1.67 g, 7.91 mmol) in dry THF (40 mL) at -78 °C, and the reaction mixture was stirred at that temperature for 3 h. Then, the reaction mixture was warmed to 0 °C and a 3 M NaOH (8.4 mL) solution was added followed by a solution of H₂O₂ (30% w/w in H₂O, 4.3 mL). The resulting mixture was warmed to room temperature and stirred for 2 h. The biphasic mixture was then concentrated in vacuo to remove THF and the aqueous layer extracted with DCM (3X). The combined organics were washed with brine, dried with Na₂SO₄, filtered, and concentrated to an oil, which was further purified by silica gel chromatography (10-90% EtOAc in hexanes), to give intermediate B-2 as a white solid (1.16 g, 5.44 mmol, 67%). MS (ESI) mass calcd. for C₁₁H₁₉NO₃, 213.1; m/z found 158.1 [M+2H-*t*Bu]⁺. ¹H NMR (400 MHz, Chloroform-*d*, Compound present as a mixture of rotamers) δ 4.38 - 4.10 (m, 2H), 3.36 (br. s, 1H), 3.09 (dd, *J* = 9.6, 1.4 Hz, 1H), 2.54 - 1.38 (m, 14H), 1.16 - 1.00 (m, 1H).

Intermediate B-5 can also be prepared from commercially available (1*S*,4*R*)-2-azabicyclo[2.2.1]hept-5-en-3-one. The procedure is as follows:


Enantiopure Route B (2-azabicyclo[2.2.1]heptan-6-ol):

Intermediate B-6: (1S,4R,6S)-2-benzyl-2-azabicyclo[2.2.1]heptan-6-ol



To a round bottom flask containing commercially available, (1S,4R)-2-azabicyclo[2.2.1]hept-5-en-3-one (2.0 g, 18.3 mmol), in THF (100 mL) at 0 °C was added a solution of LiAlH₄ (1 M in THF, 40.3 mL, 40.3 mmol), and the reaction mixture was refluxed overnight. The reaction mixture was then cooled to 0 °C and carefully quenched by the dropwise addition of H₂O (15 mL). Celite and solid Na₂CO₃ were added to the slurry and the reaction mixture was vigorously stirred at room temperature for 3 h. The slurry was then filtered and the solids washed with THF. Benzyl bromide (2.4 mL, 20.2 mmol) and an aqueous solution of Na₂CO₃ (3.2 g in 30 mL H₂O) were added to the filtrate and the reaction mixture stirred at room temperature overnight. Upon completion of the reaction, the reaction mixture was extracted with EtOAc (3X). The combined organics were washed with H₂O, brine, dried with MgSO₄, filtered, and concentrated to provide crude (1S,4R)-2-benzyl-2-azabicyclo[2.2.1]hept-5-ene as a yellow oil, which was directly hydroborated according to the procedure of F. Carroll *et al.* [*J. Med. Chem.* **1992**, 35, 2184-2191]. The crude alcohol was purified by silica gel chromatography (0-15% MeOH (with 5% NH₄OH) in DCM) to give intermediate B-6 as a clear oil (2.66 g, 13.1 mmol, 71% over 3 steps). MS (ESI) mass calcd for C₁₃H₁₇NO, 203.1; m/z found 204.1 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 7.39 - 7.28 (m, 4H), 7.26 - 7.21 (m, 1H), 4.18 - 4.09 (m, 1H), 3.76 - 3.66 (m, 2H), 3.06 (br. s, 1H), 2.51 (dt, *J* = 9.0, 3.0 Hz, 1H), 2.44 - 2.35 (m, 2H), 1.90 - 1.81 (m, 1H), 1.68 - 1.53 (m, 2H), 1.38 - 1.30 (m, 1H).


Intermediate B-7: (1S,4R,6R)-2-benzyl-2-azabicyclo[2.2.1]heptan-6-ol



Intermediate B-7 was prepared from intermediate B-6 according to the procedure of F. Carroll *et al.* [*J. Med. Chem.* **1992**, 35, 2184-2191]. MS (ESI) mass calcd for C₁₃H₁₇NO, 203.1; m/z found 204.1 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 7.37 - 7.22 (m, 5H), 4.56 (s, 1H), 4.05 - 3.94 (m, 1H), 3.80 (d, *J* = 13.0 Hz, 1H), 3.62 (d, *J* = 12.9 Hz, 1H), 3.20 - 3.11 (m, 1H), 2.77 (d, *J* =

9.2 Hz, 1H), 2.45 - 2.34 (m, 2H), 1.88 - 1.79 (m, 1H), 1.76 - 1.64 (m, 1H), 1.30 (d, $J = 10.4$ Hz, 1H), 0.99 (dt, $J = 13.3, 2.9$ Hz, 1H).

Intermediate B-5: (1S,4R,6R)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate




To a solution of intermediate B-7 (3.41 g, 16.8 mmol) in EtOH (168 mL) was added Boc_2O (5.49 g, 25.2 mmol) and 20 wt% $\text{Pd}(\text{OH})_2/\text{C}$ (2.36 g, 3.36 mmol). The reaction mixture was stirred under an atmosphere of H_2 (balloon) at room temperature overnight. Then, the reaction mixture was filtered through a pad of Celite and washed with EtOAc. The filtrate was concentrated to a clear oil, which was further purified by silica gel chromatography (10-60% EtOAc in hexanes), to give intermediate B-5 as a white solid (3.1 g, 1.5 mmol, 87%). $[\alpha]_{20}^D -11.2$ (c 0.0065, MeOH). MS (ESI) mass calcd. for $\text{C}_{11}\text{H}_{19}\text{NO}_3$, 213.1; m/z found 158.1 $[\text{M}+2\text{H}-t\text{Bu}]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers) δ 4.39 - 4.12 (m, 2H), 3.35 (br. s, 1H), 3.08 (dd, $J = 9.4, 1.4$ Hz, 1H), 2.56 - 1.39 (m, 14H), 1.15 - 0.99 (m, 1H).

15

Racemic Route (2-azabicyclo[2.2.1]heptan-6-ol):


Intermediate B-8: (R/S)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate



Intermediate B-8 was prepared from commercially available (R/S)-tert-butyl 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate following the procedure of R. Nencka *et. al.* [*Tetrahedron* **2012**, 68, 1286-1298]. MS (ESI) mass calcd. for $\text{C}_{11}\text{H}_{19}\text{NO}_3$, 213.1; m/z found 158.1 $[\text{M}+2\text{H}-t\text{Bu}]^+$. ^1H NMR (400 MHz, Chloroform- d) δ 4.39 - 4.08 (m, 2H), 3.36 (br.s, 1H), 3.10 (dd, $J = 9.6, 1.4$ Hz, 1H), 2.56-1.41 (m, 14H), 1.17 - 1.01 (m, 1H).


25 Enantiopure Route (2-azabicyclo[2.2.1]heptan-6-amine):

Intermediate B-9: (1S,4R)-tert-butyl 6-(hydroxyimino)-2-azabicyclo[2.2.1]heptane-2-carboxylate



To a flask containing Intermediate B-4 (1.0 g, 4.7 mmol) dissolved in EtOH (20 mL) was added NEt₃ (2.0 ml, 14.4 mmol), and hydroxylamine hydrochloride (789 mg, 2.40 mmol) and the reaction mixture was brought to reflux. Upon completion, the reaction mixture was concentrated, diluted with H₂O, and the aqueous layer extracted with EtOAc (3X). The combined organics were then washed with H₂O, brine, dried with MgSO₄, filtered, and concentrated to provide intermediate B-9 as an off-white solid (1.018 g) which was used without further purification. MS (ESI) mass calcd. for C₁₁H₁₈N₂O₃, 226.1; m/z found 171.1 [M+2H-*t*Bu]⁺. ¹H NMR (500 MHz, Chloroform-*d*) δ 7.71 and 7.41 (2s, 1H), 4.62 and 4.48 (2s, 1H), 3.40 - 3.33 (m, 1H), 3.15 - 2.96 (m, 1H), 2.79 - 2.70 (m, 1H), 2.54 - 2.43 (m, 1H), 2.29-2.19 (m, 1H), 1.87 - 1.64 (m, 1H), 1.61 - 1.53 (m, 1H), 1.45 (s, 9H).

Intermediate B-10: (1S,4S,6R)-tert-butyl 6-amino-2-azabicyclo[2.2.1]heptane-2-carboxylate



A mixture of NiCl₂ (1.15 g, 8.84 mmol) and intermediate B-9 (1.0 g, 4.4 mmol) in MeOH (30 mL) was cooled to -35 °C and NaBH₄ (3.34 g, 88.4 mmol) was added portion wise to the reaction mixture over 30 min. Upon complete addition of NaBH₄, the reaction mixture was stirred for an additional 25 min and then warmed to room temperature. After 30 min at room temperature the reaction mixture was quenched with H₂O and concentrated under reduced pressure to a dark brown residue, which was re-dissolved in a mixture of DCM and 15% aqueous NaOH solution, and the aqueous layer extracted with DCM (3X). The combined organics were dried with MgSO₄, filtered, and concentrated to provide intermediate B-10 (209 mg). 5 N NH₄OH solution was then added to the aqueous layer along with DCM, NaCl, and Celite and after several minutes of stirring the mixture was filtered to remove solids. The filtrate was then transferred to a separatory funnel, the layers separated, and the aqueous layer extracted with DCM (2X). The combined organics were dried with MgSO₄, filtered, and concentrated to provide additional intermediate B-10 (582 mg)

which was combined with the above fraction to provide intermediate B-10 (791 mg) as a brown oil which was used without further purification. MS (ESI) mass calcd. for $C_{11}H_{20}N_2O_2$, 212.2; m/z found 213.1 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d) δ 4.13 - 3.92 (m, 1H), 3.41 - 3.27 (m, 2H), 2.99 (dd, $J = 24.3, 9.6$ Hz, 1H), 2.51 - 2.39 (m, 1H), 2.16 - 2.05 (m, 1H), 1.68 - 1.57 (m, 1H),
5 1.47 (s, 10H), 1.22 - 1.07 (m, 2H), 0.85 - 0.74 (m, 1H).


Route A (2-azabicyclo[2.2.1]heptan-6-ol and 2-azabicyclo[2.2.2]octan-6-amine):

Intermediate C-1: (R/S)-2-benzyl-2-azabicyclo[2.2.2]oct-5-ene



10 Intermediate C-1 was prepared according to the procedure of S. Larsen *et al.* [*J. Am. Chem. Soc.* **1985**, 107, 1768-1769]. To a solution of phenylmethanamine (3.92 g, 27.3 mmol) in H_2O (5 mL) was added aqueous formaldehyde (2.03 mL, 27.3 mmol, 37 wt. % in H_2O). After 2 minutes, 1,3-cyclohexadiene (2 mL, 21 mmol) was added and the reaction mixture was heated to 55 °C for 4 days. The reaction mixture was cooled to room temperature and diluted with H_2O and extracted
15 with Et_2O (2X). The organic layer was discarded and the aqueous layer was basified with solid KOH and further extracted with Et_2O (2X). The organic layer was washed with brine, dried with $MgSO_4$, filtered, and concentrated. The concentrate was further purified by silica gel chromatography (100% DCM to 100% MeOH (with 10% 2 M NH_3) in DCM) to give intermediate C-1 as a brown oil, which contained minor impurities. Intermediate C-1 was used without further
20 purification. MS (ESI) mass calcd. for $C_{14}H_{17}N$, 199.1; m/z found 200.1 $[M+H]^+$.


Intermediate C-2: (R/S)-2-benzyl-2-azabicyclo[2.2.2]octan-6-ol



Intermediate C-2 was synthesized according to the procedure of F. Carroll *et al.* [*J. Med. Chem.* **1992**, 35, 2184-2191] on a similar substrate. A 1 M solution of BH_3 -THF (1 M BH_3 -THF in THF, 1.11 L, 1.11 mol) was added dropwise via addition funnel to a stirred solution of intermediate C-1 (37 g, 186 mmol) in THF (250 mL) at 0 °C. Upon complete addition of BH_3 -THF, the reaction


mixture was stirred at 0 °C for 3 h. Then, excess BH₃ was quenched with a solution of THF-H₂O. A 4 M NaOH (100 mL) solution was added followed by the dropwise addition of H₂O₂ (30% w/w in H₂O, 100 mL), and the reaction mixture was warmed to 40 °C and stirred overnight. The biphasic mixture was then cooled to room temperature and K₂CO₃ added portionwise. The resulting mixture was concentrated under reduced pressure to remove THF. Solid NaCl was added to the remaining aqueous layer and the crude mixture extracted with EtOAc (3X). The combined organics were then washed with brine, dried with Na₂SO₄, filtered, and concentrated to give a yellow-orange oil, which was further purified by silica gel chromatography (0-100% EtOAc in hexanes followed by 10% MeOH (with 10% 2 M NH₃) in DCM) to give intermediate C-2 as a yellow oil (20.7 g, 95.3 mmol, 51%), which contained minor impurities. Intermediate C-2 was used without further purification. MS (ESI) mass calcd. for C₁₄H₁₉NO, 217.2; m/z found 218.2 [M+H]⁺.

Intermediate C-3: (R/S)-tert-Butyl 6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate




To a solution of intermediate C-2 (20.7 g, 95.3 mmol) in EtOH (477 mL) was added Boc₂O (27.1 g, 124 mmol) and 10 wt% Pd/C wet Degussa (5 g, 4.77 mmol). The reaction mixture was stirred under an atmosphere of H₂ (balloon) at room temperature for 48 h. Analysis of the crude reaction mixture showed that the majority of the mixture was the deprotected amine, 2-azabicyclo[2.2.2]octan-6-ol. An additional equivalent of Boc₂O (27.1 g, 124 mmol) was added, and the reaction mixture was stirred at room temperature overnight. Then, the reaction mixture was filtered through a pad of Celite and washed with EtOAc. The filtrate was concentrated to a yellow oil to give intermediate C-3, which was used without further purification. MS (ESI) mass calcd. for C₁₂H₂₁NO₃, 227.2; m/z found 172.2 [M+2H-*t*Bu]⁺.

Intermediate C-4A: (R/S)-tert-Butyl 6-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate




To a solution of intermediate C-3 (21.6 g, 95.0 mmol) in EtOAc (380 mL) was added IBX (31.9 g, 114 mmol), and the heterogeneous reaction mixture was stirred at 80 °C overnight. Upon completion, the reaction mixture was then filtered through Celite, washed with EtOAc and concentrated. The crude reaction mixture was re-dissolved in EtOAc and washed once with a 5% aqueous Na₂CO₃ solution. The aqueous layer was further extracted with EtOAc (2X) and the combined organics were washed with brine, dried with Na₂SO₄, filtered, and concentrated to a brown residue. The concentrate was further purified by silica gel chromatography (0-35% EtOAc in hexanes), to give intermediate C-4A as a yellow solid. MS (ESI) mass calcd. for C₁₂H₁₉NO₃, 225.1; m/z found 170.1 [M+2H-*t*Bu]⁺. Analytical HPLC using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 2min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature = 45 °C). R_t = 1.91 min at 280 nm.

Intermediate C-4B: (1S,4R)-tert-butyl 6-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate




The title compound was obtained as a single enantiomer by Chiral SFC purification of Intermediate C-4A performed using a Chiralpak IC column (5μm, 250 x 20 mm), mobile phase of 20% iPrOH: 80% CO₂, and a flow rate of 80 mL/min (Temperature = 35 °C). Elution was monitored following absorbance at 250nm. The enantiomeric purity was confirmed by analytical SFC using a Chiralpak IC column (5μm, 150 x 4.6 mm), mobile phase of 20% iPrOH+(0.3% iPrNH₂): 80% CO₂, and a flow rate of 3 mL/min over 7 minutes (Temperature = 35°C). Elution was monitored following absorbance at 250nm. Enantiopurity 100%, which elutes at one peak (1.56 min retention time). MS (ESI) mass calcd. for C₁₂H₁₉NO₃, 225.1; m/z found 170.1 [M+2H-*t*Bu]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 4.42 - 4.15 (m, 1H), 3.62 - 3.34 (m, 2H), 2.49 - 2.32 (m, 3H), 2.21 - 2.06 (m, 1H), 1.97 - 1.85 (m, 1H), 1.79 - 1.68 (m, 1H), 1.66 - 1.56 (m, 1H), 1.45 (s, 9H).

Intermediate C-4C: (1R,4S)-tert-butyl 6-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate




The title compound was obtained as a single enantiomer by Chiral SFC purification of Intermediate C-4A performed using using a Chiralpak IC column (5 μ m, 250 x 20 mm), mobile phase of 20% iPrOH: 80% CO₂, and a flow rate of 80 mL/min (Temperature = 35 °C). Elution was monitored following absorbance at 250nm. The enantiomeric purity was confirmed by analytical SFC using a Chiralpak IC column (5 μ m, 150 x 4.6 mm), mobile phase of 20% iPrOH+(0.3% iPrNH₂): 80% CO₂, and a flow rate of 3 mL/min over 7 minutes (Temperature = 35°C). Elution was monitored following absorbance at 250nm. Enantiopurity 100%, which elutes at one peak (2.18 min retention time). MS (ESI) mass calcd. for C₁₂H₁₉NO₃, 225.1; m/z found 170.1 [M+2H-*t*Bu]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 4.41 - 4.13 (m, 1H), 3.57 - 3.31 (m, 2H), 2.46 - 2.31 (m, 3H), 2.22 - 2.08 (m, 1H), 1.96 - 1.86 (m, 1H), 1.83 - 1.68 (m, 1H), 1.67 - 1.56 (m, 1H), 1.45 (s, 9H).

Intermediate C-5A: (R/S)-tert-Butyl 6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate



A 1 M solution of L-Selectride (1 M in THF, 1.7 mL, 1.7 mmol) was added to a solution of intermediate C-4A (150 mg, 0.666 mmol) in dry THF (3 mL) at -78 °C, and the reaction mixture was stirred at that temperature for 3 h. Then, the reaction mixture was warmed to 0 °C and a 3 M NaOH (0.71 mL) solution was added followed by a solution of H₂O₂ (30% w/w in H₂O, 0.37 mL). The resulting mixture was warmed to room temperature and stirred for 2 h. The biphasic mixture was then concentrated in vacuo to remove THF and the aqueous layer extracted with DCM (3X). The combined organics were washed with brine, dried with Na₂SO₄, filtered, and concentrated to an oil, which was further purified by silica gel chromatography (10-100% EtOAc in hexanes), to give intermediate C-5A as a white solid (114 mg, 0.502 mmol, 75%). MS (ESI) mass calcd. for C₁₂H₂₁NO₃, 227.2; m/z found 172.2 [M+2H-*t*Bu]⁺. ¹H NMR (500 MHz, Methanol-d₄) δ 3.97 - 3.86 (m, 2H), 3.38 - 3.20 (m, 2H), 2.09 - 2.00 (m, 1H), 1.96 - 1.87 (m, 1H), 1.87 - 1.79 (m, 1H), 1.62 - 1.48 (m, 3H), 1.46 (d, *J* = 4.9 Hz, 9H), 1.43 - 1.37 (m, 1H).


Intermediate C-5B: (1S,4R,6R)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate



Intermediate C-5B was prepared analogous to Intermediate C-5A substituting racemic


- 5 Intermediate C-4A for enantiopure Intermediate C-4B. MS (ESI) mass calcd. for $C_{12}H_{21}NO_3$, 227.2; m/z found 172.1 $[M+2H-tBu]^+$.

Intermediate C-6A: (R/S)-tert-butyl 6-(hydroxyimino)-2-azabicyclo[2.2.2]octane-2-carboxylate




- 10 To a flask containing Intermediate C-4A (324 mg, 1.44 mmol) dissolved in EtOH (5 mL) was added NEt_3 (1 mL, 7.2 mmol), and hydroxylamine hydrochloride (300 mg, 4.32 mmol) and the reaction mixture was heated to 70 °C overnight. Upon completion, the reaction mixture was cooled to room temperature, concentrated, diluted with H_2O , and the aqueous layer extracted with EtOAc (3X). The combined organics were then dried with $MgSO_4$, filtered, and concentrated to provide
- 15 intermediate C-6A as a light purple solid (351 mg) which was used without further purification. MS (ESI) mass calcd. for $C_{12}H_{20}N_2O_3$, 240.2; m/z found 184.1 $[M+2H-tBu]^+$.

Intermediate C-6B: (1S,4R)-tert-butyl 6-(hydroxyimino)-2-azabicyclo[2.2.2]octane-2-carboxylate



- 20 Intermediate C-6B was prepared analogous to Intermediate C-6A substituting racemic Intermediate C-4A for enantiopure Intermediate C-4B. MS (ESI) mass calcd. for $C_{12}H_{20}N_2O_3$, 240.2; m/z found 241.2 $[M+H]^+$.


Intermediate C-7A: (R/S)-tert-butyl 6-amino-2-azabicyclo[2.2.2]octane-2-carboxylate



A mixture of NiCl_2 (373 mg, 2.88 mmol) and intermediate C-6A (346 mg) in MeOH (12 mL) was cooled to $-35\text{ }^\circ\text{C}$ and NaBH_4 (1.09 g, 28.8 mmol) was added portion wise to the reaction mixture. Upon complete addition of NaBH_4 , the reaction mixture was warmed to room temperature.

- 5 After 2 h at room temperature the reaction mixture was quenched with H_2O . Celite was added and the crude reaction mixture was stirred for 30 min. The crude reaction mixture was filtered and the filtrate concentrated under reduced pressure to a dark brown residue, which was re-dissolved in a mixture of DCM and 15% aqueous NaOH solution. The aqueous layer was extracted with DCM (3X). The combined organics were filtered through Celite, dried with MgSO_4 , filtered, and
- 10 concentrated to provide intermediate C-7A (308 mg) as a brown oil which was used without further purification. MS (ESI) mass calcd. for $\text{C}_{12}\text{H}_{22}\text{N}_2\text{O}_2$, 226.2; m/z found 227.2 $[\text{M}+\text{H}]^+$.


Intermediate C-7B: (1S,4R,6R)-tert-butyl 6-amino-2-azabicyclo[2.2.2]octane-2-carboxylate



- 15 Intermediate C-7B was prepared analogous to Intermediate C-7A substituting racemic Intermediate C-6A for enantiopure Intermediate C-6B. MS (ESI) mass calcd. for $\text{C}_{12}\text{H}_{22}\text{N}_2\text{O}_2$, 226.2; m/z found 227.2 $[\text{M}+\text{H}]^+$.

Alternative routes (2-azabicyclo[2.2.1]heptan-6-ol):


- 20 Intermediate C-8: (R/S)-2-((R)-1-phenylethyl)-2-azabicyclo[2.2.2]oct-5-ene



Intermediate C-8 was prepared according to the procedure of C. Chiu *et al.* [*Synthetic Communications* **1996**, 26, 577-584] on a similar substrate. To a solution of H_2O (5.4 mL) and 12


M HCl (5 mL) was added (+)- α -methyl-benzylamine (6.95 mL, 54.6 mmol), and the reaction mixture was stirred at room temperature for 5 minutes. Then, aqueous formaldehyde (4.06 mL, 54.6 mmol, 37 wt. % in H₂O) and 1,3-cyclohexadiene (4 mL, 42 mmol) were added and the reaction mixture heated to 55 °C for 4 days. The reaction mixture was cooled to room temperature and
5 diluted with H₂O and the crude reaction mixture extracted with Et₂O (2X). The aqueous phase was basified with KOH, extracted with Et₂O (2X), saturated with solid NaCl, and extracted once more with Et₂O. The combined organics were dried with Na₂SO₄, filtered, and concentrated to give an orange oil, which was further purified by silica gel chromatography (0-10% MeOH (with 10% 2 M NH₃) in DCM) to give intermediate C-8 as a yellow-orange oil (*ca.* 3:1 dr). Intermediate C-8 was
10 carried forward as a mixture of diastereoisomers. MS (ESI) mass calcd. for C₁₅H₁₉N, 213.2; *m/z* found 214.2 [M+H]⁺.

Intermediate C-9: (R/S)-2-((R)-1-phenylethyl)-2-azabicyclo[2.2.2]octan-6-ol




Intermediate C-9 was synthesized according to the procedure of F. Carroll *et al.* [*J. Med. Chem.* **1992**, 35, 2184-2191] on a similar substrate. A 1 M solution of BH₃-THF (1 M BH₃-THF in THF, 68 mL, 68 mmol) was added dropwise via addition funnel to a stirred solution of intermediate C-8 (2.88 g, 13.5 mmol) in THF (42 mL) at 0 °C. Upon complete addition of BH₃-THF, the reaction mixture was stirred at 0 °C for 2 h. Then, excess BH₃ was quenched with a solution of THF-H₂O. A
20 4 M NaOH (8 mL) solution was added followed by the dropwise addition of H₂O₂ (30% w/w in H₂O, 8 mL), and the reaction mixture was warmed to 40 °C and stirred for 2 h. The biphasic mixture was then cooled to room temperature and K₂CO₃ added in one portion. The resulting mixture was concentrated under reduced pressure to remove THF and re-dissolved in DCM. The crude reaction mixture was washed with H₂O and the aqueous phase extracted with DCM (3X). The
25 combined organics were then washed with brine, dried with Na₂SO₄, filtered, and concentrated and the concentrate was further purified by silica gel chromatography (0-10% MeOH (with 10% 2 M NH₃) in DCM) to give intermediate C-9 as an orange-brown foam (1.35 g, 5.84 mmol, 43%). MS (ESI) mass calcd. for C₁₅H₂₁NO, 231.2; *m/z* found 232.2 [M+H]⁺.

Intermediate C-10: (R/S)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate




Intermediate C-10 was prepared analogous to Intermediate C-3 substituting racemic Intermediate C-2 for schlemic Intermediate C-9. MS (ESI) mass calcd. for $C_{12}H_{21}NO_3$, 227.2; m/z found 172.2 $[M+2H-tBu]^+$. Intermediate C-10 can be carried forward to Intermediate C-4A, which can be obtained as a single enantiomer (Intermediate C-4B or C-4C) by Chiral SFC purification as described above.

Intermediate C-11: (R/S)-2-benzyl-6-hydroxy-2-azabicyclo[2.2.2]octan-3-one




Intermediate C-11 was synthesized according to the procedure in US3674793. A mixture of 7-oxabicyclo[4.1.0]heptane-3-carboxylic acid methyl ester (268.0 g, 1.72 mol) and benzylamine (170.0 g, 1.58 mol) in ethanol (1.3 L) was heated to reflux for 20 h and the reaction mixture was evaporated. The oily residue was stirred at 200 °C for 2 h to distill off low-boiling byproducts. The resulting oil was cooled to room temperature, diluted with a solution of sodium hydroxide (51.0 g, 1.27 mol) in methanol (1.0 L) and heated to reflux for 10 min. The reaction mixture was cooled to room temperature and diluted with a mixture of brine (1.5 L) and water (750 mL). The aqueous layer was extracted with dichloromethane (3X) and the combined organic layers were dried with $MgSO_4$, filtered, and concentrated. The oily residue was triturated with diisopropyl ether (400 mL) to give intermediate C-11 (190.0 g, 0.82 mol, 48%) as a white solid. MS (ESI) mass calcd. for $C_{14}H_{17}NO_2$, 231.1; m/z found 232.1 $[M+H]^+$. ^1H NMR (300 MHz, DMSO- d_6) δ 7.43 – 7.12 (m, 5H), 4.99 (d, J = 3.3 Hz, 1H), 4.48 (d, J = 14.7 Hz, 1H), 4.39 (d, J = 14.7 Hz, 1H), 3.76 – 3.61 (m, 1H), 3.31 – 3.23 (m, 1H), 2.38 – 2.24 (m, 1H), 2.15 – 1.91 (m, 2H), 1.79 – 1.51 (m, 2H), 1.45 – 1.16 (m, 2H).

Intermediate C-2: 2-benzyl-2-azabicyclo[2.2.2]octan-6-ol



To a suspension of lithium aluminum hydride (54.4 g, 1.43 mol) in THF (180 mL) under argon at 0 °C was added a solution of intermediate C-11 (170.0 g, 716.4 mmol) dropwise as a solution in THF (720 mL). The reaction mixture was allowed to warm to room temperature, then carefully heated to 60 °C and stirred for 2 h. The resulting suspension was cooled to 0 °C and diluted with diethyl ether (540 mL). To this suspension was added sodium sulfate decahydrate (450 g) in small portions. The mixture was stirred at room temperature for 16 h. The suspension was filtered and the filtrate evaporated. The residue was triturated with hexane (100 mL) to give intermediate C-2 (130.2 g, 0.60 mol, 84%) as a white solid. MS (ESI) mass calcd. for C₁₄H₁₉NO, 217.2; m/z found 218.3 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 7.41 – 7.25 (m, 4H), 7.25 – 7.10 (m, 1H), 4.50 (d, *J* = 3.6 Hz, 1H), 3.97 – 3.86 (m, 1H), 3.71 (d, *J* = 14.7 Hz, 1H), 3.66 (d, *J* = 14.4 Hz, 1H), 2.61 (d, *J* = 9.3 Hz, 1H), 2.48 – 2.32 (m, 2H), 1.94 (t, *J* = 11.1 Hz, 1H), 1.82 – 1.66 (m, 2H), 1.66 – 1.56 (m, 1H), 1.52 – 1.37 (m, 2H), 1.32 – 1.15 (m, 1H). Intermediate C-2 can be carried forward to Intermediate C-4A, which can be obtained as a single enantiomer (Intermediate C-4B or C-4C) by Chiral SFC purification as described above.

Example 1: (R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



20

Step A: (R/S)-tert-butyl 6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-8 (100 mg, 0.469 mmol) dissolved in DMF (3 mL) was added NaH (28 mg, 0.70 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-(trifluoromethyl)pyrazine (0.087 mL, 0.70 mmol) was then added and the mixture heated to 90 °C. After heating at 90 °C for 3.5 h, the mixture was cooled to room temperature,

25


quenched with saturated NH_4Cl solution, and diluted with EtOAc and H_2O . The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , brine, dried with MgSO_4 , filtered and concentrated. Purification via silica gel chromatography (0-20% EtOAc in hexanes) gave the title compound (151 mg, 0.420 mmol, 90%). MS (ESI) mass calcd. for $\text{C}_{16}\text{H}_{20}\text{F}_3\text{N}_3\text{O}_3$, 359.1; m/z found 304.1 $[\text{M}+2\text{H}-t\text{Bu}]^+$. ^1H NMR (400 MHz, Chloroform- d , compound present as a mixture of rotamers) δ 8.46 - 8.41 (m, 1H), 8.27 - 8.24 and 8.16 - 8.12 (2m, 1H), 5.45 - 5.30 (m, 1H), 4.63 - 4.48 (m, 1H), 3.48 - 3.33 (m, 1H), 3.28 - 3.13 (m, 1H), 2.67 - 2.54 (m, 1H), 2.32 - 2.19 (m, 1H), 1.85 - 1.04 (m, 12H).

Step B: (R/S)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane $\cdot x\text{HCl}$.

To the title compound of step A (151 mg, 0.42 mmol) in EtOAc (1 mL) was added 4 M HCl in dioxane (6 mL). After 3.25 h, the reaction was concentrated to give the title compound of step B which was used without further purification. MS (ESI) mass calcd. for $\text{C}_{11}\text{H}_{12}\text{F}_3\text{N}_3\text{O}$, 259.1; m/z found 260.1 $[\text{M}+\text{H}]^+$.


Step C: (R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (43 mg) and intermediate A-1 (24 mg, 0.13 mmol) in DMF (1.5 mL) was added DIPEA (0.4 mL, 2.32 mmol) and HATU (48 mg, 0.13 mmol). Upon completion of the reaction, purification was performed using Agilent Prep Method X to give the title compound (9 mg). MS (ESI) mass calcd. for $\text{C}_{20}\text{H}_{17}\text{F}_3\text{N}_6\text{O}_2$, 430.1; m/z found 431.1 $[\text{M}+\text{H}]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.80:0.20), major rotamer reported) δ 8.25 (s, 1H), 8.02 - 7.98 (m, 1H), 7.87 - 7.79 (m, 3H), 7.32 (ddd, $J = 8.2, 7.4, 1.5$ Hz, 1H), 7.04 (dd, $J = 7.7, 1.5$ Hz, 1H), 6.81 (t, $J = 7.5$ Hz, 1H), 4.97 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.03 - 3.96 (m, 1H), 3.62 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.44 (dd, $J = 10.9, 1.5$ Hz, 1H), 2.68 - 2.63 (m, 1H), 2.27 - 2.18 (m, 1H), 1.48 (dt, $J = 13.6, 3.6$ Hz, 1H), 1.40 (d, $J = 10.6$ Hz, 1H), 1.33 - 1.25 (m, 1H).

Example 2: (R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 1 substituting intermediate A-1 with intermediate A-20.
 MS (ESI) mass calcd. for $C_{20}H_{18}F_3N_7O_2$, 445.1; m/z found 446.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.78:0.22), major rotamer reported) δ
 5 8.30 - 8.27 (m, 1H), 8.05 - 8.00 (m, 2H), 7.83 (s, 2H), 7.11 - 7.07 (m, 1H), 5.01 (dt, J = 10.2, 3.2 Hz, 1H), 4.27 - 4.23 (m, 1H), 3.70 (dt, J = 11.0, 3.2 Hz, 1H), 3.49 (dd, J = 11.0, 1.4 Hz, 1H), 2.72 - 2.67 (m, 1H), 2.30-2.21 (m, 4H), 1.60 - 1.48 (m, 3H).

Example 3: (R/S)-(3-ethoxyisoquinolin-4-yl)((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-
 10 azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 1 substituting intermediate A-1 with intermediate A-21.
 MS (ESI) mass calcd. for $C_{23}H_{21}F_3N_4O_3$, 458.2; m/z found 459.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, major rotamer reported) δ
 15 8.72 (d, J = 0.8 Hz, 1H), 7.77 - 7.72 (m, 1H), 7.71 - 7.68 (m, 1H), 7.64 - 7.58 (m, 2H), 7.52 - 7.47 (m, 1H), 7.30 (ddd, J = 8.1, 6.8, 1.1 Hz, 1H), 4.87 (dt, J = 10.2, 3.4 Hz, 1H), 4.68 - 4.39 (m, 3H), 3.87 (dt, J = 11.1, 3.2 Hz, 1H), 3.56 (dd, J = 11.1, 1.6 Hz, 1H), 2.83 - 2.77 (m, 1H), 2.35 - 2.26 (m, 1H), 2.01 - 1.95 (m, 1H), 1.84 - 1.75 (m, 1H), 1.56 - 1.38 (m, 4H).

Example 4: (R/S)-5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 1 substituting intermediate A-1 with intermediate A-19.
 MS (ESI) mass calcd. for $C_{20}H_{18}F_3N_7O_2$, 445.1; m/z found 446.1 $[M+H]^+$. ^1H NMR (400 MHz,
 Chloroform- d , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ
 5 8.34 (d, $J = 1.3$ Hz, 1H), 8.00 - 7.95 (m, 2H), 7.84 - 7.80 (m, 2H), 7.62 - 7.59 (m, 1H), 5.10 (dt, $J =$
 10.3, 3.2 Hz, 1H), 4.27 - 4.24 (m, 1H), 3.71 (dt, $J = 11.0$, 3.2 Hz, 1H), 3.49 (dd, $J = 11.0$, 1.5 Hz,
 1H), 2.76 - 2.70 (m, 1H), 2.34 - 2.22 (m, 4H), 1.71 - 1.54 (m, 3H).

Example 5: (R/S)-(5-(4-fluorophenyl)-2-methylthiazol-4-yl)(6-((5-(trifluoromethyl)pyridin-2-
 10 yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Step A: (R/S)-tert-butyl 6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-
 azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-8 (200 mg, 0.94 mmol) dissolved in
 DMF (5 mL) was added NaH (56 mg, 1.41 mmol, 60% dispersion in mineral oil). After 5 minutes
 15 2-chloro-5-(trifluoromethyl)pyridine (340 mg, 1.87 mmol) was then added and the mixture heated
 to 80 °C. After heating at 80 °C for 5.75 h, the mixture was cooled to room temperature, quenched
 with saturated NH_4Cl solution, diluted with H_2O , and the aqueous layer extracted with EtOAc (3X).
 The combined organics were washed with H_2O , brine, dried with $MgSO_4$, filtered and concentrated.
 Purification via silica gel chromatography (0-30% EtOAc in hexanes) gave the title compound (300
 20 mg, 0.84 mmol, 89%). MS (ESI) mass calcd. for $C_{17}H_{21}F_3N_2O_3$, 358.2; m/z found 359.2 $[M+H]^+$.
 ^1H NMR (400 MHz, Chloroform- d) δ 8.47 - 8.37 (m, 1H), 7.84 - 7.69 (m, 1H), 6.87 - 6.68 (m, 1H),
 5.45 - 5.29 (m, 1H), 4.63 - 4.52 (m, 1H), 3.47 - 3.34 (m, 1H), 3.26 - 3.11 (m, 1H), 2.66 - 2.52 (m,
 1H), 2.31 - 2.16 (m, 1H), 1.80 - 1.09 (series of m, 12H).

Step B: (R/S)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane · xHCl.

To the title compound of step A (300 mg, 0.84 mmol) in EtOAc (1 mL) was added 4 M HCl in dioxane (5 mL). After 7 h, the reaction was concentrated to give the title compound of step B (243 mg) which was used without further purification. MS (ESI) mass calcd. for $C_{12}H_{13}F_3N_2O$, 258.1; m/z found 259.1 $[M+H]^+$.


Step C: (R/S)-(5-(4-fluorophenyl)-2-methylthiazol-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (30 mg) and intermediate A-14 (24 mg, 0.10 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (38 mg, 0.10 mmol). Upon completion, the reaction was diluted with H₂O and the aqueous layer extracted with EtOAc (3X). The combined organics were washed with H₂O, brine, dried with MgSO₄, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (40.3 mg). MS (ESI) mass calcd. for $C_{23}H_{19}F_4N_3O_2S$, 477.1 m/z found 478.1 $[M+H]^+$. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.19 - 8.14 (m, 1H), 7.63 - 7.57 (m, 1H), 7.49 - 7.41 (m, 2H), 7.12 - 7.01 (m, 2H), 6.61 - 6.54 (m, 1H), 5.03 (dt, J = 10.3, 3.2 Hz, 1H), 4.64 - 4.58 (m, 1H), 3.56 - 3.51 (m, 2H), 2.66 - 2.58 (m, 1H), 2.44 (s, 3H), 2.26 - 2.15 (m, 1H), 1.53 (d, J = 10.8 Hz, 1H), 1.45 - 1.35 (m, 2H).

Example 6: (R/S)-(6-methylimidazo[2,1-b]thiazol-5-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 5 substituting intermediate A-14 with intermediate A-17. MS (ESI) mass calcd. for $C_{19}H_{17}F_3N_4O_2S$, 422.1; m/z found 423.1 $[M+H]^+$. ¹H NMR (400 MHz, Chloroform-d) δ 8.08 (br.s, 1H), 7.54 - 7.37 (m, 2H), 6.68 (d, J = 4.5 Hz, 1H), 6.53 - 6.41 (m, 1H), 5.22 - 5.08 (m, 1H), 4.98 - 4.85 (m, 1H), 3.87 - 3.65 (m, 1H), 3.57 - 3.46 (m, 1H), 2.77 - 2.71 (m, 1H), 2.39 (s, 3H), 2.36 - 2.24 (m, 1H), 2.04 - 1.95 (m, 1H), 1.85 (d, J = 10.5 Hz, 1H), 1.49 (dt, J = 13.6, 3.5 Hz, 1H).

Example 7: (R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-1. MS (ESI) mass calcd. for

- 5 $C_{21}H_{18}F_3N_5O_2$, 429.2; m/z found 430.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, major rotamer reported) δ 8.02 - 7.99 (m, 1H), 7.87 - 7.74 (m, 4H), 7.35 - 7.29 (m, 1H), 7.03 (dd, J = 7.7, 1.5 Hz, 1H), 6.84 - 6.78 (m, 2H), 5.00 (dt, J = 10.1, 3.3 Hz, 1H), 4.07 - 4.03 (m, 1H), 3.61 (dt, J = 11.0, 3.2 Hz, 1H), 3.40 (dd, J = 10.9, 1.5 Hz, 1H), 2.65 - 2.60 (m, 1H), 2.25 - 2.16 (m, 1H), 1.45 - 1.37 (m, 2H), 1.33 - 1.25 (m, 1H).

10


Example 8: (R/S)-(3-ethoxyisoquinolin-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 5 using intermediate A-21 and additional purification using

- 15 Shimadzu Prep Method X. MS (ESI) mass calcd. for $C_{24}H_{22}F_3N_3O_3$, 457.2; m/z found 458.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d) δ 8.71 (s, 1H), 7.81 - 7.76 (m, 1H), 7.71 - 7.68 (m, 1H), 7.61 (d, J = 8.2 Hz, 1H), 7.46 (ddd, J = 8.4, 6.8, 1.3 Hz, 1H), 7.29 - 7.23 (buried m, 1H), 7.10 (dd, J = 8.7, 2.5 Hz, 1H), 6.11 (d, J = 8.6 Hz, 1H), 4.91 (dt, J = 10.3, 3.4 Hz, 1H), 4.68 - 4.66 (m, 1H), 4.65 - 4.58 (m, 1H), 4.49 - 4.40 (m, 1H), 3.86 (dt, J = 11.2, 3.2 Hz, 1H), 3.58 (dd, J = 11.1, 1.7 Hz, 1H), 2.84 - 2.76 (m, 1H), 2.36 - 2.24 (m, 1H), 1.99 - 1.94 (m, 1H), 1.80 (d, J = 10.4 Hz, 1H), 1.50 (dt, J = 13.7, 3.8 Hz, 1H), 1.44 (t, J = 7.1 Hz, 3H).
- 20


Example 9: (R/S)-(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 5 using intermediate A-19. MS (ESI) mass calcd. for $C_{21}H_{19}F_3N_6O_2$, 444.2; m/z found 445.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 7.98 - 7.95 (m, 1H), 7.95 - 7.92 (m, 1H), 7.82 (s, 2H), 7.71 (dd, J = 8.8, 2.6 Hz, 1H), 7.67 - 7.64 (m, 1H), 6.88 - 6.83 (m, 1H), 5.02 (dt, J = 10.2, 3.2 Hz, 1H), 4.28 - 4.21 (m, 1H), 3.68 (dt, J = 10.9, 3.2 Hz, 1H), 3.45 (dd, J = 11.0, 1.2 Hz, 1H), 2.71 - 2.64 (m, 1H), 2.28 (s, 3H), 2.28 - 2.17 (m, 1H), 1.59 - 1.46 (m, 3H).


10

Example 10: (R/S)-(7-ethoxyquinolin-8-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-25. MS (ESI) mass calcd. for $C_{24}H_{22}F_3N_3O_3$, 457.2; m/z found 458.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5um, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.49 min (major rotamer) at 254 nm.

Example 11: (R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 5 using intermediate A-2. MS (ESI) mass calcd. for $C_{23}H_{18}F_4N_4O_2$, 458.1; m/z found 459.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.82:0.18), major rotamer reported) δ 8.86 (d, $J = 4.9$ Hz, 2H), 8.14 - 8.10 (m, 1H), 7.79 (dd, $J = 8.8, 2.6$ Hz, 1H), 7.30 - 7.26 (m, 1H), 7.10 - 7.03 (m, 1H), 6.95 - 6.81 (m, 3H), 5.06 (dt, $J = 10.2, 3.4$ Hz, 1H), 4.27 - 4.23 (m, 1H), 3.34 - 3.30 (m, 2H), 2.57 - 2.51 (m, 1H), 2.25 - 2.14 (m, 1H), 1.46 - 1.40 (m, 1H), 1.36 (dt, $J = 13.6, 3.6$ Hz, 1H), 0.94 - 0.87 (m, 1H).


- 10 Example 12: (R/S)-4-methoxy-2-(pyrimidin-2-yl)phenyl(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



- To the title compound of Example 5 step B (20 mg) and intermediate A-15 (15 mg, 0.066 mmol) was added DCM (0.8 mL) and DIPEA (0.05 mL, 0.29 mmol). T_3P (0.11 mL, 0.18 mmol, 50% solution in DMF) was then added dropwise and the mixture heated to 45 °C. Upon completion the reaction was quenched with saturated $NaHCO_3$ solution and the aqueous layer extracted with EtOAc (3X). The combined organics were washed saturated $NaHCO_3$ solution, brine, dried with $MgSO_4$, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (9.3 mg). MS (ESI) mass calcd. for $C_{24}H_{21}F_3N_4O_3$, 470.2; m/z found 471.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.82:0.18), major rotamer reported) δ 8.78 (d, $J = 4.8$ Hz, 2H), 8.11 - 8.09 (m, 1H), 7.83 - 7.77 (m, 1H), 7.70 (d, $J = 2.6$ Hz, 1H), 7.20 (t, $J = 4.9$ Hz, 1H), 6.96 (d, $J = 8.4$ Hz, 1H), 6.87 - 6.80 (m, 1H), 6.45 (dd, $J = 8.4, 2.7$ Hz, 1H), 5.03 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.16 - 4.12 (m,

1H), 3.81 (s, 3H), 3.62 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.40 (dd, $J = 10.8, 1.4$ Hz, 1H), 2.66 - 2.60 (m, 1H), 2.26 - 2.16 (m, 1H), 1.45 - 1.35 (m, 2H), 1.29 - 1.17 (m, 1H).


Example 13: (R/S)-4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 5 using intermediate A-5. MS (ESI) mass calcd. for $C_{22}H_{20}F_3N_5O_3$, 459.1; m/z found 460.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.11 - 8.07 (m, 1H), 7.84 - 7.75 (m, 3H), 7.37 (d, $J = 2.5$ Hz, 1H), 6.96 (d, $J = 8.5$ Hz, 1H), 6.81 (d, $J = 8.7$ Hz, 1H), 6.37 (dd, $J = 8.5, 2.5$ Hz, 1H), 5.01 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.08 - 4.01 (m, 1H), 3.80 (s, 3H), 3.58 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.39 (dd, $J = 10.9, 1.4$ Hz, 1H), 2.65 - 2.58 (m, 1H), 2.25 - 2.14 (m, 1H), 1.45 - 1.35 (m, 2H), 1.30 - 1.22 (m, 1H).

An ORTEP of Example 13 is depicted in Figure 1.

Example 14: (R/S)-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-10. MS (ESI) mass calcd. for $C_{21}H_{17}F_4N_5O_2$, 447.1; m/z found 448.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.09 - 8.05 (m, 1H), 7.85 - 7.78 (m, 4H), 7.00 (ddd, $J = 9.0, 7.6, 2.9$ Hz, 1H), 6.82 (d, $J = 8.7$ Hz, 1H), 6.78 (dd, $J = 8.1, 2.9$ Hz,

1H), 5.02 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.06 – 4.01 (m, 1H), 3.59 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.40 (dd, $J = 10.9, 1.5$ Hz, 1H), 2.66 - 2.60 (m, 1H), 2.28 - 2.17 (m, 1H), 1.47 - 1.37 (m, 2H), 1.34 - 1.27 (m, 1H).

An ORTEP of Example 14 is depicted in Figure 2.

5

Example 15: (R/S)-2-methoxy-6-(2H-1,2,3-triazol-2-yl)phenyl(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-13. MS (ESI) mass calcd. for

10 $C_{22}H_{20}F_3N_5O_3$, 459.2; m/z found 460.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, major rotamer reported) δ 8.00 - 7.95 (m, 1H), 7.82 (s, 2H), 7.73 (d, $J = 10.6$ Hz, 1H), 7.46 (dd, $J = 8.2, 0.9$ Hz, 1H), 7.28 - 7.21 (m, 1H), 6.75 - 6.71 (m, 1H), 6.42 (dd, $J = 8.4, 0.9$ Hz, 1H), 4.82 (dt, $J = 10.2, 3.4$ Hz, 1H), 4.18 - 4.12 (m, 1H), 3.63 - 3.58 (m, 1H), 3.57 (s, 3H), 3.37 (dd, $J = 11.0, 1.5$ Hz, 1H), 2.58 - 2.52 (m, 1H), 2.19 - 2.09 (m, 1H), 1.74 - 1.66 (m, 1H), 1.45 - 1.37 (m, 1H), 1.32 - 1.23 (m, 1H).

15


Example 16: (R/S)-(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



20 Prepared analogous to Example 5 using intermediate A-16. MS (ESI) mass calcd. for $C_{21}H_{17}F_4N_5O_2$, 447.1; m/z found 448.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.86:0.14), major rotamer reported) δ 8.14 - 8.09 (m, 1H), 7.89 (s,


2H), 7.83 - 7.78 (m, 1H), 7.16 (ddd, $J = 9.9, 8.1, 1.6$ Hz, 1H), 6.98 - 6.81 (m, 3H), 5.06 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.19 - 4.15 (m, 1H), 3.38 - 3.30 (m, 2H), 2.59 - 2.53 (m, 1H), 2.26 - 2.16 (m, 1H), 1.50 - 1.43 (m, 1H), 1.39 - 1.30 (m, 1H), 1.19 - 1.10 (m, 1H).

- 5 Example 17: (R/S)-(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




- 10 Prepared analogous to Example 5 using intermediate A-22. MS (ESI) mass calcd. for $C_{22}H_{20}F_3N_5O_2$, 443.2 m/z found 444.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.15 - 8.11 (m, 1H), 7.86 - 7.77 (m, 3H), 7.24 - 7.19 (m, 1H), 6.99 - 6.82 (m, 3H), 5.09 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.25 - 4.19 (m, 1H), 3.31 - 3.23 (m, 2H), 2.57 - 2.50 (m, 1H), 2.27 - 2.11 (m, 4H), 1.53 - 1.47 (m, 1H), 1.37 - 1.28 (m, 1H), 1.27 - 1.21 (m, 1H).

- 15 Example 18: (R/S)-(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




- 20 Prepared analogous to Example 5 using intermediate A-11. MS (ESI) mass calcd. for $C_{21}H_{17}F_4N_5O_2$, 447.1; m/z found 448.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 8.04 - 8.02 (m, 1H), 7.85 - 7.72 (m, 4H), 7.32 - 7.26 (m, 1H), 6.92 - 6.88 (m, 1H), 6.61 (td, $J = 8.4, 1.0$ Hz, 1H), 5.00 - 4.94 (m, 1H), 4.03 - 4.00 (m, 1H), 3.65 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.44 (dd, $J = 10.9, 1.5$ Hz, 1H), 2.68 - 2.60 (m, 1H), 2.28 - 2.17 (m, 1H), 1.46 - 1.37 (m, 2H), 1.31 - 1.25 (m, 1H).

Example 19: (R/S)-(5-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




5 Prepared analogous to Example 5 using intermediate A-7. MS (ESI) mass calcd. for $C_{23}H_{18}F_4N_4O_2$, 458.1 m/z found 459.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.77 (d, $J = 4.9$ Hz, 2H), 8.22 (dd, $J = 8.8, 5.6$ Hz, 1H), 8.11 - 8.06 (m, 1H), 7.82 (dd, $J = 8.7, 2.5$ Hz, 1H), 7.19 (t, $J = 4.9$ Hz, 1H), 6.98 (ddd, $J = 8.8, 7.9, 2.7$ Hz, 1H), 6.85 (d, $J = 8.8$ Hz, 1H), 6.77 (dd, $J = 8.6, 2.7$ Hz, 1H), 5.03 (dt, $J = 10.1, 3.4$ Hz, 1H), 4.16 - 4.11 (m, 1H), 3.66 (dt, $J = 10.8, 3.2$ Hz, 1H), 3.42 (dd, $J = 10.8, 1.5$ Hz, 1H), 2.70 - 2.63 (m, 1H), 2.30 - 2.19 (m, 1H), 1.50 - 1.39 (m, 2H), 1.35 - 1.27 (m, 1H).

Example 20: (R/S)-(4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 5 using intermediate A-23. MS (ESI) mass calcd. for $C_{23}H_{18}F_4N_4O_2$, 458.1 m/z found 459.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.84:0.16), major rotamer reported) δ 8.80 (d, $J = 4.8$ Hz, 2H), 8.12 - 8.09 (m, 1H), 7.93 (dd, $J = 9.9, 2.6$ Hz, 1H), 7.83 - 7.78 (m, 1H), 7.25 - 7.21 (m, 1H), 7.01 (dd, $J = 8.4, 5.6$ Hz, 1H), 6.85 - 6.81 (m, 1H), 6.63 - 6.55 (m, 1H), 5.03 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.16 - 4.09 (m, 1H), 3.65 (dt, $J = 10.8, 3.3$ Hz, 1H), 3.46 - 3.36 (m, 1H), 2.69 - 2.62 (m, 1H), 2.29 - 2.17 (m, 1H), 1.48 - 1.37 (m, 2H), 1.31 - 1.23 (m, 1H).

Example 21: (R/S)-(2-(4H-1,2,4-triazol-4-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




- 5 Prepared analogous to Example 5 using intermediate A-9. MS (ESI) mass calcd. for $C_{21}H_{18}F_3N_5O_2$, 429.1 m/z found 430.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.84:0.16), major rotamer reported) δ 8.44 (s, 2H), 8.03 - 7.95 (m, 1H), 7.80 (dd, J = 8.9, 2.5 Hz, 1H), 7.44 - 7.34 (m, 1H), 7.30 - 7.24 (m, 1H), 7.08 - 6.92 (m, 2H), 6.83 (d, J = 8.7 Hz, 1H), 5.04 - 4.94 (m, 1H), 3.90 (br.s, 1H), 3.47 - 3.32 (m, 2H), 2.65 - 2.57 (m, 10 1H), 2.26 - 2.13 (m, 1H), 1.52 - 1.33 (m, 2H), 1.05 - 0.86 (m, 1H).

Example 22: (R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




- 15 Prepared analogous to Example 5 using intermediate A-20. MS (ESI) mass calcd. for $C_{21}H_{19}F_3N_6O_2$, 444.2; m/z found 445.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.82:0.18), major rotamer reported) δ 8.05 - 7.98 (m, 2H), 7.83 (s, 2H), 7.71 - 7.66 (m, 1H), 7.10 - 7.05 (m, 1H), 6.86 - 6.80 (m, 1H), 5.01 - 4.93 (m, 1H), 4.28 - 4.22 (m, 1H), 3.68 (dt, J = 10.9, 3.2 Hz, 1H), 3.46 (dd, J = 10.9, 1.2 Hz, 1H), 2.67 - 2.62 (m, 1H), 2.28 - 20 2.16 (m, 4H), 1.53 - 1.42 (m, 3H).

Example 23: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1R,4S,6S)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



The title compound, absolute configuration confirmed by Example 25, was obtained as a single enantiomer by Chiral SFC purification of Example 22 performed using a Chiralpak IC column (5um 250 x 21 mm), mobile phase of 20% EtOH: 80% CO₂, and a flow rate of 40 mL/min (Temperature = 40 °C). Elution was monitored following absorbance at 270nm. The enantiomeric purity was confirmed by analytical SFC using a Chiralpak IC column (5um 250 x 4.6 mm), mobile phase of 20% EtOH: 80% CO₂, and a flow rate of 2 mL/min over 45 minutes (Temperature = 40 °C). Elution was monitored following absorbance at 270nm. (enantiopurity >98%) which elutes as two peaks with an initial minor peak followed by a second major peak (due to rotamers), 6.77 min and 23.40 min retention time). MS (ESI) mass calcd. for C₂₁H₁₉F₃N₆O₂, 444.2; m/z found 445.2 [M+H]⁺. ¹H NMR data is in agreement with Example 22.

Example 24: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




The title compound, absolute configuration confirmed by Example 25, was obtained as a single enantiomer by Chiral SFC purification of Example 22 performed using a Chiralpak IC column (5um 250 x 21 mm), mobile phase of 20% EtOH: 80% CO₂, and a flow rate of 40 mL/min (Temperature = 40 °C). Elution was monitored following absorbance at 270nm. The enantiomeric purity was confirmed by analytical SFC using a Chiralpak IC column (5um 250 x 4.6 mm), mobile phase of 20% EtOH: 80% CO₂, and a flow rate of 2 mL/min over 45 minutes (Temperature = 40

°C). Elution was monitored following absorbance at 270nm. (enantiopurity >98%) which elutes as two peaks with an initial minor peak followed by a second major peak (due to rotamers), 7.75 min and 11.79 min retention time). MS (ESI) mass calcd. for C₂₁H₁₉F₃N₆O₂, 444.2; m/z found 445.2 [M+H]⁺. ¹H NMR data is in agreement with Example 22.

5

Example 25: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Step A: (1S,4R,6R)-tert-butyl 6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-

- 10 azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (422 mg, 1.98 mmol) dissolved in DMF (8 mL) was added NaH (119 mg, 2.97 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-(trifluoromethyl)pyridine (718 mg, 3.96 mmol) was then added and the mixture heated to 80 °C. After heating at 80 °C for 4.75h, the mixture was cooled to room temperature, quenched with saturated NH₄Cl solution, diluted with H₂O, and the aqueous layer extracted with EtOAc
- 15 (3X). The combined organics were washed with H₂O, brine, dried with MgSO₄, filtered and concentrated. Purification via silica gel chromatography (0-25% EtOAc in hexanes) gave the title compound (622 mg, 1.74 mmol, 88%). MS (ESI) mass calcd. for C₁₇H₂₁F₃N₂O₃, 358.2; m/z found 359.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, compound present as a mixture of rotamers (0.75:0.25)) δ 8.44 - 8.37 (m, 1H), 7.80 - 7.74 (m, 0.75H), 7.73 - 7.66 (m, 0.25H), 6.82 - 6.77 (m,
- 20 0.75H), 6.73 - 6.68 (m, 0.25H), 5.44 - 5.37 (m, 0.25H), 5.34 (dt, *J* = 10.1, 3.2 Hz, 0.75H), 4.58 - 4.53 (m, 1H), 3.44 - 3.34 (m, 1H), 3.20 (dd, *J* = 9.6, 1.3 Hz, 0.75H), 3.13 (d, *J* = 9.5 Hz, 0.25H), 2.61 - 2.52 (m, 1H), 2.29 - 2.15 (m, 1H), 1.79 - 1.58 (m, 2H), 1.47 - 1.23 (m, 3H), 1.12 (s, 7H).


Step B: (1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane · xHCl. To the title compound of step A (622 mg, 1.74 mmol) in EtOAc (1 mL) was added 4M HCl

25 in dioxane (10 mL). After 2h, the reaction was concentrated to give the title compound of step B (507 mg) which was used without further purification. MS (ESI) mass calcd. for C₁₂H₁₃F₃N₂O, 258.1; m/z found 259.1 [M+H]⁺.

Step C: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone


To the title compound of step B (100 mg) and intermediate A-20 (84 mg, 0.37 mmol) in DMF (4 mL) was added DIPEA (0.3 mL, 1.74 mmol) and HATU (142 mg, 0.37 mmol). Upon completion, the reaction was diluted with H₂O and the aqueous layer extracted with EtOAc (3X). The combined organics were washed with H₂O, brine, dried with MgSO₄, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (112 mg). The enantiomeric purity was confirmed by analytical SFC using a Chiralpak IC column (5µm 250 x 4.6 mm), mobile phase of 20% EtOH: 80% CO₂, and a flow rate of 2 mL/min over 45 minutes (Temperature = 40 °C). Elution was monitored following absorbance at 270nm. (100% single enantiomer) which elutes as two peaks with an initial minor peak followed by a second major peak (due to rotamers), 7.69 min and 11.90 min retention time). MS (ESI) mass calcd. for C₂₁H₁₉F₃N₆O₂, 444.2; m/z found 445.2 [M+H]⁺. ¹H NMR data is in agreement with Example 22.

Example 26: (4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-23. MS (ESI) mass calcd. for C₂₃H₁₈F₄N₄O₂, 458.1 m/z found 459.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.80 (d, J = 4.8 Hz, 2H), 8.13 - 8.07 (m, 1H), 7.95 - 7.90 (m, 1H), 7.84 - 7.78 (m, 1H), 7.23 (t, J = 4.8 Hz, 1H), 7.01 (dd, J = 8.4, 5.6 Hz, 1H), 6.87 - 6.81 (m, 1H), 6.59 (ddd, J = 8.5, 7.9, 2.7 Hz, 1H), 5.03 (dt, J = 10.1, 3.3 Hz, 1H), 4.15 - 4.10 (m, 1H), 3.65 (dt, J = 10.8, 3.2 Hz, 1H), 3.44 - 3.38 (m, 1H), 2.69 - 2.62 (m, 1H), 2.29 - 2.18 (m, 1H), 1.48 - 1.37 (m, 2H), 1.34 - 1.23 (m, 1H).


Example 27: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-2.

MS (ESI) mass calcd. for $C_{23}H_{18}F_4N_4O_2$, 458.1 m/z found 459.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.86 (d, $J = 4.9$ Hz, 2H), 8.14 - 8.08 (m, 1H), 7.79 (dd, $J = 8.8, 2.5$ Hz, 1H), 7.30 - 7.26 (m, 1H), 7.10 - 7.02 (m, 1H), 6.95 - 6.80 (m, 3H), 5.06 (dt, $J = 10.3, 3.4$ Hz, 1H), 4.28 - 4.22 (m, 1H), 3.34 - 3.30 (m, 2H), 2.56 - 2.51 (m, 1H), 2.25 - 2.15 (m, 1H), 1.45 - 1.40 (m, 1H), 1.36 (dt, $J = 13.6, 3.6$ Hz, 1H), 0.95 - 0.86 (m, 1H).


- 10 Example 28: (5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-19.

- 15 MS (ESI) mass calcd. for $C_{21}H_{19}F_3N_6O_2$, 444.2 m/z found 445.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.86:0.14), major rotamer reported) δ 7.98 - 7.92 (m, 2H), 7.83 (s, 2H), 7.75 - 7.69 (m, 1H), 7.67 - 7.63 (m, 1H), 6.89 - 6.83 (m, 1H), 5.02 (dt, $J = 10.3, 3.2$ Hz, 1H), 4.27 - 4.21 (m, 1H), 3.69 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.51 - 3.42 (m, 1H), 2.70 - 2.64 (m, 1H), 2.33 - 2.16 (m, 4H), 1.58 - 1.46 (m, 3H).


Example 29: (6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-3.


- 5 MS (ESI) mass calcd. $C_{21}H_{19}F_3N_6O_2$, 444.2 m/z found 445.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.83:0.17), major rotamer reported) δ 8.06 - 8.02 (m, 1H), 7.88 (s, 2H), 7.80 (dd, $J = 8.7, 2.5$ Hz, 1H), 7.31 - 7.24 (m, 1H), 6.82 (d, $J = 8.7$ Hz, 1H), 6.61 (d, $J = 7.8$ Hz, 1H), 4.98 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.06 - 4.02 (m, 1H), 3.62 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.41 (dd, $J = 10.9, 1.5$ Hz, 1H), 2.68 - 2.61 (m, 1H), 2.56 (s, 3H), 2.27 - 2.14 (m, 10 1H), 1.48 - 1.40 (m, 2H), 1.37 - 1.29 (m, 1H).

Example 30: (3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



- 15 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-28.
MS (ESI) mass calcd. $C_{20}H_{17}F_3N_6O_2$, 430.1 m/z found 431.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.80:0.20), major rotamer reported) δ 8.17 (dd, $J = 8.4, 1.5$ Hz, 1H), 7.95 - 7.91 (m, 1H), 7.88 - 7.81 (m, 3H), 7.72 (dd, $J = 8.7, 2.6$ Hz, 1H), 7.20 (dd, $J = 8.3, 4.7$ Hz, 1H), 6.86 (d, $J = 8.8$ Hz, 1H), 5.03 (dt, $J = 10.2, 3.2$ Hz, 1H), 4.27 - 20 4.23 (m, 1H), 3.74 - 3.68 (m, 1H), 3.47 (dd, $J = 11.0, 1.3$ Hz, 1H), 2.71 - 2.66 (m, 1H), 2.29 - 2.19 (m, 1H), 1.64 - 1.48 (m, 3H).


Example 31: (3-fluoro-2-methoxyphenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-18.


- 5 MS (ESI) mass calcd. $C_{20}H_{18}F_4N_2O_3$, 410.1 m/z found 411.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.83:0.17), major rotamer reported) δ 8.01 - 7.97 (m, 1H), 7.74 - 7.71 (m, 1H), 6.92 (ddd, $J = 11.5, 8.1, 1.7$ Hz, 1H), 6.79 (d, 8.7 Hz, 1H), 6.67 - 6.49 (m, 2H), 5.07 (dt, $J = 10.1, 3.2$ Hz, 1H), 4.43 - 4.38 (m, 1H), 3.90 (d, $J = 1.7$ Hz, 3H), 3.69 (dt, $J = 11.1, 3.3$ Hz, 1H), 3.45 (dd, $J = 11.1, 1.5$ Hz, 1H), 2.76 - 2.70 (m, 1H), 2.33 - 2.21 (m, 10 1H), 1.90 - 1.83 (m, 1H), 1.75 - 1.69 (m, 1H), 1.44 (dt, $J = 13.5, 3.6$ Hz, 1H).

Example 32: (3-methyl-2-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



- 15 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-27.
MS (ESI) mass calcd. $C_{23}H_{20}F_3N_3O_3$, 443.1 m/z found 444.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.07 - 8.03 (m, 1H), 7.81 - 7.73 (m, 2H), 7.30 - 7.25 (m, 1H), 7.18 - 7.13 (m, 1H), 6.91 - 6.80 (m, 3H), 5.04 (dt, $J = 10.2, 3.2$ Hz, 1H), 4.22 - 4.17 (m, 1H), 3.49 - 3.41 (m, 1H), 3.40 - 3.33 (m, 1H), 20 2.63 - 2.57 (m, 1H), 2.44 (s, 3H), 2.26 - 2.16 (m, 1H), 1.49 (d, $J = 10.4$ Hz, 1H), 1.41 - 1.26 (m, 2H).


Example 33: (3-fluoro-2-(1H-1,2,3-triazol-1-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-33.


- 5 MS (ESI) mass calcd. $C_{21}H_{17}F_4N_5O_2$, 447.1 m/z found 448.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.76:0.24), major rotamer reported) δ 8.20 - 8.15 (m, 1H), 7.92 - 7.88 (m, 1H), 7.87 - 7.80 (m, 2H), 7.24 - 7.16 (m, 1H), 7.07 - 6.99 (m, 1H), 6.92 - 6.85 (m, 2H), 5.14 (dt, $J = 9.9, 3.2$ Hz, 1H), 4.28 - 4.24 (m, 1H), 3.37 - 3.31 (m, 1H), 3.30 - 3.24 (m, 1H), 2.62 - 2.56 (m, 1H), 2.32 - 2.21 (m, 1H), 1.42 - 1.31 (m, 2H), 0.94 - 0.89 (m, 1H).
- 10

Example 34: (6-methyl-2-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



- 15 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-4. MS (ESI) mass calcd. $C_{21}H_{19}F_3N_6O_2$, 444.2 m/z found 445.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.44 (d, $J = 1.2$ Hz, 1H), 8.09 - 8.05 (m, 1H), 7.84 - 7.78 (m, 2H), 7.28 (d, $J = 7.8$ Hz, 1H), 6.88 - 6.83 (m, 1H), 6.65 (d, $J = 7.8$ Hz, 1H), 5.05 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.13 - 4.06 (m, 1H), 3.73 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.38 (dd, $J = 10.9, 1.5$ Hz, 1H), 2.72 - 2.65 (m, 1H), 2.50 (s, 3H), 2.31 - 2.21 (m, 1H), 1.73 - 1.67 (m, 1H), 1.51 - 1.40 (m, 2H).
- 20

Example 35: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-16.

- 5 MS (ESI) mass calcd. $C_{21}H_{17}F_4N_5O_2$, 447.1 m/z found 448.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.14 - 8.08 (m, 1H), 7.89 (s, 2H), 7.80 (dd, $J = 8.7, 2.5$ Hz, 1H), 7.16 (ddd, $J = 9.9, 8.2, 1.6$ Hz, 1H), 6.98 - 6.81 (m, 3H), 5.06 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.21 - 4.13 (m, 1H), 3.39 - 3.30 (m, 2H), 2.60 - 2.52 (m, 1H), 2.26 - 2.15 (m, 1H), 1.51 - 1.43 (m, 1H), 1.39 - 1.30 (m, 1H), 1.20 - 1.10 (m, 1H).

10

Example 36: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-1.

- 15 MS (ESI) mass calcd. $C_{21}H_{18}F_3N_5O_2$, 429.1 m/z found 430.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.04 - 7.98 (m, 1H), 7.89 - 7.74 (m, 4H), 7.36 - 7.28 (m, 1H), 7.02 (dd, $J = 7.7, 1.5$ Hz, 1H), 6.85 - 6.77 (m, 2H), 4.99 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.10 - 4.00 (m, 1H), 3.61 (dt, $J = 10.9, 3.3$ Hz, 1H), 3.40 (dd, $J = 10.9, 1.5$ Hz, 1H), 2.67 - 2.58 (m, 1H), 2.26 - 2.15 (m, 1H), 1.47 - 1.23 (m, 3H).

20


Example 37: (3-ethoxy-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-8.


- 5 MS (ESI) mass calcd. $C_{21}H_{22}F_3N_3O_3$, 421.2 m/z found 422.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.83:0.17), major rotamer reported) δ 7.92 - 7.88 (m, 1H), 7.71 - 7.66 (m, 1H), 6.92 (d, J = 8.5 Hz, 1H), 6.87 - 6.82 (m, 2H), 5.00 (dt, J = 10.2, 3.3 Hz, 1H), 4.68 - 4.63 (m, 1H), 4.05 - 3.85 (m, 2H), 3.72 (dt, J = 11.0, 3.2 Hz, 1H), 3.51 (dd, J = 11.0, 1.6 Hz, 1H), 2.74 - 2.68 (m, 1H), 2.31 - 2.16 (m, 4H), 1.96 - 1.88 (m, 1H), 1.78 - 1.70 (m, 1H), 1.48 (dt, J = 13.5, 3.6 Hz, 1H), 1.43 - 1.35 (m, 3H).
- 10

Example 38: (2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




- 15 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-6 and substituting purification by Agilent Prep Method X by silica gel chromatography (15-80% EtOAc (with 10% MeOH) in hexanes). MS (ESI) mass calcd. $C_{23}H_{18}F_4N_4O_2$, 458.1; m/z found 459.1 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.78:0.22), major rotamer reported) δ 8.81 (d, J = 4.9 Hz, 2H), 8.11 - 8.05 (m, 1H), 8.05 - 8.00 (m, 1H), 7.77 (dd, J = 8.7, 2.3 Hz, 1H), 7.31 - 7.27 (m, 1H), 7.23 (t, J = 4.8 Hz, 1H), 6.91 (d, J = 8.7 Hz, 1H), 6.72 - 6.64 (m, 1H), 4.97 (dt, J = 10.1, 3.4 Hz, 1H), 4.14 - 4.09 (m, 1H), 3.68 (dt, J = 10.9, 3.2 Hz, 1H), 3.46 (dd, J = 10.9, 1.5 Hz, 1H), 2.65 (s, 1H), 2.28 - 2.18 (m, 1H), 1.48 - 1.38 (m, 2H), 1.25 - 1.18 (m, 1H).
- 20

Example 39: (2-methoxy-6-(1H-pyrazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




- 5 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-30. MS (ESI) mass calcd. $C_{23}H_{21}F_3N_4O_3$, 458.2; m/z found 459.3 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, major rotamer reported) δ 8.00 (s, 1H), 7.75 (dd, J = 8.7, 2.6 Hz, 1H), 7.62 - 7.57 (m, 1H), 7.34 - 7.26 (m, 1H), 7.25 - 7.21 (m, 1H), 6.76 (d, J = 8.7 Hz, 1H), 6.53 (d, J = 2.0 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H), 4.84 (dt, J = 10.2, 3.4 Hz, 1H), 4.15 (s, 1H), 3.54 - 3.46 (m, 4H), 3.34 (d, J = 10.8 Hz, 1H), 2.49 (s, 1H), 2.19 - 2.07 (m, 1H), 1.55 - 1.22 (m, 3H).
- 10

Example 40: (2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



- 15 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-24. MS (ESI) mass calcd. $C_{24}H_{21}F_3N_4O_3$, 470.2; m/z found 471.1 $[M+H]^+$. Analytical HPLC using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 2min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature = 45 $^{\circ}C$). R_t = 2.01 and 2.24 min (major rotamers) at 254 nm.
- 20


Example 41: (2-(1,4-dimethyl-1H-pyrazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-31.


- 5 MS (ESI) mass calcd. $C_{24}H_{23}F_3N_4O_2$, 456.2; m/z found 457.2 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.74:0.26), major rotamer reported) δ 7.95 - 7.90 (m, 1H), 7.75 (dd, J = 9.0, 1.7 Hz, 1H), 7.39 (s, 1H), 7.30 - 7.27 (m, 1H), 7.13 (dd, J = 7.7, 0.7 Hz, 1H), 7.03 (dd, J = 7.7, 0.8 Hz, 1H), 6.91 - 6.87 (m, 1H), 6.80 (d, J = 8.8 Hz, 1H), 4.96 - 4.91 (m, 1H), 4.05 - 4.03 (m, 1H), 3.61 (s, 3H), 3.39 - 3.35 (m, 1H), 3.34 - 3.29 (m, 1H), 2.54 - 2.49 (m, 1H), 2.19 - 2.10 (m, 1H), 2.08 (s, 3H), 1.44 - 1.34 (m, 2H), 0.95 - 0.89 (m, 1H).
- 10

Example 42: (1H-indol-7-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



- 15 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-29 and substituting purification by Agilent Prep Method X by silica gel chromatography (0-60% EtOAc (with 10% MeOH) in hexanes). MS (ESI) mass calcd. $C_{21}H_{18}F_3N_3O_2$, 401.1; m/z found 402.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO- d_6) δ 10.82 (s, 1H), 7.92 (br. s, 1H), 7.62 (dd, J = 8.9, 2.7 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 7.21 (t, J = 2.8 Hz, 1H), 6.93 (d, J = 7.3 Hz, 1H), 6.69 (t, J = 7.5 Hz, 1H), 6.57 (d, J = 8.7 Hz, 1H), 6.32 - 6.25 (m, 1H), 5.06 (dt, J = 10.0, 3.1 Hz, 1H), 4.67 (br. s, 1H), 3.60 - 3.53 (m, 1H), 3.52 - 3.44 (m, 1H), 2.70 - 2.62 (m, 1H), 2.29 - 2.17 (m, 1H), 2.06 - 1.99 (m, 1H), 1.73 (d, J = 10.2 Hz, 1H), 1.30 (dt, J = 13.4, 3.5 Hz, 1H).
- 20


Example 43: (5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-10.


- 5 MS (ESI) mass calcd. for $C_{21}H_{17}F_4N_5O_2$, 447.2; m/z found 448.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.09 - 8.03 (m, 1H), 7.84 - 7.81 (m, 1H), 7.81 - 7.78 (m, 3H), 7.05 - 6.95 (m, 1H), 6.82 (d, J = 8.7 Hz, 1H), 6.78 (dd, J = 8.1, 2.9 Hz, 1H), 5.01 (dt, J = 10.1, 3.3 Hz, 1H), 4.07 - 3.99 (m, 1H), 3.58 (dt, J = 11.0, 3.2 Hz, 1H), 3.40 (dd, J = 10.9, 1.5 Hz, 1H), 2.67 - 2.60 (m, 1H), 2.29 - 2.17 (m, 1H), 1.46 - 1.37 (m, 2H), 1.33 - 1.27 (m, 1H).
- 10

Example 44: (4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



- 15 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-12. MS (ESI) mass calcd. for $C_{21}H_{17}F_4N_5O_2$, 447.2; m/z found 448.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.13 - 8.07 (m, 1H), 7.83 (s, 2H), 7.81 - 7.78 (m, 1H), 7.63 (dd, J = 9.5, 2.5 Hz, 1H), 7.02 (dd, J = 8.5, 5.9 Hz, 1H), 6.82 (d, J = 8.7 Hz, 1H), 6.52 (td, J = 8.1, 2.5 Hz, 1H), 5.01 (dt, J = 10.2, 3.3 Hz, 1H), 4.03 (s, 1H), 3.63 (dt, J = 11.0, 3.2 Hz, 1H), 3.40 (dd, J = 10.9, 1.4 Hz, 1H), 2.68 - 2.61 (m, 1H), 2.28 - 2.16 (m, 1H), 1.46 - 1.38 (m, 2H), 1.38 - 1.28 (m, 1H).
- 20


Example 45: (2-bromo-3-fluorophenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-32.


- 5 MS (ESI) mass calcd. for $C_{19}H_{15}BrF_4N_2O_2$, 458.0; m/z found 459.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.82:0.18), major rotamer reported) δ 8.03 (s, 1H), 7.78 (dd, $J = 8.7, 2.5$ Hz, 1H), 6.94 (td, $J = 8.3, 1.5$ Hz, 1H), 6.87 - 6.81 (m, 1H), 6.73 (br. s, 1H), 6.63 (br. s, 1H), 5.15 - 5.06 (m, 1H), 4.23 (br. s, 1H), 3.73 (dt, $J = 11.1, 3.3$ Hz, 1H), 3.45 (dd, $J = 11.0, 1.6$ Hz, 1H), 2.80 - 2.71 (m, 1H), 2.37 - 2.25 (m, 1H), 1.99 - 1.89 (m, 1H), 1.84 - 1.71 (m, 1H), 1.46 (dt, $J = 13.6, 3.6$ Hz, 1H).
- 10

Example 46: (2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



- 15 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-11. MS (ESI) mass calcd. for $C_{21}H_{17}F_4N_5O_2$, 447.2; m/z found 448.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.05 - 8.00 (m, 1H), 7.83 (s, 2H), 7.80 - 7.77 (m, 1H), 7.77 - 7.72 (m, 1H), 7.32 - 7.27 (m, 1H), 6.89 (d, $J = 8.8$ Hz, 1H), 6.60 (td, $J = 8.4, 1.0$ Hz, 1H), 4.96 (dt, $J = 10.1, 3.4$ Hz, 1H), 4.06 - 3.96 (m, 1H), 3.64 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.44 (dd, $J = 10.9, 1.5$ Hz, 1H), 2.69 - 2.60 (m, 1H), 2.28 - 2.16 (m, 1H), 1.51 - 1.34 (m, 2H), 1.30 - 1.22 (m, 1H).
- 20

Example 47: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (101 mg, 0.474 mmol) dissolved in DMF (3 mL) was added NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1.0 mL) and 5-bromo-2-fluoropyridine (0.078 mL, 0.76 mmol) was then added and the mixture heated to 70 °C. After heating at 70 °C for 3.25h, the mixture was cooled to room temperature, quenched with saturated NH₄Cl solution, diluted with H₂O, and the aqueous layer extracted with EtOAc (3X). The combined organics were washed with H₂O, brine, dried with MgSO₄, filtered and concentrated. Purification via silica gel chromatography (0-25% EtOAc in hexanes) gave the title compound (149 mg, 0.40 mmol, 85%). MS (ESI) mass calcd. for C₁₆H₂₁BrN₂O₃, 368.1; m/z found 369.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, compound is present a mixture of rotamers (0.75:0.25)) δ 8.20 - 8.11 (m, 1H), 7.63 (dd, J = 8.8, 2.6 Hz, 0.75H), 7.58 (dd, J = 8.8, 2.6 Hz, 0.25H), 6.63 (dd, J = 8.8, 0.7 Hz, 0.75H), 6.57 - 6.52 (m, 0.25H), 5.29 (dt, J = 9.8, 3.0 Hz, 0.25H), 5.22 (dt, J = 10.1, 3.2 Hz, 0.75H), 4.57 - 4.49 (m, 1H), 3.43 - 3.31 (m, 1H), 3.19 (dd, J = 9.5, 1.3 Hz, 0.75H), 3.15 - 3.09 (m, 0.25H), 2.59 - 2.50 (m, 1H), 2.26 - 2.13 (m, 1H), 1.77 - 1.66 (m, 1H), 1.65 - 1.56 (m, 1H), 1.43 (s, 2H), 1.41 - 1.23 (m, 1H), 1.16 (s, 7H).

Step B: (1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane · xHCl. To the title compound of step A (149 mg, 0.404 mmol) in EtOAc (1.5 mL) was added 4M HCl in dioxane (5 mL). After 3.25h, the reaction was concentrated to give the title compound of step B (128 mg) which was used without further purification. MS (ESI) mass calcd. for C₁₁H₁₃BrN₂O, 268.0; m/z found 269.0 [M+H]⁺.

Step C: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone. To the title compound of step B (30 mg) and intermediate A-6 (24 mg, 0.11 mmol) in DMF (1.5 mL) was added DIPEA (0.25 mL, 1.45 mmol) and HATU (41 mg, 0.11 mmol). Upon completion the reaction was diluted with H₂O and the aqueous layer extracted with EtOAc (3X). The combined organics were washed with H₂O, brine,


dried with MgSO_4 , filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (20 mg). MS (ESI) mass calcd. $\text{C}_{22}\text{H}_{18}\text{BrFN}_4\text{O}_2$, 468.1; m/z found 469.1 $[\text{M}+\text{H}]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.79:0.21), major rotamer reported) δ 8.80 (d, $J = 4.8$ Hz, 2H), 8.08 (d, $J = 8.0$ Hz, 1H), 7.77 (d, $J = 2.5$ Hz, 1H), 7.64 (dd, $J = 8.8, 2.5$ Hz, 1H), 7.39 - 7.30 (m, 1H), 7.23 (t, $J = 4.9$ Hz, 1H), 6.81 - 6.72 (m, 2H), 4.86 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.11 - 4.02 (m, 1H), 3.65 (dt, $J = 10.9, 3.1$ Hz, 1H), 3.44 (dd, $J = 10.8, 1.5$ Hz, 1H), 2.66 - 2.59 (m, 1H), 2.25 - 2.15 (m, 1H), 1.42 - 1.34 (m, 2H), 1.22 - 1.13 (m, 1H).

- 10 Example 48: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone



Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-2. MS (ESI) mass calcd. $\text{C}_{22}\text{H}_{18}\text{BrFN}_4\text{O}_2$, 468.1; m/z found 469.1 $[\text{M}+\text{H}]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.85 (d, $J = 4.9$ Hz, 2H), 7.90 - 7.83 (m, 1H), 7.66 (dd, $J = 8.8, 2.5$ Hz, 1H), 7.29 - 7.26 (m, 1H), 7.16 - 7.07 (m, 1H), 7.05 - 6.96 (m, 1H), 6.91 (dd, $J = 7.5, 1.3$ Hz, 1H), 6.67 (d, $J = 8.7$ Hz, 1H), 4.96 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.27 - 4.16 (m, 1H), 3.34 - 3.24 (m, 2H), 2.52 (s, 1H), 2.23 - 2.11 (m, 1H), 1.40 (d, $J = 10.8$ Hz, 1H), 1.31 (dt, $J = 13.5, 3.6$ Hz, 1H), 0.98 - 0.87 (m, 1H).

Example 49: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-1. MS (ESI) mass calcd. $C_{20}H_{18}BrN_5O_2$, 439.1; m/z found 440.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.89:0.11), major rotamer reported) δ

5 7.85 (dd, $J = 8.2, 1.1$ Hz, 1H), 7.81 (s, 2H), 7.75 (dd, $J = 2.5, 0.7$ Hz, 1H), 7.64 (dd, $J = 8.7, 2.6$ Hz, 1H), 7.41 - 7.35 (m, 1H), 7.05 (dd, $J = 7.7, 1.5$ Hz, 1H), 6.91 (td, $J = 7.6, 1.2$ Hz, 1H), 6.65 (d, $J = 8.7$ Hz, 1H), 4.89 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.05 - 3.97 (m, 1H), 3.59 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.38 (dd, $J = 10.9, 1.4$ Hz, 1H), 2.63 - 2.56 (m, 1H), 2.23 - 2.12 (m, 1H), 1.41 - 1.33 (m, 2H), 1.29 - 1.23 (m, 1H).

10

Example 50: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-20.

15 MS (ESI) mass calcd. $C_{20}H_{19}BrN_6O_2$, 454.1; m/z found 455.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.85: 0.15), major rotamer reported) δ

8.03 (d, $J = 8.4$ Hz, 1H), 7.82 (s, 2H), 7.70 (dd, $J = 2.6, 0.7$ Hz, 1H), 7.56 (dd, $J = 8.8, 2.6$ Hz, 1H), 7.14 (d, $J = 8.4$ Hz, 1H), 6.66 (dd, $J = 8.6, 0.7$ Hz, 1H), 4.82 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.23 - 4.16 (m, 1H), 3.65 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.43 (dd, $J = 10.9, 1.5$ Hz, 1H), 2.63 - 2.58 (m, 1H), 2.30 (s, 3H), 2.23 - 2.11 (m, 1H), 1.48 - 1.33 (m, 3H).

20

Example 51: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (101 mg, 0.474 mmol) dissolved in DMF (3 mL) was added NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1.0 mL) and 2-fluoro-3-(trifluoromethyl)pyridine (0.091 mL, 0.76 mmol) was then added and the mixture heated to 70 °C. After heating at 70 °C for 3 h, the mixture was cooled to room temperature, quenched with saturated NH₄Cl solution, diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification via silica gel chromatography (0-35% EtOAc in hexanes) gave the title compound (87 mg, 0.24 mmol, 51%) as a white solid. MS (ESI) mass calcd. for C₁₇H₂₁F₃N₂O₃, 358.2; m/z found 303.1 [M+2H-*t*Bu]⁺. ¹H NMR (400 MHz, Chloroform-*d*, Compound present as a mixture of rotamers, (0.68:0.32), major rotamer reported) δ 8.35 - 8.25 (m, 1H), 7.90 - 7.82 (m, 1H), 6.96 (dd, *J* = 7.5, 5.0 Hz, 1H), 5.32 (dt, *J* = 10.1, 3.1 Hz, 1H), 4.64 - 4.58 (m, 1H), 3.42 (dt, *J* = 9.5, 3.1 Hz, 1H), 3.15 (d, *J* = 9.5 Hz, 1H), 2.61 - 2.56 (m, 1H), 2.27 - 2.15 (m, 1H), 1.76 - 1.66 (m, 1H), 1.63 (br. s, 1H), 1.48 (dt, *J* = 13.5, 3.5 Hz, 1H), 1.08 (s, 9H).

Step B: (1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane · xHCl. To the title compound of step A (86 mg, 0.24 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (3 mL). After 2h, the reaction was concentrated to give the title compound of step B (76.5 mg) as a white solid and used without further purification. MS (ESI) mass calcd. for C₁₂H₁₃F₃N₂O, 258.1; m/z found 259.1 [M+H]⁺.

Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (25 mg) and intermediate A-1 (18 mg, 0.093 mmol) in DMF (0.8 mL) was added DIPEA (75 μL, 0.44 mmol) and HATU (36 mg, 0.093 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification via silica gel chromatography (0-60% EtOAc in hexanes)


gave the title compound (29 mg). MS (ESI) mass calcd. $C_{21}H_{18}F_3N_5O_2$, 429.1; m/z found 430.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.76:0.24), major rotamer reported) δ 7.93 - 7.82 (m, 4H), 7.81 (s, 2H), 7.07 (dd, J = 7.7, 1.5 Hz, 1H), 6.93 - 6.86 (m, 1H), 6.75 (td, J = 7.6, 1.2 Hz, 1H), 5.04 (dt, J = 10.2, 3.4 Hz, 1H), 4.15 - 4.04 (m, 1H), 3.66 (dt, J = 10.9, 3.3 Hz, 1H), 3.38 (dd, J = 10.9, 1.4 Hz, 1H), 2.66 - 2.60 (m, 1H), 2.27 - 2.15 (m, 1H), 1.48 (dt, J = 13.3, 3.6 Hz, 1H), 1.44 - 1.37 (m, 1H), 1.36 - 1.28 (m, 1H).

Example 52: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 51 substituting intermediate A-1 with intermediate A-20. MS (ESI) mass calcd. $C_{21}H_{19}F_3N_6O_2$, 444.2; m/z found 445.0 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.72:0.28), major rotamer reported) δ 8.01 (d, J = 8.5 Hz, 1H), 7.83 - 7.78 (m, 4H), 7.05 (d, J = 8.4 Hz, 1H), 6.85 - 6.78 (m, 1H), 4.97 (dt, J = 10.4, 3.3 Hz, 1H), 4.31 (br. s, 1H), 3.70 (dt, J = 10.9, 3.3 Hz, 1H), 3.42 (d, J = 10.9 Hz, 1H), 2.66 - 2.62 (m, 1H), 2.23 - 2.14 (m, 1H), 2.10 (s, 3H), 1.58 - 1.15 (m, 3H).

Example 53: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Step A: (1S,4S,6R)-tert-butyl 6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed toluene (9 mL) was added $Pd(OAc)_2$ (24 mg, 0.035 mmol) and racemic BINAP (22 mg, 0.035 mmol) at room


temperature and the reaction mixture was purged with N₂ for 5 min. Then, 2-chloro-5-(trifluoromethyl)pyridine (159 mg, 0.874 mmol), intermediate B-10 (204 mg), and sodium tert-butoxide (121 mg, 1.22 mmol) were added and the reaction mixture heated to 70 °C overnight. Upon completion of the reaction, the mixture was cooled to room temperature, filtered through

5 Celite and the filter pad washed with EtOAc. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound of step A (198 mg, 0.554 mmol, 63%). MS (ESI) mass calcd. for C₁₇H₂₂F₃N₃O₂, 357.2; m/z found 358.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 8.33 (s, 1H), 7.55 (d, *J* = 8.8 Hz, 1H), 6.37 (d, *J* = 8.8 Hz, 1H),
10 5.11 - 4.97 (m, 1H), 4.41 (s, 1H), 4.27 - 4.18 (m, 1H), 3.44 - 3.36 (m, 1H), 3.08 (d, *J* = 9.7 Hz, 1H), 2.62 - 2.55 (m, 1H), 2.39 - 2.26 (m, 1H), 1.68 - 1.61 (m, 1H), 1.45 - 1.43 (m, 1H), 1.48 and 1.22 (two s, 9H).

Step B: Step B: (1S,4R,6R)-N-(5-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine · xHCl. To the title compound of step A (198 mg, 0.554 mmol) in EtOAc (3 mL) was
15 added 4M HCl in dioxane (14 mL). After 1h, the reaction was concentrated to give the title compound of step B (183 mg), which was used without further purification. MS (ESI) mass calcd. for C₁₂H₁₄F₃N₃, 257.1; m/z found 258.1 [M+H]⁺.


Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (30 mg) and
20 intermediate A-1 (19 mg, 0.10 mmol) in DMF (1 mL) was added DIPEA (94 μL, 0.55 mmol) and HATU (38 mg, 0.10 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with 4:1 EtOAc/hexanes (3×X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification via silica gel chromatography (25-100%
25 EtOAc (with 10% MeOH) in hexanes) gave the title compound (20 mg). MS (ESI) mass calcd. C₂₁H₁₉F₃N₆O, 428.2; m/z found 429.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆, Compound presents as a mixture of rotamers, major rotamer reported) δ 8.10 (s, 2H), 7.94 - 7.77 (m, 1H), 7.70 (d, *J* = 8.1 Hz, 1H), 7.67 - 7.49 (m, 2H), 7.28 (td, *J* = 7.7, 1.5 Hz, 1H), 6.96 - 6.82 (m, 1H), 6.77 - 6.56 (m, 2H), 3.96 (br. s, 1H), 3.64 (br. s, 1H), 3.33 - 3.25 (m, 1H), 3.23 - 3.14 (m, 1H), 2.15 - 2.00
30 (m, 1H), 1.44 - 1.33 (m, 1H), 1.23 - 1.03 (m, 2H), *1 H buried under DMSO-d₆ peak.

Example 54: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-20 and substituting purification by silica gel chromatography with Agilent Prep Method X. MS (ESI) mass calcd. $C_{21}H_{20}F_3N_7O$, 443.2; m/z found 444.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 5.92 min (major rotamer) at 254 nm.

Example 55: (3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-22 and substituting purification by silica gel chromatography with Agilent Prep Method X. MS (ESI) mass calcd. $C_{22}H_{21}F_3N_6O$, 442.2; m/z found 443.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.85 min (major rotamer) at 254 nm.

Example 56: (7-ethoxyquinolin-8-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-25 and substituting purification by silica gel chromatography with Agilent Prep Method X. MS (ESI) mass calcd. $C_{24}H_{23}F_3N_4O_2$, 456.2; m/z found 457.2 $[M+H]^+$. Analytical HPLC was obtained on a
 5 Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.45 min (major rotamer) at 254 nm.

Example 57: (5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-
 10 2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-10. MS (ESI) mass calcd. $C_{21}H_{18}F_4N_6O$, 446.1; m/z found 447.1 $[M+H]^+$. ^1H NMR (400 MHz, Methanol- d_4) δ 7.95 (s, 2H), 7.91 - 7.84 (m, 1H), 7.81 (dd, J = 9.0, 4.7 Hz, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.12 - 7.02 (m, 1H), 6.78 - 6.67 (m, 1H), 6.67 - 6.47 (m, 1H), 4.02 - 3.91 (m, 1H), 3.85 (br. s, 1H), 3.42 (dt, J = 11.1, 3.2 Hz, 1H), 3.30 - 3.27 (m, 1H), 2.63 - 2.55 (m, 1H), 2.26 - 2.14 (m, 1H), 1.51 - 1.40 (m, 1H), 1.28 - 1.16 (m, 2H).

Example 58: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-
 20 yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-7 and substituting purification by silica gel chromatography with Agilent Prep Method X. MS (ESI) mass calcd. $C_{23}H_{19}F_4N_5O$, 457.2; m/z found 458.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO- d_6 , Compound presents as a mixture of rotamers (0.90:0.10), major rotamer reported) δ 8.87 (d, $J = 4.9$ Hz, 2H), 8.03 (dd, $J = 8.8, 5.6$ Hz, 1H), 7.88 (br. s, 1H), 7.64 - 7.49 (m, 2H), 7.45 (t, $J = 4.9$ Hz, 1H), 7.04 (td, $J = 8.6, 2.8$ Hz, 1H), 6.70 - 6.53 (m, 2H), 3.96 (br. s, 1H), 3.73 (br. s, 1H), 3.23 - 3.13 (m, 1H), 2.15 - 2.02 (m, 1H), 1.37 (d, $J = 9.7$ Hz, 1H), 1.21 - 0.99 (m, 3H). *1 H buried under DMSO- d_6 peak.

Example 59: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4S,6R)-tert-butyl 6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-10 (44 mg) and 2-chloro-5-(trifluoromethyl)pyrazine (45 mg, 0.25 mmol) dissolved in DMF (2 mL) was added K_2CO_3 (43 mg, 0.31 mmol) and the mixture heated to 70 °C. After heating at 70 °C for 3.5 h, the mixture was cooled to room temperature, diluted with H_2O , and the aqueous layer extracted with EtOAc (3X). The combined organics were washed with H_2O , brine, dried with $MgSO_4$, filtered and concentrated. Purification via silica gel chromatography (0-45% EtOAc in hexanes) gave the title compound (31 mg, 0.087 mmol, 42%). MS (ESI) mass calcd. for $C_{16}H_{21}F_2N_4O_2$, 358.2; m/z found 303.1 $[M+2H-tBu]^+$. ^1H NMR (500 MHz, Chloroform- d) δ 8.38 - 8.25 (m, 1H), 7.93 - 7.76 (m, 1H),

6.25 - 6.12 and 5.57 - 5.44 (2m, 1H), 4.50 - 4.38 (m, 1H), 4.34 - 4.11 (m, 1H), 3.46 - 3.33 (m, 1H), 3.16 - 3.01 (m, 1H), 2.66 - 2.57 (m, 1H), 2.42 - 2.29 (m, 1H), 1.95 - 0.80 (m, 12H).

Step B: (1S,4R,6R)-N-(5-(trifluoromethyl)pyrazin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine · xHCl. To the title compound of step A (31 mg, 0.087 mmol) in EtOAc (0.5 mL) was added 4M HCl in dioxane (4 mL). After 1.5 h additional 4 M HCl in dioxane (2 mL) was added. After an additional 1.25 h, the reaction was concentrated to give the title compound of step B (31 mg) which was used without further purification. MS (ESI) mass calcd. for C₁₁H₁₃F₃N₄, 258.1; m/z found 259.1 [M+H]⁺.

Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (29 mg) and intermediate A-1 (18 mg, 0.096 mmol) in DMF (2.0 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (37 mg, 0.096 mmol). Upon completion the reaction was diluted with H₂O and the aqueous layer extracted with EtOAc (3X). The combined organics were washed with H₂O, brine, dried with MgSO₄, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (8 mg). MS (ESI) mass calcd. C₂₀H₁₈F₃N₇O, 429.2; m/z found 430.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.27 min (major rotamer) at 254 nm.

Example 60: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Step A: (1S,4S,6R)-tert-butyl 6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing intermediate B-10 (218 mg, 1.03 mmol) in MeCN (5 mL) was added 2-chloro-5-(trifluoromethyl)pyrimidine (225 mg, 1.23


mmol) and Et₃N (0.21 mL, 1.54 mmol), and the reaction mixture was sealed and heated to 90 °C overnight. Upon completion of the reaction, the mixture was cooled to room temperature and diluted with H₂O. The reaction mixture was extracted with EtOAc (3X). The combined organics were concentrated and the concentrate subjected directly to silica gel chromatography (0-50%

5 EtOAc in hexanes) to give the title compound of step A (263 mg, 0.734 mmol, 71%). MS (ESI) mass calcd. for C₁₆H₂₁F₃N₄O₂; 358.2, m/z found 303.1 [M+2H-tBu]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 8.54-8.36 (m, 2H), 6.18 - 6.09 and 5.82-5.71 (two m, 1H), 4.49-4.36 (m, 1H), 4.34-4.23 (m, 1H), 3.45 - 3.31 (m, 1H), 3.12 (3.00, 1H), 2.63-2.55 (m, 1H), 2.38-2.27 (m, 1H), 1.77 - 1.18 (m, 12H), 1.12-1.02 (m, 1H).

10 Step B: (1S,4R,6R)-N-(5-(trifluoromethyl)pyrimidin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine · xHCl. To the title compound of step A (263 mg, 0.73 mmol) in EtOAc (2 mL) was added 4M HCl in dioxane (6 mL), and the reaction mixture was stirred at room temperature for 5h. The reaction was concentrated to give the title compound of step B (230 mg), which was used without further purification. MS (ESI) mass calcd. for C₁₁H₁₃F₃N₄, 258.1; m/z found 259.1 [M+H]⁺.

15 Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (35 mg) and intermediate A-1 (25 mg, 0.13 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (50 mg, 0.13 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc
20 (2X). The combined organics were concentrated and the concentrate subjected directly to purification via Agilent Prep Method X to give the title compound (34 mg). MS (ESI): mass calcd. for C₂₀H₁₈F₃N₇O, 429.2; m/z found, 430.9 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min
25 (Temperature = 30 °C). R_t = 6.18 min (major rotamer) at 254 nm.


Example 61: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-40.


- 5 MS (ESI): mass calcd. for $C_{20}H_{19}F_3N_8O$, 444.2; m/z found, 445.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.23 (s, 1H), 8.16 (d, $J = 8.4$ Hz, 1H), 7.92 (s, 1H), 7.86 (s, 2H), 7.73 (s, 1H), 7.32 (d, $J = 8.4$ Hz, 1H), 4.34 - 4.29 (m, 1H), 4.19 - 4.11 (m, 1H), 3.72 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.33 (dd, $J = 11.1, 1.6$ Hz, 1H), 2.83 - 2.77 (m, 1H), 2.60 (s, 3H), 2.49 - 2.39 (m, 1H), 2.00 - 1.93 (m, 1H), 1.75 - 1.69 (m, 1H), 1.21 (dt, $J = 13.2, 3.6$ Hz, 1H).
- 10

Example 62: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




- 15 Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-40.
- MS (ESI): mass calcd. for $C_{20}H_{19}F_3N_8O$, 444.2; m/z found, 445.9 $[M+H]^+$. ^1H NMR (400 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.73:0.27), major rotamer reported) δ 8.52 - 8.44 (m, 1H), 8.36 - 8.30 (m, 1H), 8.21 (d, $J = 8.5$ Hz, 1H), 7.99 (s, 2H), 7.39 (d, $J = 8.5$ Hz, 1H), 4.24 - 4.15 (m, 1H), 4.12 - 4.00 (m, 1H), 3.60 (dt, $J = 11.1, 3.3$ Hz, 1H), 3.35 - 3.32 (m, 1H), 2.75 - 2.70 (m, 1H), 2.48 (s, 3H), 2.43 - 2.30 (m, 1H), 1.76 - 1.62 (m, 2H), 1.39 - 1.29 (m, 1H).
- 20


Example 63: (4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




5 Example 64: (4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Example 65: (4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-
10 (trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 66: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-2. MS


- 5 (ESI): mass calcd. for $C_{23}H_{19}F_4N_5O$, 457.2; m/z found, 458.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.90 (d, $J = 5.0$ Hz, 2H), 7.93 (s, 1H), 7.57 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.49 (t, $J = 5.0$ Hz, 1H), 7.10 - 7.03 (m, 1H), 6.91 - 6.83 (m, 1H), 6.84 - 6.76 (m, 1H), 6.60 - 6.52 (m, 1H), 4.17 (s, 1H), 4.14 - 4.03 (m, 1H), 3.23 (s, 2H), 2.57 - 2.49 (m, 1H), 2.27 - 2.17 (m, 1H), 1.54 (d, $J = 11.3$ Hz, 1H), 1.26 - 1.17 (m, 1H), 1.04 (d, $J = 10.0$ Hz, 1H).
- 10

Example 67: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 15 Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for $C_{22}H_{18}F_4N_6O$, 458.1; m/z found, 459.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.83:0.17), major rotamer reported) δ 8.89 (d, $J = 4.9$ Hz, 2H), 8.12 (s, 1H), 7.72 (d, $J = 1.4$ Hz, 1H), 7.37 (t, $J = 5.0$ Hz, 1H), 7.18 - 7.11 (m, 1H), 7.07 (d, $J = 7.5$ Hz, 1H), 4.52 (s, 1H), 4.41 - 4.28 (m, 1H), 3.59 - 3.48 (m, 1H), 3.24 (d, $J =$
- 20 11.6 Hz, 1H), 2.79 - 2.69 (m, 1H), 2.49 - 2.38 (m, 1H), 1.81 - 1.71 (m, 2H), 1.15 - 1.05 (m, 1H). 1H buried under solvent.


Example 68: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-2. MS


- 5 (ESI): mass calcd. for $C_{22}H_{18}F_4N_6O$, 458.1; m/z found, 459.9 $[M+H]^+$. ^1H NMR (600 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.89:0.11), major rotamer reported) δ 8.91 (d, $J = 4.9$ Hz, 2H), 8.55 - 8.50 (m, 1H), 8.24 - 8.19 (m, 1H), 7.49 (t, $J = 5.0$ Hz, 1H), 7.16 - 7.08 (m, 1H), 7.06 - 6.96 (m, 1H), 6.89 (d, $J = 7.8$ Hz, 1H), 4.16 (s, 1H), 4.14 - 4.07 (m, 1H), 3.28 - 3.26 (m, 1H), 3.26 - 3.21 (m, 1H), 2.58 - 2.52 (m, 1H), 2.24 - 2.14 (m, 1H), 1.54 (d, $J = 10.0$ Hz,
- 10 1H), 1.34 - 1.28 (m, 1H), 1.09 - 1.01 (m, 1H).

Example 69: (2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




15

Example 70: (3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Example 71: (4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




5

Example 72: (3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



10 Example 73: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-2.


The enantiomeric purity of the title compound was confirmed by analytical SFC using a Chiralpak

15 AZ-H column (5 μ m, 250 x 4.6 mm), mobile phase of 35% EtOH+(0.2%TEA): 65% CO₂, and a flow rate of 2 mL/min over 45 minutes (Temperature = 40 °C). Elution was monitored following absorbance at 220nm. Enantiopurity 100%, which elutes as a major peak (R_t = 10.8 min). MS (ESI):

mass calcd. for $C_{24}H_{20}F_4N_4O_2$, 472.2; m/z found, 473.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 7.18 min (major rotamer) at 254 nm.


5

Example 74: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 77 substituting intermediate A-40 with intermediate A-2. MS (ESI):
10 mass calcd. for $C_{23}H_{19}F_4N_5O_2$, 473.2; m/z found, 474.1 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.39 min (major rotamer) at 254 nm.

15 Example 75: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone



Example 76: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Step A: (1S,4R,6R)-tert-butyl 6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (196 mg, 0.862 mmol) dissolved in DMF (7 mL) was added NaH (69 mg, 1.7 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-(trifluoromethyl)pyridine (250 mg, 1.38 mmol) was then added and the mixture stirred at room temperature for 90 min. The reaction mixture was quenched with saturated NH₄Cl solution, and diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, brine, dried with MgSO₄, filtered and concentrated. Purification via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (250 mg, 0.671 mmol, 78%). MS (ESI) mass calcd. for C₁₈H₂₃F₃N₂O₃, 372.2; m/z found 373.0 [M+H]⁺.

Step B: (1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane · xHCl. To the title compound of step A (250 mg, 0.671 mmol) in EtOAc (8 mL) was added 4 M HCl in dioxane (0.84 mL), and the reaction mixture was stirred at room temperature overnight. The reaction was then concentrated to give the title compound of step B which was used without further purification. MS (ESI) mass calcd. for C₁₃H₁₅F₃N₂O, 272.1; m/z found 273.1 [M+H]⁺.

Step C: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (35 mg) and intermediate A-40 (75 mg, 0.15 mmol, 42% purity) in DMF (1 mL) was added DIPEA (0.13 mL, 0.77 mmol) and HATU (54 mg, 0.14 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with MeOH and subjected directly to purification using Agilent Prep Method X to give the title compound (28 mg). MS (ESI): mass calcd. for C₂₂H₂₁F₃N₆O₂, 458.2; m/z found, 459.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 7.14 min (major rotamer) at 254 nm.

Example 77: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone



5 Step A: (1S,4R,6R)-tert-butyl 6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (52 mg, 0.23 mmol) dissolved in DMF (2 mL) was added NaH (18 mg, 0.46 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-(trifluoromethyl)pyrazine (45 μ L, 0.37 mmol) was then added and the mixture stirred at room temperature for 1 h. The reaction mixture was quenched with saturated NH_4Cl solution, and
10 diluted with EtOAc and H_2O . The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , brine, dried with MgSO_4 , filtered, and concentrated. Purification via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (75 mg, 0.20 mmol, 88%). MS (ESI) mass calcd. for $\text{C}_{17}\text{H}_{22}\text{F}_3\text{N}_3\text{O}_3$, 373.1; m/z found 317.9 $[\text{M}+2\text{H}-\text{tBu}]^+$.


 Step B: (1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octane ·
15 xHCl. To the title compound of step A (75 mg, 0.20 mmol) in EtOAc (3 mL) was added 4M HCl in dioxane (0.25 mL), and the reaction mixture was stirred at room temperature overnight. Analysis of the reaction mixture showed unreacted starting material. An additional equivalent of 4M HCl in dioxane (0.25 mL) was added and the reaction mixture stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B (55 mg), which was used without
20 further purification. MS (ESI) mass calcd. for $\text{C}_{12}\text{H}_{14}\text{F}_3\text{N}_3\text{O}$, 273.1; m/z found 274.1 $[\text{M}+\text{H}]^+$.

 Step C: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (27 mg) and intermediate A-40 (58 mg, 0.12 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.59 mmol) and HATU (41 mg, 0.11 mmol), and the reaction mixture was stirred at room
25 temperature overnight. The reaction was diluted with MeOH and the crude reaction mixture subjected directly to purification via Agilent Prep Method X to give the title compound (5.2 mg). MS (ESI): mass calcd. for $\text{C}_{21}\text{H}_{20}\text{F}_3\text{N}_7\text{O}_2$, 459.2; m/z found, 460.2 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz,


CDCl_3) δ 8.28 – 8.24 (m, 1H), 8.15 – 8.11 (m, 1H), 8.08 – 8.02 (m, 1H), 7.83 – 7.79 (s, 2H), 7.13 – 7.09 (d, $J = 8.3$ Hz, 1H), 5.03 – 4.94 (m, 1H), 3.84 – 3.75 (m, 2H), 3.68 – 3.58 (m, 1H), 2.77 – 2.63 (m, 1H), 2.29 – 2.24 (s, 3H), 2.25 – 2.18 (m, 3H), 1.93 – 1.81 (m, 1H), 1.71 – 1.62 (m, 1H), 1.50 – 1.43 (m, 1H).

5


Example 78: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone



10 Example 79: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




15 Example 80: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-2.
MS (ESI): mass calcd. for $\text{C}_{23}\text{H}_{20}\text{F}_4\text{N}_6\text{O}$, 472.2; m/z found, 472.9 $[\text{M}+\text{H}]^+$. Analytical HPLC was

obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.44 min (major rotamer) at 254 nm.

- 5 Example 81: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




- 10 Example 82: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone



- Example 83: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

15




Step A: (1S,4R,6R)-tert-butyl 6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octane-2-carboxylate. To a microwave vial containing intermediate C-7B (193 mg,

0.853 mmol) in MeCN (4 mL) was added 2-chloro-5-(trifluoromethyl)pyrazine (0.1 mL, 0.82 mmol) and Et₃N (0.14 mL, 1.02 mmol), and the reaction mixture was sealed and heated to reflux bench top overnight. Upon completion of the reaction, the crude reaction mixture was concentrated and subjected directly to silica gel chromatography (0-50% EtOAc in hexanes) to give the title
5 compound of step A (245 mg, 0.658 mmol, 77%) MS (ESI) mass calcd. for C₁₇H₂₃F₃N₄O₂; 372.2, m/z found 373.2 [M+H]⁺.


Step B: (1S,4R,6R)-N-(5-(trifluoromethyl)pyrazin-2-yl)-2-azabicyclo[2.2.2]octan-6-amine · xHCl. To the title compound of step A (245 mg, 0.658 mmol) in EtOAc (8 mL) was added 4M HCl in dioxane (0.82 mL), and the reaction mixture was stirred at room temperature overnight. The
10 reaction was concentrated to give the title compound of step B (179 mg), which was used without further purification. MS (ESI) mass calcd. for C₁₂H₁₅F₃N₄, 272.1; m/z found 273.1 [M+H]⁺.

Step C: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (35 mg) and intermediate A-40 (75 mg, 0.15 mmol, 42 % purity) in DMF (1.3
15 mL) was added DIPEA (0.13 mL, 0.77 mmol) and HATU (54 mg, 0.14 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction was diluted with MeOH and the crude reaction mixture subjected directly to purification via Agilent Prep Method X to give the title compound (26 mg). MS (ESI): mass calcd. for C₂₁H₂₁F₃N₈O, 458.2; m/z found, 459.2 [M+H]⁺.
Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100 x
20 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 5.97 min (major rotamer) at 254 nm.

Example 84: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
25




Example 85: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-(6-²H)-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 27 where the reduction of intermediate B-5 is carried out with NaBD₄ instead of L-Selectride. MS (ESI): mass calcd. for C₂₃H₁₇DF₄N₄O₂, 459.1; m/z found, 460.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.83:0.17), major rotamer reported) δ 8.91 (d, *J* = 5.0 Hz, 2H), 8.19 - 8.13 (m, 1H), 7.96 (dd, *J* = 8.7, 2.6 Hz, 1H), 7.50 (t, *J* = 5.0 Hz, 1H), 7.18 - 7.13 (m, 1H), 7.06 - 6.97 (m, 2H), 6.88 (dd, *J* = 7.6, 1.1 Hz, 1H), 4.33 - 4.23 (m, 1H), 3.27 - 3.24 (m, 2H), 2.59 - 2.53 (m, 1H), 2.30 - 2.21 (m, 1H), 1.54 (d, *J* = 10.6 Hz, 1H), 1.37 (dd, *J* = 13.5, 3.6 Hz, 1H), 1.01 - 0.91 (m, 1H).

Example 86: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]-(3-²H, ²H)-heptan-2-yl)methanone.



Prepared analogous to Example 27 where the Diels-Alder reaction to intermediate B-1 is carried out with formaldehyde-d₂ instead of formaldehyde. MS (ESI): mass calcd. for C₂₃H₁₆D₂F₄N₄O₂, 460.1; m/z found, 461.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.86 (d, *J* = 4.9 Hz, 2H), 8.15 - 8.09 (m, 1H), 7.79 (dd, *J* = 8.8, 2.5 Hz, 1H), 7.30 - 7.27 (m, 1H), 7.10 - 7.03 (m, 1H), 6.96 - 6.86 (m, 2H), 6.84 (d, *J* = 8.7 Hz, 1H), 5.07 (dt, *J* = 10.1, 3.3 Hz, 1H), 4.31 - 4.19 (m, 1H), 2.56 - 2.48 (m, 1H), 2.27 - 2.12 (m, 1H), 1.46 - 1.40 (m, 1H), 1.36 (dt, *J* = 13.6, 3.6 Hz, 1H), 0.96 - 0.86 (m, 1H).


Example 87: (2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-39.


- 5 MS (ESI): mass calcd. for $C_{20}H_{17}F_3N_6O_2$, 430.1; m/z found, 431.2 $[M+H]^+$. ^1H NMR (400 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.43 (dd, $J = 4.8, 1.8$ Hz, 1H), 8.18 - 8.11 (m, 1H), 8.11 - 8.02 (m, 2H), 7.95 (dd, $J = 8.6, 2.5$ Hz, 1H), 7.71 - 7.55 (m, 1H), 7.12 - 6.90 (m, 2H), 5.08 (dt, $J = 10.1, 3.2$ Hz, 1H), 4.01 (s, 1H), 3.57 (dt, $J = 11.1, 3.2$ Hz, 1H), 3.35 (dd, $J = 11.1, 1.7$ Hz, 1H), 2.75 - 2.64 (m, 1H), 2.37 - 2.24 (m, 1H), 1.57
- 10 (d, $J = 10.4$ Hz, 1H), 1.53 - 1.35 (m, 2H).

Example 88: (5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 15 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-38.
- MS (ESI): mass calcd. for $C_{21}H_{19}F_3N_6O_2$, 444.2; m/z found, 445.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.90:0.10), major rotamer reported) δ 8.26 - 8.21 (m, 1H), 8.19 - 8.14 (m, 1H), 8.05 (s, 2H), 7.98 (dd, $J = 8.7, 2.6$ Hz, 1H), 7.50 - 7.46 (m, 1H), 6.99 (d, $J = 8.8$ Hz, 1H), 5.06 (dt, $J = 10.4, 3.2$ Hz, 1H), 4.05 - 3.97 (m, 1H), 3.54 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.35 (dd, $J = 11.1, 1.6$ Hz, 1H), 2.68 - 2.62 (m, 1H), 2.32 - 2.19 (m, 1H), 2.08 (s, 3H),
- 20 1.56 (d, $J = 10.7$ Hz, 1H), 1.47 - 1.35 (m, 2H).


Example 89: (2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-34.


- 5 MS (ESI): mass calcd. for $C_{23}H_{18}F_4N_4O_2$, 458.1; m/z found, 459.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.85:0.15), major rotamer reported) δ 8.85 - 8.80 (m, 2H), 8.17 (dd, J = 8.1, 1.3 Hz, 1H), 8.09 - 8.03 (m, 1H), 7.95 (dd, J = 8.8, 2.6 Hz, 1H), 7.39 - 7.31 (m, 1H), 7.05 - 6.96 (m, 2H), 6.92 (td, J = 7.5, 1.2 Hz, 1H), 5.11 (dt, J = 10.2, 3.3 Hz, 1H), 4.16 - 4.10 (m, 1H), 3.61 (dt, J = 10.9, 3.2 Hz, 1H), 3.35 - 3.33 (m, 1H), 2.74 - 2.65 (m, 1H), 2.36 - 2.26 (m, 1H), 1.59 - 1.53 (m, 1H), 1.46 (dt, J = 13.4, 3.7 Hz, 1H), 1.41 - 1.32 (m, 1H).
- 10

Example 90: (3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 15 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-35.
- MS (ESI): mass calcd. for $C_{23}H_{17}F_5N_4O_2$, 476.1; m/z found, 477.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.81:0.19), major rotamer reported) δ 8.88 (d, J = 0.7 Hz, 2H), 8.21 - 8.15 (m, 1H), 7.96 (dd, J = 8.8, 2.6 Hz, 1H), 7.19 - 7.13 (m, 1H), 7.07 - 6.99 (m, 2H), 6.91 (dd, J = 7.6, 0.9 Hz, 1H), 5.17 (dt, J = 10.2, 3.3 Hz, 1H), 4.31 - 4.21 (m, 1H), 3.35 - 3.32 (m, 1H), 3.27 - 3.23 (m, 1H), 2.63 - 2.59 (m, 1H), 2.32 - 2.25 (m, 1H), 1.65 - 1.56 (m, 1H), 1.39 (dt, J = 13.6, 3.6 Hz, 1H), 1.20 - 1.05 (m, 1H).
- 20

Example 91: (2-(5-fluoropyrimidin-2-yl)-3-methylphenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 5 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-36.
 MS (ESI): mass calcd. for $C_{24}H_{20}F_4N_4O_2$, 472.2; m/z found, 473.1 $[M+H]^+$. ^1H NMR (400 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.81:0.19), major rotamer reported) δ 8.85 (d, J = 0.8 Hz, 2H), 8.21 - 8.10 (m, 1H), 7.96 (dd, J = 8.8, 2.6 Hz, 1H), 7.25 - 7.18 (m, 1H), 7.08 - 6.96 (m, 1H), 6.96 - 6.79 (m, 2H), 5.17 (dt, J = 10.2, 3.3 Hz, 1H), 4.33 - 4.23 (m, 1H), 3.27 -
 10 3.16 (m, 2H), 2.58 (s, 1H), 2.33 - 2.22 (m, 4H), 1.62 - 1.56 (m, 1H), 1.37 (dt, J = 13.5, 3.6 Hz, 1H), 1.21 - 1.02 (m, 1H).


Example 92: (6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 15 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-41.
 MS (ESI): mass calcd. for $C_{23}H_{20}F_3N_5O_2$, 455.2; m/z found, 456.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.90:0.10), major rotamer reported) δ 8.87 (d, J = 4.9 Hz, 2H), 8.47 (d, J = 8.2 Hz, 1H), 8.05 - 7.99 (m, 1H), 7.86 (dd, J = 8.8, 2.5 Hz, 1H), 7.42 (t, J = 4.9 Hz, 1H), 7.22 (d, J = 8.2 Hz, 1H), 6.91 - 6.87 (m, 1H), 4.99 (dt, J = 10.3, 3.4 Hz, 1H), 4.32 - 4.25 (m, 1H), 3.66 (dt, J = 10.9, 3.2 Hz, 1H), 3.39 (dd, J = 10.9, 1.6 Hz, 1H), 2.71 -
 20

2.66 (m, 1H), 2.33 - 2.24 (m, 1H), 2.19 (s, 3H), 1.62 - 1.54 (m, 1H), 1.49 (dt, $J = 13.4, 3.7$ Hz, 1H), 1.44 - 1.32 (m, 1H).


Example 93: (3-phenylpyrazin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-43.

MS (ESI): mass calcd. for $C_{23}H_{19}F_3N_4O_2$, 440.1; m/z found, 441.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 8.52 (d, $J = 2.4$ Hz, 1H), 8.04 - 8.01 (m, 1H), 7.93 (d, $J = 2.5$ Hz, 1H), 7.89 (dd, $J = 8.8, 2.7$ Hz, 1H), 7.75 - 7.71 (m, 2H), 7.56 - 7.53 (m, 3H), 6.91 - 6.84 (m, 1H), 4.95 (dt, $J = 10.3, 3.3$ Hz, 1H), 4.11 - 3.99 (m, 1H), 3.38 - 3.34 (m, 2H), 2.57 - 2.52 (m, 1H), 2.27 - 2.12 (m, 1H), 1.45 - 1.35 (m, 2H), 0.68 - 0.59 (m, 1H).

Example 94: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Step A: (1S,4R,6R)-tert-butyl 6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (50 mg, 0.23 mmol) dissolved in DMF (1 mL) was added NaH (19 mg, 0.47 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-fluoro-6-(trifluoromethyl)pyridine (0.045 mL, 0.38 mmol) was then added and the mixture stirred overnight


at room temperature. The mixture was quenched with saturated NH_4Cl solution, diluted with EtOAc and H_2O . The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , 5% aqueous LiCl, brine, dried with Na_2SO_4 , filtered, and concentrated.

Purification via silica gel chromatography (0-40% EtOAc in hexanes) gave the title compound (29 mg, 0.080 mmol, 34%) as a clear oil. MS (ESI) mass calcd. for $\text{C}_{17}\text{H}_{21}\text{F}_3\text{N}_2\text{O}_3$, 358.2; m/z found 303.1 $[\text{M}+2\text{H}-t\text{Bu}]^+$.

Step B: (1S,4R,6R)-6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane $\cdot \text{xHCl}$. To the title compound of step A (28 mg, 0.078 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (0.1 mL). After 4h, the reaction was concentrated to give the title compound of step B (23 mg) as a pink solid and used without further purification. MS (ESI) mass calcd. for $\text{C}_{12}\text{H}_{13}\text{F}_3\text{N}_2\text{O}$, 258.1; m/z found 259.1 $[\text{M}+\text{H}]^+$.

Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (23 mg) and intermediate A-2 (25 mg, 0.094 mmol) in DMF (1.1 mL) was added DIPEA (81 μL , 0.47 mmol) and HATU (33 mg, 0.086 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H_2O and the aqueous layer was extracted with EtOAc (3X). The combined organics were concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (15 mg). MS (ESI): mass calcd. for $\text{C}_{23}\text{H}_{18}\text{F}_4\text{N}_4\text{O}_2$, 458.1; m/z found, 459.1 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.84:0.16), major rotamer reported) δ 8.89 (d, $J = 4.9$ Hz, 2H), 7.95 - 7.88 (m, 1H), 7.48 (t, $J = 5.0$ Hz, 1H), 7.33 (d, $J = 7.5$ Hz, 1H), 7.17 - 7.10 (m, 2H), 7.05 - 6.99 (m, 1H), 6.86 (dd, $J = 7.9, 1.0$ Hz, 1H), 5.12 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.29 - 4.25 (m, 1H), 3.26 (t, $J = 3.0$ Hz, 1H), 3.25 (s, 1H), 2.58 (s, 1H), 2.32 - 2.24 (m, 1H), 1.60 (d, $J = 10.1$ Hz, 1H), 1.38 (dt, $J = 13.5, 3.6$ Hz, 1H), 1.11 - 1.05 (m, 1H).

Example 95: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Step A: (1S,4R,6R)-tert-butyl 6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (101 mg, 0.47 mmol) dissolved in DMF (3 mL) was added NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-chloro-4-(trifluoromethyl)pyridine (0.10 mL, 0.76 mmol) was then added and the mixture heated to 70 °C. After heating at 70 °C for 3 h, the mixture was cooled to room temperature, quenched with saturated NH₄Cl solution, diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification via silica gel chromatography (0-40% EtOAc in hexanes) gave the title compound (16 mg, 0.045 mmol, 10%) as a yellow-brown solid. MS (ESI) mass calcd. for C₁₇H₂₁F₃N₂O₃, 358.2; m/z found 359.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 8.34 - 8.23 (m, 1H), 7.12 - 7.04 (m, 1H), 7.01 - 6.92 (m, 1H), 5.35 (dt, J = 10.1, 3.2 Hz, 1H), 4.56 - 4.49 (m, 1H), 3.41 (dt, J = 9.5, 3.1 Hz, 1H), 3.27 - 3.17 (m, 1H), 2.60 - 2.55 (m, 1H), 2.28 - 2.16 (m, 1H), 1.80 - 1.71 (m, 1H), 1.68 - 1.62 (m, 1H), 1.53 - 0.93 (m, 10H).

Step B: (1S,4R,6R)-6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane · xHCl. To the title compound of step A (16 mg, 0.045 mmol) in EtOAc (0.1 mL) was added 4M HCl in dioxane (0.1 mL). After 3h, the reaction was concentrated to give the title compound of step B (16 mg) and used without further purification. MS (ESI) mass calcd. for C₁₂H₁₃F₃N₂O, 258.1; m/z found 259.2 [M+H]⁺.

Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (16 mg) and intermediate A-2 (13 mg, 0.060 mmol) in DMF (0.6 mL) was added DIPEA (56 μL, 0.33 mmol) and HATU (23 mg, 0.060 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (3.4 mg). MS (ESI): mass calcd. for C₂₃H₁₈F₄N₄O₂, 458.1; m/z

found, 459.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.80:0.20), major rotamer reported) δ 8.90 (d, J = 5.0 Hz, 2H), 8.07 (d, J = 5.3 Hz, 1H), 7.49 (t, J = 5.0 Hz, 1H), 7.20 - 7.11 (m, 3H), 7.03 - 6.97 (m, 1H), 6.91 - 6.87 (m, 1H), 5.16 (dt, J = 10.2, 3.3 Hz, 1H), 4.28 - 4.23 (m, 1H), 3.28 - 3.24 (m, 2H), 2.61 - 2.54 (m, 1H), 2.32 - 2.20 (m, 1H),
 5 1.56 (d, J = 10.6 Hz, 1H), 1.38 (dt, J = 13.6, 3.6 Hz, 1H), 1.04 - 0.96 (m, 1H).

Example 96: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



10 Step A: (1S,4R,6R)-tert-butyl 6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (101 mg, 0.47 mmol) dissolved in DMF (3 mL) was added NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-fluoro-3-(trifluoromethyl)pyridine (0.10 mL, 0.76 mmol) was then added and the mixture heated to 70 °C.
 15 After heating at 70 °C for 3 h, the mixture was cooled to room temperature, quenched with saturated NH_4Cl solution, diluted with EtOAc and H_2O . The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , 5% aqueous LiCl, brine, dried with Na_2SO_4 , filtered, and concentrated. Purification via silica gel chromatography (0-35% EtOAc in hexanes) gave the title compound (87 mg, 0.24 mmol, 51%) as a white solid. MS (ESI) mass calcd. for
 20 $C_{17}H_{21}F_3N_2O_3$, 358.2; m/z found 303.1 $[M+2H-tBu]^+$. ^1H NMR (400 MHz, Chloroform- d) δ 8.35 - 8.25 (m, 1H), 7.90 - 7.82 (m, 1H), 6.96 (dd, J = 7.5, 5.0 Hz, 1H), 5.32 (dt, J = 10.1, 3.1 Hz, 1H), 4.64 - 4.58 (m, 1H), 3.42 (dt, J = 9.5, 3.1 Hz, 1H), 3.15 (d, J = 9.5 Hz, 1H), 2.61 - 2.56 (m, 1H), 2.27 - 2.15 (m, 1H), 1.76 - 1.66 (m, 2H), 1.48 (dt, J = 13.5, 3.5 Hz, 1H), 1.08 (s, 9H).


Step B: (1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane ·
 25 xHCl. To the title compound of step A (86 mg, 0.24 mmol) in EtOAc (0.9 mL) was added 4M HCl in dioxane (3 mL). After 2h, the reaction was concentrated to give the title compound of step B (77

mg) and used without further purification. MS (ESI) mass calcd. for $C_{12}H_{13}F_3N_2O$, 258.1; m/z found 259.1 $[M+H]^+$.

Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (28 mg) and
 5 intermediate A-2 (23 mg, 0.11 mmol) in DMF (1 mL) was added DIPEA (98 μ L, 0.57 mmol) and HATU (40 mg, 0.11 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H_2O and the aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , 5% aqueous LiCl, brine, dried with Na_2SO_4 , filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep

10 Method X to give the title compound (5.4 mg). MS (ESI): mass calcd. for $C_{23}H_{18}F_4N_4O_2$, 458.1; m/z found, 459.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.86:0.14), major rotamer reported) δ 8.90 (d, J = 5.0 Hz, 2H), 8.05 - 8.01 (m, 2H), 7.49 (t, J = 5.0 Hz, 1H), 7.17 - 7.11 (m, 1H), 7.08 - 7.04 (m, 1H), 6.96 - 6.90 (m, 1H), 6.77 (dd, J = 7.6, 1.1 Hz, 1H), 5.20 (dt, J = 10.2, 3.3 Hz, 1H), 4.32 - 4.28 (m, 1H), 3.29 - 3.26 (m, 1H), 3.25 - 3.20 (m,
 15 1H), 2.60 - 2.54 (m, 1H), 2.29 - 2.21 (m, 1H), 1.53 (d, J = 10.4 Hz, 1H), 1.40 (dt, J = 13.6, 3.6 Hz, 1H), 0.95 - 0.89 (m, 1H).

Example 97: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




20 Step A: (1S,4R,6R)-tert-butyl 6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (70 mg, 0.33 mmol) and 2,3-difluoro-5-(trifluoromethyl)pyridine (90 mg, 0.49 mmol) dissolved in DMF (3 mL) was added NaH (18 mg, 0.46 mmol, 60% dispersion in mineral oil) and the reaction mixture was stirred overnight at room
 25 temperature after which analysis of the reaction mixture showed mainly starting material. Additional 2,3-difluoro-5-(trifluoromethyl)pyridine (0.05 mL) was then added and the reaction mixture heated to 70 $^{\circ}C$ and stirred overnight after which analysis of the reaction mixture still

showed starting material remaining. Additional 2,3-difluoro-5-(trifluoromethyl)pyridine (0.05 mL) was again added and the reaction mixture was heated at 70 °C for an additional 4.5 hours before additional 2,3-difluoro-5-(trifluoromethyl)pyridine (0.05 mL) was added and the reaction stirred overnight. After this time analysis still showed incomplete conversion however the reaction was cooled to room temperature and quenched with H₂O. The aqueous layer was extracted with EtOAc (3X) and the combined organics were washed with 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification via silica gel chromatography (0-25% EtOAc in hexanes) gave the title compound. MS (ESI) mass calcd. for C₁₇H₂₀F₄N₂O₃, 376.1; m/z found 321.1 [M+2H-*t*Bu]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.67:0.33), major rotamer reported) δ 8.21 - 8.18 (m, 1H), 7.51 (dd, *J* = 9.5, 2.1 Hz, 1H), 5.37 (dt, *J* = 10.1, 3.2 Hz, 1H), 4.57 - 4.50 (m, 1H), 3.41 (dt, *J* = 9.5, 3.1 Hz, 1H), 3.22 (dd, *J* = 9.5, 1.4 Hz, 1H), 2.62 - 2.57 (m, 1H), 2.30 - 2.19 (m, 1H), 1.77 - 1.73 (m, 1H), 1.67 - 1.63 (m, 1H), 1.48 (dt, *J* = 13.7, 3.6 Hz, 1H), 1.12 (s, 9H).

Step B: (1*S*,4*R*,6*R*)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane · xHCl. To the title compound of step A (130 mg, 0.345 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (3 mL) and the reaction mixture was stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B (114 mg) as a yellow oil and used without further purification. MS (ESI) mass calcd. for C₁₂H₁₂F₄N₂O, 276.1; m/z found 277.1 [M+H]⁺.

Step C: (2-(2*H*-1,2,3-triazol-2-yl)phenyl)((1*S*,4*R*,6*R*)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (28.5 mg) and intermediate A-1 (19 mg, 0.1 mmol) in DMF (0.9 mL) was added DIPEA (0.13 mL, 0.73 mmol) and HATU (38 mg, 0.1 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (3X). The combined organics were concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (18 mg). MS (ESI): mass calcd. for C₂₁H₁₇F₄N₅O₂, 447.1; m/z found, 448.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 7.87 (s, 1H), 7.81 (s, 2H), 7.57 - 7.50 (m, 2H), 7.37 - 7.30 (m, 2H), 6.96 (t, *J* = 7.5 Hz, 1H), 5.05 (dt, *J* = 10.1, 3.4 Hz, 1H), 4.03 (s, 1H), 3.64 (dt, *J* = 11.0, 3.2 Hz, 1H), 3.42 (dd, *J* = 10.9, 1.4 Hz, 1H), 2.72 - 2.62 (m, 1H), 2.36 - 2.20 (m, 1H), 1.51 - 1.36 (m, 3H).


Example 98: (1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.



Prepared analogous to Example 97 substituting intermediate A-1 with intermediate A-40.


- 5 MS (ESI): mass calcd. for $C_{21}H_{18}F_4N_6O_2$, 462.1; m/z found, 463.1 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.79:0.21), major rotamer reported) δ 8.00 (d, $J = 8.4$ Hz, 1H), 7.81 (s, 2H), 7.72 - 7.69 (m, 1H), 7.39 (dd, $J = 9.4, 2.1$ Hz, 1H), 7.07 (d, $J = 8.4$ Hz, 1H), 4.96 (dt, $J = 10.3, 3.3$ Hz, 1H), 4.47 - 4.40 (m, 1H), 3.72 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.48 (dd, $J = 11.0, 1.4$ Hz, 1H), 2.72 - 2.64 (m, 1H), 2.29 - 2.21 (m, 4H), 1.66 - 1.61 (m, 1H), 1.57 - 1.50 (m, 2H).
- 10

Example 99: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone.



- 15 Prepared analogous to Example 97 substituting intermediate A-1 with intermediate A-37.
- MS (ESI): mass calcd. for $C_{23}H_{18}F_4N_4O_2$, 458.1; m/z found, 459.1 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.79 (d, $J = 4.8$ Hz, 2H), 8.21 - 8.18 (m, 1H), 7.89 - 7.84 (m, 1H), 7.57 - 7.52 (m, 1H), 7.36 - 7.29 (m, 1H), 7.29 - 7.26 (m, 1H), 7.20 (t, $J = 4.8$ Hz, 1H), 7.01 (td, $J = 7.5, 1.3$ Hz, 1H), 5.06 (dt, $J = 10.0, 3.3$ Hz, 1H), 4.17 - 4.11 (m, 1H), 3.69 (dt, $J = 10.8, 3.2$ Hz, 1H), 3.43 (dd, $J = 10.8, 1.5$ Hz, 1H), 2.72 - 2.65 (m, 1H), 2.37 - 2.23 (m, 1H), 1.51 - 1.43 (m, 2H), 1.42 - 1.30 (m, 1H).
- 20


Example 100: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 97 substituting intermediate A-1 with intermediate A-2. MS

- 5 (ESI): mass calcd. for $C_{23}H_{17}F_5N_4O_2$, 476.1; m/z found, 477.2 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.85 (d, $J = 4.8$ Hz, 2H), 8.00 - 7.94 (m, 1H), 7.55 (dd, $J = 9.5, 2.1$ Hz, 1H), 7.30 - 7.27 (m, 1H), 7.19 (dd, $J = 7.1, 1.7$ Hz, 1H), 7.13 - 7.03 (m, 2H), 5.10 (dt, $J = 10.0, 3.3$ Hz, 1H), 4.31 - 4.24 (m, 1H), 3.45 - 3.29 (m, 2H), 2.65 - 2.53 (m, 1H), 2.35 - 2.23 (m, 1H), 1.48 (d, $J = 9.9$ Hz, 1H), 1.40 (dt, 10 $J = 13.6, 3.7$ Hz, 1H), 1.18 - 0.99 (m, 1H).

Example 101: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 15 Step A: (1S,4R,6R)-tert-butyl 6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (101 mg, 0.47 mmol) dissolved in DMF (3 mL) was added NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-chloro-5-methylpyridine (0.08 mL, 0.76 mmol) was then added and the mixture heated to 70 °C. After heating at 70 °C for 3 h, the mixture was cooled to 20 room temperature, quenched with saturated NH_4Cl solution, diluted with EtOAc and H_2O . The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , 5% aqueous LiCl, brine, dried with Na_2SO_4 , filtered, and concentrated. Purification via silica gel chromatography (0-35% EtOAc in hexanes) gave the title compound (16 mg, 0.053 mmol, 11%) as

a white solid. MS (ESI) mass calcd. for $C_{17}H_{24}N_2O_3$, 304.2; m/z found 305.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, major rotamer reported) δ 7.97 - 7.89 (m, 1H), 7.37 (dd, J = 8.4, 2.5 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 5.25 (dt, J = 10.1, 3.2 Hz, 1H), 4.56 - 4.48 (m, 1H), 3.38 (dt, J = 9.5, 3.1 Hz, 1H), 3.19 (d, J = 9.5 Hz, 1H), 2.59 - 2.52 (m, 1H), 2.23 (s, 3H), 2.20 - 2.14 (m, 1H), 1.76 - 1.68 (m, 1H), 1.65 - 1.60 (m, 1H), 1.35 (dt, J = 13.4, 3.6 Hz, 1H), 1.14 (s, 9H).

Step B: (1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane $\cdot$ xHCl. To the title compound of step A (16 mg, 0.053 mmol) in EtOAc (0.1 mL) was added 4M HCl in dioxane (0.1 mL). After 3h, the reaction was concentrated to give the title compound of step B (15 mg) and used without further purification. MS (ESI) mass calcd. for $C_{12}H_{16}N_2O$, 204.1; m/z found 205.2 $[M+H]^+$.

Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (16 mg) and intermediate A-2 (16 mg, 0.07 mmol) in DMF (1 mL) was added DIPEA (69 μ L, 0.40 mmol) and HATU (28 mg, 0.073 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H_2O and the aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , 5% aqueous LiCl, brine, dried with Na_2SO_4 , filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (6 mg). MS (ESI): mass calcd. for $C_{23}H_{21}FN_4O_2$, 404.2; m/z found, 405.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.85:0.15), major rotamer reported) δ 8.89 (d, J = 4.9 Hz, 2H), 7.69 - 7.65 (m, 1H), 7.52 (dd, J = 8.4, 2.5 Hz, 1H), 7.48 (t, J = 4.9 Hz, 1H), 7.21 - 7.14 (m, 1H), 7.07 - 7.00 (m, 1H), 6.92 (dd, J = 7.6, 1.1 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 5.02 (dt, J = 10.1, 3.3 Hz, 1H), 4.25 - 4.19 (m, 1H), 3.26 - 3.18 (m, 2H), 2.57 - 2.53 (m, 1H), 2.25 (s, 3H), 2.24 - 2.19 (m, 1H), 1.56 - 1.51 (m, 1H), 1.34 - 1.28 (m, 1H), 1.08 - 1.02 (m, 1H).

Example 102: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Step A: (1S,4R,6R)-tert-butyl 6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (150 mg, 0.70 mmol) dissolved in DMF (5 mL) was added NaH (37 mg, 0.91 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were
5 rinsed with additional DMF (1 mL) and 2-fluoropyridine (0.10 mL, 1.13 mmol) was then added and the mixture heated to 70 °C. After heating at 70 °C for 7 h, the mixture was cooled to room temperature, quenched with saturated NH₄Cl solution, diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification via silica gel
10 chromatography (0-30% EtOAc in hexanes) gave the title compound (73 mg, 0.25 mmol, 36%) as a colorless solid. MS (ESI) mass calcd. for C₁₆H₂₂N₂O₃, 290.2; m/z found 291.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major rotamer reported) δ 8.11 (ddd, *J* = 5.1, 2.0, 0.8 Hz, 1H), 7.59 - 7.50 (m, 1H), 6.89 - 6.80 (m, 1H), 6.70 (dt, *J* = 8.4, 0.9 Hz, 1H), 5.29 (dt, *J* = 10.1, 3.2 Hz, 1H), 4.61 - 4.49 (m, 1H), 3.39 (dt, *J* = 9.5, 3.1 Hz, 1H), 3.20 (dd,
15 *J* = 9.5, 1.3 Hz, 1H), 2.59 - 2.50 (m, 1H), 2.26 - 2.15 (m, 1H), 1.76 - 1.69 (m, 1H), 1.67 - 1.63 (m, 1H), 1.38 (dt, *J* = 13.3, 3.6 Hz, 1H), 1.12 (s, 9H).

Step B: (1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptane · xHCl. To the title compound of step A (73 mg, 0.25 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred overnight. Then, the reaction was concentrated to give the title
20 compound of step B (68 mg) and used without further purification. MS (ESI) mass calcd. for C₁₁H₁₄N₂O, 190.1; m/z found 191.1 [M+H]⁺.

Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (23 mg) and intermediate A-1 (18 mg, 0.094 mmol) in DMF (1 mL) was added DIPEA (0.17 mL, 0.99 mmol) and HATU (36
25 mg, 0.094 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to


give the title compound (22 mg). MS (ESI): mass calcd. for $C_{20}H_{19}N_5O_2$, 361.2; m/z found, 362.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.90:0.10), major rotamer reported) δ 7.84 (dd, $J = 8.3, 1.2$ Hz, 1H), 7.82 - 7.77 (m, 3H), 7.60 - 7.54 (m, 1H), 7.36 - 7.28 (m, 1H), 7.16 (dd, $J = 7.8, 1.5$ Hz, 1H), 6.88 (td, $J = 7.6, 1.2$ Hz, 1H), 6.82 - 6.77 (m, 1H), 6.74 (d, $J = 8.3$ Hz, 1H), 5.03 (dt, $J = 10.3, 3.2$ Hz, 1H), 4.06 - 3.97 (m, 1H), 3.60 (dt, $J = 10.9, 3.3$ Hz, 1H), 3.39 (dd, $J = 10.8, 1.4$ Hz, 1H), 2.68 - 2.56 (m, 1H), 2.27 - 2.13 (m, 1H), 1.48 - 1.31 (m, 3H).

Example 103: (6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 102 substituting intermediate A-1 with intermediate A-3. MS (ESI): mass calcd. for $C_{20}H_{20}N_6O_2$, 376.2; m/z found, 377.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.92:0.08), major rotamer reported) δ 7.86 (s, 2H), 7.82 - 7.78 (m, 1H), 7.60 - 7.54 (m, 1H), 7.40 (d, $J = 7.7$ Hz, 1H), 6.85 - 6.79 (m, 1H), 6.74 - 6.64 (m, 2H), 4.98 (dt, $J = 10.1, 3.2$ Hz, 1H), 4.05 - 3.97 (m, 1H), 3.61 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.40 (dd, $J = 10.8, 1.4$ Hz, 1H), 2.65 - 2.59 (m, 1H), 2.56 (s, 3H), 2.25 - 2.15 (m, 1H), 1.48 - 1.33 (m, 3H).

Example 104: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 102 substituting intermediate A-1 with intermediate A-2.
MS (ESI): mass calcd. for $C_{22}H_{19}FN_4O_2$, 390.1; m/z found, 391.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.89:0.11), major rotamer reported) δ 8.84 (d, $J = 4.9$ Hz, 2H), 7.92 - 7.85 (m, 1H), 7.63 - 7.56 (m, 1H), 7.28 - 7.24 (m, 2H), 7.09 - 6.96 (m, 2H), 6.85 - 6.80 (m, 1H), 6.76 (dt, $J = 8.3, 0.9$ Hz, 1H), 5.10 (dt, $J = 10.0, 3.3$ Hz, 1H), 4.26 - 4.15 (m, 1H), 3.34 - 3.30 (m, 2H), 2.59 - 2.48 (m, 1H), 2.27 - 2.15 (m, 1H), 1.45 (d, $J = 11.0$ Hz, 1H), 1.32 (dt, $J = 13.4, 3.6$ Hz, 1H), 1.13 - 1.01 (m, 1H).

Example 105: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone.



Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-3. MS (ESI): mass calcd. for $C_{20}H_{19}BrN_6O_2$, 454.1; m/z found, 455.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.93:0.07), major rotamer reported) δ 7.87 (s, 2H), 7.76 (d, $J = 2.6$ Hz, 1H), 7.64 (dd, $J = 8.7, 2.6$ Hz, 1H), 7.29 (d, $J = 7.8$ Hz, 1H), 6.69 (d, $J = 7.7$ Hz, 1H), 6.62 (d, $J = 8.7$ Hz, 1H), 4.83 (dt, $J = 10.3, 3.3$ Hz, 1H), 4.05 - 3.94 (m, 1H), 3.59 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.38 (d, $J = 11.0$ Hz, 1H), 2.66 - 2.56 (m, 4H), 2.23 - 2.10 (m, 1H), 1.44 - 1.33 (m, 2H), 1.32 - 1.23 (m, 1H).


Example 106: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.



Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-16.

MS (ESI): mass calcd. for $C_{20}H_{17}BrFN_5O_2$, 457.1; m/z found, 458.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.90:0.10), major rotamer reported) δ 7.87 (s, 2H), 7.85 (dd, $J = 2.6, 0.7$ Hz, 1H), 7.66 (dd, $J = 8.7, 2.5$ Hz, 1H), 7.24 - 7.17 (m, 1H), 7.07 - 6.98 (m, 1H), 6.91 (dt, $J = 7.7, 1.2$ Hz, 1H), 6.66 (dd, $J = 8.8, 0.7$ Hz, 1H), 4.95 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.19 - 4.10 (m, 1H), 3.35 - 3.30 (m, 2H), 2.60 - 2.49 (m, 1H), 2.24 - 2.12 (m, 1H), 1.48 - 1.41 (m, 1H), 1.31 (dt, $J = 13.5, 3.6$ Hz, 1H), 1.21 - 1.09 (m, 1H).


Example 107: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.



Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-12.

MS (ESI): mass calcd. for $C_{20}H_{17}BrFN_5O_2$, 457.1; m/z found, 458.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.89:0.11), major rotamer reported) δ 7.85 (d, $J = 2.6$ Hz, 1H), 7.82 (s, 2H), 7.71 - 7.61 (m, 2H), 7.05 (dd, $J = 8.5, 5.9$ Hz, 1H), 6.68 - 6.58 (m, 2H), 4.91 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.00 (s, 1H), 3.61 (dt, $J = 10.9, 3.3$ Hz, 1H), 3.38 (dd, $J = 10.9, 1.4$ Hz, 1H), 2.69 - 2.59 (m, 1H), 2.26 - 2.14 (m, 1H), 1.47 - 1.25 (m, 3H).


Example 108: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.



Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-10.

MS (ESI): mass calcd. for $C_{20}H_{17}BrFN_5O_2$, 457.1; m/z found, 458.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.91:0.09), major rotamer reported) δ 7.84 - 7.81 (m, 2H), 7.80 (s, 2H), 7.68 (dd, $J = 8.8, 2.6$ Hz, 1H), 7.07 (ddd, $J = 9.0, 7.6, 2.9$ Hz, 1H),
 5 6.81 (dd, $J = 8.1, 2.9$ Hz, 1H), 6.66 (d, $J = 8.8$ Hz, 1H), 4.90 (dt, $J = 10.2, 3.4$ Hz, 1H), 4.04 - 4.00 (m, 1H), 3.56 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.37 (dd, $J = 11.0, 1.5$ Hz, 1H), 2.65 - 2.57 (m, 1H), 2.25 - 2.13 (m, 1H), 1.50 - 1.32 (m, 2H), 1.32 - 1.23 (m, 1H).


Example 109: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-
 10 6-(2H-1,2,3-triazol-2-yl)phenyl)methanone.



Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-11.

MS (ESI): mass calcd. for $C_{20}H_{17}BrFN_5O_2$, 457.1; m/z found, 458.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ 7.83 (s, 2H), 7.79 - 7.76 (m, 1H), 7.75 (dt, $J = 8.2, 1.0$ Hz, 1H), 7.63 (dd, $J = 8.8, 2.5$ Hz, 1H), 7.39 - 7.31 (m, 1H), 6.76 - 6.66 (m, 2H), 4.85 (dt, $J = 10.1, 3.4$ Hz, 1H), 4.01 - 3.92 (m, 1H), 3.62 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.42 (dd, $J = 10.9, 1.5$ Hz, 1H), 2.64 - 2.58 (m, 1H), 2.24 - 2.14 (m, 1H), 1.42 - 1.31 (m, 2H), 1.30 - 1.17 (m, 1H).


Example 110: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-
 20 2-(pyrimidin-2-yl)phenyl)methanone.



Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-23.

MS (ESI): mass calcd. for $C_{22}H_{18}BrFN_4O_2$, 468.1; m/z found, 469.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Chloroform-d, Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ 8.79 (d, J = 4.9 Hz, 2H), 7.93 (dd, J = 10.0, 2.7 Hz, 1H), 7.86 (dd, J = 2.6, 0.6 Hz, 1H), 7.67 (dd, J = 8.8, 2.6 Hz, 1H), 7.22 (t, J = 4.9 Hz, 1H), 7.04 (dd, J = 8.4, 5.6 Hz, 1H), 6.70 - 6.64 (m, 2H), 4.93 (dt, J = 10.1, 3.3 Hz, 1H), 4.09 - 4.04 (m, 1H), 3.63 (dt, J = 10.9, 3.1 Hz, 1H), 3.43 - 3.34 (m, 1H), 2.66 - 2.59 (m, 1H), 2.26 - 2.15 (m, 1H), 1.46 - 1.33 (m, 2H), 1.31 - 1.23 (m, 1H).

- 10 Example 111: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




Prepared analogous to Example 47 substituting intermediate A-6 with intermediate A-7. MS

(ESI): mass calcd. for $C_{22}H_{18}BrFN_4O_2$, 468.1; m/z found, 469.1 $[M+H]^+$. ^1H NMR (400 MHz,

- 15 Chloroform-d, Compound present as a mixture of rotamers, (0.90:0.10), major rotamer reported) δ 8.76 (d, J = 4.9 Hz, 2H), 8.23 (dd, J = 8.8, 5.6 Hz, 1H), 7.83 (dd, J = 2.6, 0.7 Hz, 1H), 7.68 (dd, J = 8.8, 2.6 Hz, 1H), 7.18 (t, J = 4.9 Hz, 1H), 7.08 - 7.02 (m, 1H), 6.81 (dd, J = 8.6, 2.7 Hz, 1H), 6.68 (d, J = 8.8 Hz, 1H), 4.93 (dt, J = 10.0, 3.3 Hz, 1H), 4.14 - 4.06 (m, 1H), 3.64 (dt, J = 10.9, 3.2 Hz, 1H), 3.40 (dd, J = 10.7, 1.5 Hz, 1H), 2.69 - 2.61 (m, 1H), 2.30 - 2.15 (m, 1H), 1.47 - 1.35 (m, 2H),
20 1.34 - 1.24 (m, 1H).

Example 112: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Step A: (1S,4R,6R)-tert-butyl 6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (150 mg, 0.70 mmol) dissolved in DMF (5 mL) was added NaH (37 mg, 0.91 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were
5 rinsed with additional DMF (1 mL) and 5-chloro-2-fluoropyridine (0.11 mL, 1.13 mmol) was then added and the mixture heated to 70 °C. After heating at 70 °C for 7 h, the mixture was cooled to room temperature, quenched with saturated NH₄Cl solution, diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification via silica gel
10 chromatography (0-25% EtOAc in hexanes) gave the title compound (149 mg, 0.46 mmol, 65%) as a colorless solid. MS (ESI) mass calcd. for C₁₆H₂₁ClN₂O₃, 324.1; m/z found 325.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, only major rotamer reported) δ 8.06 (d, *J* = 2.6 Hz, 1H), 7.51 (dd, *J* = 8.8, 2.7 Hz, 1H), 6.66 (d, *J* = 8.7 Hz, 1H), 5.22 (dt, *J* = 10.1, 3.2 Hz, 1H), 4.52 - 4.49 (m, 1H), 3.38 (dt, *J* = 9.6, 3.1 Hz, 1H), 3.18 (dd, *J* = 9.5, 1.3
15 Hz, 1H), 2.58 - 2.54 (m, 1H), 2.23 - 2.12 (m, 1H), 1.75 - 1.68 (m, 1H), 1.64 - 1.59 (m, 1H), 1.36 (dt, *J* = 13.4, 3.6 Hz, 1H), 1.15 (s, 9H).

Step B: (1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane · xHCl. To the title compound of step A (149 mg, 0.46 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 3h. Then, the reaction was
20 concentrated to give the title compound of step B (129 mg) as a colorless solid and used without further purification. MS (ESI) mass calcd. for C₁₁H₁₃ClN₂O, 224.1; m/z found 225.1 [M+H]⁺.

Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (32 mg) and intermediate A-1 (25 mg, 0.14 mmol) in DMF (1 mL) was added DIPEA (0.25 mL, 1.5 mmol) and HATU (51
25 mg, 0.135 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (3X). The combined organics were concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (34 mg). MS (ESI): mass calcd. for C₂₀H₁₈ClN₅O₂,


395.1; m/z found, 396.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.89:0.11), major rotamer reported) δ 7.85 (dd, J = 8.2, 1.1 Hz, 1H), 7.81 (s, 2H), 7.67 (d, J = 2.6 Hz, 1H), 7.53 (dd, J = 8.8, 2.7 Hz, 1H), 7.40 - 7.34 (m, 1H), 7.07 (dd, J = 7.6, 1.5 Hz, 1H), 6.91 (td, J = 7.5, 1.2 Hz, 1H), 6.69 (d, J = 8.8 Hz, 1H), 4.90 (dt, J = 10.1, 3.3 Hz, 1H),
5 4.07 - 3.97 (m, 1H), 3.59 (dt, J = 10.9, 3.2 Hz, 1H), 3.38 (dd, J = 10.8, 1.4 Hz, 1H), 2.65 - 2.56 (m, 1H), 2.26 - 2.12 (m, 1H), 1.42 - 1.34 (m, 2H), 1.31 - 1.23 (m, 1H).

Example 113: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.




Prepared analogous to Example 112 substituting intermediate A-1 with intermediate A-10.
MS (ESI): mass calcd. for $C_{20}H_{17}ClFN_5O_2$, 413.1; m/z found, 414.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.92:0.08), major rotamer reported) δ 7.85 - 7.79 (m, 3H), 7.72 (d, J = 2.7 Hz, 1H), 7.56 (dd, J = 8.8, 2.7 Hz, 1H), 7.11 - 7.01 (m, 1H),
15 6.81 (dd, J = 8.2, 2.9 Hz, 1H), 6.70 (d, J = 8.7 Hz, 1H), 4.91 (dt, J = 10.1, 3.4 Hz, 1H), 4.11 - 3.98 (m, 1H), 3.56 (dt, J = 10.9, 3.2 Hz, 1H), 3.37 (dd, J = 10.9, 1.5 Hz, 1H), 2.68 - 2.56 (m, 1H), 2.26 - 2.13 (m, 1H), 1.47 - 1.32 (m, 2H), 1.32 - 1.22 (m, 1H).

Example 114: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.




Prepared analogous to Example 112 substituting intermediate A-1 with intermediate A-40.
 MS (ESI): mass calcd. for $C_{20}H_{19}ClN_6O_2$, 410.1; m/z found, 411.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ
 8.04 (d, $J = 8.4$ Hz, 1H), 7.83 (s, 2H), 7.61 (d, $J = 2.7$ Hz, 1H), 7.44 (dd, $J = 8.8, 2.7$ Hz, 1H), 7.14
 5 (d, $J = 8.4$ Hz, 1H), 6.70 (d, $J = 8.8$ Hz, 1H), 4.83 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.22 - 4.14 (m, 1H),
 3.65 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.43 (dd, $J = 11.0, 1.4$ Hz, 1H), 2.63 - 2.58 (m, 1H), 2.29 (s, 3H),
 2.23 - 2.13 (m, 1H), 1.48 - 1.32 (m, 3H).

Example 115: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-
 10 2-(pyrimidin-2-yl)phenyl)methanone.




Prepared analogous to Example 112 substituting intermediate A-1 with intermediate A-2.
 MS (ESI): mass calcd. for $C_{22}H_{18}ClFN_4O_2$, 424.1; m/z found, 425.1 $[M+H]^+$. ^1H NMR (400 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.84:0.16), major rotamer reported) δ
 15 8.90 (d, $J = 4.9$ Hz, 2H), 7.80 (d, $J = 2.8$ Hz, 1H), 7.69 (dd, $J = 8.8, 2.7$ Hz, 1H), 7.49 (t, $J = 5.0$ Hz,
 1H), 7.26 - 7.18 (m, 1H), 7.14 - 7.05 (m, 1H), 6.95 - 6.81 (m, 2H), 5.02 (dt, $J = 10.1, 3.3$ Hz, 1H),
 4.29 - 4.20 (m, 1H), 3.28 - 3.17 (m, 2H), 2.59 - 2.50 (m, 1H), 2.29 - 2.17 (m, 1H), 1.52 (d, $J = 10.6$
 Hz, 1H), 1.33 (dt, $J = 13.5, 3.6$ Hz, 1H), 1.04 - 0.89 (m, 1H).

20 Example 116: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone.



Prepared analogous to Example 112 substituting intermediate A-1 with intermediate A-34.
 MS (ESI): mass calcd. for $C_{22}H_{18}ClFN_4O_2$, 424.1; m/z found, 425.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ
 8.81 (d, $J = 0.6$ Hz, 2H), 8.21 - 8.15 (m, 1H), 7.73 - 7.67 (m, 2H), 7.44 - 7.39 (m, 1H), 7.02 - 6.99
 5 (m, 2H), 6.85 (d, $J = 8.7$ Hz, 1H), 5.00 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.13 - 4.06 (m, 1H), 3.60 (dt, $J =$
 11.0, 3.2 Hz, 1H), 3.34 - 3.32 (m, 1H), 2.71 - 2.64 (m, 1H), 2.31 - 2.22 (m, 1H), 1.58 - 1.50 (m, 1H),
 1.41 (dt, $J = 13.3, 3.6$ Hz, 1H), 1.38 - 1.33 (m, 1H).


Example 117: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-
 10 2-(5-fluoropyrimidin-2-yl)phenyl)methanone.



Prepared analogous to Example 112 substituting intermediate A-1 with intermediate A-35.
 MS (ESI): mass calcd. for $C_{22}H_{17}ClF_2N_4O_2$, 442.1; m/z found, 443.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.82:0.18), major rotamer reported) δ
 8.87 (d, $J = 0.7$ Hz, 2H), 7.82 (dd, $J = 2.7, 0.7$ Hz, 1H), 7.70 (dd, $J = 8.8, 2.7$ Hz, 1H), 7.24 - 7.18
 15 (m, 1H), 7.13 - 7.06 (m, 1H), 6.93 (dd, $J = 7.6, 1.4$ Hz, 1H), 6.87 (dd, $J = 8.8, 0.7$ Hz, 1H), 5.06 (dt,
 $J = 10.1, 3.3$ Hz, 1H), 4.26 - 4.20 (m, 1H), 3.26 - 3.20 (m, 1H), 2.61 - 2.57 (m, 1H), 2.31 - 2.22 (m,
 1H), 1.61 - 1.55 (m, 1H), 1.35 (dt, $J = 13.5, 3.6$ Hz, 1H), 1.17 - 1.09 (m, 1H). 1H buried under
 solvent peak.

20

Example 118: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-
 azabicyclo[2.2.1]heptan-2-yl)methanone.




Step A: (1S,4R,6R)-tert-butyl 6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (200 mg, 0.94 mmol) dissolved in DMF (3 mL) was added NaH (41 mg, 1.03 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were
5 rinsed with additional DMF (1 mL) and 2,5-difluoropyridine (0.11 mL, 1.22 mmol) was then added and the mixture heated to 60 °C. After heating at 60 °C for 3 h, the mixture was cooled to room temperature, quenched with saturated NH₄Cl solution, diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification via silica gel
10 chromatography (0-30% EtOAc in hexanes) gave the title compound (193 mg, 0.63 mmol, 67%) as a colorless solid. MS (ESI) mass calcd. for C₁₆H₂₁FN₂O₃, 308.2; m/z found 309.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, only major rotamer reported) δ 7.95 (d, *J* = 3.1 Hz, 1H), 7.37 - 7.30 (m, 1H), 6.67 (dd, *J* = 9.0, 3.6 Hz, 1H), 5.21 (dt, *J* = 10.2, 3.2 Hz, 1H), 4.53 - 4.50 (m, 1H), 3.39 (dt, *J* = 9.6, 3.1 Hz, 1H), 3.19 (dd, *J* = 9.5, 1.4 Hz, 1H),
15 2.58 - 2.53 (m, 1H), 2.24 - 2.12 (m, 1H), 1.77 - 1.69 (m, 1H), 1.64 - 1.59 (m, 1H), 1.36 (dt, *J* = 13.4, 3.6 Hz, 1H), 1.15 (s, 9H).

Step B: (1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane · xHCl. To the title compound of step A (193 mg, 0.63 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 2h. The reaction was
20 concentrated to give the title compound of step B (182 mg) as an off-white solid and used without further purification. MS (ESI) mass calcd. for C₁₁H₁₃FN₂O, 208.1; m/z found 209.1 [M+H]⁺.

Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (32 mg) and intermediate A-1 (27 mg, 0.13 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (48
25 mg, 0.13 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (3X). The combined organics were concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (31 mg). MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₂, 379.1;


m/z found, 380.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ 7.85 (dd, J = 8.2, 1.1 Hz, 1H), 7.81 (s, 2H), 7.60 (d, J = 3.1 Hz, 1H), 7.39 - 7.31 (m, 2H), 7.12 (dd, J = 7.7, 1.5 Hz, 1H), 6.92 (td, J = 7.6, 1.2 Hz, 1H), 6.70 (dd, J = 9.0, 3.6 Hz, 1H), 4.91 (dt, J = 10.1, 3.3 Hz, 1H), 4.04 - 3.95 (m, 1H), 3.59 (dt, J = 10.9, 3.2 Hz, 1H), 3.38 (dd, J = 11.0, 1.4 Hz, 1H), 2.65 - 2.58 (m, 1H), 2.24 - 2.13 (m, 1H), 1.44 - 1.20 (m, 3H).

Example 119: ((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.




Prepared analogous to Example 118 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for $C_{20}H_{19}FN_6O_2$, 394.2; m/z found, 395.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ 8.03 (d, J = 8.4 Hz, 1H), 7.82 (s, 2H), 7.53 (d, J = 3.1 Hz, 1H), 7.29 - 7.22 (m, 1H), 7.13 (d, J = 8.4 Hz, 1H), 6.71 (dd, J = 9.0, 3.7 Hz, 1H), 4.84 (dt, J = 10.3, 3.2 Hz, 1H), 4.19 - 4.15 (m, 1H), 3.65 (dt, J = 11.0, 3.2 Hz, 1H), 3.44 (dd, J = 10.8, 1.4 Hz, 1H), 2.63 - 2.58 (m, 1H), 2.30 (s, 3H), 2.23 - 2.13 (m, 1H), 1.47 - 1.33 (m, 3H).

Example 120: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 118 substituting intermediate A-1 with intermediate A-2.
MS (ESI): mass calcd. for $C_{22}H_{18}F_2N_4O_2$, 408.1; m/z found, 409.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.89:0.11), major rotamer reported) δ 8.85 (d, J = 4.9 Hz, 2H), 7.70 (d, J = 3.1 Hz, 1H), 7.40 - 7.32 (m, 1H), 7.28 - 7.27 (m, 1H), 7.15 - 7.05 (m, 1H), 7.06 - 6.94 (m, 2H), 6.72 (dd, J = 9.0, 3.6 Hz, 1H), 4.98 (dt, J = 10.0, 3.3 Hz, 1H), 4.26 - 4.15 (m, 1H), 3.35 - 3.26 (m, 2H), 2.60 - 2.48 (m, 1H), 2.25 - 2.14 (m, 1H), 1.42 (d, J = 10.3 Hz, 1H), 1.30 (dt, J = 13.4, 3.5 Hz, 1H), 1.00 - 0.92 (m, 1H).

Example 121: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Step A: (1S,4R,6R)-tert-butyl 6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (200 mg, 0.94 mmol) dissolved in DMF (3 mL) was added NaH (41 mg, 1.03 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-chloro-5-(difluoromethyl)pyridine (0.15 mL, 1.22 mmol) was then added and the mixture heated to 60 °C. After heating at 60 °C for 3 h, the mixture was cooled to room temperature, quenched with saturated NH_4Cl solution, diluted with EtOAc and H_2O . The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , 5% aqueous LiCl, brine, dried with Na_2SO_4 , filtered, and concentrated. Purification via silica gel chromatography (0-20% EtOAc in hexanes) gave the title compound (76 mg, 0.22 mmol, 24%) as a colorless solid. MS (ESI) mass calcd. for $C_{17}H_{22}F_2N_4O_3$, 340.2; m/z found 341.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, only major rotamer reported) δ 8.27 - 8.23 (m, 1H), 7.72 (dd, J = 8.7, 2.5 Hz, 1H), 6.83 - 6.46 (m, 2H), 5.32 (dt, J = 10.1, 3.2 Hz, 1H), 4.57 - 4.52 (m, 1H), 3.40 (dt, J = 9.6, 3.1 Hz, 1H), 3.20 (dd, J = 9.5, 1.3 Hz, 1H), 2.61 - 2.55 (m, 1H), 2.26 - 2.15 (m, 1H), 1.77 - 1.71 (m, 1H), 1.67 - 1.60 (m, 1H), 1.40 (dt, J = 13.5, 3.8 Hz, 1H), 1.12 (s, 9H).

Step B: (1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane · xHCl. To the title compound of step A (76 mg, 0.22 mmol) in EtOAc (4 mL) was added 4M HCl in dioxane (1 mL) and the reaction mixture was stirred at room temperature for 2h. The reaction was concentrated to give the title compound of step B (74 mg) as an off-white solid and used without further purification. MS (ESI) mass calcd. for C₁₂H₁₄F₂N₂O, 240.1; m/z found 241.1 [M+H]⁺.

Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (24 mg) and intermediate A-1 (20 mg, 0.095 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (36 mg, 0.095 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (29 mg). MS (ESI): mass calcd. for C₂₁H₁₉F₂N₅O₂, 411.2; m/z found, 412.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.89:0.11), major rotamer reported) δ 7.88 - 7.85 (m, 1H), 7.83 (dd, J = 8.3, 1.1 Hz, 1H), 7.81 (s, 2H), 7.77 - 7.70 (m, 1H), 7.34 - 7.28 (m, 1H), 7.05 (dd, J = 7.6, 1.5 Hz, 1H), 6.85 - 6.79 (m, 2H), 6.60 (t, J = 56.0 Hz, 1H), 5.00 (dt, J = 10.2, 3.3 Hz, 1H), 4.09 - 3.99 (m, 1H), 3.60 (dt, J = 11.0, 3.2 Hz, 1H), 3.40 (dd, J = 10.9, 1.4 Hz, 1H), 2.66 - 2.56 (m, 1H), 2.28 - 2.13 (m, 1H), 1.44 - 1.35 (m, 2H), 1.33 - 1.25 (m, 1H).


Example 122: ((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.



Prepared analogous to Example 121 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C₂₁H₂₀F₂N₆O₂, 426.2; m/z found, 427.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, (0.86:0.14), major rotamer reported) δ 8.01 (d, J = 8.4 Hz, 1H), 7.87 - 7.81 (m, 3H), 7.64 (dd, J = 8.7, 2.4 Hz, 1H), 7.06 (d, J = 8.4 Hz,

1H), 6.81 (d, $J = 8.6$ Hz, 1H), 6.57 (t, $J = 56.0$ Hz, 1H), 4.95 (dt, $J = 10.4, 3.3$ Hz, 1H), 4.25 - 4.17 (m, 1H), 3.67 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.46 (dd, $J = 11.0, 1.4$ Hz, 1H), 2.68 - 2.61 (m, 1H), 2.27 - 2.16 (m, 4H), 1.50 - 1.40 (m, 3H).

- 5 Example 123: ((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




Prepared analogous to Example 121 substituting intermediate A-1 with intermediate A-2.

MS (ESI): mass calcd. for $C_{23}H_{19}F_3N_4O_2$, 440.1; m/z found, 441.2 $[M+H]^+$. ^1H NMR (400 MHz,

- 10 Chloroform- d , Compound present as a mixture of rotamers, (0.88:0.12), major rotamer reported) δ 8.85 (d, $J = 4.9$ Hz, 2H), 7.98 - 7.92 (m, 1H), 7.75 (dd, $J = 8.6, 2.4$ Hz, 1H), 7.29 - 7.26 (m, 1H), 7.09 - 7.02 (m, 1H), 6.96 - 6.88 (m, 2H), 6.83 (d, $J = 8.6$ Hz, 1H), 6.61 (t, $J = 55.9$ Hz, 1H), 5.07 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.27 - 4.20 (m, 1H), 3.35 - 3.28 (m, 2H), 2.59 - 2.51 (m, 1H), 2.25 - 2.12 (m, 1H), 1.43 (d, $J = 10.3$ Hz, 1H), 1.35 (dt, $J = 13.5, 3.5$ Hz, 1H), 1.01 - 0.89 (m, 1H).

15

Example 124: (5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 20 Step A: (1S,4R,6R)-tert-butyl 6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (125 mg, 0.59 mmol) dissolved in DMF (5 mL) was added NaH (47 mg, 1.17 mmol, 60% dispersion in mineral oil). After 5 minutes the sides of the flask were rinsed with additional DMF (1 mL) and 2-chloro-5-

(trifluoromethyl)pyrazine (0.12 mL, 0.94 mmol) was then added and the reaction mixture stirred overnight at room temperature. Then, the mixture was quenched with saturated NH_4Cl solution, diluted with EtOAc and H_2O . The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , 5% aqueous LiCl, brine, dried with Na_2SO_4 , filtered, and concentrated. Purification via silica gel chromatography (0-40% EtOAc in hexanes) gave the title compound (89 mg, 0.25 mmol, 42%) as a colorless solid. MS (ESI) mass calcd. for $\text{C}_{16}\text{H}_{20}\text{F}_3\text{N}_3\text{O}_3$, 359.2; m/z found 304.0 $[\text{M}+2\text{H}-t\text{Bu}]^+$. ^1H NMR (500 MHz, Methanol- d_4) δ 8.60 (s, 1H), 8.35 - 8.26 (m, 1H), 5.49 - 5.39 (m, 1H), 4.59 - 4.53 (m, 1H), 3.39 (dt, $J = 9.6, 3.2$ Hz, 1H), 3.15 (d, $J = 9.5$ Hz, 1H), 2.67 - 2.62 (m, 1H), 2.37 - 2.22 (m, 1H), 1.80 - 1.73 (m, 3H), 1.08 (s, 9H).

Step B: (1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane $\cdot$ xHCl. To the title compound of step A (89 mg, 0.25 mmol) in EtOAc (3 mL) was added 4M HCl in dioxane (0.3 mL) and the reaction mixture was stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B (80 mg) as a yellow oil and used without further purification. MS (ESI) mass calcd. for $\text{C}_{11}\text{H}_{12}\text{F}_3\text{N}_3\text{O}$, 259.1; m/z found 260.1 $[\text{M}+\text{H}]^+$.

Step C: (5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (24 mg) and intermediate A-10 (20 mg, 0.097 mmol) in DMF (1 mL) was added DIPEA (84 μL , 0.49 mmol) and HATU (34 mg, 0.089 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction was quenched by the addition of H_2O and the aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , 5% aqueous LiCl, brine, dried with Na_2SO_4 , filtered, and concentrated. Purification of the concentrate was performed using Gilson Prep Method X to give the title compound (17 mg). MS (ESI): mass calcd. for $\text{C}_{20}\text{H}_{16}\text{F}_4\text{N}_6\text{O}_2$, 448.1; m/z found, 449.1 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.83:0.17), major rotamer reported) δ 8.40 (s, 1H), 8.23 (s, 1H), 7.96 (s, 2H), 7.90 (dd, $J = 9.0, 4.7$ Hz, 1H), 7.22 - 7.14 (m, 1H), 6.87 (d, $J = 8.1$ Hz, 1H), 5.10 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.02 (s, 1H), 3.52 (dt, $J = 10.9, 3.3$ Hz, 1H), 3.35 (dd, $J = 11.1, 1.6$ Hz, 1H), 2.71 - 2.63 (m, 1H), 2.35 - 2.24 (m, 1H), 1.59 - 1.51 (m, 1H), 1.49 (dt, $J = 13.5, 3.7$ Hz, 1H), 1.46 - 1.21 (m, 1H).

Example 125: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 124 substituting intermediate A-10 with intermediate A-40.

MS (ESI): mass calcd. for $C_{20}H_{18}F_3N_7O_2$, 445.1; m/z found, 446.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.90:0.10), major rotamer reported) δ

- 5 8.28 (d, $J = 1.3$ Hz, 1H), 8.19 - 8.14 (m, 2H), 8.00 (s, 2H), 7.29 (d, $J = 8.5$ Hz, 1H), 5.08 (dt, $J = 10.4, 3.2$ Hz, 1H), 4.25 - 4.20 (m, 1H), 3.61 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.41 (dd, $J = 11.0, 1.6$ Hz, 1H), 2.75 - 2.67 (m, 1H), 2.36 - 2.27 (m, 1H), 2.22 (s, 3H), 1.66 - 1.59 (m, 1H), 1.60 - 1.49 (m, 2H).

Example 126: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.

10




Prepared analogous to Example 124 substituting intermediate A-10 with intermediate A-2.

MS (ESI): mass calcd. for $C_{22}H_{17}F_4N_5O_2$, 459.1; m/z found, 460.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.76:0.24), major rotamer reported) δ

- 15 8.91 (d, $J = 5.0$ Hz, 2H), 8.42 (d, $J = 1.3$ Hz, 1H), 8.26 - 8.23 (m, 1H), 7.50 (t, $J = 5.0$ Hz, 1H), 7.21 - 7.15 (m, 1H), 7.07 - 7.00 (m, 1H), 6.95 (dd, $J = 7.6, 1.2$ Hz, 1H), 5.14 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.33 - 4.24 (m, 1H), 3.29 - 3.27 (m, 2H), 2.63 - 2.56 (m, 1H), 2.34 - 2.25 (m, 1H), 1.56 (d, $J = 11.1$ Hz, 1H), 1.44 (dt, $J = 13.7, 3.6$ Hz, 1H), 1.05 - 0.91 (m, 1H).

- 20 Example 127: (4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 124 substituting intermediate A-10 with intermediate A-23.

MS (ESI): mass calcd. for $C_{22}H_{17}F_4N_5O_2$, 459.1; m/z found, 460.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.80:0.20), major rotamer reported) δ

5 8.88 (d, $J = 4.9$ Hz, 2H), 8.40 (s, 1H), 8.20 (s, 1H), 7.92 (dd, $J = 10.1, 2.7$ Hz, 1H), 7.46 - 7.41 (m, 1H), 7.08 (dd, $J = 8.4, 5.5$ Hz, 1H), 6.66 (td, $J = 8.2, 2.7$ Hz, 1H), 5.09 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.11 (s, 1H), 3.60 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.36 (dd, $J = 11.0, 1.6$ Hz, 1H), 2.74 - 2.65 (m, 1H), 2.35 - 2.27 (m, 1H), 1.56 - 1.47 (m, 2H), 1.35 - 1.27 (m, 1H).

- 10 Example 128: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 124 substituting intermediate A-10 with intermediate A-7.

MS (ESI): mass calcd. for $C_{22}H_{17}F_4N_5O_2$, 459.1; m/z found, 460.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.85:0.15), major rotamer reported) δ

15 8.85 (d, $J = 4.9$ Hz, 2H), 8.40 (s, 1H), 8.26 (dd, $J = 8.8, 5.5$ Hz, 1H), 8.22 (s, 1H), 7.39 (t, $J = 4.9$ Hz, 1H), 7.15 - 7.09 (m, 1H), 6.78 (dd, $J = 8.6, 2.7$ Hz, 1H), 5.11 (dt, $J = 10.2, 3.4$ Hz, 1H), 4.14 (s, 1H), 3.61 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.36 (dd, $J = 10.9, 1.6$ Hz, 1H), 2.74 - 2.66 (m, 1H), 2.36 - 2.26 (m, 1H), 1.58 - 1.54 (m, 1H), 1.52 (dt, $J = 13.6, 3.6$ Hz, 1H), 1.40 - 1.33 (m, 1H).


Example 129: (2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 124 substituting intermediate A-10 with intermediate A-6.


- 5 MS (ESI): mass calcd. for $C_{22}H_{17}F_4N_5O_2$, 459.1; m/z found, 460.0 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.74:0.26), major rotamer reported) δ 8.88 (d, J = 4.9 Hz, 2H), 8.35 - 8.33 (m, 1H), 8.17 - 8.12 (m, 2H), 7.43 (t, J = 4.9 Hz, 1H), 7.41 - 7.35 (m, 1H), 6.70 - 6.64 (m, 1H), 5.07 (dt, J = 10.2, 3.4 Hz, 1H), 4.13 - 4.10 (m, 1H), 3.64 (dt, J = 11.0, 3.2 Hz, 1H), 3.39 (dd, J = 11.0, 1.6 Hz, 1H), 2.72 - 2.68 (m, 1H), 2.36 - 2.27 (m, 1H), 1.87 - 1.83 (m, 1H), 1.55 - 1.53 (m, 1H), 1.32 - 1.25 (m, 1H).
- 10

Example 130: (2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 15 Prepared analogous to Example 124 substituting intermediate A-10 with intermediate A-37.
- MS (ESI): mass calcd. for $C_{22}H_{18}F_3N_5O_2$, 441.1; m/z found, 442.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, (0.85:0.15), major rotamer reported) δ 8.86 (d, J = 4.9 Hz, 2H), 8.38 (s, 1H), 8.16 (dd, J = 8.0, 1.2 Hz, 1H), 8.11 (s, 1H), 7.44 - 7.33 (m, 2H), 7.01 (dd, J = 7.7, 1.4 Hz, 1H), 6.91 (t, J = 7.5, 1.3 Hz, 1H), 5.08 (dt, J = 10.2, 3.3 Hz, 1H), 4.12 (s, 1H), 3.58 (dt, J = 10.9, 3.2 Hz, 1H), 3.37 (dd, J = 10.9, 1.6 Hz, 1H), 2.73 - 2.66 (m, 1H), 2.35 - 2.22 (m, 1H), 1.56 - 1.48 (m, 2H), 1.28 - 1.21 (m, 1H).
- 20

Example 131: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Step A: (1S,4R,6R)-tert-butyl 6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (106 mg, 0.497 mmol) and 2-chloro-5-methylpyrimidine (93 mg, 0.72 mmol) dissolved in DMF (2 mL) was added NaH (40 mg, 0.99 mmol, 60% dispersion in mineral oil), and the reaction mixture was stirred at room temperature for 2 h. Then, the mixture was quenched with H₂O, diluted with EtOAc and the aqueous layer extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification of the concentrate via silica gel chromatography (0-60% EtOAc in hexanes) gave the title compound (129 mg, 0.422 mmol, 85%) as a colorless solid. MS (ESI) mass calcd. for C₁₆H₂₃N₃O₃, 305.2; m/z found 306.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.68:0.32), major rotamer reported) δ 8.29 (s, 2H), 5.22 - 5.14 (m, 1H), 4.59 - 4.51 (m, 1H), 3.37 (dt, J = 9.5, 3.1 Hz, 1H), 3.20 (dd, J = 9.4, 1.4 Hz, 1H), 2.55 - 2.51 (m, 1H), 2.21 (s, 3H), 2.17 - 2.11 (m, 1H), 1.69 - 1.67 (m, 1H), 1.63 - 1.59 (m, 1H), 1.54 - 1.47 (m, 1H), 1.07 (s, 9H).

Step B: (1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane · xHCl. To the title compound of step A (129 mg, 0.422 mmol) in EtOAc (2 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 1 h. The reaction was concentrated to give the title compound of step B (147 mg) as a colorless solid and used without further purification. MS (ESI) mass calcd. for C₁₁H₁₅N₃O, 205.1; m/z found 206.1 [M+H]⁺.

Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (34 mg) and intermediate A-1 (29 mg, 0.16 mmol) in DMF (0.8 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (59 mg, 0.16 mmol), and the reaction mixture was stirred at room temperature for 6 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to


give the title compound (20 mg). MS (ESI): mass calcd. for $C_{20}H_{20}N_6O_2$, 376.2; m/z found, 377.2 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.78:0.22), major rotamer reported) δ 8.11 (s, 2H), 7.83 (dd, $J = 8.2, 1.1$ Hz, 1H), 7.80 (s, 2H), 7.30 - 7.26 (m, 1H), 7.20 (dd, $J = 7.7, 1.5$ Hz, 1H), 6.82 (t, $J = 7.6$ Hz, 1H), 4.92 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.15 - 3.99 (m, 1H), 3.62 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.41 (d, $J = 10.8$ Hz, 1H), 2.65 - 2.60 (m, 1H), 2.24 - 2.20 (m, 4H), 1.53 (dt, $J = 13.5, 3.4$ Hz, 1H), 1.41 (d, $J = 3.2$ Hz, 2H).

Example 132: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 131 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for $C_{20}H_{21}N_7O_2$, 391.2; m/z found, 392.2 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.74:0.26), major rotamer reported) δ 8.04 (d, $J = 8.4$ Hz, 1H), 8.03 (d, $J = 0.9$ Hz, 2H), 7.80 (s, 2H), 7.07 (d, $J = 8.4$ Hz, 1H), 4.81 (dt, $J = 10.3, 3.4$ Hz, 1H), 4.38 - 4.29 (m, 1H), 3.72 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.46 (dd, $J = 10.9, 1.5$ Hz, 1H), 2.67 - 2.65 (m, 1H), 2.25 (s, 3H), 2.24 - 2.19 (m, 1H), 2.16 (s, 3H), 1.66 - 1.61 (m, 1H), 1.57 - 1.52 (m, 1H), 1.51 - 1.47 (m, 1H).


Example 133: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 131 substituting intermediate A-1 with intermediate A-2.


MS (ESI): mass calcd. for $C_{22}H_{20}FN_5O_2$, 405.2; m/z found, 406.1 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.75:0.25), major rotamer reported) δ 8.83 (d, $J = 4.9$ Hz, 2H), 8.18 (d, $J = 0.9$ Hz, 2H), 7.26 - 7.24 (m, 1H), 7.08 (dd, $J = 7.5, 1.2$ Hz, 1H), 7.05 - 7.00 (m, 1H), 6.95 - 6.91 (m, 1H), 5.00 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.31 - 4.22 (m, 1H), 3.36 - 3.32 (m, 2H), 2.61 - 2.50 (m, 1H), 2.22 (s, 3H), 1.52 - 1.41 (m, 2H), 1.12 - 1.07 (m, 1H). 1H buried under water peak.

Example 134: (5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 131 substituting intermediate A-1 with intermediate A-47. MS (ESI): mass calcd. for $C_{22}H_{22}N_6O_2$, 402.2; m/z found, 403.2 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.60:0.40), major rotamer reported) δ 8.76 (d, $J = 4.8$ Hz, 2H), 8.28 (dd, $J = 2.2, 0.8$ Hz, 1H), 8.03 (d, $J = 0.9$ Hz, 2H), 7.81 (dd, $J = 2.2, 0.8$ Hz, 1H), 7.19 (t, $J = 4.8$ Hz, 1H), 4.88 (dt, $J = 10.3, 3.4$ Hz, 1H), 4.45 - 4.38 (m, 1H), 3.76 (dt, $J = 10.8, 3.2$ Hz, 1H), 3.45 (dd, $J = 10.7, 1.4$ Hz, 1H), 2.72 - 2.64 (m, 1H), 2.31 (s, 3H), 2.20 (s, 3H), 1.74 - 1.53 (m, 3H). 1H buried under solvent.

Example 135: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (120 mg, 0.563 mmol) and 2-chloro-5-ethylpyrimidine (128 mg, 0.9 mmol), dissolved in DMF (4 mL), was added NaH (29 mg, 0.73 mmol, 60% dispersion in mineral oil) and the mixture stirred at room temperature for 1 h. The reaction mixture was

- 5 quenched with H₂O, diluted with EtOAc and the aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purification of the concentrate via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (160 mg, 0.501 mmol, 89%) as a colorless solid. MS (ESI) mass calcd. for C₁₇H₂₅N₃O₃, 319.2; m/z found 320.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, 10 Compound present as a mixture of rotamers, only major rotamer reported) δ 8.34 (s, 2H), 5.21 (dt, *J* = 10.3, 3.4 Hz, 1H), 4.60 - 4.55 (m, 1H), 3.40 (dt, *J* = 9.5, 3.1 Hz, 1H), 3.23 (dd, *J* = 9.5, 1.4 Hz, 1H), 2.61 - 2.55 (m, 3H), 2.22 - 2.15 (m, 1H), 1.75 - 1.69 (m, 1H), 1.65 - 1.62 (m, 1H), 1.55 (dt, *J* = 13.5, 3.8 Hz, 1H), 1.25 - 1.22 (m, 3H), 1.09 (s, 9H).

- Step B: (1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane · xHCl. To 15 the title compound of step A (160 mg, 0.501 mmol) in EtOAc (1.5 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 1h. Then, the reaction was concentrated to give the title compound of step B (148 mg) as a colorless solid and used without further purification. MS (ESI) mass calcd. for C₁₂H₁₇N₃O, 219.1; m/z found 220.1 [M+H]⁺.

- Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2- 20 azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (37 mg) and intermediate A-1 (30 mg, 0.16 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.6 mmol) and HATU (61 mg, 0.16 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (3X). The combined organics were concentrated. Purification of the concentrate was performed using Agilent 25 Prep Method X to give the title compound (33 mg). MS (ESI): mass calcd. for C₂₁H₂₂N₆O₂, 390.2; m/z found, 391.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19), only major rotamer reported) δ 8.14 - 7.16 (m, 7H), 6.79 (t, *J* = 7.6 Hz, 1H), 4.92 (dt, *J* = 10.3, 3.3 Hz, 1H), 4.05 (s, 1H), 3.62 (dt, *J* = 10.9, 3.2 Hz, 1H), 3.41 (d, *J* = 10.8 Hz, 1H), 2.65 - 2.59 (m, 1H), 2.54 (q, *J* = 7.6 Hz, 2H), 2.28 - 2.12 (m, 1H), 1.85 - 1.76 (m, 1H), 1.70 - 30 1.63 (m, 1H), 1.53 (dt, *J* = 13.3, 3.2 Hz, 1H), 1.26 (t, *J* = 7.6 Hz, 3H).


Example 136: ((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.



Prepared analogous to Example 135 substituting intermediate A-1 with intermediate A-40.

- 5 MS (ESI): mass calcd. for $C_{21}H_{23}N_7O_2$, 405.2; m/z found, 406.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.69:0.31), only major rotamer reported) δ 8.08 - 8.01 (m, 3H), 7.80 (s, 2H), 7.05 (d, J = 8.5 Hz, 1H), 4.82 (dt, J = 10.3, 3.4 Hz, 1H), 4.47 - 4.30 (m, 1H), 3.73 (dt, J = 10.8, 3.2 Hz, 1H), 3.47 (dd, J = 10.9, 1.5 Hz, 1H), 2.70 - 2.65 (m, 1H), 2.55 - 2.45 (m, 2H), 2.27 - 2.16 (m, 4H), 1.65 (dt, J = 13.3, 3.7 Hz, 1H), 1.64 - 1.47 (m, 2H), 1.27 - 1.18 (m, 3H).
- 10

Example 137: ((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




15

Prepared analogous to Example 135 substituting intermediate A-1 with intermediate A-2.

- MS (ESI): mass calcd. for $C_{23}H_{22}FN_5O_2$, 419.2; m/z found, 420.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.78:0.22), only major rotamer reported) δ 8.84 (d, J = 4.9 Hz, 2H), 8.20 (s, 2H), 7.07 (dd, J = 7.5, 1.2 Hz, 1H), 7.01 - 6.97 (m, 1H), 6.94 - 6.89 (m, 1H), 5.00 (dt, J = 10.1, 3.3 Hz, 1H), 4.31 - 4.22 (m, 1H), 3.37 - 3.29 (m, 2H), 2.57 (q, J = 7.6 Hz, 3H), 2.25 - 2.16 (m, 1H), 1.53 - 1.44 (m, 2H), 1.27 (t, J = 7.6 Hz, 3H), 1.15 - 1.06 (m, 1H). 1H buried under solvent.
- 20


Example 138: ((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.



Prepared analogous to Example 135 substituting intermediate A-1 with intermediate A-41.

- 5 MS (ESI): mass calcd. for $C_{23}H_{24}N_6O_2$, 416.2; m/z found, 417.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , , Compound present as a mixture of rotamers (0.63:0.37), only major rotamer reported) δ 8.74 (d, J = 4.8 Hz, 2H), 8.38 (d, J = 8.1 Hz, 1H), 8.00 (s, 2H), 7.17 (t, J = 4.8 Hz, 1H), 7.04 (d, J = 8.2 Hz, 1H), 4.81 (dt, J = 10.4, 3.4 Hz, 1H), 4.51 - 4.46 (m, 1H), 3.80 (dt, J = 10.8, 3.2 Hz, 1H), 3.47 (dd, J = 10.6, 1.4 Hz, 1H), 2.72 - 2.66 (m, 1H), 2.48 (q, J = 7.6 Hz, 2H), 2.28 - 2.17
- 10 (m, 4H), 1.67 (dt, J = 13.3, 3.7 Hz, 1H), 1.61 - 1.54 (m, 2H), 1.21 (t, J = 7.7 Hz, 3H).

Example 139: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 15 Step A: (1S,4R,6R)-tert-butyl 6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (106 mg, 0.457 mmol) and 3-chloro-6-(trifluoromethyl)pyridazine (120 mg, 0.66 mmol) dissolved in DMF (2 mL) was added NaH (40 mg, 0.99 mmol, 60% dispersion in mineral oil), and the reaction mixture was stirred at room temperature for 2 h. Then, the mixture was quenched with saturated NH_4Cl solution, diluted with
- 20 EtOAc and H_2O . The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , 5% aqueous LiCl, brine, dried with Na_2SO_4 , filtered, and concentrated. Purification of the concentrate via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (189 mg) as an off-white solid. MS (ESI) mass calcd. for $C_{16}H_{20}F_3N_3O_3$, 359.2; m/z

found 304.1 $[M+2H-tBu]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers, (0.74:0.26), major rotamer reported) δ 7.70 (d, J = 9.2 Hz, 1H), 7.07 (d, J = 9.2 Hz, 1H), 5.59 (dt, J = 10.1, 3.1 Hz, 1H), 4.76 - 4.67 (m, 1H), 3.43 (dt, J = 9.6, 3.1 Hz, 1H), 3.23 - 3.17 (m, 1H), 2.64 - 2.60 (m, 1H), 2.34 - 2.26 (m, 1H), 1.81 - 1.76 (m, 1H), 1.68 - 1.65 (m, 1H), 1.50 - 1.45 (m, 1H), 1.10 (s, 9H).

Step B: (1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptane $\cdot$ xHCl. To the title compound of step A (189 mg, 0.53 mmol) in EtOAc (2 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 6 h. The reaction was concentrated to give the title compound of step B (146 mg) as an off-white solid and used without further purification. MS (ESI) mass calcd. for $C_{11}H_{12}F_3N_3O$, 259.1; m/z found 260.1 $[M+H]^+$.


Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (34 mg) and intermediate A-1 (24 mg, 0.126 mmol) in DMF (0.5 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (48 mg, 0.126 mmol), and the reaction mixture was stirred at room temperature for 1 h. Analysis of the reaction mixture showed unreacted starting material and additional intermediate A-1 (10 mg) was added. The reaction mixture was stirred for an additional 15 minutes at room temperature. The reaction was then quenched by the addition of H_2O and the aqueous layer was extracted with EtOAc (3X). The combined organics were concentrated and subjected directly to purification using Agilent Prep Method X to give the title compound (33 mg). MS (ESI): mass calcd. for $C_{20}H_{17}F_3N_6O_2$, 430.1; m/z found, 431.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 $^{\circ}C$). R_t = 6.08 min (major rotamer) at 254 nm.

Example 140: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 139 substituting intermediate A-1 with intermediate A-40.
 MS (ESI): mass calcd. for $C_{20}H_{18}F_3N_7O_2$, 445.1; m/z found, 446.2 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.82:0.18), major rotamer reported) δ
 5 8.04 (d, $J = 8.4$ Hz, 1H), 7.81 (s, 2H), 7.62 (d, $J = 9.1$ Hz, 1H), 7.15 (dd, $J = 9.2, 0.7$ Hz, 1H), 7.11 (d, $J = 8.5$ Hz, 1H), 5.31 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.46 - 4.41 (m, 1H), 3.70 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.47 (dd, $J = 11.0, 1.5$ Hz, 1H), 2.73 - 2.68 (m, 1H), 2.37 - 2.28 (m, 1H), 2.23 (s, 3H), 1.63 - 1.58 (m, 1H), 1.57 - 1.49 (m, 2H).


- 10 Example 141: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 139 substituting intermediate A-1 with intermediate A-2.
 MS (ESI): mass calcd. for $C_{22}H_{17}F_4N_5O_2$, 459.1; m/z found, 460.1 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.78:0.22), major rotamer reported) δ
 15 8.85 (d, $J = 4.9$ Hz, 2H), 7.73 (d, $J = 9.2$ Hz, 1H), 7.28 (t, $J = 4.9$ Hz, 1H), 7.15 (dd, $J = 9.2, 0.7$ Hz, 1H), 7.12 - 7.09 (m, 1H), 7.09 - 7.04 (m, 1H), 6.98 (dd, $J = 7.5, 1.3$ Hz, 1H), 5.39 (dt, $J = 9.9, 3.3$ Hz, 1H), 4.40 - 4.31 (m, 1H), 3.41 - 3.33 (m, 1H), 3.32 (dd, $J = 11.0, 1.3$ Hz, 1H), 2.66 - 2.57 (m, 1H), 2.41 - 2.33 (m, 1H), 1.53 - 1.48 (m, 1H), 1.38 (dt, $J = 13.7, 3.6$ Hz, 1H), 1.20 - 1.10 (m, 1H).

20

Example 142: (6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 139 substituting intermediate A-1 with intermediate A-41.

MS (ESI): mass calcd. for $C_{22}H_{19}F_3N_6O_2$, 456.2; m/z found, 457.2 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.78:0.22), major rotamer reported) δ

- 5 8.77 (d, $J = 4.8$ Hz, 2H), 8.39 (d, $J = 8.1$ Hz, 1H), 7.64 (d, $J = 9.2$ Hz, 1H), 7.23 - 7.19 (m, 2H), 7.09 (d, $J = 8.1$ Hz, 1H), 5.34 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.47 - 4.42 (m, 1H), 3.75 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.49 (dd, $J = 10.8, 1.3$ Hz, 1H), 2.75 - 2.70 (m, 1H), 2.38 - 2.28 (m, 1H), 2.20 (s, 3H), 1.58 - 1.51 (m, 3H).


- 10 Example 143: (6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-3. MS

- 15 (ESI): mass calcd. for $C_{21}H_{20}F_3N_7O$, 443.2; m/z found, 444.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 $^{\circ}C$). $R_t = 5.80$ min (major rotamer) at 254 nm.

- 20 Example 144: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-16.

MS (ESI): mass calcd. for $C_{21}H_{18}F_4N_6O$, 446.1; m/z found, 447.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 8.00 (s, 2H),

5 7.91 (s, 1H), 7.58 (dd, J = 8.9, 2.6 Hz, 1H), 7.23 - 7.16 (m, 1H), 6.92 - 6.84 (m, 1H), 6.80 (d, J = 7.6 Hz, 1H), 6.64 - 6.53 (m, 1H), 4.15 - 3.93 (m, 2H), 3.27 - 3.18 (m, 2H), 2.56 - 2.50 (m, 1H), 2.28 - 2.14 (m, 1H), 1.55 (d, J = 10.2 Hz, 1H), 1.29 - 1.09 (m, 2H).


Example 145: (4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-
10 2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-12.

MS (ESI): mass calcd. for $C_{21}H_{18}F_4N_6O$, 446.1; m/z found, 447.1 $[M+H]^+$. Analytical HPLC using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH
15 over 2 min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature = 45 $^{\circ}C$). R_t = 2.05 min at 254 nm.


Example 146: (2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-
2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-11.


MS (ESI): mass calcd. for $C_{21}H_{18}F_4N_6O$, 446.1; m/z found, 447.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 7.98 (s, 2H), 7.78 (s, 1H), 7.75 (dt, J = 8.3, 0.9 Hz, 1H), 7.56 (dd, J = 8.8, 2.4 Hz, 1H), 7.35 - 7.27 (m, 1H), 6.66 - 6.56 (m, 1H), 6.49 (t, J = 8.6 Hz, 1H), 3.98 - 3.89 (m, 1H), 3.88 - 3.82 (m, 1H), 3.49 (dt, J = 11.0, 3.2 Hz, 1H), 3.34 - 3.32 (m, 1H), 2.63 - 2.55 (m, 1H), 2.27 - 2.15 (m, 1H), 1.44 (d, J = 10.1 Hz, 1H), 1.32 - 1.19 (m, 2H).

- 10 Example 147: (2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-6. MS (ESI): mass calcd. for $C_{23}H_{19}F_4N_5O$, 457.2; m/z found, 458.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 8.86 (d, J = 4.9 Hz, 2H), 8.06 (dd, J = 7.9, 1.0 Hz, 1H), 7.83 - 7.73 (m, 1H), 7.56 (dd, J = 8.9, 2.4 Hz, 1H), 7.41 (t, J = 4.9 Hz, 1H), 7.31 - 7.24 (m, 1H), 6.66 - 6.59 (m, 1H), 6.58 - 6.53 (m, 1H), 3.99 - 3.90 (m, 2H), 3.55 (dt, J = 10.9, 3.2 Hz, 1H), 3.35 - 3.32 (m, 1H), 2.64 - 2.58 (m, 1H), 2.26 - 2.16 (m, 1H), 1.44 (d, J = 10.4 Hz, 1H), 1.33 - 1.26 (m, 1H), 1.19 - 1.13 (m, 1H).


Example 148: (2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-37.


- 5 MS (ESI): mass calcd. for $C_{23}H_{20}F_3N_5O$, 439.2; m/z found, 440.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.84 (d, $J = 4.9$ Hz, 2H), 8.13 (dd, $J = 7.9, 1.2$ Hz, 1H), 7.87 - 7.78 (m, 1H), 7.65 - 7.54 (m, 1H), 7.38 (t, $J = 4.9$ Hz, 1H), 7.29 (td, $J = 7.7, 1.4$ Hz, 1H), 6.98 - 6.87 (m, 1H), 6.87 - 6.76 (m, 1H), 6.66 - 6.49 (m, 1H), 4.08 - 3.92 (m, 1H), 3.52 (dt, $J = 10.9, 3.3$ Hz, 1H), 2.66 - 2.59 (m, 1H), 2.30 - 2.19
- 10 (m, 1H), 1.54 - 1.45 (m, 1H), 1.35 - 1.19 (m, 3H). 1H buried under solvent peak.

Example 149: (5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 15 Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-47.
- MS (ESI): mass calcd. for $C_{23}H_{21}F_3N_6O$, 454.2; m/z found, 455.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.89:0.11), only major rotamer reported) δ 8.82 (d, $J = 4.9$ Hz, 2H), 8.41 - 8.37 (m, 1H), 8.33 (dd, $J = 2.1, 0.9$ Hz, 1H), 8.26 - 8.22 (m, 1H), 7.70 - 7.58 (m, 1H), 7.45 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.28 (t, $J = 4.9$ Hz, 1H), 6.38 (d, $J = 8.8$
- 20 Hz, 1H), 4.32 - 4.28 (m, 1H), 4.22 - 4.11 (m, 1H), 3.72 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.32 (dd, $J = 10.9, 1.5$ Hz, 1H), 2.83 - 2.72 (m, 1H), 2.46 - 2.36 (m, 4H), 1.94 - 1.87 (m, 1H), 1.71 (d, $J = 10.0$ Hz, 1H), 1.20 (dt, $J = 13.0, 3.5$ Hz, 1H).


Example 150: (6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-41.

- 5 MS (ESI): mass calcd. for $C_{23}H_{21}F_3N_6O$, 454.2; m/z found, 455.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.91:0.09), only major rotamer reported) δ 8.79 (d, J = 4.9 Hz, 2H), 8.45 (d, J = 8.1 Hz, 1H), 8.31 - 8.23 (m, 1H), 7.70 - 7.59 (m, 1H), 7.47 (dd, J = 8.8, 2.5 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.24 (t, J = 4.9 Hz, 1H), 6.44 (d, J = 8.8 Hz, 1H), 4.26 - 4.21 (m, 1H), 4.13 (s, 1H), 3.73 (dt, J = 10.8, 3.2 Hz, 1H), 3.31 (dd, J = 10.8, 1.5
- 10 Hz, 1H), 2.82 - 2.73 (m, 1H), 2.62 (s, 3H), 2.51 - 2.37 (m, 1H), 1.98 - 1.85 (m, 1H), 1.70 (d, J = 10.2 Hz, 1H), 1.20 (dt, J = 13.5, 3.5 Hz, 1H).

Example 151: (5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




15

Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-46.

- MS (ESI): mass calcd. for $C_{23}H_{21}F_3N_6O$, 454.2; m/z found, 455.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
- 20 rate of 1 mL/min (Temperature = 30 $^{\circ}C$). R_t = 5.33 min (major rotamer) at 254 nm.


Example 152: (4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-51.

- 5 MS (ESI): mass calcd. for $C_{22}H_{19}F_4N_5O_2$, 461.1; m/z found, 462.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 7.84 (s, 1H), 7.70 (dd, $J = 9.1, 2.6$ Hz, 1H), 7.59 - 7.53 (m, 1H), 7.02 (dd, $J = 8.5, 5.3$ Hz, 1H), 6.72 (td, $J = 8.2, 2.6$ Hz, 1H), 6.62 - 6.47 (m, 1H), 4.06 - 3.97 (m, 2H), 3.61 (dt, $J = 11.1, 3.2$ Hz, 1H), 3.41 - 3.35 (m, 1H), 2.76 - 2.67 (m, 1H), 2.44 (s, 3H), 2.34 - 2.23 (m, 1H), 1.74 - 1.60 (m, 2H), 1.35 - 1.26 (m, 1H).
- 10


Example 153: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 15 To the title compound of example 53 (10 mg, 0.023 mmol) dissolved in DMF (0.5 mL) was added NaOtBu (2.5 mg, 0.026 mmol). After 5 minutes, MeI (1.5 μ L, 0.025 mmol) was added and the reaction mixture as stirred at room temperature overnight. Then, the mixture was diluted with EtOAc and H_2O . The aqueous layer was extracted with EtOAc (2X). The combined organics were washed with H_2O , dried with Na_2SO_4 , filtered, and concentrated. Purification of the concentrate
- 20 was performed using Agilent Prep Method X to give the title compound (3 mg) as a brown solid. MS (ESI): mass calcd. for $C_{22}H_{21}F_3N_6O$, 442.2; m/z found, 443.1 $[M+H]^+$. ^1H NMR (400 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.06 (s, 1H), 7.95 (s, 2H), 7.80 (d, $J = 8.3$ Hz, 1H), 7.68 - 7.60 (m, 1H), 7.35 - 7.25 (m, 1H), 7.00 -

6.90 (m, 1H), 6.82 - 6.75 (m, 1H), 6.65 (d, J = 8.9 Hz, 1H), 4.58 - 4.46 (m, 1H), 3.88 (s, 1H), 3.49 - 3.42 (m, 2H), 3.11 (s, 3H), 2.69 (s, 1H), 2.09 - 1.98 (m, 1H), 1.99 - 1.88 (m, 1H), 1.49 (d, J = 9.9 Hz, 1H), 1.27 - 1.17 (m, 1H).


- 5 Example 154: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-16 followed by the alkylation step of Example 153. MS (ESI): mass calcd. for C₂₂H₂₀F₄N₆O, 460.2; m/z found, 461.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.86:0.14), major rotamer reported) δ 7.98 (s, 3H), 7.76 - 7.70 (m, 1H), 7.65 (dd, J = 9.1, 2.5 Hz, 1H), 7.33 - 7.26 (m, 1H), 6.70 (d, J = 9.1 Hz, 1H), 6.59 - 6.50 (m, 1H), 4.49 - 4.40 (m, 1H), 3.99 - 3.93 (m, 1H), 3.51 (dt, J = 11.4, 3.0 Hz, 1H), 3.43 (dd, J = 11.4, 1.6 Hz, 1H), 3.09 (d, J = 1.3 Hz, 3H), 2.69 (s, 1H), 2.08 - 1.93 (m, 2H), 1.46 (d, J = 9.7 Hz, 1H), 1.19 - 1.12 (m, 1H).

15


- Example 155: (5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-10 followed by the alkylation step of Example 153. MS (ESI): mass calcd. for C₂₂H₂₀F₄N₆O, 460.2; m/z found, 461.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.08 (s, 1H), 7.95 (s, 2H), 7.79 (dd, J = 9.0, 4.7 Hz,


1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.07 - 6.99 (m, 1H), 6.69 (dd, J = 8.1, 2.9 Hz, 1H), 6.66 (d, J = 9.1 Hz, 1H), 4.52 - 4.44 (m, 1H), 3.92 - 3.87 (m, 1H), 3.44 - 3.40 (m, 2H), 3.10 (s, 3H), 2.70 - 2.65 (m, 1H), 2.08 - 1.99 (m, 1H), 1.97 - 1.90 (m, 1H), 1.52 - 1.45 (m, 1H), 1.19 - 1.11 (m, 1H).

- 5 Example 156: ((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.



- Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-40 followed by the alkylation step of Example 153. MS (ESI): mass calcd. for $C_{22}H_{22}F_3N_7O$, 457.2; m/z found, 458.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.09 (d, J = 8.4 Hz, 1H), 8.07 (s, 1H), 7.97 (s, 2H), 7.66 (dd, J = 9.1, 2.6 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 6.68 (d, J = 9.1 Hz, 1H), 4.72 - 4.63 (m, 1H), 3.95 - 3.87 (m, 1H), 3.54 (dt, J = 11.4, 3.1 Hz, 1H), 3.51 - 3.42 (m, 1H), 3.12 (s, 3H), 2.77 - 2.69 (m, 1H), 2.15 (s, 3H), 2.11 - 1.99 (m, 1H), 1.92 - 1.80 (m, 1H), 1.57 (d, J = 10.4 Hz, 1H), 1.47 - 1.38 (m, 1H).


Example 157: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 20 Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-2 followed by the alkylation step of Example 153. MS (ESI): mass calcd. for $C_{24}H_{21}F_4N_5O$, 471.2; m/z found, 472.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of


rotamers (0.90:0.10), major rotamer reported) δ 8.89 (d, J = 5.0 Hz, 2H), 8.20 - 8.12 (m, 1H), 7.66 (dd, J = 9.1, 2.6 Hz, 1H), 7.49 (t, J = 4.9 Hz, 1H), 7.09 - 7.00 (m, 1H), 6.87 - 6.80 (m, 1H), 6.72 - 6.66 (m, 2H), 4.62 - 4.53 (m, 1H), 4.15 - 4.08 (m, 1H), 3.36 (dd, J = 11.5, 1.6 Hz, 1H), 3.20 (dt, J = 11.5, 3.2 Hz, 1H), 3.10 (s, 3H), 2.66 - 2.57 (m, 1H), 2.08 - 1.98 (m, 1H), 1.90 (dt, J = 13.8, 3.7 Hz, 1H), 1.54 (d, J = 10.1 Hz, 1H), 0.95 - 0.87 (m, 1H).

Example 158: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-7 followed by the alkylation step of Example 153. MS (ESI): mass calcd. for $C_{24}H_{21}F_4N_5O$, 471.2; m/z found, 472.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.83 (d, J = 4.9 Hz, 2H), 8.15 (dd, J = 8.8, 5.5 Hz, 1H), 8.08 (s, 1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.38 (t, J = 4.9 Hz, 1H), 6.98 (ddd, J = 8.8, 8.1, 2.7 Hz, 1H), 6.66 (d, J = 9.1 Hz, 1H), 6.58 (dd, J = 8.4, 2.7 Hz, 1H), 4.55 - 4.45 (m, 1H), 4.02 - 3.95 (m, 1H), 3.51 (dt, J = 11.3, 3.1 Hz, 1H), 3.48 - 3.41 (m, 1H), 3.14 (s, 3H), 2.75 - 2.67 (m, 1H), 2.10 - 2.00 (m, 1H), 1.99 - 1.92 (m, 1H), 1.49 (d, J = 10.1 Hz, 1H), 1.19 - 1.09 (m, 1H).

Example 159: (2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-6 followed by the alkylation step of Example 153. MS (ESI): mass calcd. for $C_{24}H_{21}F_4N_5O$, 471.2; m/z found, 472.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.86 (d, $J = 4.9$ Hz, 2H), 8.02 (dd, $J = 7.8, 1.0$ Hz, 1H), 7.98 (s, 1H), 7.63 (dd, $J = 9.2, 2.6$ Hz, 1H), 7.42 (t, $J = 4.9$ Hz, 1H), 7.28 - 7.22 (m, 1H), 6.68 (d, $J = 9.2$ Hz, 1H), 6.63 - 6.58 (m, 1H), 4.48 - 4.40 (m, 1H), 4.08 - 4.00 (m, 1H), 3.55 (dt, $J = 11.3, 3.0$ Hz, 1H), 3.46 - 3.41 (m, 1H), 3.11 - 3.09 (m, 3H), 2.72 - 2.68 (m, 1H), 2.07 - 1.94 (m, 2H), 1.48 - 1.42 (m, 1H), 1.07 - 1.02 (m, 1H).

- 10 Example 160: (2-fluoro-6-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- To the title compound of Example 66 (38 mg, 0.066 mmol) dissolved in DMF (1.3 mL) was added NaOtBu (7 mg, 0.072 mmol). After 5 minutes, EtI (5.5 μ L, 0.069 mmol) was added and the reaction mixture as stirred at room temperature overnight. Analysis of the reaction mixture showed that starting material (Example 66) still remained. NaH (5 mg, 0.13 mmol, 60% dispersion in mineral oil) and additional EtI (5.5 μ L, 0.069 mmol) were added to the reaction flask, and the reaction mixture was stirred at room temperature for 2h. Then, the mixture was diluted with EtOAc and H_2O . The aqueous layer was extracted with EtOAc (2X). The combined organics were washed with H_2O , dried with Na_2SO_4 , filtered, and concentrated. Purification of the concentrate was performed using Agilent Prep Method X to give the title compound (16 mg) as a white solid. MS (ESI): mass calcd. for $C_{25}H_{23}F_4N_5O$, 485.2; m/z found, 486.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.89 (d, $J = 5.0$ Hz, 2H), 8.12 (s, 1H), 7.63 (dd, $J = 9.0, 2.6$ Hz, 1H), 7.49 (t, $J = 5.0$ Hz, 1H), 7.03 - 6.96 (m, 1H), 6.83 - 6.76 (m, 1H), 6.71 - 6.64 (m, 2H), 4.48 - 4.39 (m, 1H), 4.13 (s, 1H), 3.88 - 3.75 (m, 1H), 3.36 - 3.32 (m, 2H), 3.16 (dt, $J = 11.4, 3.2$ Hz, 1H), 2.61 (s, 1H), 2.14 - 2.05 (m, 1H), 1.83 - 1.75 (m, 1H), 1.53 (d, $J = 10.1$ Hz, 1H), 1.17 (t, $J = 7.0$ Hz, 3H), 0.86 - 0.79 (m, 1H).

Example 161: ((1S,4S,6R)-6-((cyclopropylmethyl)(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




- 5 To the title compound of Example 66 (30 mg, 0.053 mmol) dissolved in DMF (1 mL) was added NaH (6 mg, 0.16 mmol, 60% dispersion in mineral oil). After 10 minutes, (bromomethyl)cyclopropane (10 μ L, 0.11 mmol) was added and the reaction mixture as stirred at room temperature overnight. Then, the mixture was diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc (2X). The combined organics were washed with H₂O, dried with
- 10 Na₂SO₄, filtered, and concentrated. Purification of the concentrate was performed using Gilson Prep Method X to give the title compound (19 mg) as a white solid. MS (ESI): mass calcd. for C₂₇H₂₅F₄N₅O, 511.2; m/z found, 512.3 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.89 (d, J = 4.9 Hz, 2H), 8.13 (s, 1H), 7.61 (dd, J = 9.1, 2.6 Hz, 1H), 7.48 (t, J = 5.0 Hz, 1H), 7.02 - 6.95 (m, 1H), 6.85 - 6.78
- 15 (m, 1H), 6.75 (d, J = 9.1 Hz, 1H), 6.68 (dd, J = 7.6, 1.1 Hz, 1H), 4.51 - 4.41 (m, 1H), 4.20 - 4.10 (m, 1H), 3.85 - 3.73 (m, 1H), 3.28 - 3.23 (m, 1H), 3.20 - 3.11 (m, 1H), 2.63 - 2.58 (m, 1H), 2.19 - 2.08 (m, 1H), 1.90 - 1.82 (m, 1H), 1.57 - 1.51 (m, 1H), 1.29 (s, 1H), 0.99 - 0.90 (m, 1H), 0.86 - 0.77 (m, 1H), 0.62 - 0.49 (m, 2H), 0.49 - 0.42 (m, 1H), 0.37 - 0.28 (m, 1H).

- 20 Example 162: N-((1S,4R,6R)-2-(3-fluoro-2-(pyrimidin-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)-N-(5-(trifluoromethyl)pyridin-2-yl)acetamide.



To the title compound of Example 66 (30 mg, 0.053 mmol) was added Ac₂O (0.1 mL, 1.05 mmol), and the reaction mixture as stirred at 100 °C overnight. Then, the mixture was concentrated and the concentrate was purified directly using Gilson Prep Method X to give the title compound. MS (ESI): mass calcd. for C₂₅H₂₁F₄N₅O₂, 499.2; m/z found, 500.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.79:0.21), major rotamer reported) δ 9.02 - 8.98 (m, 1H), 8.89 (d, J = 4.9 Hz, 2H), 8.31 (dd, J = 8.1, 2.5 Hz, 1H), 7.64 - 7.46 (m, 4H), 7.38 - 7.32 (m, 1H), 4.55 - 4.48 (m, 1H), 4.38 - 4.33 (m, 1H), 3.08 (dt, J = 11.1, 3.2 Hz, 1H), 2.68 (d, J = 11.2 Hz, 1H), 2.39 (s, 1H), 1.91 - 1.81 (m, 1H), 1.75 (s, 3H), 1.52 (d, J = 10.4 Hz, 1H), 0.96 - 0.90 (m, 1H), 0.69 - 0.61 (m, 1H).


Example 163: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((2-methoxyethyl)(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




To the title compound of Example 66 (43 mg, 0.094 mmol) dissolved in DMF (2 mL) was added NaH (19 mg, 0.47 mmol, 60% dispersion in mineral oil). After 10 minutes, 2-chloroethyl methyl ether (26 µL, 0.28 mmol) was added and the reaction mixture as stirred at room temperature overnight. Analysis of the reaction mixture showed that starting material (Example 66) still remained. NaH (19 mg, 0.47 mmol, 60% dispersion in mineral oil) and additional 2-chloroethyl methyl ether (26 µL, 0.28 mmol) were added to the reaction flask, and the reaction mixture was stirred at 50 °C for 3h. Then, the mixture was diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc (2X). The combined organics were washed with H₂O, dried with Na₂SO₄, filtered, and concentrated. Purification of the concentrate was performed using Gilson Prep Method X to give the title compound (10 mg) as an off-white solid. MS (ESI): mass calcd. for C₂₆H₂₅F₄N₅O₂, 515.2; m/z found, 516.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.92:0.08), major rotamer reported) δ 8.89 (d, J = 5.0 Hz, 2H), 8.16 (s, 1H), 7.61 (dd, J = 9.1, 2.6 Hz, 1H), 7.49 (t, J = 5.0 Hz, 1H), 7.03 - 6.96 (m, 1H), 6.84 - 6.77 (m, 1H), 6.74 (d, J = 8.9 Hz, 1H), 6.71 (dd, J = 7.6, 1.1 Hz, 1H), 4.46 - 4.36 (m, 1H), 4.16 (s, 1H),

4.04 - 3.90 (m, 1H), 3.61 - 3.43 (m, 3H), 3.38 - 3.32 (m, 3H), 3.16 (dt, J = 12.1, 3.1 Hz, 1H), 2.65 - 2.56 (m, 1H), 2.14 - 2.02 (m, 1H), 1.91 - 1.82 (m, 1H), 1.54 (d, J = 10.3 Hz, 1H), 0.83 (d, J = 10.3 Hz, 1H). 1H buried under solvent peak.


- 5 Example 164: (2-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



- 10 Example 165: (6-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Example 166: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Step A: (1S,4S,6R)-tert-butyl 6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing 5-bromo-2-iodopyridine (669 mg, 2.36 mmol) and


degassed THF (12 mL) was added NaOtBu (453 mg, 4.71 mmol), Xantphos (98 mg, 0.17 mmol) and Pd₂(dba)₃ (86 mg, 0.094 mmol). The reaction mixture was purged with N₂ for 10 minutes and then intermediate B-10 (500 mg, 2.36 mmol) was added and the reaction mixture heated to 90 °C overnight. Upon completion of the reaction, the mixture was cooled to room temperature, filtered

5 through Celite and washed with EtOAc. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (0-60% EtOAc in hexanes) to give the title compound of step A (91 mg). Further flushing of the column with 0-10% MeOH (with 10% 2 M NH₃) in DCM gave (1S,4R,6R)-N-(5-bromopyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine (483 mg). (1S,4S,6R)-tert-butyl 6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-

10 carboxylate: MS (ESI) mass calcd. for C₁₆H₂₂BrN₃O₂, 367.1; m/z found 370.0 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄) δ 7.98 (d, J = 2.5 Hz, 1H), 7.49 (dd, J = 9.0, 2.5 Hz, 1H), 6.51 (d, J = 8.9 Hz, 1H), 4.46 - 4.41 (m, 1H), 4.12 - 4.05 (m, 1H), 3.29 - 3.27 (m, 1H), 3.07 (d, J = 9.6 Hz, 1H), 2.57 - 2.51 (m, 1H), 2.27 - 2.18 (m, 1H), 1.70 - 1.67 (m, 2H), 1.18 - 1.09 (m, 10H). (1S,4R,6R)-N-(5-bromopyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine: ¹H NMR (500 MHz, Methanol-d₄) δ 8.11
15 (dd, J = 2.5, 0.7 Hz, 1H), 7.58 (dd, J = 8.9, 2.5 Hz, 1H), 6.65 (dd, J = 8.9, 0.7 Hz, 1H), 4.44 (dd, J = 3.1, 2.0 Hz, 1H), 4.14 - 4.10 (m, 1H), 3.21 (dt, J = 10.9, 3.4 Hz, 1H), 3.11 (dd, J = 10.9, 1.8 Hz, 1H), 2.74 - 2.70 (m, 1H), 2.39 - 2.29 (m, 1H), 2.05 - 2.02 (m, 1H), 1.90 - 1.83 (m, 1H), 1.38 (dt, J = 13.4, 3.5 Hz, 1H).


Step B: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To (1S,4R,6R)-N-(5-bromopyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine from Step A (70 mg, 0.26 mmol) and intermediate A-1 (63 mg, 0.33 mmol) in DMF (2 mL) was added DIPEA (0.27 mL, 1.57 mmol) and HATU (109 mg, 0.29 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (2X). The combined
25 organics were concentrated and subjected to purification via Gilson Prep Method X to give the title compound (42 mg) as an off-white powder. MS (ESI): mass calcd. for C₂₀H₁₉BrN₆O, 438.1; m/z found, 439.0 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers, major rotamer reported) δ 7.94 (s, 2H), 7.83 (d, J = 7.8 Hz, 1H), 7.60 - 7.55 (m, 1H), 7.50 - 7.43 (m, 1H), 7.40 (td, J = 7.9, 1.5 Hz, 1H), 6.96 (s, 1H), 6.82 (s, 1H), 6.46 (s, 1H), 3.85 (s, 2H),
30 3.50 - 3.41 (m, 1H), 3.28 (dd, J = 11.1, 1.6 Hz, 1H), 2.58 (s, 1H), 2.26 - 2.15 (m, 1H), 1.53 - 1.38 (m, 1H), 1.35 - 1.24 (m, 1H), 1.23 - 1.14 (m, 1H).

Example 167: ((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




5 Prepared analogous to Example 166 substituting intermediate A-1 with intermediate A-2.
MS (ESI): mass calcd. for $C_{22}H_{19}BrFN_5O$, 467.1; m/z found, 470.0 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.86 (d, J = 4.9 Hz, 2H), 8.07 (dd, J = 8.0, 1.0 Hz, 1H), 7.52 (d, J = 2.4 Hz, 1H), 7.46 - 7.32 (m, 3H), 6.70 - 6.62 (m, 1H), 6.47 (d, J = 9.4 Hz, 1H), 3.96 - 3.89 (m, 1H), 3.87 - 3.78 (m, 1H), 3.53 (dt, J = 10.9, 3.2 Hz, 1H), 2.62 - 2.55 (m, 1H), 2.24 - 2.14 (m, 1H), 1.44 - 1.39 (m, 1H), 1.29 - 1.18 (m, 1H), 1.16 - 1.11 (m, 1H). 1H buried under solvent peak

Example 168: ((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone.



15 Prepared analogous to Example 166 substituting intermediate A-1 with intermediate A-6.
MS (ESI): mass calcd. for $C_{22}H_{19}BrFN_5O$, 467.1; m/z found, 468.0 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.92:0.08), major rotamer reported) δ 8.89 (d, J = 4.9 Hz, 2H), 7.69 (d, J = 2.5 Hz, 1H), 7.48 (t, J = 5.0 Hz, 1H), 7.45 (dd, J = 8.9, 2.5 Hz, 1H), 7.17 - 7.10 (m, 1H), 6.99 - 6.92 (m, 1H), 6.81 (d, J = 7.5 Hz, 1H), 6.43 (d, J = 8.9 Hz, 1H), 4.15 (s, 1H), 4.01 - 3.91 (m, 1H), 3.25 - 3.18 (m, 2H), 2.52 (s, 1H), 2.27 - 2.15 (m, 1H), 1.52 (d, J = 11.7 Hz, 1H), 1.22 - 1.13 (m, 1H), 1.06 (d, J = 10.2 Hz, 1H).

Example 169: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5 Step A: (1S,4S,6R)-tert-butyl 6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed toluene (3 mL) was added Pd(OAc)₂ (6 mg, 0.028 mmol) and racemic BINAP (17 mg, 0.028 mmol) at room temperature and the reaction mixture was purged with N₂ for 5 min. Then, 2-bromo-5-chloropyridine (90 mg, 0.47 mmol), intermediate B-10 (109 mg), and sodium tert-butoxide (63 mg, 0.66 mmol) were added and the
10 reaction mixture heated to 90 °C overnight. Upon completion of the reaction, the mixture was cooled to room temperature, filtered through Celite and washed with EtOAc. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (0-10% MeOH (with 10% 2N NH₃) in DCM) to give the title compound of step A. MS (ESI) mass calcd. for C₁₆H₂₂ClN₃O₂, 323.1; m/z found 324.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄) δ 7.90 (d, *J* = 2.6 Hz, 1H), 7.39 (dd, *J* = 8.9, 2.7 Hz, 1H), 6.54 (d, *J* = 9.0 Hz, 1H), 4.43 (s, 1H), 4.12 - 4.06 (m, 1H), 3.30 - 3.27 (m, 1H), 3.09 - 3.05 (m, 1H), 2.57 - 2.50 (m, 1H), 2.28 - 2.17 (m, 1H), 1.70 - 1.67 (m, 2H), 1.48 - 1.38 (m, 2H), 1.12 (s, 9H).

 Step B: (1S,4R,6R)-N-(5-chloropyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine · xHCl. To the title compound of step A (252 mg, 0.701 mmol) in EtOAc (9 mL) was added 4M HCl in
20 dioxane (0.9 mL). After 1h, the reaction was concentrated to give the title compound of step B (231 mg, 90% purity), which was used without further purification. MS (ESI) mass calcd. for C₁₁H₁₄ClN₃, 223.1; m/z found 224.1 [M+H]⁺.

 Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (40 mg) and intermediate
25 A-1 (28 mg, 0.15 mmol) in DMF (1 mL) was added DIPEA (0.2 mL, 1.2 mmol) and HATU (56 mg, 0.15 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (4X). The


combined organics were concentrated and the concentrate subjected directly to purification via Agilent Prep Method X to give the title compound (30 mg). MS (ESI): mass calcd. for $C_{20}H_{19}ClN_6O$, 394.1; m/z found, 395.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.25 min (major rotamer) at 254 nm.

Example 170: ((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




Prepared analogous to Example 169 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for $C_{22}H_{19}ClFN_5O$, 423.1; m/z found, 424.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.84:0.16), major rotamer reported) δ 8.89 (d, J = 4.9 Hz, 2H), 7.83 (d, J = 2.0 Hz, 1H), 7.33 (t, J = 4.9 Hz, 1H), 7.21 - 7.13 (m, 2H), 7.12 - 7.06 (m, 1H), 6.99 (d, J = 7.2 Hz, 1H), 6.14 (d, J = 8.9 Hz, 1H), 4.42 (s, 1H), 4.24 - 4.13 (m, 1H), 3.46 (dt, J = 11.1, 3.2 Hz, 1H), 3.22 (dd, J = 11.2, 1.6 Hz, 1H), 2.68 - 2.61 (m, 1H), 2.42 - 2.27 (m, 1H), 1.71 - 1.66 (m, 1H), 1.58 - 1.52 (m, 1H), 1.09 - 0.99 (m, 1H).

Example 171: ((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




Prepared analogous to Example 169 substituting intermediate A-1 with intermediate A-23.
MS (ESI): mass calcd. for $C_{22}H_{19}ClFN_5O$, 423.1; m/z found, 424.0 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 8.86 (d, J = 4.9 Hz, 2H), 7.88 (dd, J = 10.1, 2.7 Hz, 1H), 7.58 (d, J = 2.6 Hz, 1H), 7.44 - 7.35 (m, 2H), 6.98 - 6.92 (m, 1H), 6.64 - 6.56 (m, 1H), 6.51 - 6.43 (m, 1H), 3.93 (s, 1H), 3.91 - 3.86 (m, 1H), 3.52 (dt, J = 10.9, 3.3 Hz, 1H), 3.30 - 3.28 (m, 1H), 2.63 - 2.58 (m, 1H), 2.27 - 2.17 (m, 1H), 1.47 (d, J = 10.0 Hz, 1H), 1.33 - 1.26 (m, 1H), 1.24 - 1.17 (m, 1H).

Example 172: ((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.



Prepared analogous to Example 169 substituting intermediate A-1 with intermediate A-7.
MS (ESI): mass calcd. for $C_{22}H_{19}ClFN_5O$, 423.1; m/z found, 424.0 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.83 (d, J = 4.8 Hz, 2H), 8.19 (dd, J = 8.8, 5.5 Hz, 1H), 7.55 (d, J = 2.6 Hz, 1H), 7.39 - 7.32 (m, 2H), 7.08 (td, J = 8.5, 2.7 Hz, 1H), 6.72 - 6.64 (m, 1H), 6.50 - 6.42 (m, 1H), 3.95 (s, 1H), 3.92 - 3.86 (m, 1H), 3.50 (dt, J = 11.0, 3.2 Hz, 1H), 3.30 - 3.28 (m, 1H), 2.62 - 2.58 (m, 1H), 2.26 - 2.18 (m, 1H), 1.46 (d, J = 10.1 Hz, 1H), 1.28 - 1.17 (m, 2H).

Example 173: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Step A: (1S,4S,6R)-tert-butyl 6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed toluene (6 mL) was added Pd(OAc)₂ (25 mg, 0.038 mmol) and racemic BINAP (27 mg, 0.043 mmol) at room temperature and the reaction mixture was purged with N₂ for 5 min. Then, 2-chloro-5-(difluoromethyl)pyridine (70 µL, 0.59 mmol), intermediate B-10 (137 mg), and sodium tert-butoxide (81 mg, 0.82 mmol) were added and the reaction mixture heated to 90 °C overnight. Upon completion of the reaction, the mixture was cooled to room temperature, filtered through Celite and washed with EtOAc. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (0-60% EtOAc in hexanes) to give the title compound of step A (71 mg, 0.21 mmol, 36%). MS (ESI) mass calcd. for C₁₇H₂₃F₂N₃O₂, 339.2; m/z found 340.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄) δ 8.12 - 8.07 (m, 1H), 7.56 (dd, J = 8.6, 2.3 Hz, 1H), 6.80 - 6.49 (m, 2H), 4.49 - 4.44 (m, 1H), 4.23 - 4.14 (m, 1H), 3.09 (d, J = 9.5 Hz, 1H), 2.59 - 2.54 (m, 1H), 2.31 - 2.18 (m, 1H), 1.74 - 1.68 (m, 2H), 1.22 - 1.16 (m, 1H), 1.09 (s, 9H). 1 H buried under solvent peak.

Step B: (1S,4R,6R)-N-(5-(difluoromethyl)pyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine·xHCl. To the title compound of step A (71 mg, 0.21 mmol) in EtOAc (3 mL) was added 4M HCl in dioxane (0.3 mL). After 1h, the reaction was concentrated to give the title compound of step B (65 mg), which was used without further purification. MS (ESI) mass calcd. for C₁₂H₁₅F₂N₃, 239.1; m/z found 240.1 [M+H]⁺.

Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (33 mg) and intermediate A-1 (24 mg, 0.13 mmol) in DMF (1.5 mL) was added DIPEA (0.11 mL, 0.63 mmol) and HATU (44 mg, 0.12 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (2X). The combined organics were concentrated and the concentrate subjected directly to purification via Agilent Prep Method X to give the title compound (27 mg). MS (ESI): mass calcd. for C₂₁H₂₀F₂N₆O, 410.2; m/z found, 411.1 [M+H]⁺. Analytical HPLC using a XBridge C18 column (5µm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 2min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature = 45 °C). R_t = 1.83 and 2.03 min (major rotamers) at 254 nm.


Example 174: ((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.



Prepared analogous to Example 173 substituting intermediate A-1 with intermediate A-2.

- 5 MS (ESI): mass calcd. for $C_{23}H_{20}F_3N_5O$, 439.2; m/z found, 440.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.92:0.08), major rotamer reported) δ 8.89 (d, J = 5.0 Hz, 2H), 7.81 (s, 1H), 7.53 (dd, J = 8.8, 2.4 Hz, 1H), 7.48 (t, J = 4.9 Hz, 1H), 7.10 - 7.02 (m, 1H), 6.91 - 6.82 (m, 1H), 6.82 - 6.51 (m, 3H), 4.20 - 4.13 (m, 1H), 4.11 - 4.01 (m, 1H), 3.27 - 3.22 (m, 2H), 2.58 - 2.51 (m, 1H), 2.29 - 2.18 (m, 1H), 1.55 (d, J = 9.6 Hz, 1H), 1.25 - 1.17
- 10 (m, 1H), 1.11 (d, J = 9.5 Hz, 1H).

Example 175: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 15 Step A: (1S,4S,6R)-tert-butyl 6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed toluene (4 mL) was added $Pd(OAc)_2$ (9 mg, 0.038 mmol) and racemic BINAP (24 mg, 0.038 mmol) at room temperature and the reaction mixture was purged with N_2 for 5 min. Then, 2-chloro-5-methoxypyridine (75 μ L, 0.63 mmol), intermediate B-10 (148 mg, 0.695 mmol), and sodium tert-butoxide (85 mg, 0.89 mmol) were added and the reaction mixture heated to 90 $^{\circ}C$ overnight. Upon
- 20 completion of the reaction, the mixture was cooled to room temperature, filtered through Celite and washed with EtOAc. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (0-10% MeOH (with 10% 2 N NH_3) in DCM) to give the title

compound of step A (158 mg, 0.49 mmol, 90% purity, 70%) MS (ESI) mass calcd. for $C_{17}H_{25}N_3O_3$, 319.2; m/z found 320.3 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4) δ 7.65 (d, $J = 3.0$ Hz, 1H), 7.18 (dd, $J = 9.1, 3.0$ Hz, 1H), 6.55 (d, $J = 9.1$ Hz, 1H), 4.44 - 4.40 (m, 1H), 4.09 - 4.01 (m, 1H), 3.75 (s, 3H), 3.30 - 3.26 (m, 1H), 3.07 (d, $J = 9.4$ Hz, 1H), 2.57 - 2.49 (m, 1H), 2.30 - 2.19 (m, 1H), 1.71 - 1.67 (m, 2H), 1.48 - 1.45 (m, 1H), 1.11 (s, 9H).

Step B: (1S,4R,6R)-N-(5-methoxypyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine $\cdot xHCl$. To the title compound of step A (176 mg, 0.49 mmol, 90 % purity) in EtOAc (6 mL) was added 4M HCl in dioxane (0.6 mL). After 3h, the reaction was concentrated to give the title compound of step B (150 mg), which was used without further purification. MS (ESI) mass calcd. for $C_{12}H_{17}N_3O$, 219.1; m/z found 220.2 $[M+H]^+$.


Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (30 mg) and intermediate A-1 (21 mg, 0.11 mmol) in DMF (1 mL) was added DIPEA (0.10 mL, 0.55 mmol) and HATU (39 mg, 0.10 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H_2O and the aqueous layer was extracted with EtOAc (2X). The combined organics were concentrated and the concentrate subjected directly to purification via Gilson Prep Method X to give the title compound (17 mg). MS (ESI): mass calcd. for $C_{21}H_{22}N_6O_2$, 390.2; m/z found, 391.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 7.93 (s, 2H), 7.82 (d, $J = 8.1$ Hz, 1H), 7.39 - 7.33 (m, 1H), 7.29 (d, $J = 2.4$ Hz, 1H), 7.17 - 7.10 (m, 1H), 7.02 - 6.92 (m, 1H), 6.85 - 6.69 (m, 1H), 6.57 - 6.38 (m, 1H), 3.93 - 3.80 (m, 2H), 3.76 (s, 3H), 3.49 - 3.41 (m, 1H), 3.30 - 3.26 (m, 1H), 2.57 (s, 1H), 2.27 - 2.16 (m, 1H), 1.53 - 1.43 (m, 1H), 1.41 - 1.26 (m, 1H), 1.20 - 1.12 (m, 1H).

Example 176: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 175 substituting intermediate A-1 with intermediate A-2.
 MS (ESI): mass calcd. for $C_{23}H_{22}FN_5O_2$, 419.2; m/z found, 420.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.89 (d, $J = 5.0$ Hz, 2H), 7.47 (t, $J = 4.9$ Hz, 1H), 7.41 (d, $J = 3.0$ Hz, 1H), 7.15 - 7.10 (m, 1H), 7.11 - 7.07 (m, 1H), 6.94 - 6.88 (m, 1H), 6.82 (d, $J = 7.6$ Hz, 1H), 6.44 (d, $J = 9.1$ Hz, 1H), 4.18 - 4.11 (m, 1H), 3.98 - 3.92 (m, 1H), 3.76 (s, 3H), 3.23 (t, $J = 3.0$ Hz, 1H), 3.22 - 3.20 (m, 1H), 2.55 - 2.50 (m, 1H), 2.29 - 2.19 (m, 1H), 1.57 (d, $J = 11.2$ Hz, 1H), 1.22 - 1.16 (m, 1H), 1.16 - 1.11 (m, 1H).

Example 177: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Step A: (1S,4S,6R)-tert-butyl 6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing intermediate B-10 (170 mg, 0.801 mmol) in DMF (2.5 mL) was added 2,3-difluoro-5-(trifluoromethyl)pyridine (176 mg, 0.961 mmol) and Et_3N (0.17 mL, 1.20 mmol), and the reaction mixture was sealed and heated to 90 °C bench top overnight. Upon completion of the reaction, the mixture was cooled to room temperature and directly subjected to silica gel chromatography (0-30% EtOAc in hexanes) to give the title compound of step A (322 mg). MS (ESI) mass calcd. for $C_{17}H_{21}F_4N_3O_2$; 375.16, m/z found 376.0 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers, major rotamer reported) δ 8.15 (s, 1H), 7.33 - 7.28 (m, 1H), 5.37 - 5.23 (m, 1H), 4.42 - 4.34 (m, 2H), 3.44 - 3.39 (m, 1H), 3.11 (d, $J = 9.3$ Hz, 1H), 2.64 - 2.60 (m, 1H), 2.42 - 2.31 (m, 1H), 1.69 - 1.63 (m, 1H), 1.26 (s, 9H), 1.10 - 1.04 (m, 1H).

Step B: (1S,4R,6R)-N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine $\cdot xHCl$. To the title compound of step A (322 mg) in EtOAc (1 mL) was added 4M HCl in dioxane (3 mL), and the reaction mixture was stirred at room temperature for 2 h. The reaction was concentrated to give the title compound of step B (327 mg), which was used without further purification. MS (ESI) mass calcd. for $C_{12}H_{13}F_4N_3$, 275.1; m/z found 276.0 $[M+H]^+$.


Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (40 mg) and intermediate A-1 (24 mg, 0.126 mmol) in DMF (0.5 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (48 mg, 0.13 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (2X). The combined organics were concentrated and the concentrate subjected directly to purification via Agilent Prep Method X to give the title compound (26 mg). MS (ESI): mass calcd. for C₂₁H₁₈F₄N₆O, 446.1; m/z found, 447.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 7.95 (s, 2H), 7.81 (d, *J* = 8.2 Hz, 1H), 7.66 (s, 1H), 7.58 - 7.44 (m, 1H), 7.30 (t, *J* = 7.8 Hz, 1H), 7.04-6.95 (m, 1H), 6.83-6.72 (m, 1H), 4.11 - 4.03 (m, 1H), 3.88-3.79 (m, 1H), 3.50 - 3.33 (m, 2H), 2.63-2.57 (m, 1H), 2.22-2.12 (m, 1H), 1.51-1.41 (m, 2H), 1.29-1.18 (m, 1H). Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.81 min (major rotamer) at 254 nm.

Example 178: ((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.



Prepared analogous to Example 177 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C₂₁H₁₉F₄N₇O, 461.2; m/z found, 462.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.14 (d, *J* = 8.4 Hz, 1H), 7.98 (s, 2H), 7.84 - 7.78 (m, 1H), 7.43 (dd, *J* = 11.1, 2.0 Hz, 1H), 7.31 (d, *J* = 8.6 Hz, 1H), 4.25 - 4.19 (m, 1H), 4.12 - 4.04 (m, 1H), 3.56 (dt, *J* = 11.0, 3.2 Hz, 1H), 3.35 (dd, *J* = 10.9, 1.4 Hz, 1H), 2.72 - 2.67 (m, 1H), 2.37 (s, 3H), 2.35 - 2.27 (m, 1H), 1.65 - 1.61 (m, 2H), 1.44 - 1.38 (m, 1H).


Example 179: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 177 substituting intermediate A-1 with intermediate A-2.


- 5 MS (ESI): mass calcd. for $C_{23}H_{18}F_5N_5O$, 475.1; m/z found, 476.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.90 (d, $J = 4.9$ Hz, 2H), 7.80 - 7.73 (m, 1H), 7.52 - 7.46 (m, 2H), 7.08 - 7.01 (m, 1H), 6.95 - 6.87 (m, 1H), 6.80 (d, $J = 7.7$ Hz, 1H), 4.20 (s, 1H), 4.17 - 4.10 (m, 1H), 3.33 - 3.32 (m, 1H), 3.19 (dt, $J = 11.1, 3.2$ Hz, 1H), 2.57 - 2.49 (m, 1H), 2.23 - 2.13 (m, 1H), 1.52 (d, $J = 9.8$ Hz, 1H), 1.45 - 1.36
- 10 (m, 1H), 0.93 (d, $J = 10.1$ Hz, 1H).

Example 180: ((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone.



- 15 Prepared analogous to Example 177 substituting intermediate A-1 with intermediate A-34.
- MS (ESI): mass calcd. for $C_{23}H_{18}F_5N_5O$, 475.1; m/z found, 476.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.81 (d, $J = 0.6$ Hz, 2H), 8.11 (d, $J = 7.3$ Hz, 1H), 7.70 - 7.63 (m, 1H), 7.62 - 7.42 (m, 1H), 7.32 - 7.22 (m, 1H), 7.01 - 6.90 (m, 1H), 6.90 - 6.79 (m, 1H), 4.16 - 4.08 (m, 1H), 4.07 - 3.95 (m, 1H),
- 20 3.53 (dt, $J = 10.8, 3.2$ Hz, 1H), 3.40 (dd, $J = 10.8, 1.6$ Hz, 1H), 2.68 - 2.63 (m, 1H), 2.26 - 2.16 (m, 1H), 1.58 - 1.51 (m, 1H), 1.51 - 1.45 (m, 1H), 1.38 - 1.28 (m, 1H).

Example 181: ((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.



Step A: (1S,4S)-tert-butyl 6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing intermediate B-10 (183 mg, 0.862 mmol) in MeCN (2 mL) was added 2-chlorobenzoxazole (0.12 mL, 1.03 mmol) and Et₃N (0.18 mL, 1.29 mmol), and the reaction mixture was sealed and heated to 100 °C bench top overnight. Upon completion of the reaction, the mixture was cooled to room temperature and diluted with H₂O. The reaction mixture was extracted with EtOAc (3X). The combined organics were concentrated and the concentrate subjected directly to silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound of step A (199 mg, 0.604 mmol, 70%) MS (ESI) mass calcd. for C₁₈H₂₃N₃O₃; 329.2 m/z found 330.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 7.40-7.34 (m, 1H), 7.26-7.20 (m, 1H), 7.20-7.12 (m, 1H), 7.07-6.99 (m, 1H), 5.88-5.78 and 5.29-5.19 (two m, 1H), 4.51-4.43 (m, 1H), 4.33-4.19 (m, 1H), 3.45-3.33 (m, 1H), 3.15-3.04 (m, 1H), 2.64-2.57 (m, 1H), 2.46-2.31 (m, 1H), 1.80 - 0.99 (series of m, 12H).


Step B: N-((1S,4R)-2-azabicyclo[2.2.1]heptan-6-yl)benzo[d]oxazol-2-amine · xHCl. To the title compound of step A (199 mg, 0.604 mmol) in EtOAc (1.5 mL) was added 4M HCl in dioxane (4 mL). After 1h, the reaction was concentrated to give the title compound of step B (194 mg), which was used without further purification. MS (ESI) mass calcd. for C₁₃H₁₅N₃O; 229.1; m/z found 230.1 [M+H]⁺.

Step C: ((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone. To the title compound of step B (40 mg) and intermediate A-40 (30 mg, 0.15 mmol) in DMF (1 mL) was added DIPEA (0.13 mL, 0.75 mmol) and HATU (55 mg, 0.15 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (2X). The combined organics were concentrated and the concentrate subjected directly to purification via Agilent Prep Method X to give the title compound (24 mg). MS (ESI): mass calcd. for C₂₂H₂₁N₇O₂; 415.2; m/z found, 416.2 [M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄, Compound

present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.12 - 8.05 (m, 1H), 7.99 (s, 2H), 7.26 - 7.21 (m, 1H), 7.16 - 7.08 (m, 3H), 7.08 - 7.01 (m, 1H), 4.26 - 4.21 (m, 1H), 3.98 - 3.88 (m, 1H), 3.59 (dt, J = 11.0, 3.2 Hz, 1H), 3.35 (d, J = 11.0 Hz, 1H), 2.76 - 2.68 (m, 1H), 2.40 - 2.28 (m, 1H), 2.09 (s, 3H), 1.68 - 1.60 (m, 2H), 1.40 - 1.33 (m, 1H).

5

Example 182: ((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.




Prepared analogous to Example 181 substituting intermediate A-40 with intermediate A-16.

- 10 MS (ESI): mass calcd. for $C_{22}H_{19}FN_6O_2$, 418.2; m/z found, 419.2 $[M+H]^+$. ^1H NMR (400 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.00 (s, 2H), 7.37 - 7.31 (m, 1H), 7.20 - 7.16 (m, 1H), 7.12 (d, J = 7.1 Hz, 2H), 6.91 (d, J = 8.2 Hz, 2H), 6.49 - 6.37 (m, 1H), 4.12 (s, 1H), 4.01 - 3.88 (m, 1H), 3.63 (s, 1H), 3.27 - 3.22 (m, 1H), 2.60 - 2.54 (m, 1H), 2.31 - 2.21 (m, 1H), 1.59 (d, J = 10.3 Hz, 1H), 1.32 - 1.19 (m, 2H).

15

Example 183: ((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




Prepared analogous to Example 181 substituting intermediate A-40 with intermediate A-2.

- 20 MS (ESI): mass calcd. for $C_{24}H_{20}FN_5O_2$, 429.2; m/z found, 430.2 $[M+H]^+$. ^1H NMR (400 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.91 (d, J = 5.0 Hz, 2H), 7.49 (t, J = 5.0 Hz, 1H), 7.30 (d, J = 7.9 Hz, 1H), 7.21 - 7.06 (m, 3H), 6.93

(d, $J = 7.5$ Hz, 1H), 6.86 - 6.79 (m, 1H), 6.62 - 6.49 (m, 1H), 4.27 (s, 1H), 4.05 - 3.97 (m, 1H), 3.29 - 3.28 (m, 1H), 3.27 (s, 1H), 2.67 - 2.56 (m, 1H), 2.37 - 2.25 (m, 1H), 1.63 (d, $J = 10.2$ Hz, 1H), 1.35 - 1.23 (m, 2H).

- 5 Example 184: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(p-tolylamino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- Step A: (1S,4S)-tert-butyl 6-(p-tolylamino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed dioxane (2 mL), intermediate B-10 (60 mg, 0.28 mmol) and 4-bromotoluene (73 mg, 0.42 mmol) was added BrettPhos Palladacycle (11 mg, 0.014 mmol), BrettPhos (8 mg, 0.014 mmol) and sodium tert-butoxide (33 mg, 0.34 mmol). The reaction mixture was heated to 90 °C bench top for 3 h. Upon completion of the reaction, the mixture was cooled to room temperature and diluted with H₂O and EtOAc. The reaction mixture was extracted with EtOAc (3X) and the combined organics washed with brine, dried (Na₂SO₄), and filtered. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (0-40% EtOAc in hexanes) to give the title compound of step A (68 mg, 0.22 mmol, 80%) MS (ESI) mass calcd. for C₁₈H₂₆N₂O₂, 302.2; m/z found 303.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers, major rotamer reported) δ 6.91 (d, $J = 8.1$ Hz, 2H), 6.55 (d, $J = 8.3$ Hz, 2H), 4.39 (s, 1H), 3.86 - 3.73 (m, 1H), 3.27 (dt, $J = 9.4, 3.2$ Hz, 1H), 3.05 (d, $J = 9.3$ Hz, 1H), 2.52 - 2.48 (m, 1H), 2.28 - 2.21 (m, 1H), 2.18 (s, 3H), 1.74 - 1.40 (m, 3H), 1.08 (s, 9H).


- Step B: (1S,4R)-N-(p-tolyl)-2-azabicyclo[2.2.1]heptan-6-amine · xHCl. To the title compound of step A (68 mg, 0.22 mmol) in EtOAc (3 mL) was added 4M HCl in dioxane (0.3 mL), and the reaction mixture was stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B (70 mg), which was used without further purification. MS (ESI) mass calcd. for C₁₃H₁₈N₂, 202.2; m/z found 203.3 [M+H]⁺.

Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(p-tolylamino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (61 mg) and intermediate

A-2 (71 mg, 0.27 mmol, 82% purity) in DMF (2 mL) was added DIPEA (0.23 mL, 1.33 mmol) and HATU (93 mg, 0.24 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (2X). The combined organics were concentrated and the concentrate subjected directly to


- 5 purification via Gilson Prep Method X to give the title compound (31 mg). MS (ESI): mass calcd. for C₂₄H₂₃FN₄O, 402.2; m/z found, 403.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.88 (d, J = 5.0 Hz, 2H), 7.48 (t, J = 5.0 Hz, 1H), 7.09 - 7.02 (m, 1H), 6.85 - 6.77 (m, 4H), 6.34 - 6.27 (m, 2H), 4.10 (s, 1H), 3.73 - 3.64 (m, 1H), 3.29 - 3.11 (m, 2H), 2.57 - 2.48 (m, 1H), 2.32 - 2.23 (m, 1H), 2.21 (s, 3H), 1.60
10 (d, J = 10.1 Hz, 1H), 1.26 - 1.19 (m, 1H), 1.15 - 1.09 (m, 1H).

Example 185: (1H-indol-7-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 15 Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-29. MS (ESI): mass calcd. for C₂₁H₁₉F₃N₄O, 400.2; m/z found, 401.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers, major rotamer reported) δ 7.53 (s, 1H), 7.32 - 7.25 (m, 1H), 7.23 (d, J = 3.1 Hz, 1H), 7.17 (dt, J = 8.0, 1.0 Hz, 1H), 6.70 - 6.60 (m, 2H), 6.37 (dd, J = 3.1, 0.9 Hz, 1H), 6.33 (s, 1H), 4.59 (s, 1H), 3.98 - 3.89 (m, 1H), 3.63 (dt, J = 11.1, 3.3 Hz,
20 1H), 3.51 (dd, J = 11.2, 1.6 Hz, 1H), 2.76 - 2.66 (m, 1H), 2.33 - 2.20 (m, 1H), 2.05 - 1.95 (m, 1H), 1.81 - 1.74 (m, 1H), 1.36 - 1.25 (m, 1H).

Example 186: (1H-indazol-7-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 53 substituting intermediate A-1 with intermediate A-44.

- 5 MS (ESI): mass calcd. for $C_{20}H_{18}F_3N_5O$, 401.1; m/z found, 402.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4) δ 7.88 (s, 1H), 7.55 (d, $J = 8.1$ Hz, 1H), 7.52 (s, 1H), 7.22 (d, $J = 7.1$ Hz, 1H), 7.09 (dd, $J = 8.9, 2.5$ Hz, 1H), 6.89 - 6.80 (m, 1H), 6.11 (d, $J = 8.9$ Hz, 1H), 4.76 (s, 1H), 4.00 - 3.92 (m, 1H), 3.67 - 3.56 (m, 2H), 2.76 - 2.68 (m, 1H), 2.36 - 2.25 (m, 1H), 2.17 - 2.08 (m, 1H), 1.83 (d, $J = 10.4$ Hz, 1H), 1.33 - 1.22 (m, 1H).

10

Example 187: (5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-19.

- 15 MS (ESI): mass calcd. for $C_{20}H_{19}F_3N_8O$, 444.2; m/z found, 445.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.32 - 8.26 (m, 1H), 8.18 (s, 1H), 8.11 - 8.06 (m, 1H), 7.88 (s, 3H), 7.56 (s, 1H), 4.31 (s, 1H), 4.26 - 4.12 (m, 1H), 3.72 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.35 (dd, $J = 11.0, 1.7$ Hz, 1H), 2.85 - 2.72 (m, 1H), 2.47 - 2.36 (m, 4H), 1.98 - 1.89 (m, 1H), 1.72 (d, $J = 10.5$ Hz, 1H), 1.21 (dt, $J = 13.4, 4.0$ Hz, 1H).

20

Example 188: (2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-39.

MS (ESI): mass calcd. for $C_{19}H_{17}F_3N_8O$, 430.1; m/z found, 431.1 $[M+H]^+$. ^1H NMR (500 MHz,

Methanol- d_4 , Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ

- 5 8.36 (dd, $J = 4.8, 1.8$ Hz, 1H), 8.07 (s, 2H), 7.98 - 7.83 (m, 2H), 7.61 - 7.48 (m, 1H), 6.89 - 6.75 (m, 1H), 4.01 - 3.89 (m, 1H), 3.85 - 3.70 (m, 1H), 3.51 (dt, $J = 11.2, 3.2$ Hz, 1H), 3.35 (dd, $J = 11.1, 1.7$ Hz, 1H), 2.64 (s, 1H), 2.30 - 2.19 (m, 1H), 1.57 - 1.47 (m, 1H), 1.43 - 1.32 (m, 1H), 1.32 - 1.21 (m, 1H).


- 10 Example 189: (3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-42.


- 15 MS (ESI): mass calcd. for $C_{21}H_{18}F_3N_7O$, 441.2; m/z found, 442.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ
- 8.89 (d, $J = 4.9$ Hz, 2H), 8.53 (dd, $J = 8.0, 1.6$ Hz, 1H), 8.02 (d, $J = 4.8$ Hz, 1H), 7.94 - 7.86 (m, 2H), 7.44 (t, $J = 4.9$ Hz, 1H), 7.37 (dd, $J = 8.0, 4.8$ Hz, 1H), 4.20 - 4.14 (m, 1H), 4.11 - 4.01 (m, 1H), 3.63 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.35 (d, $J = 10.9$ Hz, 1H), 2.77 - 2.68 (m, 1H), 2.36 - 2.30 (m, 20 1H), 1.70 - 1.54 (m, 2H), 1.40 - 1.30 (m, 1H).

Example 190: (5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 5 Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-47.
 MS (ESI): mass calcd. for $C_{22}H_{20}F_3N_7O$, 455.2; m/z found, 456.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.88 (d, $J = 4.9$ Hz, 2H), 8.33 (dd, $J = 2.1, 0.9$ Hz, 1H), 7.90 (s, 1H), 7.89 - 7.88 (m, 1H), 7.82 (s, 1H), 7.43 (t, $J = 4.9$ Hz, 1H), 4.20 - 4.15 (m, 1H), 4.10 - 3.99 (m, 1H), 3.60 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.35 (dd, $J = 11.0, 1.5$ Hz, 1H), 2.73 - 2.67 (m, 1H), 2.33 (s, 3H), 2.32 - 2.26 (m, 1H), 1.66 - 1.51 (m, 2H), 1.38 - 1.31 (m, 1H).
- 10

Example 191: (6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 15 Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-41.
 MS (ESI): mass calcd. for $C_{22}H_{20}F_3N_7O$, 455.2; m/z found, 456.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.86:0.14), major rotamer reported) δ 7.37 (d, $J = 4.9$ Hz, 2H), 6.88 (d, $J = 8.1$ Hz, 1H), 6.45 (s, 1H), 6.33 (d, $J = 1.4$ Hz, 1H), 5.91 (t, $J = 4.9$ Hz, 1H), 5.74 (d, $J = 8.1$ Hz, 1H), 2.76 - 2.67 (m, 1H), 2.59 - 2.48 (m, 1H), 2.11 (dt, $J = 11.0, 3.2$ Hz, 1H), 1.83 (dd, $J = 10.9, 1.6$ Hz, 1H), 1.20 - 1.18 (m, 1H), 0.87 - 0.75 (m, 4H), 0.17 - -0.00 (m, 2H), -0.13 - -0.27 (m, 1H).
- 20


Example 192: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



- 5 Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-16. MS (ESI): mass calcd. for $C_{20}H_{17}F_4N_7O$, 447.1; m/z found, 448.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.35 min (major rotamer) at 254 nm.


10

Example 193: (4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




- 15 Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-12. MS (ESI): mass calcd. for $C_{20}H_{17}F_4N_7O$, 447.1; m/z found, 448.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.56 min (major rotamer) at 254 nm.

- 20 Example 194: ((5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-10.
 MS (ESI): mass calcd. for $C_{20}H_{17}F_4N_7O$, 447.1; m/z found, 448.2 $[M+H]^+$. Analytical HPLC was
 obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase
 5 of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
 rate of 1 mL/min (Temperature = 30 °C). R_t = 6.36 min (major rotamer) at 254 nm.

Example 195: (2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-11.
 MS (ESI): mass calcd. for $C_{20}H_{17}F_4N_7O$, 447.1; m/z found, 448.2 $[M+H]^+$. Analytical HPLC was
 obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase
 of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
 15 rate of 1 mL/min (Temperature = 30 °C). R_t = 6.41 min (major rotamer) at 254 nm.


Example 196: (3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-22.


MS (ESI): mass calcd. for $C_{21}H_{20}F_3N_7O$, 443.2; m/z found, 444.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.61 min (major rotamer) at 254 nm.

Example 197: (4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-5. MS (ESI): mass calcd. for $C_{21}H_{20}F_3N_7O_2$, 459.2; m/z found, 460.1 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.30 min (major rotamer) at 254 nm.


Example 198: (4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-23.


MS (ESI): mass calcd. for $C_{22}H_{18}F_4N_6O$, 458.1; m/z found, 459.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.24 min (major rotamer) at 254 nm.

Example 199: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-7. MS (ESI): mass calcd. for $C_{22}H_{18}F_4N_6O$, 458.1; m/z found, 459.9 $[M+H]^+$. ^1H NMR (600 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.84 (d, J = 4.8 Hz, 2H), 8.19 (dd, J = 8.8, 5.5 Hz, 1H), 7.95 - 7.87 (m, 2H), 7.38 (t, J = 4.9 Hz, 1H), 7.04 (td, J = 8.4, 2.7 Hz, 1H), 6.74 - 6.64 (m, 1H), 4.04 - 3.93 (m, 2H), 3.54 (dt, J = 11.0, 3.2 Hz, 1H), 3.36 - 3.33 (m, 1H), 2.66 - 2.62 (m, 1H), 2.30 - 2.22 (m, 1H), 1.50 (d, J = 10.0 Hz, 1H), 1.34 - 1.24 (m, 2H).

Example 200: (2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-6. MS (ESI): mass calcd. for $C_{22}H_{18}F_4N_6O$, 458.1; m/z found, 459.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.16 min (major rotamer) at 254 nm.

Example 201: (2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-37. MS (ESI): mass calcd. for $C_{22}H_{19}F_3N_6O$, 440.2; m/z found, 441.9 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.86 (d, J = 4.9 Hz, 2H), 8.12 (d, J = 7.6 Hz, 1H), 7.94 - 7.87 (m, 1H), 7.86 - 7.78 (m, 1H), 7.40 (t, J = 4.9 Hz, 1H), 7.30 (td, J = 7.7, 1.4 Hz, 1H), 7.02 - 6.92 (m, 1H), 6.87 - 6.75 (m, 1H), 4.06 - 3.90 (m, 2H), 3.52 (dt, J = 11.0, 3.1 Hz, 1H), 3.36 - 3.33 (m, 1H), 2.67 - 2.60 (m, 1H), 2.31 - 2.20 (m, 1H), 1.47 (d, J = 10.0 Hz, 1H), 1.32 - 1.26 (m, 1H), 1.25 - 1.15 (m, 1H).


Example 202: (5-fluoro-2-(oxazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-49.

MS (ESI): mass calcd. for $C_{21}H_{17}F_4N_5O_2$, 447.1; m/z found, 448.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers, major rotamer reported) δ 8.30 (s, 1H), 8.11 (dd, $J = 8.8, 5.3$ Hz, 1H), 7.99 - 7.89 (m, 1H), 7.85 (d, $J = 1.4$ Hz, 1H), 7.80 (d, $J = 0.9$ Hz, 1H), 7.29 - 7.26 (m, 1H), 7.21 (ddd, $J = 8.9, 7.9, 2.7$ Hz, 1H), 7.05 (dd, $J = 8.3, 2.6$ Hz, 1H), 4.88 (s, 1H), 4.85 - 4.70 (m, 1H), 3.22 (dt, $J = 8.9, 2.9$ Hz, 1H), 2.95 (dd, $J = 8.9, 1.5$ Hz, 1H), 2.63 - 2.55 (m, 1H), 2.49 - 2.31 (m, 1H), 1.90 - 1.75 (m, 2H), 1.18 - 1.11 (m, 1H).


- 10 Example 203: (2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-34.

MS (ESI): mass calcd. for $C_{22}H_{18}F_4N_6O$, 458.1; m/z found, 459.2 $[M+H]^+$. ^1H NMR (400 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.81 (s, 2H), 8.12 (d, $J = 7.9$ Hz, 1H), 7.97 - 7.87 (m, 1H), 7.86 - 7.76 (m, 1H), 7.29 (td, $J = 7.7, 1.4$ Hz, 1H), 6.95 (d, $J = 7.5$ Hz, 1H), 6.85 - 6.70 (m, 1H), 4.08 - 3.90 (m, 2H), 3.55 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.38 - 3.32 (m, 1H), 2.66 (s, 1H), 2.31 - 2.18 (m, 1H), 1.51 (d, $J = 10.0$ Hz, 1H), 1.41 - 1.24 (m, 2H).

- 20 Example 204: (3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-35.

MS (ESI): mass calcd. for $C_{22}H_{17}F_5N_6O$, 476.1; m/z found, 477.9 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ

- 5 8.88 (d, $J = 0.7$ Hz, 2H), 7.96 - 7.89 (m, 2H), 7.11 - 7.03 (m, 1H), 6.93 - 6.81 (m, 2H), 4.20 (s, 1H), 4.10 - 4.02 (m, 1H), 3.28 - 3.25 (m, 2H), 2.58 (s, 1H), 2.32 - 2.19 (m, 1H), 1.57 (d, $J = 10.1$ Hz, 1H), 1.32 - 1.21 (m, 1H), 1.15 - 1.02 (m, 1H).

Example 205: (3-phenylpyrazin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.

10




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-43.

MS (ESI): mass calcd. for $C_{22}H_{19}F_3N_6O$, 440.2; m/z found, 441.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 8.48 (d, $J = 2.4$ Hz, 1H), 7.93 (s, 1H), 7.84 (s, 1H), 7.78 (d, $J = 2.4$ Hz, 1H), 7.73 - 7.66 (m, 2H), 7.56 - 7.50 (m, 3H), 3.90 - 3.82 (m, 1H), 3.81 - 3.73 (m, 1H), 3.34 (dd, $J = 11.3, 1.6$ Hz, 1H), 3.27 (dt, $J = 11.3, 3.2$ Hz, 1H), 2.53 - 2.48 (m, 1H), 2.20 - 2.08 (m, 1H), 1.38 - 1.28 (m, 1H), 1.29 - 1.19 (m, 1H), 0.66 - 0.55 (m, 1H).


15

20 Example 206: [1,1'-biphenyl]-2-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 59 substituting intermediate A-1 with [1,1'-biphenyl]-2-carboxylic acid. MS (ESI): mass calcd. for $C_{24}H_{21}F_3N_4O$, 438.2; m/z found, 439.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4) δ 7.91 (br. s, 1H), 7.76 (br. s, 1H), 7.49 - 7.33 (m, 6H), 7.25 (td, J = 7.6, 1.4 Hz, 1H), 6.87 (dd, J = 7.6, 1.3 Hz, 1H), 6.68 (td, J = 7.5, 1.3 Hz, 1H), 3.93 - 3.72 (m, 2H), 3.25 (dd, J = 11.2, 1.6 Hz, 1H), 3.09 (dt, J = 11.2, 3.2 Hz, 1H), 2.43 - 2.33 (m, 1H), 2.16 - 2.05 (m, 1H), 1.26 - 1.11 (m, 3H).

Example 207: (3-phenylfuran-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-45. MS (ESI): mass calcd. for $C_{22}H_{19}F_3N_4O_2$, 428.1; m/z found, 429.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.09 - 8.05 (m, 1H), 7.74 (d, J = 1.4 Hz, 1H), 7.43 - 7.36 (m, 4H), 7.36 - 7.31 (m, 1H), 7.06 (d, J = 1.8 Hz, 1H), 6.41 (d, J = 1.8 Hz, 1H), 4.50 - 4.46 (m, 1H), 4.04 - 3.96 (m, 1H), 3.49 - 3.45 (m, 2H), 2.64 - 2.58 (m, 1H), 2.28 - 2.20 (m, 1H), 1.61 - 1.49 (m, 2H), 1.32 - 1.24 (m, 1H).

Example 208: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-2, followed by alkylation step of Example 153. MS (ESI): mass calcd. for $C_{23}H_{20}F_4N_6O$, 472.2; m/z found, 473.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of

5 rotamers (0.88:0.12), major rotamer reported) δ 8.90 (d, $J = 5.0$ Hz, 2H), 8.18 - 8.16 (m, 1H), 8.14 - 8.12 (m, 1H), 7.50 (t, $J = 5.0$ Hz, 1H), 7.10 - 7.01 (m, 1H), 6.91 - 6.83 (m, 1H), 6.78 (dd, $J = 7.6$, 1.2 Hz, 1H), 4.56 - 4.47 (m, 1H), 4.15 - 4.09 (m, 1H), 3.37 (dd, $J = 11.5$, 1.6 Hz, 1H), 3.22 - 3.16 (m, 4H), 2.63 - 2.59 (m, 1H), 2.08 - 1.98 (m, 1H), 1.97 - 1.88 (m, 1H), 1.55 - 1.48 (m, 1H), 0.84 - 0.77 (m, 1H).

10


Example 209: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



15 Prepared analogous to Example 208 substituting intermediate A-2 with intermediate A-7. MS (ESI): mass calcd. for $C_{23}H_{20}F_4N_6O$, 472.2; m/z found, 473.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.89:0.11), major rotamer reported) δ 8.84 (d, $J = 4.9$ Hz, 2H), 8.18 (dd, $J = 8.8$, 5.5 Hz, 1H), 8.15 (s, 1H), 8.09 - 8.04 (m, 1H), 7.39 (t, $J = 4.9$ Hz, 1H), 7.05 - 6.96 (m, 1H), 6.64 (dd, $J = 8.5$, 2.7 Hz, 1H), 4.51 - 4.41 (m, 1H), 4.03 - 3.95 (m,

20 1H), 3.54 (dt, $J = 11.3$, 3.1 Hz, 1H), 3.45 (dd, $J = 11.3$, 1.6 Hz, 1H), 3.24 (s, 3H), 2.78 - 2.69 (m, 1H), 2.13 - 1.97 (m, 2H), 1.57 - 1.46 (m, 1H), 1.23 - 1.11 (m, 1H).


Example 210: ((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone.



Prepared analogous to Example 208 substituting intermediate A-2 with intermediate A-37.


- 5 MS (ESI): mass calcd. for $C_{23}H_{21}F_3N_6O$, 454.2; m/z found, 455.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.85 (d, $J = 4.9$ Hz, 2H), 8.10 (dd, $J = 7.9, 1.2$ Hz, 1H), 8.08 (s, 2H), 7.39 (t, $J = 4.9$ Hz, 1H), 7.26 (td, $J = 7.7, 1.4$ Hz, 1H), 6.92 (dd, $J = 7.6, 1.3$ Hz, 1H), 6.82 (td, $J = 7.5, 1.3$ Hz, 1H), 4.50 - 4.43 (m, 1H), 3.99 - 3.92 (m, 1H), 3.52 (dt, $J = 11.3, 3.1$ Hz, 1H), 3.44 (dd, $J = 11.3, 1.5$ Hz, 1H), 3.23 (s, 10 3H), 2.76 - 2.67 (m, 1H), 2.12 - 1.91 (m, 2H), 1.52 - 1.42 (m, 1H), 1.19 - 1.07 (m, 1H).

Example 211: ((1S,4S,6R)-6-((cyclopropylmethyl)(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.



- 15 Prepared analogous to Example 59 substituting intermediate A-1 with intermediate A-2, followed by alkylation step of Example 161. MS (ESI): mass calcd. for $C_{26}H_{24}F_4N_6O$, 512.2; m/z found, 513.2 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.89 (d, $J = 4.9$ Hz, 2H), 8.18 (br. s, 1H), 8.15 (br. s, 1H), 7.49 (t, $J = 5.0$ Hz, 1H), 7.04 - 6.98 (m, 1H), 6.89 - 6.81 (m, 1H), 6.78 (dd, $J = 7.6, 1.2$ Hz, 1H), 4.48 - 4.40 (m, 1H), 4.18 - 4.14 (m, 1H), 3.84 (dd, $J = 16.1, 5.9$ Hz, 1H), 3.39 - 3.33 (m, 2H), 20 3.14 (dt, $J = 11.4, 3.2$ Hz, 1H), 2.63 - 2.58 (m, 1H), 2.19 - 2.08 (m, 1H), 1.91 - 1.84 (m, 1H), 1.53 (d, $J = 10.3$ Hz, 1H), 1.01 - 0.92 (m, 1H), 0.77 - 0.70 (m, 1H), 0.65 - 0.52 (m, 2H), 0.51 - 0.43 (m, 1H), 0.38 - 0.30 (m, 1H).

Example 212: ((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.




5 Step A: (1S,4S,6R)-tert-butyl 6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing intermediate B-10 (300 mg, 1.41 mmol) in MeCN (3 mL) was added 2,5-dichloropyrazine (0.17 mL, 1.70 mmol) and Et₃N (0.30 mL, 2.12 mmol), and the reaction mixture was sealed and heated to 90 °C bench top overnight. Upon completion of the reaction, the mixture was cooled to room temperature and diluted with H₂O. The reaction mixture
10 was extracted with EtOAc (3X). The combined organics were concentrated and the concentrate subjected directly to silica gel chromatography (0-60% EtOAc in hexanes) to give the title compound of step A (153 mg, 0.471 mmol, 33%) MS (ESI) mass calcd. for C₁₅H₂₁ClN₄O₂; 324.1, m/z found 269.1 [M+2H-tBu]⁺. ¹H NMR (500 MHz, Methanol-d₄) δ 7.99 (d, J = 1.4 Hz, 1H), 7.71 (d, J = 1.4 Hz, 1H), 4.45 - 4.39 (m, 1H), 4.16 - 4.12 (m, 1H), 3.08 (d, J = 10.1 Hz, 1H), 2.62 - 2.50
15 (m, 1H), 2.29 - 2.19 (m, 1H), 1.74 - 1.64 (m, 2H), 1.22 - 1.16 (m, 1H), 1.11 (s, 9H). 1 H buried under solvent.

 Step B: (1S,4R,6R)-N-(5-chloropyrazin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine · xHCl. To the title compound of step A (150 mg, 0.46 mmol) in EtOAc (5 mL) was added 4M HCl in dioxane (0.6 mL), and the reaction mixture was stirred overnight. The reaction was concentrated to
20 give the title compound of step B (137 mg), which was used without further purification. MS (ESI) mass calcd. for C₁₀H₁₃ClN₄, 224.1; m/z found 225.1 [M+H]⁺.

 Step C: ((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone. To the title compound of step B (34 mg) and intermediate A-16 (28 mg, 0.14 mmol) in DMF (1 mL) was added DIPEA (0.12 mL, 0.69 mmol)
25 and HATU (48 mg, 0.13 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (2X). The combined organics were concentrated and the concentrate subjected directly to


purification via Gilson Prep Method X to give the title compound (35 mg). MS (ESI): mass calcd. for $C_{19}H_{17}ClFN_7O$, 413.1; m/z found, 414.0 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.92:0.08), major rotamer reported) δ 8.01 (s, 2H), 7.70 - 7.66 (m, 1H), 7.62 (d, J = 1.4 Hz, 1H), 7.33 - 7.27 (m, 1H), 7.02 - 6.93 (m, 1H), 6.87 (d, J = 7.7 Hz, 1H),
5 4.02 (s, 1H), 3.95 - 3.86 (m, 1H), 3.24 - 3.20 (m, 2H), 2.53 (s, 1H), 2.27 - 2.15 (m, 1H), 1.52 (d, J = 10.3 Hz, 1H), 1.22 - 1.05 (m, 2H).

Example 213: 1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.



Prepared analogous to Example 212 substituting intermediate A-16 with intermediate A-10. MS (ESI): mass calcd. for $C_{19}H_{17}ClFN_7O$, 413.1; m/z found, 414.0 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 7.95 (s, 2H), 7.84 (dd, J = 9.0, 4.7 Hz, 1H), 7.69 - 7.62 (m, 1H), 7.60 (d, J = 1.4 Hz, 1H), 7.22 - 7.15 (m, 1H),
15 6.81 - 6.70 (m, 1H), 3.92 - 3.74 (m, 1H), 3.48 - 3.39 (m, 1H), 3.29 - 3.27 (m, 1H), 2.59 (s, 1H), 2.27 - 2.16 (m, 1H), 1.51 - 1.41 (m, 1H), 1.29 - 1.16 (m, 2H). 1H buried under solvent peak.


Example 214: ((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.



Prepared analogous to Example 212 substituting intermediate A-16 with intermediate A-2. MS (ESI): mass calcd. for $C_{21}H_{18}ClFN_6O$, 424.1; m/z found, 425.1 $[M+H]^+$. ^1H NMR (500 MHz,


Methanol-d₄, Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.91 (d, J = 5.0 Hz, 2H), 7.63 (dd, J = 9.3, 1.5 Hz, 2H), 7.50 (t, J = 5.0 Hz, 1H), 7.19 - 7.12 (m, 1H), 7.01 - 6.93 (m, 1H), 6.85 (d, J = 6.9 Hz, 1H), 4.15 (s, 1H), 3.97 - 3.91 (m, 1H), 3.24 - 3.20 (m, 2H), 2.56 - 2.48 (m, 1H), 2.27 - 2.17 (m, 1H), 1.50 (d, J = 10.3 Hz, 1H), 1.22 - 1.15 (m, 1H), 0.94 (d, J = 10.2 Hz, 1H).

Example 215: ((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone.



Prepared analogous to Example 212 substituting intermediate A-16 with intermediate A-37. MS (ESI): mass calcd. for C₂₁H₁₉ClN₆O, 406.1; m/z found, 407.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.92:0.08), major rotamer reported) δ 8.85 (d, J = 4.9 Hz, 2H), 8.12 (d, J = 8.0 Hz, 1H), 7.68 - 7.61 (m, 1H), 7.54 - 7.50 (m, 1H), 7.43 - 7.34 (m, 2H), 6.97 (d, J = 7.6 Hz, 1H), 6.95 - 6.85 (m, 1H), 3.94 (s, 1H), 3.91 - 3.84 (m, 1H), 3.50 (dt, J = 11.0, 3.2 Hz, 1H), 3.30 - 3.29 (m, 1H), 2.66 - 2.58 (m, 1H), 2.28 - 2.17 (m, 1H), 1.51 - 1.42 (m, J = 10.1 Hz, 1H), 1.27 - 1.14 (m, 2H).

Example 216: ((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone.




Prepared analogous to Example 212 substituting intermediate A-16 with intermediate A-35. MS (ESI): mass calcd. for C₂₃H₁₈F₅N₅O, 475.1; m/z found, 476.1 [M+H]⁺. ¹H NMR (500 MHz,

Methanol- d_4 , Compound present as a mixture of rotamers (0.92:0.08), major rotamer reported) δ 8.87 (s, 2H), 7.93 (s, 1H), 7.58 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.13 - 7.00 (m, 1H), 6.90 - 6.82 (m, 1H), 6.82 - 6.75 (m, 1H), 6.65 - 6.54 (m, 1H), 4.17 (s, 1H), 4.13 - 4.04 (m, 1H), 3.28 - 3.21 (m, 2H), 2.61 - 2.50 (m, 1H), 2.31 - 2.16 (m, 1H), 1.59 (d, $J = 10.2$ Hz, 1H), 1.27 - 1.08 (m, 2H).

5

Example 217: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Step A: (1S,4S,6R)-tert-butyl 6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed toluene (9 mL) was added $\text{Pd}(\text{OAc})_2$ (24 mg, 0.035 mmol) and racemic BINAP (22 mg, 0.035 mmol) at room temperature and the reaction mixture was purged with N_2 for 5 min. Then, 2-chloro-5-methylpyrazine (112 mg, 0.87 mmol), intermediate B-10 (204 mg), and sodium tert-butoxide (121 mg, 1.22 mmol) were added and the reaction mixture heated to 70 °C overnight. Upon completion of the reaction, the mixture was cooled to room temperature, filtered through Celite and washed with EtOAc. The filtrate was concentrated in vacuo and the crude residue subjected directly to silica gel chromatography (10-80% EtOAc in hexanes) to give the title compound of step A (139 mg, 0.457 mmol, 52%). MS (ESI) mass calcd. for $\text{C}_{16}\text{H}_{24}\text{N}_4\text{O}_2$, 304.2; m/z found 305.2 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, Methanol- d_4) δ 7.93 - 7.79 (m, 2H), 4.45 - 4.40 (m, 1H), 4.16 - 4.12 (m, 1H), 3.09 (dd, $J = 9.5, 1.2$ Hz, 1H), 2.60 - 2.53 (m, 1H), 2.33 (s, 3H), 2.29 - 2.20 (m, 1H), 1.74 - 1.64 (m, 2H), 1.20 - 1.15 (m, 1H), 1.08 (s, 9H). 1 H buried under solvent.

Step B: (1S,4R,6R)-N-(5-methylpyrazin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine $\cdot$ xHCl. To the title compound of step A (139 mg, 0.46 mmol) in EtOAc (5 mL) was added 4M HCl in dioxane (0.6 mL), and the reaction mixture was stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B (140 mg), which was used without further purification. MS (ESI) mass calcd. for $\text{C}_{11}\text{H}_{16}\text{N}_4$, 204.1; m/z found 205.2 $[\text{M}+\text{H}]^+$.


Step C: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (31 mg) and intermediate A-16 (28 mg, 0.13 mmol) in DMF (1 mL) was added DIPEA (0.12 mL, 0.67 mmol) and HATU (47 mg, 0.12 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (2X). The combined organics were concentrated and the concentrate subjected directly to purification via Gilson Prep Method X to give the title compound (18 mg). MS (ESI): mass calcd. for C₂₀H₂₀FN₇O, 393.2; m/z found, 394.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers, major rotamer reported) δ 8.00 (s, 2H), 7.80 - 7.75 (m, 1H), 7.55 - 7.49 (m, 1H), 7.29 - 7.22 (m, 1H), 6.93 - 6.78 (m, 2H), 4.10 - 3.97 (m, 1H), 3.97 - 3.89 (m, 1H), 3.25 - 3.20 (m, 2H), 2.53 (s, 1H), 2.33 (s, 3H), 2.27 - 2.17 (m, 1H), 1.54 (d, J = 10.1 Hz, 1H), 1.23 - 1.11 (m, 2H).

Example 218: (5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 217 substituting intermediate A-16 with intermediate A-10. MS (ESI): mass calcd. for C₂₀H₂₀FN₇O, 393.2; m/z found, 394.5 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers, major rotamer reported) δ 7.95 (s, 2H), 7.82 (dd, J = 9.0, 4.7 Hz, 1H), 7.78 (s, 1H), 7.50 - 7.45 (m, 1H), 7.19 - 7.11 (m, 1H), 6.69 (s, 1H), 3.91 - 3.77 (m, 2H), 3.48 - 3.38 (m, 1H), 2.58 (s, 1H), 2.32 (s, 3H), 2.27 - 2.18 (m, 1H), 1.50 - 1.38 (m, 1H), 1.29 - 1.14 (m, 2H). 1H buried under solvent.

Example 219: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 217 substituting intermediate A-16 with intermediate A-2.

MS (ESI): mass calcd. for $C_{22}H_{21}FN_6O$, 404.2; m/z found, 405.5 $[M+H]^+$. ^1H NMR (500 MHz,

Methanol- d_4 , Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ

- 5 8.90 (d, $J = 5.0$ Hz, 2H), 7.75 (d, $J = 1.5$ Hz, 1H), 7.55 - 7.52 (m, 1H), 7.49 (t, $J = 5.0$ Hz, 1H), 7.15 - 7.09 (m, 1H), 6.92 - 6.86 (m, 1H), 6.85 - 6.82 (m, 1H), 4.18 - 4.13 (m, 1H), 4.01 - 3.93 (m, 1H), 3.27 - 3.20 (m, 2H), 2.53 (s, 1H), 2.33 (s, 3H), 2.27 - 2.19 (m, 1H), 1.53 (d, $J = 10.3$ Hz, 1H), 1.21 - 1.14 (m, 1H), 1.06 - 1.00 (m, 1H).

- 10 Example 220: ((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone




Prepared analogous to Example 217 substituting intermediate A-16 with intermediate A-37.

MS (ESI): mass calcd. for $C_{22}H_{22}N_6O$, 386.2; m/z found, 387.1 $[M+H]^+$. ^1H NMR (500 MHz,

- 15 Methanol- d_4 , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.85 (d, $J = 4.9$ Hz, 2H), 8.11 (d, $J = 7.9$ Hz, 1H), 7.75 (s, 1H), 7.43 (s, 1H), 7.39 (t, $J = 4.9$ Hz, 1H), 7.33 (t, $J = 7.7$ Hz, 1H), 6.96 (d, $J = 7.5$ Hz, 1H), 6.87 - 6.76 (m, 1H), 4.03 - 3.84 (m, 2H), 3.51 (dt, $J = 11.1, 3.2$ Hz, 1H), 2.67 - 2.57 (m, 1H), 2.33 (s, 3H), 2.28 - 2.14 (m, 1H), 1.48 (d, $J = 9.8$ Hz, 1H), 1.34 - 1.18 (m, 2H). 1H buried under solvent peak.

20

Example 221: methyl 5-(((1S,4S,6R)-2-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)amino)pyrazine-2-carboxylate




Step A: (1S,4S,6R)-tert-butyl 6-((5-(methoxycarbonyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing intermediate B-10 (100 mg, 0.471 mmol) in DMF (2 mL) was added methyl 5-chloropyrazine-2-carboxylate (98 mg, 0.57 mmol) and Et₃N (0.1 mL, 0.72 mmol), and the reaction mixture was sealed and heated to 70 °C bench top overnight. After 14 hours, LCMS analysis of the reaction mixture showed incomplete conversion of the starting material. The temperature was raised to 100 °C and the reaction mixture heated overnight. Upon completion of the reaction, the mixture was cooled to room temperature and directly subjected to silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound of step A (112 mg). MS (ESI) mass calcd. for C₁₇H₂₄N₄O₄; 348.2, m/z found 349.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 8.78 - 8.68 (m, 1H), 7.93-7.74 (m, 1H), 6.30-6.18 and 5.90 - 5.77 (two m, 1H), 4.46 - 4.36 (m, 1H), 4.33-4.12 (m, 1H), 3.91 (s, 3H), 3.41-3.30 (m, 1H), 3.11-2.99 (m, 1H), 2.63 - 2.51 (m, 1H), 2.39-2.25 (m, 1H), 1.78 - 1.59 (m, 2H), 1.51 - 1.01 (m, 10H).

Step B: methyl 5-((1S,4R,6R)-2-azabicyclo[2.2.1]heptan-6-ylamino)pyrazine-2-carboxylate·xHCl. To the title compound of step A (112 mg, 0.321 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (3 mL), and the reaction mixture was stirred at room temperature for 2 h. The reaction was concentrated to give the title compound of step B (99 mg), which was used without further purification. MS (ESI) mass calcd. for C₁₂H₁₆N₄O₂, 248.1; m/z found 249.1 [M+H]⁺.

Step C: methyl 5-(((1S,4S,6R)-2-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)amino)pyrazine-2-carboxylate. To the title compound of step B (99 mg) and intermediate A-1 (70 mg, 0.37 mmol) in DMF (2 mL) was added DIPEA (0.3 mL, 1.7 mmol) and HATU (129 mg, 0.339 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (2X). The combined organics were concentrated and the concentrate subjected directly to purification via Gilson Prep Method X to give the title compound. MS (ESI): mass calcd. for C₂₁H₂₁N₇O₃, 419.2; m/z found, 420.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20


mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 4.75 min (major rotamer) at 254 nm.

Example 222: (2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-39.
MS (ESI): mass calcd. for C₁₉H₁₇F₃N₈O, 430.1; m/z found, 430.9 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 5.15 min (major rotamer) at 254 nm.

Example 223: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-16.
MS (ESI): mass calcd. for C₂₀H₁₇F₄N₇O, 447.1; m/z found, 448.9 [M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.56 (d, J = 3.2 Hz, 1H), 8.20 (d, J = 3.1 Hz, 1H), 8.01 (s, 2H), 7.28 - 7.19 (m, 1H), 7.06 - 6.95 (m, 1H), 6.93 - 6.85 (m, 1H), 4.10 - 3.99 (m, 2H), 3.29 - 3.26 (m, 1H), 3.20 (dt, J = 11.2, 3.2 Hz, 1H), 2.57 - 2.51 (m, 1H), 2.25 - 2.12 (m, 1H), 1.54 (d, J = 10.3 Hz, 1H), 1.39 - 1.28 (m, 1H), 1.23 - 1.08 (m, 1H).

Example 224: (4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5 Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-12.
MS (ESI): mass calcd. for $C_{20}H_{17}F_4N_7O$, 447.1; m/z found, 448.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 8.56 (s, 1H), 8.22 - 8.13 (m, 1H), 7.98 (s, 2H), 7.64 (dd, J = 9.6, 2.6 Hz, 1H), 7.12 - 6.99 (m, 1H), 6.68 - 6.50 (m, 1H), 4.07 - 3.95 (m, 1H), 3.80 (s, 1H), 3.54 - 3.43 (m, 1H), 3.36 (dd, J = 10.9, 1.6 Hz, 1H), 2.62 (s, 10 1H), 2.26 - 2.14 (m, 1H), 1.52 - 1.42 (m, 1H), 1.38 - 1.29 (m, 2H).

Example 225: (5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




15 Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-10.
MS (ESI): mass calcd. for $C_{20}H_{17}F_4N_7O$, 447.1; m/z found, 447.9 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 8.52 (s, 1H), 8.17 (d, J = 3.1 Hz, 1H), 7.95 (s, 2H), 7.85 (dd, J = 9.0, 4.8 Hz, 1H), 7.16 - 7.06 (m, 1H), 6.86 - 6.74 (m, 1H), 4.07 - 3.97 (m, 1H), 3.80 (s, 1H), 3.47 - 3.33 (m, 2H), 2.65 - 2.54 (m, 1H), 2.25 - 2.15 (m, 20 1H), 1.47 (d, J = 10.2 Hz, 1H), 1.38 - 1.31 (m, 1H), 1.31 - 1.21 (m, 1H).

Example 226: (2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-11.

- 5 MS (ESI): mass calcd. for $C_{20}H_{17}F_4N_7O$, 447.1; m/z found, 447.9 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.18 min (major rotamer) at 254 nm.
- 10 Example 227: (4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-23.

- MS (ESI): mass calcd. for $C_{22}H_{18}F_4N_6O$, 458.1; m/z found, 459.9 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ
- 15 8.88 (d, J = 4.9 Hz, 2H), 8.64 - 8.47 (m, 1H), 8.16 (d, J = 3.1 Hz, 1H), 7.89 (dd, J = 10.0, 2.7 Hz, 1H), 7.42 (t, J = 4.9 Hz, 1H), 7.12 - 6.93 (m, 1H), 6.68 (s, 1H), 4.09 - 3.85 (m, 2H), 3.53 (dt, J = 10.9, 3.2 Hz, 1H), 3.36 (dd, J = 10.9, 1.6 Hz, 1H), 2.69 - 2.61 (m, 1H), 2.30 - 2.16 (m, 1H), 1.54 - 1.43 (m, 1H), 1.41 - 1.34 (m, 1H), 1.33 - 1.23 (m, 1H).


20

Example 228: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous Example 60 substituting intermediate A-1 with intermediate A-7. MS (ESI): mass calcd. for $C_{22}H_{18}F_4N_6O$, 458.1; m/z found, 459.9 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.91:0.09), major rotamer reported) δ 8.84 (d, $J = 4.8$ Hz, 2H), 8.51 (s, 1H), 8.21 (dd, $J = 8.8, 5.5$ Hz, 1H), 8.16 (d, $J = 3.1$ Hz, 1H), 7.38 (t, $J = 4.9$ Hz, 1H), 7.05 (td, $J = 8.3, 2.7$ Hz, 1H), 6.80 - 6.71 (m, 1H), 4.10 - 4.00 (m, 1H), 3.94 (s, 1H), 3.52 (dt, $J = 10.7, 3.1$ Hz, 1H), 3.36 (dd, $J = 10.9, 1.6$ Hz, 1H), 2.68 - 2.60 (m, 1H), 2.27 - 2.15 (m, 1H), 1.49 (d, $J = 10.1$ Hz, 1H), 1.41 - 1.33 (m, 1H), 1.33 - 1.23 (m, 1H).


- 10 Example 229: (2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-6. MS (ESI): mass calcd. for $C_{22}H_{18}F_4N_6O$, 458.1; m/z found, 459.9 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 8.87 (d, $J = 4.9$ Hz, 2H), 8.56 - 8.51 (m, 1H), 8.12 - 8.04 (m, 2H), 7.42 (t, $J = 4.9$ Hz, 1H), 7.36 - 7.30 (m, 1H), 6.73 - 6.67 (m, 1H), 4.03 - 3.97 (m, 1H), 3.97 - 3.90 (m, 1H), 3.56 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.36 (dd, $J = 10.9, 1.7$ Hz, 1H), 2.65 - 2.60 (m, 1H), 2.25 - 2.14 (m, 1H), 1.49 - 1.39 (m, 2H), 1.20 - 1.14 (m, 1H).

20

Example 230: (2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-37.

MS (ESI): mass calcd. for $C_{22}H_{19}F_3N_6O$, 440.2; m/z found, 441.9 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ

5 8.86 (d, $J = 4.9$ Hz, 2H), 8.56 - 8.48 (m, 1H), 8.15 (d, $J = 8.0$ Hz, 1H), 8.10 (s, 1H), 7.39 (t, $J = 4.9$ Hz, 1H), 7.36 - 7.28 (m, 1H), 7.01 (s, 1H), 6.95 (s, 1H), 4.11 - 3.91 (m, 2H), 3.52 (dt, $J = 11.0, 3.3$ Hz, 1H), 3.35 (dd, $J = 10.9, 1.6$ Hz, 1H), 2.64 (s, 1H), 2.28 - 2.16 (m, 1H), 1.56 - 1.44 (m, 1H), 1.41 - 1.16 (m, 2H).

- 10 Example 231: (2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-34.

MS (ESI): mass calcd. for $C_{22}H_{18}F_4N_6O$, 458.1; m/z found, 459.9 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ

15 8.82 (s, 2H), 8.58 - 8.47 (m, 1H), 8.15 (d, $J = 7.8$ Hz, 1H), 8.13 - 8.04 (m, 1H), 7.32 (t, $J = 7.6$ Hz, 1H), 7.10 - 6.83 (m, 2H), 4.12 - 4.03 (m, 1H), 4.04 - 3.89 (m, 1H), 3.56 (dt, $J = 10.9, 3.3$ Hz, 1H), 3.36 (dd, $J = 10.9, 1.6$ Hz, 1H), 2.70 - 2.62 (m, 1H), 2.29 - 2.17 (m, 1H), 1.61 - 1.14 (m, 3H).


- 20 Example 232: (2-fluoro-6-(oxazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone



Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-50.


MS (ESI): mass calcd. for $C_{21}H_{17}F_4N_5O_2$, 447.1; m/z found, 447.9 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.15 min (major rotamer) at 254 nm.

Example 233: (3-ethoxy-6-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 60 substituting intermediate A-1 with intermediate A-8. MS (ESI): mass calcd. for $C_{20}H_{22}F_3N_5O_2$, 421.2; m/z found, 422.0 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.47 (d, J = 3.2 Hz, 1H), 8.11 (d, J = 3.1 Hz, 1H), 7.23 (d, J = 8.6 Hz, 1H), 7.06 (d, J = 8.9 Hz, 1H), 4.47 - 4.42 (m, 1H), 4.08 - 3.95 (m, 3H), 3.60 (dt, J = 11.1, 3.2 Hz, 1H), 3.38 (dd, J = 11.1, 1.6 Hz, 1H), 2.77 - 2.69 (m, 1H), 2.36 - 2.28 (m, 1H), 2.26 (s, 3H), 1.92 - 1.87 (m, 1H), 1.83 - 1.78 (m, 1H), 1.42 - 1.35 (m, 4H).

Example 234: ((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.




Step A: (1S,4S,6R)-tert-butyl 6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing intermediate B-10 (305 mg, 1.44 mmol) in DMF (6 mL) was added 2,5-dichloropyrimidine (257 mg, 1.72 mmol) and
5 DIPEA (0.99 mL, 5.75 mmol), and the reaction mixture was sealed and heated to 80 °C bench top overnight. Upon completion of the reaction, the mixture was cooled to room temperature and diluted with H₂O. The reaction mixture was extracted with EtOAc (3X). The combined organics were washed with 5% aqueous LiCl, dried (Na₂SO₄), filtered, and concentrated. The concentrate was subjected directly to silica gel chromatography (10-90% EtOAc in hexanes) to give the title
10 compound of step A (433 mg, 1.33 mmol, 93%). MS (ESI) mass calcd. for C₁₅H₂₁ClN₄O₂; 324.1, m/z found 269.1 [M+2H-tBu]⁺.

Step B: (1S,4R,6R)-N-(5-chloropyrimidin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine · xHCl. To the title compound of step A (433 mg, 1.33 mmol) in EtOAc (7 mL) was added 4M HCl in dioxane (2 mL), and the reaction mixture was stirred at room temperature overnight. The reaction
15 was concentrated to give the title compound of step B (370 mg), which was used without further purification. MS (ESI) mass calcd. for C₁₀H₁₃ClN₄, 224.1; m/z found 225.1 [M+H]⁺.


Step C: ((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone. To the title compound of step B (30 mg) and intermediate A-16 (25 mg, 0.12 mmol) in DMF (1 mL) was added DIPEA (0.10 mL, 0.61 mmol)
20 and HATU (42 mg, 0.11 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (2X). The combined organics were concentrated and the concentrate subjected directly to purification via Gilson Prep Method X to give the title compound (32 mg). MS (ESI): mass calcd. for C₁₉H₁₇ClFN₇O, 413.1; m/z found, 414.0 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound
25 present as a mixture of rotamers (0.89:0.11), major rotamer reported) δ 8.35 - 8.20 (m, 1H), 8.00 (s, 2H), 7.94 - 7.82 (m, 1H), 7.33 - 7.24 (m, 1H), 7.08 - 7.00 (m, 1H), 6.88 (d, J = 7.7 Hz, 1H), 4.01 (s, 1H), 3.98 - 3.92 (m, 1H), 3.27 (dd, J = 11.1, 1.6 Hz, 1H), 3.18 (dt, J = 10.8, 3.0 Hz, 1H), 2.55 - 2.48 (m, 1H), 2.22 - 2.12 (m, 1H), 1.52 (d, J = 10.3 Hz, 1H), 1.30 - 1.22 (m, 1H), 1.18 - 1.10 (m, 1H).

Example 235: ((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.




- 5 Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-10.
 MS (ESI): mass calcd. for $C_{19}H_{17}ClFN_7O$, 413.1; m/z found, 414.0 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4) δ 8.25 (s, 1H), 8.14 - 8.01 (m, 1H), 7.95 (s, 2H), 7.85 (dd, $J = 9.0, 4.8$ Hz, 1H), 7.17 (ddd, $J = 9.0, 7.8, 2.9$ Hz, 1H), 6.84 - 6.75 (m, 1H), 3.98 - 3.86 (m, 1H), 3.85 - 3.75 (m, 1H), 3.44 - 3.38 (m, 1H), 3.36 - 3.32 (m, 1H), 2.63 - 2.54 (m, 1H), 2.23 - 2.12 (m, 1H), 1.49 - 1.41 (m, 1H),
 10 1.34 - 1.20 (m, 2H).

Example 236: ((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.



- 15 Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-2.
 MS (ESI): mass calcd. for $C_{21}H_{18}ClFN_6O$, 424.1; m/z found, 425.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.89:0.11), major rotamer reported) δ 8.91 (d, $J = 5.0$ Hz, 2H), 8.35 - 8.15 (m, 1H), 8.02 - 7.85 (m, 1H), 7.49 (t, $J = 5.0$ Hz, 1H), 7.20 - 7.12 (m, 1H), 7.10 - 7.01 (m, 1H), 6.88 (d, $J = 7.9$ Hz, 1H), 4.14 (s, 1H), 4.05 - 3.95 (m, 1H), 3.26 - 3.21 (m, 1H), 2.56 - 2.48 (m, 1H), 2.24 - 2.12 (m, 1H), 1.52 (d, $J = 9.5$ Hz, 1H), 1.31 - 1.18 (m, 1H),
 20 1.03 (d, $J = 10.1$ Hz, 1H). 1H buried under solvent.

Example 237: ((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-23.

- 5 MS (ESI): mass calcd. for $C_{21}H_{18}ClFN_6O$, 424.1; m/z found, 425.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 8.87 (d, J = 4.9 Hz, 2H), 8.34 - 8.19 (m, 1H), 8.03 - 7.76 (m, 2H), 7.41 (t, J = 4.9 Hz, 1H), 7.10 - 6.98 (m, 1H), 6.80 - 6.67 (m, 1H), 4.01 - 3.85 (m, 2H), 3.51 (dt, J = 11.0, 3.2 Hz, 1H), 3.37 - 3.31 (m, 1H), 2.62 (s, 1H), 2.25 - 2.14 (m, 1H), 1.47 (d, J = 9.9 Hz, 1H), 1.37 - 1.20 (m, 2H).

10


Example 238: ((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.



Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-7.

- 15 MS (ESI): mass calcd. for $C_{21}H_{18}ClFN_6O$, 424.1; m/z found, 425.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.84 (d, J = 4.8 Hz, 2H), 8.29-8.19 (m, 2H), 7.86 (br. s, 1H), 7.38 (t, J = 4.9 Hz, 1H), 7.11 (td, J = 8.5, 2.7 Hz, 1H), 6.79-6.70 (m, 1H), 3.98-3.88 (m, 2H), 3.50 (dt, J = 10.9, 3.2 Hz, 1H), 3.34 (dd, J = 11.0, 1.7 Hz, 1H), 2.64-2.59 (m, 1H), 2.24-2.15 (m, 1H), 1.47 (d, J = 10.0 Hz, 1H), 1.35 - 1.19 (m, 20 2H).

Example 239: ((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone.




Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-6.

- 5 MS (ESI): mass calcd. for $C_{21}H_{18}ClFN_6O$, 424.1; m/z found, 425.1 $[M+H]^+$. Analytical HPLC using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 2min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature = 45 °C). R_t = 1.85 and 2.12 min (major rotamers) at 254 nm.

Example 240: ((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone.

10




Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-37.

- 15 MS (ESI): mass calcd. for $C_{21}H_{19}ClN_6O$, 406.1; m/z found, 407.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.85 (d, J = 4.9 Hz, 2H), 8.29 - 8.18 (m, 1H), 8.14 (dt, J = 8.0, 0.9 Hz, 1H), 7.92 - 7.70 (m, 1H), 7.42 - 7.35 (m, 2H), 7.07 - 6.92 (m, 2H), 4.10 - 3.86 (m, 2H), 3.50 (dt, J = 10.8, 3.3 Hz, 1H), 3.35 - 3.32 (m, 1H), 2.65 - 2.59 (m, 1H), 2.27 - 2.13 (m, 1H), 1.54 - 1.43 (m, 1H), 1.36 - 1.19 (m, 2H).

Example 241: ((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone.


20



Prepared analogous to Example 234 substituting intermediate A-16 with intermediate A-34.

MS (ESI): mass calcd. for $C_{21}H_{18}ClFN_6O$, 424.1; m/z found, 425.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.81 (s, 2H), 8.38 - 8.17 (m, 1H), 8.17 - 8.13 (m, 1H), 7.93 - 7.75 (m, 1H), 7.44 - 7.32 (m, 1H), 7.11 - 6.91 (m, 2H), 4.06 - 3.86 (m, 2H), 3.54 (dt, $J = 10.8, 3.3$ Hz, 1H), 3.34 (dd, $J = 11.0, 1.7$ Hz, 1H), 2.71 - 2.61 (m, 1H), 2.29 - 2.15 (m, 1H), 1.59 - 1.46 (m, 1H), 1.45 - 1.27 (m, 2H).

Example 242: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Step A: (1S,4S,6R)-tert-butyl 6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a vial containing intermediate B-10 (100 mg, 0.471 mmol) in MeCN (2 mL) was added 3-chloro-6-(trifluoromethyl)pyridazine (103 mg, 0.565 mmol) and Et_3N (0.15 mL, 1.1 mmol), and the reaction mixture was sealed and heated to 90 °C bench top overnight. Upon completion of the reaction, the mixture was cooled to room temperature and subjected directly to silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound of step A (143 mg), which contained a small amount of impurity. The title compound was carried forward as is to the next step. MS (ESI) mass calcd. for $C_{16}H_{21}F_3N_4O_2$; 358.2, m/z found 359.2 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers) δ 7.45 - 7.33 (m, 1H), 6.71-6.56 (m, 1H), 6.12 and 5.60 (2 br. s, 1H), 4.53 - 4.21 (m, 2H), 3.44 - 3.29 (m, 1H), 3.13-3.01 (m, 1H), 2.63-2.56 (m, 1H), 2.50-2.28 (m, 1H), 1.77 - 1.06 (m, 12H).

Step B: (1S,4R,6R)-N-(6-(trifluoromethyl)pyridazin-3-yl)-2-azabicyclo[2.2.1]heptan-6-amine · xHCl. To the title compound of step A (143 mg, 0.399 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (4 mL), and the reaction mixture was stirred at room temperature for 1.5 h. The reaction was concentrated to give the title compound of step B (130 mg), which was used without further purification. MS (ESI) mass calcd. for C₁₁H₁₃F₃N₄, 258.1; m/z found 259.2 [M+H]⁺.

Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (33 mg) and intermediate A-1 (21 mg, 0.11 mmol) in DMF (0.5 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (42 mg, 0.11 mmol), and the reaction mixture was stirred at room temperature for 1 h.


The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc (2X). The combined organics were concentrated and the concentrate subjected directly to purification via Agilent Prep Method X to give the title compound (26 mg). MS (ESI): mass calcd. for C₂₀H₁₈F₃N₇O, 429.2; m/z found, 430.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 5.48 min (major rotamer) at 254 nm.

Example 243: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 242 substituting intermediate A-1 with intermediate A-40. MS (ESI): mass calcd. for C₂₀H₁₉F₃N₈O, 444.2; m/z found, 445.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.86:0.14), major rotamer reported) δ 8.18 (d, J = 8.4 Hz, 1H), 7.86 (s, 2H), 7.36 (d, J = 9.3 Hz, 1H), 7.33 (d, J = 8.3 Hz, 1H), 6.73 (d, J = 9.3 Hz, 1H), 4.34 - 4.29 (m, 1H), 3.72 (dt, J = 11.0, 3.2 Hz, 1H), 3.32 (dd, J = 11.0, 1.6 Hz, 1H), 2.84 - 2.76 (m, 1H), 2.62 - 2.44 (m, 5H), 2.01 - 1.92 (m, 1H), 1.78 - 1.69 (m, 1H), 1.26 (dt, J = 13.4, 3.4 Hz, 1H).

Example 244: (6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 5 Prepared analogous to Example 242 substituting intermediate A-1 with intermediate A-41.
 MS (ESI): mass calcd. for $C_{22}H_{20}F_3N_7O$, 455.2; m/z found, 456.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.79 (d, J = 4.8 Hz, 2H), 8.48 (d, J = 8.1 Hz, 1H), 8.16 - 7.96 (m, 1H), 7.37 (d, J = 9.3 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.26 - 7.23 (m, 1H), 6.77 (d, J = 9.2 Hz, 1H), 4.27 (s, 1H), 3.74 (dt, J = 10.9, 3.2
 10 Hz, 1H), 3.33 (dd, J = 10.8, 1.6 Hz, 1H), 2.86 - 2.77 (m, 1H), 2.64 - 2.49 (m, 5H), 2.03 - 1.90 (m, 1H), 1.73 (d, J = 10.1 Hz, 1H), 1.27 (dt, J = 13.2, 3.5 Hz, 1H).

Example 245: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 15 Prepared analogous to Example 242 substituting intermediate A-1 with intermediate A-2.
 MS (ESI): mass calcd. for $C_{22}H_{18}F_4N_6O$, 458.1; m/z found, 459.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.90 (d, J = 4.9 Hz, 2H), 7.39 (t, J = 5.0 Hz, 1H), 7.32 - 7.22 (m, 2H), 7.22 - 7.16 (m, 1H), 7.11 -
 20 7.06 (m, 1H), 6.47 (d, J = 9.3 Hz, 1H), 4.67 (s, 1H), 3.55 (dt, J = 11.1, 3.2 Hz, 1H), 3.26 (dd, J = 11.0, 1.5 Hz, 1H), 2.79 - 2.69 (m, 1H), 2.54 - 2.42 (m, 1H), 1.95 - 1.72 (m, 2H), 1.69 - 1.61 (m, 1H), 1.20 - 1.07 (m, 1H).

Example 246: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




5 Step A: (1S,4S,6R)-tert-butyl 6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To a microwave vial containing degassed toluene (2 mL) was added 5-bromo-2-(trifluoromethyl)pyridine (116 mg, 0.514 mmol), intermediate B-10 (120 mg) and racemic BINAP (13 mg, 0.021 mmol) at room temperature and the reaction mixture was purged with N₂ for 5 min. Then, Pd(OAc)₂ (14 mg, 0.021 mmol) and sodium tert-butoxide (71 mg, 0.72
10 mmol) were added and the reaction mixture heated to 70 °C overnight. Upon completion of the reaction, the mixture was cooled to room temperature and the crude material subjected directly to silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound of step A (184 mg). MS (ESI) mass calcd. for C₁₇H₂₂F₃N₃O₂, 357.2; m/z found 358.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ 8.02 and 7.90 (two s, 1H),
15 7.46-7.35 (m, 1H), 6.88-6.81 and 6.77 - 6.68 (two m, 1H), 5.39-5.29 and 4.72-4.62 (two m, 1H), 4.47-4.33 (m, 1H), 3.87 - 3.72 (m, 1H), 3.41-3.31 (m, 1H), 3.11-2.99 (m, 1H), 2.64 - 2.56 (m, 1H), 2.37 - 2.17 (m, 1H), 1.81-1.67 (m, 1H), 1.66-1.60 (m, 1H), 1.53 - 1.01 (m, 11H).

Step B: (1S,4R,6R)-N-(6-(trifluoromethyl)pyridin-3-yl)-2-azabicyclo[2.2.1]heptan-6-amine · xHCl. To the title compound of step A (77 mg, 0.22 mmol) in EtOAc (0.6 mL) was added 4M
20 HCl in dioxane (3 mL), and the reaction mixture was stirred at room temperature for 2.5 h. The reaction was concentrated to give the title compound of step B (72 mg), which was used without further purification. MS (ESI) mass calcd. for C₁₂H₁₄F₃N₃, 257.1; m/z found 258.1 [M+H]⁺.

Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone. To the title compound of step B (36 mg) and
25 intermediate A-1 (25 mg, 0.13 mmol) in DMF (1 mL) was added DIPEA (0.2 mL, 1.2 mmol) and HATU (46 mg, 0.12 mmol), and the reaction mixture was stirred at room temperature for 1.5 h. The reaction was quenched by the addition of H₂O and the aqueous layer was extracted with EtOAc


(2X). The combined organics were concentrated and the concentrate subjected directly to purification via Gilson Prep Method X to give the title compound (29 mg). MS (ESI): mass calcd. for $C_{21}H_{19}F_3N_6O$, 428.2; m/z found, 429.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.07 min (major rotamer) at 254 nm.

Example 247: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 246 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for $C_{23}H_{19}F_4N_5O$, 457.2; m/z found, 458.1 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers (0.89:0.11), major rotamer reported) δ 8.91 (d, J = 5.0 Hz, 2H), 7.87 (d, J = 2.7 Hz, 1H), 7.50 (t, J = 5.0 Hz, 1H), 7.31 (d, J = 8.7 Hz, 1H), 7.06 - 6.99 (m, 1H), 6.87 - 6.80 (m, 2H), 6.73 (dd, J = 8.7, 2.8 Hz, 1H), 4.11 (s, 1H), 3.80 - 3.71 (m, 1H), 3.28 - 3.22 (m, 2H), 2.60 - 2.52 (m, 1H), 2.34 - 2.25 (m, 1H), 1.59 (d, J = 10.8 Hz, 1H), 1.24 - 1.18 (m, 1H), 1.11 (d, J = 10.3 Hz, 1H).

Example 248: (R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Step A: (R/S)-tert-butyl 6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5A (50 mg, 0.22 mmol) dissolved in DMF (2 mL) was added NaH (18 mg, 0.44 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-(trifluoromethyl)pyridine (64 mg, 0.35 mmol) was then added and the mixture stirred at room temperature for 3 h. The reaction mixture was quenched with saturated NH₄Cl solution, and diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, brine, dried with MgSO₄, filtered and concentrated. Purification via silica gel chromatography (0-40% EtOAc in hexanes) gave the title compound (67 mg, 0.18 mmol, 82%). MS (ESI) mass calcd. for C₁₈H₂₃F₃N₂O₃, 372.2; m/z found 373.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers, (0.68:0.32), major rotamer reported) δ 8.49 - 8.45 (m, 1H), 7.94 (dd, J = 8.8, 2.6 Hz, 1H), 6.90 (d, J = 8.7, 0.8 Hz, 1H), 5.22 (dt, J = 9.7, 2.9 Hz, 1H), 4.48 - 4.41 (m, 1H), 3.42 (dt, J = 10.9, 2.5 Hz, 1H), 3.25 (dt, J = 11.0, 2.6 Hz, 1H), 2.27 - 2.18 (m, 1H), 2.09 - 2.04 (m, 1H), 1.97 - 1.87 (m, 1H), 1.77 - 1.71 (m, 1H), 1.68 - 1.59 (m, 3H), 1.13 (s, 9H).

Step B: (R/S)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane · xHCl. To the title compound of step A (67 mg, 0.18 mmol) in EtOAc (2 mL) was added 4 M HCl in dioxane (0.23 mL). After 3 h, the reaction was concentrated to give the title compound of step B which was used without further purification. MS (ESI) mass calcd. for C₁₃H₁₅F₃N₂O, 272.1; m/z found 273.1 [M+H]⁺.


Step C: (R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (46 mg) and intermediate A-2 (54 mg, 0.20 mmol, 82% purity) in DMF (1.7 mL) was added DIPEA (0.18 mL, 1.01 mmol) and HATU (71 mg, 0.19 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with H₂O and EtOAc. The aqueous layer was extracted with EtOAc (3X) and the combined organics were concentrated and subjected directly to purification using Gilson Prep Method X to give the title compound (20 mg). MS (ESI): mass calcd. for C₂₄H₂₀F₄N₄O₂, 472.2; m/z found, 473.1 [M+H]⁺. Analytical HPLC using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 2 min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature = 45 °C). R_t = 2.18 and 2.29 min (major rotamers) at 254 nm. Enantiomers of Example 248 can be separated by Chiral SFC purification using a Chiralpak AZ-H column (5μm 250 x 21 mm), mobile phase of 35% EtOH+(0.2%TEA): 65% CO₂, and a flow rate of 40 mL/min (Temperature = 40 °C).

Example 249: (R/S)- (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 5 Prepared analogous to Example 248 substituting intermediate A-2 with intermediate A-16.
MS (ESI): mass calcd. for $C_{22}H_{19}F_4N_5O_2$, 461.2; m/z found, 461.9 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound present as a mixture of rotamers, major rotamer reported) δ 8.25 (s, 1H), 8.11 - 7.95 (m, 3H), 7.27 (t, J = 9.3 Hz, 1H), 7.14 - 7.00 (m, 2H), 6.91 (d, J = 7.8 Hz, 1H), 5.14 - 5.06 (m, 1H), 3.82 (s, 1H), 3.60 (d, J = 12.8 Hz, 1H), 3.24 (d, J = 12.7 Hz, 1H), 2.34 - 2.24 (m, 1H),
10 2.11 (s, 1H), 1.81 - 1.41 (series of m, 5H).

Example 250: (R/S)- (4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone



- 15 Prepared analogous to Example 248 substituting intermediate A-2 with intermediate A-23.
MS (ESI): mass calcd. for $C_{24}H_{20}F_4N_4O_2$, 472.2; m/z found, 472.9 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound is present as a mixture of rotamers) δ 8.96 - 8.78 (m, 2H), 8.22 - 8.14 (m, 1H), 8.04 - 7.97 (m, 1H), 7.92 (dd, J = 10.1, 2.6 Hz, 1H), 7.49 - 7.42 (m, 1H), 7.10 - 6.88 (m, 2H), 6.76 - 6.58 (m, 1H), 5.05 - 4.98 (m, 1H), 3.85 - 3.73 (m, 1H), 3.69 (d, J = 12.3 Hz, 1H), 3.55 - 3.48
20 (m, 1H), 2.33 - 2.24 (m, 1H), 2.21 - 2.07 (m, 1H), 1.86 - 1.77 (m, 1H), 1.74 - 1.37 (m, 3H), 1.27 - 1.14 (m, 1H).

Example 251: (R/S)- (2-(5-fluoropyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Prepared analogous to Example 248 substituting intermediate A-2 with intermediate A-34.

- 5 MS (ESI): mass calcd. for $C_{24}H_{20}F_4N_4O_2$, 472.2; m/z found, 472.9 $[M+H]^+$. ^1H NMR (500 MHz, Methanol- d_4 , Compound is present as a mixture of rotamers) δ 8.87 - 8.74 (m, 2H), 8.20 - 8.12 (m, 2H), 8.05 - 7.93 (m, 1H), 7.65 - 7.55 (m, 1H), 7.38 - 7.30 (m, 1H), 7.09 - 6.86 (m, 2H), 5.13 - 5.02 (m, 1H), 3.84 - 3.76 (m, 1H), 3.71 - 3.64 (m, 1H), 3.60 - 3.51 (m, 1H), 2.35 - 2.26 (m, 1H), 2.22 - 2.13 (m, 1H), 1.87 - 1.76 (m, 1H), 1.73 - 1.29 (m, 4H).

10

Example 252: (R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone



Step A: (R/S)-tert-butyl 6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-

- 15 azabicyclo[2.2.2]octane-2-carboxylate. To a microwave vial containing C-7A (308 mg, 1.36 mmol) in MeCN (5 mL) was added 2-chloro-5-(trifluoromethyl)pyrazine (0.20 mL, 1.63 mmol) and Et_3N (0.28 mL, 2.04 mmol), and the reaction mixture was sealed and heated to 70 °C bench top overnight. Analysis of the reaction mixture still showed unreacted starting material. Additional equivalents of 2-chloro-5-(trifluoromethyl)pyrazine (0.20 mL, 1.63 mmol) and Et_3N (0.28 mL, 2.04
- 20 mmol) were added, and the reaction mixture was heated again to 70 °C bench top overnight. Upon completion of the reaction, the mixture was cooled to room temperature and diluted with H_2O . The reaction mixture was extracted with EtOAc (3X). The combined organics were concentrated and the

concentrate subjected directly to silica gel chromatography (0-30% EtOAc in hexanes) to give the title compound of step A (245 mg, 0.658 mmol, 48%) MS (ESI) mass calcd. for $C_{17}H_{23}F_3N_4O_2$; 372.2, m/z found 371.1 $[M+2H-tBu]^+$.


Step B: (R/S)-N-(5-(trifluoromethyl)pyrazin-2-yl)-2-azabicyclo[2.2.2]octan-6-amine · xHCl.

- 5 To the title compound of step A (245 mg, 0.658 mmol) in EtOAc (1 mL) was added 4M HCl in dioxane (4 mL), and the reaction mixture was stirred at room temperature for 3 h. The reaction was concentrated to give the title compound of step B (249 mg), which was used without further purification. MS (ESI) mass calcd. for $C_{12}H_{15}F_3N_4$, 272.1; m/z found 273.0 $[M+H]^+$.

Step C: (R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-


- 10 (trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (50 mg) and intermediate A-40 (36 mg, 0.18 mmol) in DMF (0.5 mL) was added DIPEA (0.15 mL, 0.87 mmol) and HATU (68 mg, 0.18 mmol), and the reaction mixture was stirred at room temperature for 3 h. The reaction was diluted with MeOH and the crude reaction mixture subjected directly to purification via Agilent Prep Method X to give the title compound (25
15 mg). MS (ESI): mass calcd. for $C_{21}H_{21}F_3N_8O$, 458.2; m/z found, 458.9 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.45 min (major rotamer) at 254 nm.

- 20 Example 253: (R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



- Prepared analogous to Example 252, isolated from Step C during HPLC purification. MS (ESI): mass calcd. for $C_{21}H_{21}F_3N_8O$, 458.2; m/z found, 459.2 $[M+H]^+$. Analytical HPLC was
25 obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.26 min (major rotamer) at 254 nm.


Example 254: (R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



- 5 Prepared analogous to Example 252 substituting intermediate A-40 with intermediate A-1. MS (ESI): mass calcd. for $C_{21}H_{20}F_3N_7O$, 443.2; m/z found, 443.9 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.65 min (major rotamer) at 254 nm.


10

Example 255: (R/S)- (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 15 Prepared analogous to Example 252 substituting intermediate A-40 with intermediate A-16. MS (ESI): mass calcd. for $C_{21}H_{19}F_4N_7O$, 461.2; m/z found, 461.9 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.65 min (major rotamer) at 254 nm.

- 20 Example 256: (R/S)- (3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Prepared analogous to Example 252 substituting intermediate A-40 with intermediate A-22.
 MS (ESI): mass calcd. for $C_{22}H_{22}F_3N_7O$, 457.2; m/z found, 458.0 $[M+H]^+$. Analytical HPLC was
 5 of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
 rate of 1 mL/min (Temperature = 30 °C). R_t = 6.96 min (major rotamer) at 254 nm.


Example 257: (R/S)- (3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-
 yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



10


Prepared analogous to Example 252 substituting intermediate A-40 with intermediate A-2.
 MS (ESI): mass calcd. for $C_{23}H_{20}F_4N_6O$, 472.2; m/z found, 472.9 $[M+H]^+$. Analytical HPLC was
 obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase
 of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
 15 rate of 1 mL/min (Temperature = 30 °C). R_t = 6.49 min (major rotamer) at 254 nm.

Example 258: (R/S)- (4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-
 yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Prepared analogous to Example 252 substituting intermediate A-40 with intermediate A-23.
MS (ESI): mass calcd. for $C_{23}H_{20}F_4N_6O$, 472.2; m/z found, 472.9 $[M+H]^+$. Analytical HPLC was
obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase
of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
rate of 1 mL/min (Temperature = 30 °C). R_t = 6.57 min (major rotamer) at 254 nm.

Example 259: (4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-23.
MS (ESI): mass calcd. for $C_{24}H_{20}F_4N_4O_2$, 472.2; m/z found, 473.2 $[M+H]^+$. Analytical HPLC was
obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase
of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
rate of 1 mL/min (Temperature = 30 °C). R_t = 7.28 min (major rotamer) at 254 nm.


Example 260: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-7.

MS (ESI): mass calcd. for $C_{24}H_{20}F_4N_4O_2$, 472.2; m/z found, 473.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 7.59 min (major rotamer) at 254 nm.


Example 261: (2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone



Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-6.


MS (ESI): mass calcd. for $C_{24}H_{20}F_4N_4O_2$, 472.2; m/z found, 473.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 7.41 min (major rotamer) at 254 nm.

Example 262: (2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-34.
 MS (ESI): mass calcd. for $C_{24}H_{20}F_4N_4O_2$, 472.2; m/z found, 473.2 $[M+H]^+$. Analytical HPLC was
 obtained on a Agilent 1100 Series using a XBridge C18 column ($5\mu m$, $100 \times 4.6 mm$), mobile phase
 of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
 rate of 1 mL/min (Temperature = $30^\circ C$). R_t = 7.83 min (major rotamer) at 254 nm.

Example 263: (3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-35.
 MS (ESI): mass calcd. for $C_{24}H_{19}F_5N_4O_2$, 490.1; m/z found, 491.2 $[M+H]^+$. Analytical HPLC was
 obtained on a Agilent 1100 Series using a XBridge C18 column ($5\mu m$, $100 \times 4.6 mm$), mobile phase
 of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
 rate of 1 mL/min (Temperature = $30^\circ C$). R_t = 7.78 min (major rotamer) at 254 nm.

Example 264: (5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-47.
 MS (ESI): mass calcd. for $C_{24}H_{22}F_3N_5O_2$, 469.2; m/z found, 470.2 $[M+H]^+$. Analytical HPLC was
 obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase
 of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
 rate of 1 mL/min (Temperature = 30 °C). R_t = 6.999 min (major rotamer) at 254 nm.

Example 265: (6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Prepared analogous to Example 76 substituting intermediate A-40 with intermediate A-41.
 MS (ESI): mass calcd. for $C_{24}H_{22}F_3N_5O_2$, 469.2; m/z found, 470.2 $[M+H]^+$. Analytical HPLC was
 obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase
 of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
 rate of 1 mL/min (Temperature = 30 °C). R_t = 6.73 min (major rotamer) at 254 nm.

Example 266: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Step A: (1S,4R,6R)-tert-butyl 6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (52 mg, 0.23 mmol) dissolved in DMF (2 mL) was added NaH (18 mg, 0.46 mmol, 60% dispersion in mineral oil). After 5 minutes 2,3-difluoro-5-(trifluoromethyl)pyridine (63 mg, 0.34 mmol) was then added and the mixture stirred at room temperature for 1 h. The reaction mixture was quenched with saturated NH₄Cl solution, and diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, brine, dried with MgSO₄, filtered, and concentrated. Purification via silica gel chromatography (0-100% EtOAc in hexanes) gave the title compound (67 mg, 0.17 mmol, 75%). MS (ESI) mass calcd. for C₁₈H₂₂F₄N₂O₃, 390.2; m/z found 336.1 [M+2H-tBu]⁺.

Step B: (1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane · xHCl. To the title compound of step A (67 mg, 0.17 mmol) in EtOAc (2 mL) was added 4 M HCl in dioxane (0.22 mL), and the reaction mixture was stirred at room temperature overnight. Analysis of the reaction mixture showed mostly starting material. Additional 4 M HCl in dioxane (0.5 mL) was added and the reaction mixture stirred at room temperature for 5 h. The reaction mixture was then concentrated to give the title compound of step B (30 mg) which was used without further purification. MS (ESI) mass calcd. for C₁₃H₁₄F₄N₂O, 290.1; m/z found 291.1 [M+H]⁺.

Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (30 mg) and intermediate A-2 (27 mg, 0.12 mmol) in DMF (1 mL) was added DIPEA (0.11 mL, 0.62 mmol) and HATU (43 mg, 0.11 mmol). Upon completion of the reaction, purification was performed using Agilent Prep Method X to give the title compound (11 mg). MS (ESI): mass calcd. for C₂₄H₁₉F₅N₄O₂, 490.2; m/z found, 491.1 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 7.35 min (major rotamer) at 254 nm.

Example 267: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




5 Step A: (1S,4R,6R)-tert-butyl 6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (37 mg, 0.16 mmol) dissolved in DMF (1.4 mL) was added NaH (13 mg, 0.33 mmol, 60% dispersion in mineral oil). After 5 minutes 2-chloro-5-methylpyridine (0.03 mL, 0.26 mmol) was then added and the mixture stirred at room temperature for 2 h. Analysis of the reaction mixture showed only starting material was present. The reaction mixture was heated
10 to 70 °C overnight. Analysis of the reaction mixture showed small amount of product formation. Additional NaH was added and the reaction mixture heated to 70 °C over the weekend. The reaction mixture was quenched with saturated NH₄Cl solution, and diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, brine, dried with MgSO₄, filtered and concentrated. Purification via silica gel chromatography (0-
15 50% EtOAc in hexanes) gave the title compound (8 mg, 0.03 mmol, 15%). MS (ESI) mass calcd. for C₁₈H₂₆N₂O₃, 318.2; m/z found 319.2 [M+H]⁺.

 Step B: (1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane · xHCl. To the title compound of step A (8 mg, 0.03 mmol) in EtOAc (0.3 mL) was added 4 M HCl in dioxane (0.03 mL) and the reaction mixture was stirred at room temperature overnight. Analysis of the
20 reaction mixture showed that starting material still remained. Additional 4 M HCl in dioxane (0.25 mL) was added and the reaction mixture stirred at room temperature for 5 h. The reaction was concentrated to give the title compound of step B which was used without further purification. MS (ESI) mass calcd. for C₁₃H₁₈N₂O, 218.1; m/z found 219.2 [M+H]⁺.

 Step C: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (5 mg) and intermediate A-
25 2 (6 mg, 0.03 mmol) in DMF (0.3 mL) was added DIPEA (0.02 mL, 0.14 mmol) and HATU (10 mg, 0.03 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction

mixture was diluted with MeOH and the crude reaction mixture directly subjected to purification using Agilent Prep Method X to give the title compound (1 mg). MS (ESI): mass calcd. for $C_{24}H_{23}FN_4O_2$, 418.2; m/z found, 419.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.35 min (major rotamer) at 254 nm.

Example 268: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Step A: (1S,4R,6R)-tert-butyl 6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (37 mg, 0.16 mmol) dissolved in DMF (1.4 mL) was added NaH (13 mg, 0.33 mmol, 60% dispersion in mineral oil). After 5 minutes 5-bromo-2-fluoropyridine (0.03 mL, 0.26 mmol) was then added and the mixture stirred at room temperature for 2 h. The reaction mixture was quenched with saturated NH_4Cl solution, and diluted with EtOAc and H_2O . The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , brine, dried with $MgSO_4$, filtered and concentrated. Purification via silica gel chromatography (0-100% EtOAc in hexanes) gave the title compound (63 mg, 0.16 mmol, 100%). MS (ESI) mass calcd. for $C_{17}H_{23}BrN_2O_3$, 382.1; m/z found 383.1 $[M+H]^+$.

Step B: (1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane · xHCl. To the title compound of step A (63 mg, 0.16 mmol) in EtOAc (2 mL) was added 4 M HCl in dioxane (0.21 mL) and the reaction mixture was stirred at room temperature overnight. Analysis of the reaction mixture showed that starting material still remained. Additional 4 M HCl in dioxane (0.21 mL) was added and the reaction mixture stirred at room temperature for 5 h. The reaction was concentrated to give the title compound of step B which was used without further purification. MS (ESI) mass calcd. for $C_{12}H_{15}BrN_2O$, 282.0; m/z found 283.0 $[M+H]^+$.


Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (23 mg) and intermediate A-1 (47 mg, 0.25 mmol) in DMF (0.8 mL) was added DIPEA (0.08 mL, 0.49 mmol) and HATU (34 mg, 0.09 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with MeOH and the crude reaction mixture directly subjected to purification using Agilent Prep Method X to give the title compound (7.7 mg). MS (ESI): mass calcd. for $C_{21}H_{20}BrN_5O_2$, 453.1; m/z found, 454.1 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 7.51 min (major rotamer) at 254 nm.

Example 269: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.



Prepared analogous to Example 268 substituting intermediate A-1 with intermediate A-2. MS (ESI): mass calcd. for $C_{23}H_{20}BrFN_4O_2$, 482.1; m/z found, 483.1 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 7.10 min (major rotamer) at 254 nm.

Example 270: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Step A: (1S,4R,6R)-tert-butyl 6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (37 mg, 0.16 mmol) dissolved in DMF (1.4 mL) was added NaH (13 mg, 0.33 mmol, 60% dispersion in mineral oil). After 5 minutes 5-chloro-2-fluoropyridine (0.03 mL, 0.26 mmol) was then added and the mixture stirred at room temperature for 1.5 h. The reaction mixture was quenched with saturated NH₄Cl solution, and diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, brine, dried with MgSO₄, filtered and concentrated. Purification via silica gel chromatography (0-50% EtOAc in hexanes) gave the title compound (52 mg, 0.15 mmol, 94%). MS (ESI) mass calcd. for C₁₇H₂₃ClN₂O₃, 338.1; m/z found 339.2 [M+H]⁺.

Step B: (1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane · xHCl. To the title compound of step A (52 mg, 0.15 mmol) in EtOAc (2 mL) was added 4 M HCl in dioxane (0.19 mL) and the reaction mixture was stirred at room temperature overnight. The reaction was concentrated to give the title compound of step B which was used without further purification. MS (ESI) mass calcd. for C₁₂H₁₅ClN₂O, 238.1; m/z found 239.1 [M+H]⁺.

Step C: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone. To the title compound of step B (18 mg) and intermediate A-1 (44 mg, 0.23 mmol) in DMF (0.8 mL) was added DIPEA (0.08 mL, 0.45 mmol) and HATU (44 mg, 0.23 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with MeOH and the crude reaction mixture directly subjected to purification using Agilent Prep Method X to give the title compound (16 mg). MS (ESI): mass calcd. for C₂₁H₂₀ClN₅O₂, 409.1; m/z found, 410.1 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 7.35 min (major rotamer) at 254 nm.


Example 271: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone



Prepared analogous to Example 270 substituting intermediate A-1 with intermediate A-2.


MS (ESI): mass calcd. for $C_{23}H_{20}ClFN_4O_2$, 438.1; m/z found, 439.1 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.94 min (major rotamer) at 254 nm.

Example 272: (2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Prepared analogous to Example 77 substituting intermediate A-40 with intermediate A-34. MS (ESI): mass calcd. for $C_{23}H_{19}F_4N_5O_2$, 473.1; m/z found, 474.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 7.16 min (major rotamer) at 254 nm.


Example 273: (3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Prepared analogous to Example 77 substituting intermediate A-40 with intermediate A-35.

MS (ESI): mass calcd. for $C_{23}H_{18}F_5N_5O_2$, 491.1; m/z found, 492.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 7.29 min (major rotamer) at 254 nm.


Example 274: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-16. MS


(ESI): mass calcd. for $C_{21}H_{19}F_4N_7O$, 461.2; m/z found, 462.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.71 min (major rotamer) at 254 nm.

Example 275: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-1. MS (ESI): mass calcd. for $C_{21}H_{20}F_3N_7O$, 443.2; m/z found, 444.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.67 min (major rotamer) at 254 nm.

10 Example 276: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1R,4S,6S)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-2 (step C), and substituting intermediate C-7B with its enantiomer (step A), (1R,4S,6S)-tert-butyl 6-amino-2-azabicyclo[2.2.2]octane-2-carboxylate. MS (ESI): mass calcd. for $C_{23}H_{20}F_4N_6O$, 472.2; m/z found, 472.9 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.39 min (major rotamer) at 254 nm.


20 Example 277: (4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-23.


MS (ESI): mass calcd. for $C_{23}H_{20}F_4N_6O$, 472.2; m/z found, 473.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.62 min (major rotamer) at 254 nm.

Example 278: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-7. MS (ESI): mass calcd. for $C_{23}H_{20}F_4N_6O$, 472.2; m/z found, 473.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.44 min (major rotamer) at 254 nm.

Example 279: (2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-6.
 MS (ESI): mass calcd. for $C_{23}H_{20}F_4N_6O$, 472.2; m/z found, 473.2 $[M+H]^+$. Analytical HPLC was
 obtained on a Agilent 1100 Series using a XBridge C18 column ($5\mu m$, $100 \times 4.6 mm$), mobile phase
 of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
 rate of 1 mL/min (Temperature = $30^\circ C$). R_t = 6.27 min (major rotamer) and 6.95 at 254 nm.

Example 280: (2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Prepared analogous to Example 83 substituting intermediate A-40 with intermediate A-37.
 MS (ESI): mass calcd. for $C_{23}H_{21}F_3N_6O$, 454.2; m/z found, 455.4 $[M+H]^+$. Analytical HPLC using
 a XBridge C18 column ($5\mu m$, $100 \times 4.6 mm$), mobile phase of 10-100% ACN in 20 mM NH_4OH
 over 2min and then hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature = $45^\circ C$).
 R_t = 2.01 and 1.98 min (major rotamer) at 254 nm.

Example 281: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




Step A: (1S,4R,6R)-tert-butyl 6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. To intermediate C-5B (100 mg, 0.44 mmol) dissolved in DMF (4 mL) was added NaH (35 mg, 0.88 mmol, 60% dispersion in mineral oil). After 5 minutes 3-chloro-2-fluoro-5-(trifluoromethyl)pyridine (86 μ L, 0.66 mmol) was then added and the mixture stirred at room temperature over the weekend. Analysis of the reaction mixture showed mostly starting material. Additional NaH was added. Analysis still showed incomplete conversion, however the reaction mixture was quenched with saturated NH_4Cl solution, and diluted with EtOAc and H_2O . The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H_2O , brine, dried with MgSO_4 , filtered, and concentrated. Purification via silica gel chromatography (0-100% EtOAc in hexanes) gave the title compound (38 mg, 0.093 mmol, 21%). MS (ESI) mass calcd. for $\text{C}_{18}\text{H}_{22}\text{ClF}_3\text{N}_2\text{O}_3$, 406.1; m/z found 351.1 $[\text{M}+2\text{H}-t\text{Bu}]^+$.

Step B: (1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane $\cdot$ xHCl. To the title compound of step A (38 mg, 0.093 mmol) in EtOAc (1.2 mL) was added 4 M HCl in dioxane (0.12 mL), and the reaction mixture was stirred at room temperature overnight. Analysis of the reaction mixture showed that starting material was still present. Additional 4 M HCl in dioxane (0.12 mL) was added and the reaction mixture stirred at room temperature overnight. The reaction mixture was then concentrated to give the title compound of step B (29 mg) which was used without further purification. MS (ESI) mass calcd. for $\text{C}_{13}\text{H}_{14}\text{ClF}_3\text{N}_2\text{O}$, 306.1; m/z found 307.1 $[\text{M}+\text{H}]^+$.

Step C: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone. To the title compound of step B (27 mg) and intermediate A-2 (23 mg, 0.11 mmol) in DMF (0.9 mL) was added DIPEA (0.09 mL, 0.53 mmol) and HATU (37 mg, 0.097 mmol), and the reaction mixture was stirred overnight at room temperature. The crude reaction mixture was diluted with MeOH, syringe filtered, and subjected directly to purification using Agilent Prep Method X to give the title compound (11 mg). MS (ESI): mass calcd. for $\text{C}_{24}\text{H}_{19}\text{ClF}_4\text{N}_4\text{O}_2$, 506.1; m/z found, 507.1 $[\text{M}+\text{H}]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x

4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 7.87 min (major rotamer) at 254 nm.


- 5 Example 282: (5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Prepared analogous to Example 77 substituting intermediate A-40 with intermediate A-47.
MS (ESI): mass calcd. for C₂₃H₂₁F₃N₆O₂, 470.2; m/z found, 471.2 [M+H]⁺. Analytical HPLC was

- 10 obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 6.77 min (major rotamer) at 254 nm.


- Example 283: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-
15 azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.



Prepared analogous to Example 266 substituting intermediate A-2 with intermediate A-47.
MS (ESI): mass calcd. for C₂₄H₂₁F₄N₅O₂, 487.2; m/z found, 488.2 [M+H]⁺. Analytical HPLC was

- 20 obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 30 °C). R_t = 7.38 min (major rotamer) at 254 nm.

Example 284: ((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.



Step A: (1S,4R,6R)-tert-butyl 6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (150 mg, 0.70 mmol) and 2,5-dichloropyrimidine (225mg, 1.51 mmol) dissolved in DMF (2 mL) was added NaH (37 mg, 0.91 mmol, 60% dispersion in mineral oil). After 3h LCMS analysis showed that the reaction was incomplete and additional NaH (40 mg, 1.0 mmol, 60% dispersion in mineral oil) was added and the reaction mixture allowed to stir for an additional 45 min and then quenched with H₂O. The aqueous layer was extracted with EtOAc (3X). The combined organics were washed with H₂O, 5% aqueous LiCl, dried with MgSO₄, filtered, and concentrated. Purification via silica gel chromatography (0-40% EtOAc in hexanes) gave the title compound (211 mg, 0.65 mmol, 92%) as a colorless solid. MS (ESI) mass calcd. for C₁₅H₂₀ClN₃O₃, 325.1; m/z found 370.1 [M+2H-*t*Bu]⁺. ¹H NMR (500 MHz, Chloroform-*d*, Compound present as a mixture of rotamers, both rotamers reported) δ 8.44 and 8.39 (two s, 2H), 5.25 - 5.16 (m, 1H), 4.68-4.65 and 4.56-4.52 (two m, 1H), 3.42-3.37 and 3.35-3.31 (two m, 1H), 3.24-3.16 (m, 1H), 2.61 - 2.51 (m, 1H), 2.24 - 2.13 (m, 1H), 1.77 - 1.40 (m, 3H), 1.35 and 1.12 (2s, 9H).

Step B: (1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane · xHCl. To the title compound of step A (211 mg, 0.65 mmol) in EtOAc (2 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 1.5h. Then, the reaction was concentrated to give the title compound of step B (155 mg) as an off-white solid and used without further purification. MS (ESI) mass calcd. for C₁₀H₁₂ClN₃O, 225.1; m/z found 226.1 [M+H]⁺.

Step C: ((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone. To the title compound of step B (30 mg) and intermediate A-2 (27 mg, 0.13 mmol) in DMF (0.4 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (48 mg, 0.13 mmol), and the reaction mixture was stirred at room temperature for 2 h. The reaction was diluted with MeOH, filtered, and purified using Agilent Prep Method X to give the

title compound (27 mg). MS (ESI): mass calcd. for $C_{21}H_{17}ClFN_5O_2$, 425.1; m/z found, 426.1


$[M+H]^+$. ^1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers

(0.72:0.28), major rotamer reported) δ 8.85 (d, $J = 4.9$ Hz, 2H), 8.29 (s, 2H), 7.29 - 7.26 (m, 1H),

7.12 - 6.97 (m, 3H), 4.95 (dt, $J = 10.1, 3.3$ Hz, 1H), 4.32 - 4.20 (m, 1H), 3.39 - 3.31 (m, 2H), 2.63 -

5 2.47 (m, 1H), 2.26 - 2.15 (m, 1H), 1.50 - 1.39 (m, 2H), 1.07 - 0.97 (m, 1H).

Example 285: ((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.



10

Prepared analogous to Example 284 substituting intermediate A-2 with intermediate A-41.

MS (ESI): mass calcd. for $C_{21}H_{19}ClN_6O_2$, 422.1; m/z found, 423.2 $[M+H]^+$. ^1H NMR (500 MHz,

Chloroform-d, Compound present as a mixture of rotamers (0.63:0.37), major rotamer reported) δ

8.76 (d, $J = 4.8$ Hz, 2H), 8.43 - 8.41 (m, 1H), 8.11 (s, 2H), 7.19 (t, $J = 4.9$ Hz, 1H), 7.12 (d, $J = 7.9$


15 Hz, 1H), 4.79 (dt, $J = 10.3, 3.2$ Hz, 1H), 4.48 - 4.39 (m, 1H), 3.78 (dt, $J = 10.8, 3.0$ Hz, 1H), 3.46

(dd, $J = 10.9, 1.4$ Hz, 1H), 2.72 - 2.64 (m, 1H), 2.30 (s, 3H), 2.26 - 2.18 (m, 1H), 1.67 (dt, $J = 13.5,$

3.6 Hz, 1H), 1.56 - 1.45 (m, 2H).


Example 286: ((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-

20 methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.



Prepared analogous to Example 287 substituting intermediate A-1 with intermediate A-40.
 MS (ESI): mass calcd. for $C_{23}H_{21}N_7O_2$, 427.2; m/z found, 428.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d) δ 8.86 (dd, $J = 4.4, 2.0$ Hz, 1H), 8.06 (dd, $J = 7.9, 2.0$ Hz, 1H), 7.92 (d, $J = 8.7$ Hz, 1H), 7.86 (d, $J = 8.4$ Hz, 1H), 7.81 (s, 2H), 7.33 (dd, $J = 7.9, 4.4$ Hz, 1H), 7.03 (d, $J = 8.8$ Hz, 1H),
 5 6.67 (d, $J = 8.4$ Hz, 1H), 5.39 (dt, $J = 9.9, 3.1$ Hz, 1H), 4.54 - 4.43 (m, 1H), 3.71 (dt, $J = 11.0, 3.2$ Hz, 1H), 3.49 (d, $J = 11.0$ Hz, 1H), 2.69 - 2.66 (m, 1H), 2.39 - 2.23 (m, 1H), 2.03 (s, 3H), 1.58 - 1.50 (m, 3H).

Example 287: ((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(2H-
 10 1,2,3-triazol-2-yl)phenyl)methanone.




Step A: (1S,4R,6R)-tert-butyl 6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To intermediate B-5 (150 mg, 0.70 mmol) and 2-chloro-1,8-naphthyridine (225mg, 1.37 mmol) dissolved in DMF (2 mL) was added NaH (37 mg, 0.91 mmol, 60% dispersion in
 15 mineral oil). After 50 min the mixture was quenched with H_2O and the aqueous layer was extracted with EtOAc (3X). The combined organics were washed with 5% aqueous LiCl, brine, dried with $MgSO_4$, filtered, and concentrated. Purification via silica gel chromatography (0-100% EtOAc in hexanes) gave the title compound (200 mg) as a colorless solid. MS (ESI) mass calcd. for $C_{19}H_{23}N_3O_3$, 341.2; m/z found 342.2 $[M+H]^+$.

20 Step B: 2-((1S,4R,6R)-2-azabicyclo[2.2.1]heptan-6-yloxy)-1,8-naphthyridine $\cdot xHCl$. To the title compound of step A (200 mg, 0.59 mmol) in EtOAc (2 mL) was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirred at room temperature for 2h. Then, the reaction was concentrated to give the title compound of step B (192 mg) as a colorless solid and used without further purification. MS (ESI) mass calcd. for $C_{14}H_{15}N_3O_3$, 241.1; m/z found 242.1 $[M+H]^+$.

25 Step C: ((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(2H-1,2,3-triazol-2-yl)phenyl)methanone. To the title compound of step B (30 mg) and intermediate A-1 (20 mg, 0.11 mmol) in DMF (0.5 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU (40 mg,

0.11 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with MeOH, filtered, and purified using Agilent Prep Method X to give the title compound (22 mg). MS (ESI): mass calcd. for $C_{23}H_{20}N_6O_2$, 412.2; m/z found, 413.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d) δ 8.87 (dd, $J = 4.4, 2.0$ Hz, 1H), 8.11 (dd, $J = 7.9, 2.0$ Hz, 1H), 8.05 (d, $J = 8.8$ Hz, 1H), 7.82 - 7.74 (m, 3H), 7.35 (dd, $J = 7.9, 4.4$ Hz, 1H), 7.10 (dd, $J = 7.7, 1.5$ Hz, 1H), 7.03 (d, $J = 8.7$ Hz, 1H), 7.00 - 6.92 (m, 1H), 6.54 (t, $J = 7.6$ Hz, 1H), 5.44 (dt, $J = 10.2, 3.2$ Hz, 1H), 4.28 - 4.19 (m, 1H), 3.65 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.43 (d, $J = 9.5$ Hz, 1H), 2.72 - 2.62 (m, 1H), 2.45 - 2.31 (m, 1H), 1.52 - 1.42 (m, 3H).

- 10 Example 288: ((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




Prepared analogous to Example 121 substituting intermediate A-1 with intermediate A-47.

- MS (ESI): mass calcd. for $C_{23}H_{21}F_2N_5O_2$, 437.2; m/z found, 438.2 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform- d) δ 8.77 (d, $J = 4.9$ Hz, 2H), 8.28 - 8.19 (m, 1H), 7.83 - 7.77 (m, 1H), 7.69 (dd, $J = 8.7, 2.4$ Hz, 1H), 7.66 - 7.64 (m, 1H), 7.21 (t, $J = 4.9$ Hz, 1H), 6.91 (d, $J = 8.6$ Hz, 1H), 6.59 (t, $J = 56.1$ Hz, 1H), 5.02 (dt, $J = 10.3, 3.4$ Hz, 1H), 4.33 - 4.21 (m, 1H), 3.70 (dt, $J = 10.8, 3.2$ Hz, 1H), 3.46 (dd, $J = 10.7, 1.4$ Hz, 1H), 2.72 - 2.63 (m, 1H), 2.26 (s, 3H), 2.23 - 2.16 (m, 1H), 1.61 - 1.35 (m, 3H).


20

Example 289: (2-methoxy-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-13.
 MS (ESI): mass calcd. for $C_{22}H_{20}F_3N_5O_3$, 459.2; m/z found, 460.2 $[M+H]^+$. Analytical HPLC was
 obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase
 of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
 5 rate of 1 mL/min (Temperature = 45 °C). R_t = 6.84 min (major rotamer) at 254 nm.

Example 290: (5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



10 Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-46.
 MS (ESI): mass calcd. for $C_{23}H_{20}F_3N_5O_2$, 455.2; m/z found, 456.4 $[M+H]^+$. ^1H NMR (500 MHz,
 Chloroform-d, Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ
 8.87 (d, J = 4.8 Hz, 2H), 8.47 (dd, J = 2.1, 0.8 Hz, 1H), 8.18 - 8.10 (m, 1H), 7.80 (dd, J = 8.7, 2.5
 Hz, 1H), 7.31 - 7.28 (m, 2H), 6.83 - 6.78 (m, 1H), 5.02 (dt, J = 10.1, 3.3 Hz, 1H), 4.18 - 4.09 (m,
 15 1H), 3.65 (dt, J = 10.9, 3.2 Hz, 1H), 3.43 (dd, J = 10.9, 1.5 Hz, 1H), 2.70 - 2.60 (m, 1H), 2.28 - 2.18
 (m, 1H), 2.04 (s, 3H), 1.47 - 1.38 (m, 2H), 1.32 - 1.24 (m, 1H).

Example 291: (4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




20

Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-51.
 MS (ESI): mass calcd. for $C_{22}H_{18}F_4N_4O_3$, 462.1; m/z found, 463.4 $[M+H]^+$. ^1H NMR (500 MHz,


Chloroform-d) δ 8.10 - 8.01 (m, 1H), 7.80 (dd, J = 8.8, 2.5 Hz, 1H), 7.72 (dd, J = 8.9, 2.6 Hz, 1H), 7.02 (dd, J = 8.5, 5.4 Hz, 1H), 6.82 (d, J = 8.7 Hz, 1H), 6.76 - 6.68 (m, 1H), 5.06 (dt, J = 10.1, 3.3 Hz, 1H), 4.14 - 4.08 (m, 1H), 3.77 (dt, J = 11.0, 3.2 Hz, 1H), 3.44 (dd, J = 10.9, 1.5 Hz, 1H), 2.76 - 2.71 (m, 1H), 2.45 (s, 3H), 2.35 - 2.22 (m, 1H), 1.73 - 1.66 (m, 1H), 1.59 - 1.55 (m, 1H), 1.46 (dt, J = 13.6, 3.6 Hz, 1H).

Example 292: (2-fluoro-6-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-50. MS (ESI): mass calcd. for $C_{22}H_{17}F_4N_3O_3$, 447.1; m/z found, 448.5 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 45 °C). R_t = 7.18 min (major rotamer) at 254 nm.


Example 293: (5-fluoro-2-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-49. MS (ESI): mass calcd. for $C_{22}H_{17}F_4N_3O_3$, 447.1; m/z found, 448.5 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform-d) δ 8.05 - 8.02 (m, 1H), 7.92 (dd, J = 8.7, 5.3 Hz, 1H), 7.80 (dd, J = 8.6, 2.5 Hz, 1H), 7.69 (d, J = 0.8 Hz, 1H), 7.21 (d, J = 0.8 Hz, 1H), 6.99 - 6.92 (m, 1H), 6.81 (d, J = 8.7 Hz, 1H), 6.69 (dd, J = 8.4, 2.7 Hz, 1H), 5.03 (dt, J = 10.2, 3.3 Hz, 1H), 4.16 - 4.08 (m, 1H), 3.74 (dt, J = 11.0, 3.2


Hz, 1H), 3.44 (dd, $J = 10.9, 1.5$ Hz, 1H), 2.74 - 2.63 (m, 1H), 2.30 - 2.21 (m, 1H), 1.63 - 1.56 (m, 1H), 1.55 - 1.49 (m, 1H), 1.45 (dt, $J = 13.5, 3.6$ Hz, 1H).

Example 294: (5-methyl-3-(1H-1,2,3-triazol-1-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 25 substituting intermediate A-20 with the N-1 isomer, 5-methyl-3-(1H-1,2,3-triazol-1-yl)picolinonitrile, from intermediate A-19. MS (ESI): mass calcd. for $C_{21}H_{19}F_3N_6O_2$, 444.2; m/z found, 445.6 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d) δ 8.12 (d, $J = 1.1$ Hz, 1H), 8.02 - 7.98 (m, 1H), 7.97 - 7.94 (m, 1H), 7.81 (d, $J = 1.1$ Hz, 1H), 7.78 - 7.76 (m, 1H), 7.72 (dd, $J = 8.8, 2.5$ Hz, 1H), 6.74 - 6.69 (m, 1H), 4.99 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.43 - 4.34 (m, 1H), 3.48 (dt, $J = 11.2, 3.1$ Hz, 1H), 3.41 (dd, $J = 11.2, 1.5$ Hz, 1H), 2.66 - 2.60 (m, 1H), 2.34 (s, 3H), 2.25 - 2.17 (m, 1H), 1.60 - 1.53 (m, 1H), 1.40 (dt, $J = 13.6, 3.6$ Hz, 1H), 1.34 - 1.27 (m, 1H).


Example 295: (4-methoxy-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-15. MS (ESI): mass calcd. for $C_{24}H_{21}F_3N_4O_3$, 470.2; m/z found, 471.4 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform- d , Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.78 (d, $J = 4.8$ Hz, 2H), 8.14 - 8.06 (m, 1H), 7.79 (dd, $J = 8.7, 2.5$ Hz, 1H), 7.70 (d, $J = 2.6$ Hz, 1H), 7.19 (t, $J = 4.8$ Hz, 1H), 6.96 (d, $J = 8.4$ Hz, 1H), 6.85 - 6.83 (m, 1H), 6.45 (dd, $J = 8.4, 2.6$ Hz, 1H), 5.04 (dt, $J = 10.1, 3.4$ Hz, 1H), 4.19 - 4.09 (m, 1H), 3.81 (s, 3H), 3.62 (dt, $J = 10.9, 3.2$ Hz,

1H), 3.40 (dd, $J = 10.8, 1.5$ Hz, 1H), 2.65 - 2.59 (m, 1H), 2.27 - 2.15 (m, 1H), 1.44 - 1.35 (m, 2H), 1.29 - 1.17 (m, 1H).

Example 296: (3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-42.

MS (ESI): mass calcd. for $C_{22}H_{18}F_3N_5O_2$, 441.1; m/z found, 442.4 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19), major rotamer reported) δ

8.78 (d, $J = 4.8$ Hz, 2H), 8.47 (dd, $J = 8.0, 1.7$ Hz, 1H), 7.97 - 7.90 (m, 1H), 7.83 (dd, $J = 4.7, 1.7$ Hz, 1H), 7.73 (dd, $J = 8.8, 2.6$ Hz, 1H), 7.22 (t, $J = 4.9$ Hz, 1H), 7.15 (dd, $J = 8.0, 4.7$ Hz, 1H), 6.91 (d, $J = 8.7$ Hz, 1H), 5.04 (dt, $J = 10.2, 3.4$ Hz, 1H), 4.35 - 4.20 (m, 1H), 3.73 (dt, $J = 10.8, 3.2$ Hz, 1H), 3.47 (d, $J = 10.9$ Hz, 1H), 2.72 - 2.65 (m, 1H), 2.30 - 2.13 (m, 1H), 1.60 - 1.44 (m, 3H).

Example 297: (2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-37.

MS (ESI): mass calcd. for $C_{23}H_{19}F_3N_4O_2$, 440.1; m/z found, 441.4 $[M+H]^+$. ^1H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12), major rotamer reported) δ

8.78 (d, $J = 4.8$ Hz, 2H), 8.17 (dd, $J = 8.0, 1.2$ Hz, 1H), 8.06 - 8.00 (m, 1H), 7.78 (dd, $J = 8.7, 2.5$ Hz, 1H), 7.30 (td, $J = 7.7, 1.4$ Hz, 1H), 7.19 (t, $J = 4.8$ Hz, 1H), 7.00 (dd, $J = 7.6, 1.3$ Hz, 1H), 6.88

(td, $J = 7.5, 1.3$ Hz, 1H), 6.83 (d, $J = 8.7$ Hz, 1H), 5.01 (dt, $J = 10.2, 3.4$ Hz, 1H), 4.24 - 4.10 (m, 1H), 3.64 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.41 (dd, $J = 10.8, 1.5$ Hz, 1H), 2.66 - 2.61 (m, 1H), 2.27 - 2.12 (m, 1H), 1.47 - 1.37 (m, 2H), 1.34 - 1.19 (m, 1H).

- 5 Example 298: (5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Prepared analogous to Example 25 substituting intermediate A-20 with intermediate A-47.

MS (ESI): mass calcd. for $C_{23}H_{20}F_3N_5O_2$, 455.2; m/z found, 456.4 $[M+H]^+$. ^1H NMR (500 MHz,

- 10 Chloroform- d , Compound present as a mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.78 (d, $J = 4.8$ Hz, 2H), 8.27 - 8.21 (m, 1H), 7.95 - 7.92 (m, 1H), 7.74 (dd, $J = 8.4, 2.7$ Hz, 1H), 7.65 - 7.62 (m, 1H), 7.22 (t, $J = 4.8$ Hz, 1H), 6.95 - 6.90 (m, 1H), 5.03 (dt, $J = 10.3, 3.3$ Hz, 1H), 4.32 - 4.27 (m, 1H), 3.71 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.46 (dd, $J = 10.8, 1.4$ Hz, 1H), 2.72 - 2.64 (m, 1H), 2.26 (s, 3H), 2.25 - 2.18 (m, 1H), 1.59 - 1.45 (m, 3H).

15


Example 299: ((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.



Prepared analogous to Example 284 substituting intermediate A-2 with intermediate A-40.


- 20 MS (ESI): mass calcd. for $C_{19}H_{18}ClN_7O_2$, 411.1; m/z found, 412.3 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 45 $^{\circ}C$). $R_t = 5.23$ min (major rotamer) at 254 nm.

Example 300: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5 Prepared analogous to Example 284 substituting intermediate A-2 with intermediate A-1.
MS (ESI): mass calcd. for $C_{19}H_{17}ClN_6O_2$, 396.1; m/z found, 397.1 $[M+H]^+$. ^1H NMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers, major reported) δ 8.22 (s, 2H), 7.88 - 7.85 (m, 1H), 7.81 (s, 2H), 7.40 - 7.31 (m, 1H), 7.17 (dd, $J = 7.7, 1.5$ Hz, 1H), 6.90 (t, $J = 7.5$ Hz, 1H), 4.87 (dt, $J = 10.2, 3.3$ Hz, 1H), 4.10 - 3.98 (m, 1H), 3.63 (dt, $J = 10.9, 3.2$ Hz, 1H), 3.42 (dd, $J = 10.9, 1.4$ Hz, 1H), 2.66 - 2.60 (m, 1H), 2.29 - 2.12 (m, 1H), 1.54 (dt, $J = 13.6, 3.5$ Hz, 1H), 1.42 - 1.33 (m, 2H).

Example 301: ((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




15 Prepared analogous to Example 287 substituting intermediate A-1 with intermediate A-2.
MS (ESI): mass calcd. for $C_{25}H_{20}FN_5O_2$, 441.2; m/z found, 442.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 45 $^{\circ}C$). $R_t = 4.68$ min at 254 nm.

Example 302: ((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




Prepared analogous to Example 287 substituting intermediate A-1 with intermediate A-41.


- 5 MS (ESI): mass calcd. for $C_{25}H_{22}N_6O_2$, 438.2; m/z found, 439.2 $[M+H]^+$. Analytical HPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature = 45 °C). R_t = 4.33 min (major rotamer) at 254 nm.
- 10 Example 303: (2-(pyridazin-3-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- Example 304: (2-(pyridazin-4-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.
- 15




Example 305: (2-(pyridin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5 Example 306: (2-(pyridin-3-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




10 Example 307: (2-(pyridin-4-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Example 308: (2-(pyrazin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 309: (2-(3-methylpyridin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 310: (2-(5-methylisoxazol-3-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10

Example 311: (2-(3,5-dimethylisoxazol-4-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 312: ((1S,4R,6R)-6-((4,6-dimethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




5


Example 313: ((1S,4R,6R)-6-((4,6-dimethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




10 Example 314: (6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



15 Example 315: ((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




Example 316: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(hydroxymethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 317: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(fluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10

Example 318: ((1S,4R,6R)-6-((5-(hydroxymethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




Example 319: ((1S,4R,6R)-6-((5-(fluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




5


Example 320: (3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10 Example 321: (2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



15 Example 322: (3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 323: (2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 324: (3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10


Example 325: (3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 326: (2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 327: (5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Example 328: (6-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 329: (6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5


Example 330: (5-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10 Example 331: (4'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



15 Example 332: [2,3'-bipyridin]-2'-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 333: [2,2'-bipyridin]-3-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 334: (3,5'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10

Example 335: (3',6-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 336: (3,6'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5


Example 337: (3',5-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10 Example 338: (3,4'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



15 Example 339: (3-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 340: (3'-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 341: (3-fluoro-5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10

Example 342: (3'-fluoro-6-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 343: (3-fluoro-6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5


Example 344: (3'-fluoro-5-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10 Example 345: (3-fluoro-4'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



15 Example 346: (3-fluoro-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 347: (3'-fluoro-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 348: (5-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10


Example 349: (6-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 350: (6-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 5 Example 351: (5-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 352: (4-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10

Example 353: (3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 354: (2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5


Example 355: (5-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10 Example 356: (6-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Example 357: (6-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 358: (5-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5


Example 359: (4-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10 Example 360: (3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 361: (2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 5 Example 362: (2-(pyridazin-3-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 10 Example 363: (2-(pyridazin-4-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Example 364: (2-(pyridin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 365: (2-(pyridin-3-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 366: (2-(pyridin-4-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10

Example 367: (2-(pyrazin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 368: (2-(3-methylpyridin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5


Example 369: (2-(5-methylisoxazol-3-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10 Example 370: (2-(3,5-dimethylisoxazol-4-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



15 Example 371: (3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 372: (2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 373: (3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10

Example 374: (2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 375: (3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 376: (3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10

Example 377: (2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 378: (5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 379: (6-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10

Example 380: (6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 381: (5-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5


Example 382: (4'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10 Example 383: [2,3'-bipyridin]-2'-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



15 Example 384: [2,2'-bipyridin]-3-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 385: (3,5'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 386: (3',6-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10


Example 387: (3,6'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 388: (3',5-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 389: (3,4'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 390: (3-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Example 391: (3'-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 392: (3-fluoro-5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5


Example 393: (3'-fluoro-6-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10 Example 394: (3-fluoro-6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




15 Example 395: (3'-fluoro-5-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 396: (3-fluoro-4'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 5 Example 397: (3-fluoro-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 10 Example 398: (3'-fluoro-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Example 399: (5-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 400: (6-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 401: (6-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10


Example 402: (5-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 403: (4-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 404: (3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 405: (2-(oxazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Example 406: (5-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 407: (6-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5


Example 408: (6-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10 Example 409: (5-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



15 Example 410: (4-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 411: (3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5


Example 412: (2-(thiazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10 Example 413: ((1S,4S,6R)-6-((4,6-dimethylpyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




Example 414: ((1S,4S,6R)-6-((4,6-dimethylpyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




5 Example 415: (6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 416: ((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.



Example 417: (5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 418: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 419: (5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10

Example 420: (2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Prepared analogous to Example 77 substituting intermediate A-40 with intermediate A-6.
MS (ESI): mass calcd. for $C_{23}H_{19}F_4N_5O_2$, 473.2; m/z found, 474.2 $[M+H]^+$. Analytical HPLC was
obtained on a Agilent 1100 Series using a XBridge C18 column (5 μ m, 100 x 4.6mm), mobile phase
of 10-100% ACN in 20 mM NH_4OH over 8 min and then hold at 100% ACN for 3 min, at a flow
5 rate of 1 mL/min (Temperature = 45 °C). R_t = 6.79 min (major rotamer) at 254 nm.

Example 421: (6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10

Example 422: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 423: (4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




15


Example 424: (6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5 Example 425: (5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 426: (6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-
10 (trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Example 427: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 428: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 429: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone.




10


Example 430: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 431: (4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5 Example 432: (3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 433: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.



Example 434: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone.




Example 435: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




5

Example 436: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




10

Example 437: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone.




Example 438: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.




5


Example 439: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 440: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



15 Example 441: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone.




Example 442: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




5

Example 443: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




10

Example 444: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone.




Example 445: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




5


Example 446: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone.




10 Example 447: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.



15 Example 448: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




Example 449: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




5

Example 450: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone.




10


Example 451: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.




Example 452: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



- 5 Example 453: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.




Example 454: (2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10


Example 455: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 456: (4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 5 Example 457: (3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 10 Example 458: (6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Example 459: (2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 460: (6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 461: (5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10

Example 462: (5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 463: (5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5


Example 464: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 465: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 466: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 5 Example 467: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone.




- 10 Example 468: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.



Example 469: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




Example 470: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone.




5

Example 471: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone.




10

Example 472: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




Example 473: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




5

Example 474: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




10

Example 475: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




Example 476: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone.




5


Example 477: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.




10 Example 478: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.



15 Example 479: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone.




Example 480: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




5

Example 481: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




10

Example 482: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone.




Example 483: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone.




5


Example 484: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




10 Example 485: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.



15 Example 486: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




Example 487: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




5

Example 488: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone.




10


Example 489: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.




Example 490: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.




- 5 Example 491: (5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 10 Example 492: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Example 493: (5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 494: (2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 495: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10

Example 496: (4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 497: (6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5


Example 498: (6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 499: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 500: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 5 Example 501: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 10 Example 502: (5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Example 503: (6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 504: (5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 505: (2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10


Example 506: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 507: (4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 5 Example 508: (6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 10 Example 509: (6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Example 510: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 511: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 512: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10


Example 513: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




Example 514: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.




- 5 Example 515: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone.




- Example 516: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone.
- 10



Example 517: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




5 Example 518: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




Example 519: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.


10



Example 520: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




Example 521: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 522: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.




10


Example 523: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




Example 524: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




- 5 Example 525: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.




- 10 Example 526: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone.



Example 527: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone.




Example 528: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




5

Example 529: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




10


Example 530: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




Example 531: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




5 Example 532: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 533: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.



Example 534: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




Example 535: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




5


Example 536: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.




10 Example 537: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone.



15 Example 538: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone.




Example 539: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 540: (4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10

Example 541: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




Example 542: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




5


Example 543: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 544: (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



15 Example 545: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 546: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




5

Example 547: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.




10


Example 548: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone.




Example 549: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone.




- 5 Example 550: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




- 10 Example 551: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.



Example 552: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




Example 553: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




5

Example 554: (2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10


Example 555: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.




Example 556: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.




- 5 Example 557: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




- 10 Example 558: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.



Example 559: (5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 560: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




5

Example 561: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone.




10

Example 562: ((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone.




Example 563: (5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5


Example 564: (5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 565: (6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



15 Example 566: (6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 567: (5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 568: (5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10

Example 569: (2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 570: ((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-methoxy-6-(pyrimidin-2-yl)phenyl)methanone.




5


Example 571: (2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 572: ((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-methoxy-6-(pyrimidin-2-yl)phenyl)methanone.



15 Example 573: ((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-methoxy-6-(pyrimidin-2-yl)phenyl)methanone.




Example 574: (2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 575: (2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10

Example 576: (2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 577: (3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5


Example 578: ((1S,4R,6R)-6-((5-methylpyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone.




10 Example 579: (3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



15 Example 580: (2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 581: (3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 582: (2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10

Example 583: (3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 584: (3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 585: (2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10


Example 586: (5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 5 Example 587: (6-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 10 Example 588: (6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Example 589: (5-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 590: (4'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 591: [2,3'-bipyridin]-2'-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10

Example 592: [2,2'-bipyridin]-3-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 593: (3,5'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5


Example 594: (3',6-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 595: (3,6'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



15 Example 596: (3',5-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 597: (3,4'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 598: (3-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10

Example 599: (3'-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 600: (3-fluoro-5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 601: (3'-fluoro-6-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 602: (3-fluoro-6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 603: (3'-fluoro-5-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.

15




Example 604: (3-fluoro-4'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 605: (3-fluoro-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10

Example 606: (3'-fluoro-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 607: (5-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5


Example 608: (6-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 609: (6-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Example 610: (5-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 611: (4-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5


Example 612: 3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 613: (2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 614: 5-methyl-3-((thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5 Example 615: (6-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 616: (6-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Example 617: (5-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 618: (4-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 619: (3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10


Example 620: (2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 621: (2-(1-methyl-1H-imidazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



- 5 Example 622: (2-(1-methyl-1H-imidazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 623: (3-(1-methyl-1H-imidazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10


Example 624: (5-methyl-3-(1-methyl-1H-imidazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 625: (6-methyl-2-(1-methyl-1H-imidazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 5 Example 626: (6-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




- 10 Example 627: (2-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Example 628: (2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 629: (2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 630: (2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10

Example 631: (5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 632: (6-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 633: (5-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10


Example 634: [2,2'-bipyridin]-3-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 635: (3,5'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 636: (3',6-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 637: (3',5-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10 Example 638: (3'-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.



Example 639: (3-fluoro-5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 640: (3'-fluoro-6-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




5

Example 641: (3'-fluoro-5-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




10


Example 642: (3'-fluoro-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.




Example 643: (3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5 Example 644: (2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 645: (3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



10 Example 646: (2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 647: (3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5


Example 648: (5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10 Example 649: (6-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 650: (6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 5 Example 651: (3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




- 10 Example 652: (2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Example 653: (3,5'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 654: (3',6-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5

Example 655: (3,6'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




10

Example 656: (3-fluoro-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




Example 657: (3'-fluoro-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.




5


Example 658: (3-fluoro-5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



10 Example 659: (3'-fluoro-6-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



Example 660: (3-fluoro-6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.



5 Assays:

The *in vitro* affinity of the compounds of the invention for the rat/human orexin 1 and human orexin 2 receptors was determined by competitive radioligand binding using [^3H] (1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone)(Langmead et al., 2004) and [^3H]EMPA (n-ethyl-2[96-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl acetamide), respectively (Langmead et al., 2004, British Journal of Pharmacology 141:340-346; Malherbe et al., 2004, British Journal of Pharmacology 156:1326-41).

The *in vitro* functional antagonism of the compounds on the human orexin 1 and orexin 2 receptors was determined using fluorometric imaging plate reader (FLIPR) based calcium assays.

Data are analyzed using pc-Sandy macro and graphed on Graphpad Prism 5. For analysis, each concentration point is averaged from triplicate values and the averaged values are plotted on Graphpad Prism. The IC₅₀ was determined by applying the following equation (GraphPad Prism 5.0, SanDiego) for one site competition where X=log (concentration) and Y=specific binding. Top denotes the total [^3H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone) binding, bottom denotes the nonspecific [^3H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone) binding. Graphpad Prism calculates K_i value from IC₅₀ and the pre-determined K_d values for [^3H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone) and [^3H]-EMPA. The K_i for each compound is then uploaded into 3DX. Each run comprises individual compounds in triplicate. The data in Table 1 and Table 2 represent averages from between 2-20 runs

Rat and human orexin 1 receptor radioligand binding studies

Human Embryonic Kidney 293 cells (HEK293) stably expressing rat orexin 1 receptor (Genebank accession number NM_001525) or Chinese ovary cells (CHO) stably expressing human orexin 1 receptor (Genebank accession number NM_001526) were grown to confluency in DMEM (Hyclone, cat # SH30022), 10% FBS, 1X Pen/Strep, 1X sodium pyruvate, 10 mM HEPES, 600 µg/mL G418 and DMEM/F12 (Gibco, Cat #11039), 10%FBS, 1X Pen/Strep, 600 µg/mL G418 media, respectively on 150 cm² tissue culture plates, washed with 5 mM EDTA in PBS (HyClone Dulbecco's Phosphate Buffered Saline 1X with Calcium and Magnesium, Cat # SH30264.01, hereafter referred to simply as PBS) and scraped into 50 ml tubes. After centrifugation (2K xG, 5 min at 4 °C), the supernatant was aspirated and the pellets frozen and stored at -80°C. Cells were resuspended in PBS in the presence of 1 tablet of protease inhibitor cocktail (Roche, Cat. #11836145001) per 50 mL. Each cell pellet from a 15 cm plate was resuspended in 10 mL, stored on ice, and homogenized for 45 sec prior to addition to the reactions. Competition binding experiments in 96 well polypropylene plates were performed using [³H]- (1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone) (Moraveck Corporation, specific activity = 35.3 Ci/mmol), diluted to a 10 nM concentration in PBS (4 nM final). Compounds were solubilized in 100% DMSO (Acros Organics, Cat. #61042-1000) and tested over a range of 7 concentrations (from 0.1 nM to 10 µM). The final concentration of DMSO in the reactions is equal to or less than 0.1%. Total and nonspecific binding was determined in the absence and presence of 10 µM almorexant. The total volume of each reaction is 200 µL (20 µL of diluted compounds, 80 µL of [³H]- (1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone) diluted in PBS and 100 µL of the cell suspension). Reactions were run for 60 min at room temperature and terminated by filtration through GF/C filter plates (PerkinElmer, Cat. #6005174) presoaked in 0.3% polyethylenimine using the cell harvester (PerkinElmer Filtermate). The plates were washed 3 times by aspirating 30 ml PBS through the plates. Plates were dried in 55 °C oven for 60 min, scintillation fluid was added, and the radioactivity was counted on a Topcount (Packard).

IC₅₀ values (i.e. concentration of unlabelled compound required to compete for 50% of specific binding to the radioligand) was calculated using the GraphPad Prism software (GraphPad Prism Software Inc., San Diego, CA) with a fit to a sigmoidal dose-response curve. Apparent Ki

values were calculated as $K_i = IC_{50}/(1+C/K_d)$, where C is concentration of radioligand and $K_d = 4$ nM for rat orexin 1 receptor and 6 nM for human orexin 1 receptor.

Human orexin 2 receptor radioligand binding studies

5 HEK293 stably expressing human orexin 2 receptor (Genebank accession number NM_001526) were grown to confluency in DMEM (Hyclone, cat # SH30022) , 10%FBS, 1X Pen/Strep, 1X NaPyruvate, 10 mM HEPES, 600 ug/ml G418 media on 150 cm² tissue culture plates, washed with 5 mM EDTA in PBS (HyClone Dulbecco's Phosphate Buffered Saline 1X with Calcium and Magnesium, Cat # SH30264.01, hereafter referred to simply as PBS) and scraped into
10 50 ml tubes. After centrifugation (2K xG, 5 min at 4°C), the supernatant was aspirated and the pellets frozen and stored at -80°C. Cells were resuspended in PBS in the presence of 1 tablet of protease inhibitor cocktail (Roche, Cat. #11836145001) per 50 mL. Each cell pellet from a 15 cm plate was resuspended in 10 mL, stored on ice, and homogenized for 45 sec just prior to addition to the reactions. Competition binding experiments in 96 well polypropylene plates were performed
15 using [³H]-EMPA (Moraveck Corporation, specific activity = 29.6 Ci/mmol), diluted to a 5 nM concentration in PBS (2 nM final concentration). Compounds were solubilized in 100% DMSO (Acros Organics, Cat. #61042-1000) and tested over a range of 7 concentration (from 0.1 nM to 10 μM). The final concentration of DMSO in the reactions is equal to or less than 0.1%. Total and nonspecific binding was determined in the absence and presence of 10 μM almorexant. The total
20 volume of each reaction is 200 μL (20 μL of diluted compounds, 80 μL of [³H]-EMPA diluted in PBS and 100 μL of the cell suspension). Reactions were run for 60 min at room temperature and terminated by filtration through GF/C filter plates (PerkinElmer, Cat. #6005174) presoaked in 0.3% polyethylenimine using the cell harvester (PerkinElmer Filtermate). The plates were washed 3 times by aspirating 30 ml PBS through the plates. Plates were dried in 55°C oven for 60 min,
25 scintillation fluid was added, and the radioactivity was counted on a Topcount (Packard).

IC₅₀ values (i.e. concentration of unlabelled compound required to compete for 50% of specific binding to the radioligand) was calculated using the GraphPad Prism software (GraphPad Prism Software Inc., San Diego, CA) with a fit to a sigmoidal dose-response curve. Apparent K_i values were calculated as $K_i = IC_{50}/(1+C/K_d)$, where C is concentration of radioligand and $K_d = 2$
30 nM.

Human orexin 1 receptor Ca^{2+} mobilization assay

CHO cells stably transfected with the human orexin 1 receptor (Genebank accession number NM_001526) were grown to confluency in DMEM/F12, 10% FBS, 1X pen-strep, 400 $\mu\text{g}/\text{ml}$ G418. Cells were seeded on to 384-well Packard viewplates at a density of 10,000 cells/well and incubated overnight at 37°C , 5% CO_2 . The cells were dye-loaded with BD Calcium Assay kit (BD, cat # 640178) in HBSS (Gibco, cat# 14025-092) with 2.5 mM probenecid and incubated at 37°C , 5% CO_2 for 45 min. Cells were pre-incubated with compounds (diluted in DMEM/F-12) for 15-30 minutes before agonist (orexin A, 10 nM) stimulation. Ligand-induced Ca^{2+} release was measured using a Fluorometric Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, CA).





Functional responses were measured as peak fluorescence intensity minus basal. The concentration of agonist that produced a half-maximal response is represented by the EC_{50} value. Antagonistic potency values were converted to apparent pK_B values using a modified Cheng-Prusoff correction. Apparent $\text{pK}_B = -\log \text{IC}_{50}/1 + [\text{conc agonist}/\text{EC}_{50}]$.





Human orexin 2 receptor Ca^{2+} mobilization assay





PFSK-1 cells endogenously expressing the human orexin 2 receptor were grown to confluency in RPMI1640 (Hyclone, cat# 30027.02), 10% FBS, 1X pen-strep. Cells were seeded on to 384-well Packard viewplates at a density of 5,000 cells/well and incubated overnight at 37°C , 5% CO_2 . The cells were dye-loaded with BD Calcium Assay kit (BD, cat # 640178) in HBSS (Gibco, cat# 14025-092) with 2.5 mM probenecid and incubated at 37°C , 5% CO_2 for 45 min. Cells were pre-incubated with compounds (diluted in DMEM/F-12) for 15-30 minutes before agonist (orexin B, 100 nM) stimulation. Ligand-induced Ca^{2+} release was measured using a Fluorometric Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, CA). Functional responses were measured as peak fluorescence intensity minus basal. The concentration of agonist that produced a half-maximal response is represented by the EC_{50} value. Antagonistic potency values were converted to apparent pK_B values using a modified Cheng-Prusoff correction. Apparent $\text{pK}_B = -\log \text{IC}_{50}/1 + [\text{conc agonist}/\text{EC}_{50}]$.





Preferred compounds of the invention are set forth in the table below. Orexin receptor activity of certain compounds of the invention is also set forth in Table 1 below.





Table 1





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
1		74	120	4700	(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
2		200	342	10000	(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
3		63	123	8900	(R/S)-(3-ethoxyisoquinolin-4-yl)((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
4		837		>10000	(R/S)-5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
7		21	12	800	(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
8		16	15	1450	(R/S)-(3-ethoxyisoquinolin-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
9		56	101	2554	(R/S)-(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
10		18	27	526	(R/S)-(7-ethoxyquinolin-8-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
11		11	8	1475	(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
12		44	59	>10000	(R/S)-(4-methoxy-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
13		52	109	>10000	(R/S)-4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
14		16	21	855	(R/S)-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
15		17	40	229	(R/S)-2-methoxy-6-(2H-1,2,3-triazol-2-yl)phenyl(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
16		8	7	1000	(R/S)-(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
17		8	3	234	(R/S)-(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
18		25	23	1800	(R/S)-(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
19		18	9	945	(R/S)-(5-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
20		15	15	2700	(R/S)-(4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
21		>10000		>10000	(R/S)-(2-(4H-1,2,4-triazol-4-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
22		25	23	1000	(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
23		>10000		>10000	(6-methyl-3-((2H-1,2,3-triazol-2-yl)pyridin-2-yl))((1R,4S,6S)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
24		20	16	692	(6-methyl-3-((2H-1,2,3-triazol-2-yl)pyridin-2-yl))((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
25		17	15	466	(6-methyl-3-((2H-1,2,3-triazol-2-yl)pyridin-2-yl))((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
26		12	15	2100	(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
27		4	4	767	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
28		32	21	1600	(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
29		55	47	>10000	(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
30		19	22	1700	(3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
31		707		>10000	(3-fluoro-2-methoxyphenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
32		3	4	143	(3-methyl-2-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
33		74	86	3500	(3-fluoro-2-(1H-1,2,3-triazol-1-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
34		117	462	1100	(6-methyl-2-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
35		8	3	542	(3-fluoro-2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
36		5	11	322	(2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
37		170	265	1800	(3-ethoxy-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
38		8	8	690	(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					-2-yl)methanone
39		132	17	108	(2-methoxy-6-(1H-pyrazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
40		16	9	340	(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
41		4399		>10000	(2-(1,4-dimethyl-1H-pyrazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
42		184	175	5800	(1H-indol-7-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
43		16	8	557	(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
44		22	42	2198	(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
45		60	55	1500	(2-bromo-3-fluorophenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
46		10	12	650	(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
47		7	11	503	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone
48		3	6	972	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
49		6	6	507	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
50		7	9	670	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
51		294		676	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
52		550		4000	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
53		3	3	165	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
54		5	6	132	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
55		3	3	46	(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
56		8	10	192	(7-ethoxyquinolin-8-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
57		6	5	252	(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
58		4	2	181	(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
59		6	9	213	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
60					(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
61					(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
62					(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
63					(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
64					(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
65					(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-



Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					azabicyclo[2.2.1]heptan-2-yl)methanone
66					(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
67					(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
68					(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
69					(2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
70					(3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
71					(4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
72					(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.
73					(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
74					(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
75					(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
76					(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
77					(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
78					(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
79					(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
80					(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
81					(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
82					(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					2-yl)methanone
83					(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
84					(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone





Preferred compounds of the invention are set forth in the table below. Orexin receptor activity of certain compounds of the invention is also set forth in Table 2 below.





Table 2





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
1		74	120	4700	(R/S)-2-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
2		200	342	10000	(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
3		63	123	8900	(R/S)-(3-ethoxyisoquinolin-4-yl)((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
4		837		>10000	(R/S)-5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
5		25	18	779	(R/S)-(5-(4-fluorophenyl)-2-methylthiazol-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
6		>10000		>10000	(R/S)-(6-methylimidazo[2,1-b]thiazol-5-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
7		21	12	800	(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
8		16	15	1450	(R/S)-(3-ethoxyisoquinolin-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
9		56	102	2575	(R/S)-(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
10		18	27	526	(R/S)-(7-ethoxyquinolin-8-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
11		11	9	1475	(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
12		44	59	>10000	(R/S)-(4-methoxy-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
13		52	109	>10000	(R/S)-4-methoxy-2-((2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
14		17	23	882	(R/S)-5-fluoro-2-((2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
15		17	40	229	(R/S)-2-methoxy-6-((2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
16		8	7	1000	(R/S)-3-fluoro-2-((2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
17		8	3	234	(R/S)-(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
18		25	23	1800	(R/S)-(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
19		18	9	945	(R/S)-(5-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
20		15	15	2700	(R/S)-(4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
21		>10000		>10000	(R/S)-(2-(4H-1,2,4-triazol-4-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
22		25	23	1000	(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
23		>10000		>10000	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1R,4S,6S)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
24		20	16	692	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
25		14	15	483	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
26		12	15	2100	(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
27		6	5	725	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
28		32	21	1600	(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					-2-yl)methanone
29		55	47	>10000	(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
30		19	22	1700	(3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
31		707		>10000	(3-fluoro-2-methoxyphenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
32		3	6	149	(3-methyl-2-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
33		74	86	3500	(3-fluoro-2-((1H-1,2,3-triazol-1-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
34		162	368	1050	(6-methyl-2-((1H-1,2,3-triazol-1-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
35		8	3	546	(3-fluoro-2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
36		5	13	343	(2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					-2-yl)methanone
37		170	265	1800	(3-ethoxy-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
38		8	8	633	(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
39		72	17	104	(2-methoxy-6-(1H-pyrazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
40		15	9	333	(2-methoxy-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
41		4400		>10000	(2-(1,4-dimethyl-1H-pyrazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
42		184	175	5800	(1H-indol-7-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
43		24	16	550	(5-fluoro-2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					-2-yl)methanone
44		21	39	2333	(4-fluoro-2-((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
45		60	55	1500	(2-bromo-3-fluorophenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
46		10	12	650	(2-fluoro-6-((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
47		6	9	524	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone
48		4	5	903	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
49		6	5	443	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
50		7	10	578	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
51		294		676	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
52		550		4000	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
53		3	4	169	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
54		6	5	126	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
55		3	3	46	(3-methyl-2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
56		8	10	192	(7-ethoxyquinolin-8-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
57		5	5	225	(5-fluoro-2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
58		5	3	193	(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					-2-yl)methanone
59		6	7	192	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
60		20	12	617	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
61		15	19	248	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
62		28	19	569	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
66		2	5	181	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
67		7	7	264	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
68		7	8	612	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
73		8	11	575	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
74		16	16	1800	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
76		4	3	211	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
77		9	13	1700	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					2-yl)methanone
80		9	7	456	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
83		8	5	289	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
85		6	6	910	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-(6- ² H)-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
86		7	9	946	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]- (3- ² H, ² H)-heptan-2-yl)methanone
87		156	211	>10000	(2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
88		45	36	>10000	(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
89		18	8	1100	(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					-2-yl)methanone
90		15	19	2150	(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
91		8	6	331	(2-(5-fluoropyrimidin-2-yl)-3-methylphenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
92		13	19	362	(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
93		125	76	3100	(3-phenylpyrazin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
94		35	30	848	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
95		29	37	137	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
96		320		1700	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					-2-yl)methanone
97		21	15	1100	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
98		37	28	1200	((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
99		11	10	725	((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
100		13	12	1600	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
101		26	11	710	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
102		404		1600	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
103		>10000		>10000	(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
104		497		5000	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
105		119	337	>10000	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone
106		3	4	436	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
107		16	26	1960	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
108		8	31	776	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
109		6	5	442	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone
110		6	11	1200	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
111		5	5	458	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
112		8	10	459	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
113		17	14	984	((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
114		11	23	668	((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
115		7	8	852	((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
116		11	12	939	((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone
117		16	28	1600	((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone
118		133	105	1600	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
119		262		3600	((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
120		60	111	4100	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
121		10	11	50	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
122		28	30	218	((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
123		11	10	149	((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					yl)phenyl)methanone
124		200	109	4500	(5-fluoro-2-((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
125		220	88	5500	(6-methyl-3-((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
126		27	22	4200	(3-fluoro-2-((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
127		116	143	>10000	(4-fluoro-2-((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
128		69	62	3800	(5-fluoro-2-((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
129		53	47	4400	(2-fluoro-6-((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
130		29	27	3500	(2-((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
131		140	132	2200	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
132		425		6800	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
133		60	102	4200	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
134		668		>10000	(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
135		61	100	1200	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
136		380		4700	((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
137		39	65	1700	((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
138		300		2700	((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
139		208	150	3700	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
140		330		7700	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
141		208	348	>10000	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
142		376		7900	(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
143		24	34	7300	(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
144		3	3	133	(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
145		17	7	934	(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
146		6	3	150	(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					-2-yl)methanone
147		5	6	190	(2-fluoro-6-((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone)phenyl
148		3	5	189	(2-((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone)phenyl
149		14	7	4600	(5-methyl-3-((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone)pyridin-2-yl
150		13	9	88	(6-methyl-3-((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone)pyridin-2-yl

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					-2-yl)methanone
151		21	47	5100	(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
152		30	16	1600	(4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
153		3	3	342	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
154		4	6	329	(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					azabicyclo[2.2.1]heptan-2-yl)methanone
155		5	3	303	(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
156		7	5	274	((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
157		6	3	351	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
158		5	2	340	(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
159		6	4	209	(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
160		9	6	208	(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
161		14	5	384	((1S,4S,6R)-6-((cyclopropylmethyl)(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
162		>10000		>10000	N-((1S,4R,6R)-2-(3-fluoro-2-(pyrimidin-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)-N-(5-(trifluoromethyl)pyridin-2-yl)acetamide
163		19	12	962	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((2-methoxyethyl)(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
166		2	4	236	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
167		2	6	239	((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
168		2	4	351	((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone
169		3	4	285	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
170		4	12	321	((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
171		27	25	1900	((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
172		8	7	400	((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
173		55	33	264	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
174		18	15	230	((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
175		170	191	844	(2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
176		56	52	1300	(3-fluoro-2-((pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
177		3	3	200	(2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
178		6	8	112	((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
179		5	5	217	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
180		6	5	380	((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone
181		5	8	163	((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
182		3	4	218	((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
183		5	7	206	((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
184		13	15	337	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(p-tolylamino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
185		27	33	146	(1H-indol-7-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
186		123	151	2700	(1H-indazol-7-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
187		28	30	1600	(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
188		191	210	>10000	(2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
189		14	11	678	(3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
190		12	12	>10000	(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
191		15	13	163	(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
192		8	7	249	(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
193		40	65	2000	(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					-2-yl)methanone
194		8	8	241	((5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
195		9	8	199	(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
196		6	4	60	(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
197		93	39	9700	(4-methoxy-2-((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone)phenyl
198		11	9	1375	(4-fluoro-2-((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone)phenyl
199		6	8	221	(5-fluoro-2-((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone)phenyl





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
200		7	6	240	(2-fluoro-6-((pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
201		6	6	213	(2-((pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
202		13	13	302	(5-fluoro-2-((oxazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
203		9	9	545	(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					-2-yl)methanone
204		9	9	960	(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
205		51	35	846	(3-phenylpyrazin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
206		8	10	103	[1,1'-biphenyl]-2-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
207		143	127	611	(3-phenylfuran-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
208		7	6	846	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
209		9	5	753	(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
210		6	5	502	((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone
211		31	16	1300	((1S,4S,6R)-6-((cyclopropylmethyl)(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					(pyrimidin-2-yl)phenyl)methanone
212		14	9	607	((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
213		39	31	871	((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
214		13	14	708	((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
215		12	13	435	((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone
216		9	9	500	((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone
217		12	29	390	(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
218		31	49	490	(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
219		20	27	480	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
220		11	17	284	((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone
221		2100		3000	Methyl 5-(((1S,4S,6R)-2-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)amino)pyrazine-2-carboxylate
222		261		>10000	(2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
223		11	6	619	(3-fluoro-2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
224		37	33	1900	(4-fluoro-2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
225		20	16	800	(5-fluoro-2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
226		17	19	874	(2-fluoro-6-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					din-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
227		12	13	3100	(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
228		11	9	544	(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
229		9	11	724	(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
230		4	4	470	(2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
231		9	12	1300	(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
232		24	25	1352	(2-fluoro-6-(oxazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
233		280		1100	(3-ethoxy-6-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
234		17	12	827	((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
235		36	41	1300	((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
236		10	9	1020	((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
237		32	13	1900	((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
238		20	8	991	((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)(methyl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
239		23	41	726	((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone
240		17	12	831	((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone
241		21	12	971	((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)(methyl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
242		89	113	2100	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
243		112	131	1800	(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
244		114	143	1700	(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
245		65	53	4300	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
246		194	155	843	(2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
247		26	31	939	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
248		11	14	467	(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
249		8	15	758	(R/S)-(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
250		22	24	1800	(R/S)- (4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
251		18	11	760	(R/S)- (2-(5-fluoropyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
252		13	14	312	(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
253		>10000		>10000	(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)-((1S,4R,6S)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
254		12	10	307	(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
255		12	11	1000	(R/S)-(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
256		20	10	348	(R/S)-(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
257		21	24	741	(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					2-yl)methanone
258		26	17	2600	(R/S)- (4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
259		16	19	865	(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
260		11	10	294	(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
261		21	9	400	(2-fluoro-6-((pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
262		10	10	550	(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
263		11	9	1100	(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
264		10	16	>10000	(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					azabicyclo[2.2.2]octan-2-yl)methanone
265		14	19	306	(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
266		11	11	654	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
267		26	19	1100	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone




Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
268		5	4	200	(2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
269		4	5	363	((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
270		4	3	200	(2-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
271		7	8	452	((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
272		23	11	1400	(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
273		44	16	3800	(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
274		11	8	534	(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
275		8	5	175	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					azabicyclo[2.2.2]octan-2-yl)methanone
276		2700		>10000	(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1R,4S,6S)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
277		17	15	998	(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
278		14	7	243	(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone





Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
279		11	13	177	(2-fluoro-6-((1S,4R,6R)-2-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone)phenyl
280		7	4	189	(2-((1S,4R,6R)-2-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone)phenyl
281		5	19	336	((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-((pyrimidin-2-yl)phenyl)methanone)
282		81	65	>10000	(5-methyl-3-((1S,4R,6R)-2-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone)phenyl


Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					2-yl)methanone
283		21	27	>10000	((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
284		45	47	5600	((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
285		117	215	6000	((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
286		822		3100	((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
					yl)pyridin-2-yl)methanone
287		155	226	2700	((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
288		29	39	5100	((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
289		14	24	207	(2-methoxy-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
290		97	188	>10000	(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
291		43	82	4200	(4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
292		19	40	673	(2-fluoro-6-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
293		16	26	535	(5-fluoro-2-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone


Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
294		166	580	1400	(5-methyl-3-(1H-1,2,3-triazol-1-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
295		19	34	5800	(4-methoxy-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
296		8	14	474	(3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
297		10	10	606	(2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
298		24	29	>10000	(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
299					((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
300		92	112	3700	(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
301					((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Ex. No.	Compound	rOX1 K _i (nM)	hOX1 K _i (nM)	hOX2 K _i (nM)	Compound Name
302					((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

What is Claimed:

1. A compound of formula I



or an enantiomer or diastereomer thereof;

or a pharmaceutically acceptable salt thereof;

wherein

X is N or CR₁;

Y is N or CR₂;

R₁ is H, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl,

oxadiazolyl, pyridyl, phenyl or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl;

R₂ is H, alkyl, alkoxy, or halo;

Z is NH, N-CH₃, N-CH₂CH₃, N-CH₂-cyclopropyl, N-C(=O)CH₃, N-CH₂CH₂OCH₃ or O;

R₃ is H, alkyl, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl,

isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl;

R₄ is H or alkyl;

or R₃ and R₄, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring;

R₅ is phenyl, pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl,

wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl is optionally substituted with up to two groups selected from halo, alkoxy, hydroxymethyl and alkyl; and

n is 1 or 2.

2. The compound of claim 1, wherein Z is NH.

3. The compound of claim 1, wherein Z is O.
4. The compound of any one of claims 1 to 3, wherein X is CR₁ and Y is CR₂.
5. The compound of any one of claims 1 to 3, wherein X is CR₁ and Y is N.
6. The compound of any one of claims 1 to 3, wherein X is N and Y is CR₂.
- 5 7. The compound of any one of claims 1 to 5, wherein R₁ is alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, or pyrazolyl.
8. The compound of claim 7, wherein R₁ is alkoxy, halo, triazolyl, or pyrimidinyl.
9. The compound of claim 7, wherein pyrazolyl is methyl-pyrazolyl or dimethyl-pyrazolyl.
10. The compound of claim 7, wherein oxadiazolyl is methyl-oxadiazolyl.
- 10 11. The compound of any one of claims 1 to 4 or 6, wherein R₂ is H.
12. The compound of any one of claims 1 to 4 or 6, wherein R₂ is alkyl.
13. The compound of claim 12, wherein alkyl is -CH₃.
14. The compound of any one of claims 1 to 4 or 6, wherein R₂ is alkoxy.
15. The compound of any one of claims 1 to 4 or 6, wherein R₂ is halo.
- 15 16. The compound of claim 15, wherein halo is F.
17. The compound of any one of the preceding claims, wherein R₃ is H.
18. The compound of any one of claims 1 to 16, wherein R₃ is alkyl.
19. The compound of any one of claims 1 to 16, wherein R₃ is alkoxy.
20. The compound of any one of claims 1 to 16, wherein R₃ is halo.
- 20 21. The compound of any one of claims 1 to 16, wherein R₃ is triazolyl.
22. The compound of any one of the preceding claims, wherein R₄ is H.

23. The compound of any one of claims 1 to 21, wherein R₄ is alkyl.

24. The compound of claim 23, wherein alkyl is -CH₃.

25. The compound of any one of claims 1 to 16, wherein R₃ and R₄ together with the atoms to which they are attached, form a 6-membered aryl ring.

5 26. The compound of any one of claims 1 to 16, wherein R₃ and R₄ together with the atoms to which they are attached, form a 6-membered heteroaryl ring containing one N.

27. The compound of any one of claims 1 to 16, wherein R₃ and R₄ together with the atoms to which they are attached, form a 5-membered heteroaryl ring containing one N.

10 28. The compound of any one of the preceding claims, wherein R₅ is pyridyl, optionally substituted with halo or alkyl.

29. The compound of claim 28, wherein alkyl is trihaloalkyl.

30. The compound of claim 28, wherein R₅ is pyridyl optionally substituted with trifluoromethyl.

15 31. The compound of any one of claims 1 to 27, wherein R₅ is pyrazinyl, optionally substituted with halo or alkyl.

32. The compound of claim 31, wherein alkyl is trihaloalkyl.

33. The compound of claim 31, wherein R₅ is pyrazinyl optionally substituted with trifluoromethyl.

20 34. The compound of any one of claims 1 to 27, wherein R₅ is pyrimidinyl, optionally substituted with halo or alkyl.

35. The compound of claim 34, wherein alkyl is trihaloalkyl.






36. The compound of claim 34, wherein R₅ is pyrimidinyl optionally substituted with trifluoromethyl.






37. The compound of any one of the preceding claims, wherein n is 1.

38. The compound of any one of claims 1 to 36, wherein n is 2.






39. A compound selected from the group consisting of

Ex. No.	Compound	Compound Name
1		(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
2		(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
3		(R/S)-(3-ethoxyisoquinolin-4-yl)((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
4		(R/S)-5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
7		(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
8		(R/S)-(3-ethoxyisoquinolin-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
9		(R/S)-(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
10		(R/S)-(7-ethoxyquinolin-8-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
11		(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
12		(R/S)-(4-methoxy-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
13		(R/S)-4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
14		(R/S)-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
15		(R/S)-2-methoxy-6-(2H-1,2,3-triazol-2-yl)phenyl(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
16		(R/S)-(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
17		(R/S)-(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
18		(R/S)-(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
19		(R/S)-(5-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
20		(R/S)-(4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
21		(R/S)-(2-(4H-1,2,4-triazol-4-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
22		(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
23		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1R,4S,6S)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
24		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
25		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
26		(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
27		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
28		(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
29		(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
30		(3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
31		(3-fluoro-2-methoxyphenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
32		(3-methyl-2-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
33		(3-fluoro-2-(1H-1,2,3-triazol-1-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
34		(6-methyl-2-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
35		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
36		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
37		(3-ethoxy-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
38		(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
39		(2-methoxy-6-(1H-pyrazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
40		(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
41		(2-(1,4-dimethyl-1H-pyrazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
42		(1H-indol-7-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	Compound Name
43		(5-fluoro-2-((2H-1,2,3-triazol-2-yl)phenyl))((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
44		(4-fluoro-2-((2H-1,2,3-triazol-2-yl)phenyl))((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
45		(2-bromo-3-fluorophenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
46		(2-fluoro-6-((2H-1,2,3-triazol-2-yl)phenyl))((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
47		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)((2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone)






Ex. No.	Compound	Compound Name
48		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
49		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
50		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
51		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
52		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
53		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
54		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
55		(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
56		(7-ethoxyquinolin-8-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
57		(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
58		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
59		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
60		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
61		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
62		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
63		(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
64		(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
65		(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
66		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
67		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
68		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
69		(2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
70		(3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
71		(4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
72		(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
73		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
74		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
75		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
76		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
77		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
78		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
79		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
80		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
81		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
82		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
83		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
84		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
85		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
86		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]-(3- ² H, ² H)-heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
87		(2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
88		(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
89		(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
90		(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
91		(2-(5-fluoropyrimidin-2-yl)-3-methylphenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
92		(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
94		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
95		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
96		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
97		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
98		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
99		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone
100		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
101		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
102		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
103		(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
104		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
105		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone
106		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
107		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Ex. No.	Compound	Compound Name
108		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
109		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone
110		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
111		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
112		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
113		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
114		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
115		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
116		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone
117		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone






Ex. No.	Compound	Compound Name
118		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
119		((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
120		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
121		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
122		((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone






Ex. No.	Compound	Compound Name
123		((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
124		(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
125		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
126		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
127		(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
128		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
129		(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
130		(2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
131		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
132		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	Compound Name
133		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
134		(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
135		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
136		((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
137		((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone






Ex. No.	Compound	Compound Name
138		((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
139		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
140		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
141		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
142		(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
143		(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
144		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
145		(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
146		(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
147		(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
148		(2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
149		(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
150		(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
151		(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
152		(4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
153		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
154		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
155		(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
156		((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
157		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
158		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
159		(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
160		(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
161		((1S,4S,6R)-6-((cyclopropylmethyl)(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone





Ex. No.	Compound	Compound Name
162		N-((1S,4R,6R)-2-(3-fluoro-2-(pyrimidin-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)-N-(5-(trifluoromethyl)pyridin-2-yl)acetamide
163		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((2-methoxyethyl)(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
164		(2-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
165		(6-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
166		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
167		((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
168		((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone
169		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
170		((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
171		((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone





Ex. No.	Compound	Compound Name
172		((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
173		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
174		((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
175		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
176		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	Compound Name
177		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
178		((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
179		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
180		((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone
181		((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone






Ex. No.	Compound	Compound Name
182		((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
183		((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
184		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(p-tolylamino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
185		(1H-indol-7-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
186		(1H-indazol-7-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
187		(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
188		(2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
189		(3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.
190		(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
191		(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
192		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
193		(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
194		((5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
195		(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
196		(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
197		(4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
198		(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
199		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
200		(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
201		(2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
202		(5-fluoro-2-(oxazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
203		(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
204		(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
206		[1,1'-biphenyl]-2-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
208		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
209		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
210		((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone

Ex. No.	Compound	Compound Name
211		((1S,4S,6R)-6-((cyclopropylmethyl)(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
212		((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
213		((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
214		((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
215		((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone






Ex. No.	Compound	Compound Name
216		((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone
217		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
218		(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
219		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
220		((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone

Ex. No.	Compound	Compound Name
221		Methyl 5-(((1S,4S,6R)-2-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)amino)pyrazine-2-carboxylate
222		(2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
223		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
224		(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
225		(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
226		(2-fluoro-6-((2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
227		(4-fluoro-2-((pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
228		(5-fluoro-2-((pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
229		(2-fluoro-6-((pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
230		(2-((pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
231		(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
232		(2-fluoro-6-(oxazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
233		(3-ethoxy-6-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
234		((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
235		((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone






Ex. No.	Compound	Compound Name
236		((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
237		((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
238		((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)(methyl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
239		((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone
240		((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone






Ex. No.	Compound	Compound Name
241		((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)(methyl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone
242		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
243		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
244		(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
245		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-

Ex. No.	Compound	Compound Name
		yl)methanone
246		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
247		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
248		(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
249		(R/S)- (3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
250		(R/S)- (4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
251		(R/S)- 2-((5-fluoropyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
252		(R/S)-6-methyl-3-((2H-1,2,3-triazol-2-yl)pyridin-2-yl)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
253		(R/S)-6-methyl-3-((2H-1,2,3-triazol-2-yl)pyridin-2-yl)-((1S,4R,6S)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
254		(R/S)-2-((2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
255		(R/S)- 3-fluoro-2-((2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
256		(R/S)- (3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
257		(R/S)- (3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
258		(R/S)- (4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
259		(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
260		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
261		(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
262		(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
263		(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
264		(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
265		(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
266		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
267		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
268		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
269		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
270		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
271		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
272		(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
273		(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
274		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
275		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
276		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1R,4S,6S)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
277		(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
278		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
279		(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
280		(2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
281		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
282		(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
283		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
284		((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
285		((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Ex. No.	Compound	Compound Name
286		((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
287		((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
288		((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
289		(2-methoxy-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
290		(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
291		(4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
292		(2-fluoro-6-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
293		(5-fluoro-2-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
294		(5-methyl-3-(1H-1,2,3-triazol-1-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
295		(4-methoxy-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	Compound Name
296		(3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
297		(2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
298		(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
299		((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
300		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
301		((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
302		((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
303		(2-(pyridazin-3-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
304		(2-(pyridazin-4-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
305		(2-(pyridin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
306		(2-(pyridin-3-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
307		(2-(pyridin-4-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
308		(2-(pyrazin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
309		(2-(3-methylpyridin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
310		(2-(5-methylisoxazol-3-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
311		(2-(3,5-dimethylisoxazol-4-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
312		((1S,4R,6R)-6-((4,6-dimethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
313		((1S,4R,6R)-6-((4,6-dimethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
314		(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
315		((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone






Ex. No.	Compound	Compound Name
316		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(hydroxymethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
317		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(fluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
318		((1S,4R,6R)-6-((5-(hydroxymethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
319		((1S,4R,6R)-6-((5-(fluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
320		(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
321		(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
322		(3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
323		(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
324		(3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
325		(3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
326		(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
327		(5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
328		(6-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
329		(6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
330		(5-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
331		(4'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
332		[2,3'-bipyridin]-2'-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
333		[2,2'-bipyridin]-3-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
334		(3,5'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
335		(3',6-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
336		(3,6'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
337		(3',5-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
338		(3,4'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
339		(3-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
340		(3'-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
341		(3-fluoro-5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
342		(3'-fluoro-6-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
343		(3-fluoro-6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
344		(3'-fluoro-5-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone





Ex. No.	Compound	Compound Name
345		(3-fluoro-4'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
346		(3-fluoro-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
347		(3'-fluoro-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
348		(5-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
349		(6-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
350		(6-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
351		(5-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
352		(4-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
353		(3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
354		(2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
355		(5-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
356		(6-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
357		(6-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
358		(5-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
359		(4-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
360		(3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
361		(2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
362		(2-(pyridazin-3-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
363		(2-(pyridazin-4-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
364		(2-(pyridin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
365		(2-(pyridin-3-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
366		(2-(pyridin-4-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
367		(2-(pyrazin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
368		(2-(3-methylpyridin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
369		(2-(5-methylisoxazol-3-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
370		(2-(3,5-dimethylisoxazol-4-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
371		(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
372		(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
373		(3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
374		(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
375		(3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
376		(3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
377		(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
378		(5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-






Ex. No.	Compound	Compound Name
		yl)methanone
379		(6-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
380		(6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
381		(5-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
382		(4'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
383		[2,3'-bipyridin]-2'-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
384		[2,2'-bipyridin]-3-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
385		(3,5'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
386		(3',6-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
387		(3,6'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
388		(3',5-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
389		(3,4'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
390		(3-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
391		(3'-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
392		(3-fluoro-5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
393		(3'-fluoro-6-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
394		(3-fluoro-6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
395		(3'-fluoro-5-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
396		(3-fluoro-4'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
397		(3-fluoro-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
398		(3'-fluoro-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
399		(5-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
400		(6-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
401		(6-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
402		(5-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
403		(4-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
404		(3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
405		(2-(oxazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
406		(5-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
407		(6-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
408		(6-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
409		(5-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
410		(4-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
411		(3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
412		(2-(thiazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
413		((1S,4S,6R)-6-((4,6-dimethylpyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
414		((1S,4S,6R)-6-((4,6-dimethylpyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
415		(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
416		((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
417		(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
418		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
419		(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
420		(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
421		(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
422		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
423		(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
424		(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
425		(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
426		(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
427		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
428		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
429		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone
430		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
431		(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
432		(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
433		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
434		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone
435		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
436		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
437		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone






Ex. No.	Compound	Compound Name
438		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
439		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
440		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
441		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone
442		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Ex. No.	Compound	Compound Name
443		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
444		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone
445		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
446		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone
447		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Ex. No.	Compound	Compound Name
448		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
449		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
450		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone
451		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
452		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
453		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
454		(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
455		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
456		(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
457		(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
458		(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
459		(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
460		(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
461		(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
462		(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
463		(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
464		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
465		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
466		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
467		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone

Ex. No.	Compound	Compound Name
468		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
469		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
470		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone
471		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone
472		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone






Ex. No.	Compound	Compound Name
473		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
474		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
475		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
476		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone
477		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone






Ex. No.	Compound	Compound Name
478		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
479		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone
480		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
481		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
482		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone






Ex. No.	Compound	Compound Name
483		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone
484		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
485		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
486		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
487		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone






Ex. No.	Compound	Compound Name
488		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone
489		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
490		((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
491		(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
492		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
493		(5-methyl-2-((2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
494		(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
495		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
496		(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
497		(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
498		(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
499		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
500		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
501		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
502		(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
503		(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
504		(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
505		(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
506		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
507		(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
508		(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
509		(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
510		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
511		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
512		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone





Ex. No.	Compound	Compound Name
513		((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
514		((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
515		((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone
516		((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone
517		((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone






Ex. No.	Compound	Compound Name
518		((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
519		((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
520		((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
521		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
522		((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone






Ex. No.	Compound	Compound Name
523		((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
524		((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
525		((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
526		((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone
527		((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone






Ex. No.	Compound	Compound Name
528		((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
529		((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
530		((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
531		((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
532		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
533		((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
534		((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
535		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
536		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
537		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone






Ex. No.	Compound	Compound Name
538		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone
539		(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
540		(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
541		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone






Ex. No.	Compound	Compound Name
542		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
543		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
544		(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
545		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
546		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone






Ex. No.	Compound	Compound Name
547		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone
548		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone
549		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone
550		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone
551		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone






Ex. No.	Compound	Compound Name
552		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
553		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone
554		(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
555		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
556		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone





Ex. No.	Compound	Compound Name
557		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
558		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
559		(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
560		((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
561		((1S,4R,6R)-6-((5-chloropyridin-3-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone






Ex. No.	Compound	Compound Name
562		((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone
563		(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
564		(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
565		(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
566		(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
567		(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
568		(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
569		(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
570		((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-methoxy-6-(pyrimidin-2-yl)phenyl)methanone
571		(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
572		((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-methoxy-6-(pyrimidin-2-yl)phenyl)methanone
573		((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-methoxy-6-(pyrimidin-2-yl)phenyl)methanone
574		(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
575		(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
576		(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
577		(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
578		((1S,4R,6R)-6-((5-methylpyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone
579		(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
580		(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
581		(3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
582		(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
583		(3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
584		(3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
585		(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
586		(5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
587		(6-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
588		(6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
589		(5-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
590		(4'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
591		[2,3'-bipyridin]-2'-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
592		[2,2'-bipyridin]-3-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
593		(3,5'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
594		(3',6-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
595		(3,6'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
596		(3',5'-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
597		(3,4'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
598		(3-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
599		(3'-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
600		(3-fluoro-5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
601		(3'-fluoro-6-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
602		(3-fluoro-6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
603		(3'-fluoro-5-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
604		(3-fluoro-4'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
605		(3-fluoro-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
606		(3'-fluoro-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
607		(5-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
608		(6-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
609		(6-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
610		(5-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone






Ex. No.	Compound	Compound Name
611		(4-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
612		(3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
613		(2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
614		(5-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
615		(6-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone





Ex. No.	Compound	Compound Name
616		(6-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
617		(5-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
618		(4-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
619		(3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone
620		(2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
621		(2-(1-methyl-1H-imidazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
622		(2-(1-methyl-1H-imidazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
623		(3-(1-methyl-1H-imidazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
624		(5-methyl-3-(1-methyl-1H-imidazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
625		(6-methyl-2-(1-methyl-1H-imidazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
626		(6-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
627		(2-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
628		(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
629		(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
630		(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone






Ex. No.	Compound	Compound Name
631		(5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
632		(6-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
633		(5-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
634		[2,2'-bipyridin]-3-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
635		(3,5'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone


Ex. No.	Compound	Compound Name
636		(3',6-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
637		(3',5-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
638		(3'-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
639		(3-fluoro-5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
640		(3'-fluoro-6-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Ex. No.	Compound	Compound Name
641		(3'-fluoro-5-methyl-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
642		(3'-fluoro-[2,2'-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
643		(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
644		(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
645		(3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
646		(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
647		(3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
648		(5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
649		(6-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
650		(6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
651		(3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
652		(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
653		(3,5'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
654		(3',6-dimethyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
655		(3,6'-dimethyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
656		(3-fluoro-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
657		(3'-fluoro-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
658		(3-fluoro-5'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone
659		(3'-fluoro-6-methyl-[2,2'-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Ex. No.	Compound	Compound Name
660		(3-fluoro-6'-methyl-[2,3'-bipyridin]-2'-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone


40. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of the preceding claims and at least one pharmaceutically acceptable excipient.

5 41. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by orexin receptor activity, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 39.

42. The method of claim 41, wherein the disease, disorder, or medical condition mediated by orexin receptor activity is a disorder of the sleep-wake cycle, insomnia, restless legs
10 syndrome, jet-lag, disturbed sleep, a sleep disorder secondary to neurological disorders, mania, depression, manic depression, schizophrenia, a pain syndromes, fibromyalgia, neuropathic pain, catatonia, Parkinson's disease, Tourette's syndrome, anxiety, delirium, dementia, overweight, obesity or a condition related to overweight or obesity, insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness,
15 tachycardia, infertility, sleep apnea, back and joint pain, varicose veins, osteoarthritis, hypertension, tachycardia, arrhythmias, angina pectoris, acute heart failure, ulcers, irritable bowel syndrome, diarrhea, gastroesophageal reflux, post-traumatic stress disorder, panic disorders, attention deficit disorders, cognitive deficiencies, or substance abuse.

43. The method of claim 42 wherein the disease, disorder, or medical condition is mood
20 disorders, post-traumatic stress disorder, panic disorders, attention deficit disorders, cognitive deficiencies, or substance abuse.

44. A compound of Formula IA:



or an enantiomer or diastereomer thereof;

or a pharmaceutically acceptable salt thereof;

wherein

ring A is a heteroaryl ring selected from furanyl, thiazolyl, imidazothiazolyl and pyrazinyl;

R₁ is H, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl, or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl;

R₂ is H, alkyl, alkoxy, or halo;

Z is NH, N-CH₃, N-CH₂CH₃, N-CH₂-cyclopropyl, N-C(=O)CH₃, N-CH₂CH₂OCH₃ or O;

R₃ is H, alkyl, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl, or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo and alkyl;






R₄ is H or alkyl;

or R₃ and R₄, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring;

R₅ is pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl, wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl is optionally substituted with up to two substituents selected from halo, alkoxy, hydroxymethyl or alkyl; and

n is 1 or 2.

45. A compound selected from

5		(R/S)-(5-(4-fluorophenyl)-2-methylthiazol-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
6		(R/S)-(6-methylimidazo[2,1-b]thiazol-5-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
93		(3-phenylpyrazin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
205		(3-phenylpyrazin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
207		(3-phenylfuran-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

1/2




Figure 1

2/2




Figure 2

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2014/024293

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D487/08 A61K31/407 C07D519/00 A61P25/00 C07D471/08
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2009/104155 A1 (ACTELION PHARM LTD) 27 August 2009 (2009-08-27) page 1, line 3 - line 7; claim 1; table 1 -----	1-45
A	WO 2008/150364 A1 (MERCK & CO INC [US]; COLEMAN PAUL J [US]; MERCER SWATI P [US]; ROECKER) 11 December 2008 (2008-12-11) page 2, line 28 - line 33; claim 1; examples 1-7 -----	1-45

☐

Further documents are listed in the continuation of Box C.

☒

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 May 2014

Date of mailing of the international search report

22/05/2014

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Seelmann, Ingo

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2014/024293

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2009104155 A1	27-08-2009	AR 070459 A1 AT 555107 T AU 2009215243 A1 CA 2713184 A1 CN 101965343 A EP 2247586 A1 ES 2385699 T3 JP 2011512400 A KR 20100119576 A NZ 588080 A RU 2010138640 A US 2011009401 A1 WO 2009104155 A1	07-04-2010 15-05-2012 27-08-2009 27-08-2009 02-02-2011 10-11-2010 30-07-2012 21-04-2011 09-11-2010 27-04-2012 27-03-2012 13-01-2011 27-08-2009
-----	-----	-----	-----
WO 2008150364 A1	11-12-2008	AU 2008260647 A1 CA 2687230 A1 EP 2150115 A1 JP 2010528007 A US 2010152191 A1 WO 2008150364 A1	11-12-2008 11-12-2008 10-02-2010 19-08-2010 17-06-2010 11-12-2008
-----	-----	-----	-----